labetalol has been researched along with Hypertension in 891 studies
Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.
labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The efficacy and the clinical and biological safety of labetalol were assessed, in primary care, in an ambulatory hypertensive elderly population, with systolo-diastolic hypertension (mean 175 +/- 14/100 +/- 7 mmHg) monitored during a 6 month period by general practitioners." | 10.16 | [Evaluation of labetalol in general medicine in aged patients with hypertension. Compliance, efficacy and safety in long-term treatment]. ( Herrero, G; Hugonot, L; Hugonot, R, 1990) |
| "The present review shows that labetalol has many advantageous properties in the treatment of patients suffering from angina pectoris with or without hypertension." | 10.16 | Labetalol in the treatment of angina pectoris. ( Kanto, JH, 1987) |
| "The cost effectiveness of labetalol and propranolol in the treatment of black adults with mild to moderate hypertension was assessed using published reports from US clinical trials of these agents among such patients." | 10.16 | Cost effectiveness of labetalol and propranolol in the treatment of hypertension among blacks. ( Colditz, GA; Delea, TE; Huse, DM; Oster, G; Savage, DD, 1987) |
| "The Giant PANDA study is a pragmatic, open-label, multicentre, randomised controlled trial of a treatment initiation strategy with nifedipine (calcium channel blocker), versus labetalol (mixed alpha/beta blocker) in 2300 women with pregnancy hypertension." | 9.69 | A treatment strategy with nifedipine versus labetalol for women with pregnancy hypertension: study protocol for a randomised controlled trial (Giant PANDA). ( Ashworth, D; Battersby, C; Bick, D; Chappell, LC; Green, M; Hardy, P; Leighton, L; Magee, LA; Maher, A; McManus, RJ; Moakes, C; Morris, RK; Myers, J; Nelson-Piercy, C; Rivero-Arias, O; Sparkes, J; Webb, A; Wilson, H, 2023) |
| "The objectives were to compare the efficacy and safety of intravenous hydralazine and labetalol for acutely lowering severe hypertension in pregnancy." | 9.51 | Comparison of intravenous labetalol and hydralazine for severe hypertension in pregnancy in Northeastern Nigeria: A randomized controlled trial. ( Bako, B; Dawha, YM; Muhammad, S; Usman, H; Yahya, A; Yekeen, A, 2022) |
| "The purpose is to investigate the influence of nifedipine, labetalol, and magnesium sulfate on blood pressure control, blood coagulation, and maternal and infant outcome in those suffering from pregnancy-induced hypertension (PIH)." | 9.51 | Effects of Nifedipine and Labetalol Combined with Magnesium Sulfate on Blood Pressure Control, Blood Coagulation Function, and Maternal and Infant Outcome in Patients with Pregnancy-Induced Hypertension. ( Gu, S; Shao, Y; Zhang, X, 2022) |
| "to assess the maternal and fetal outcome in women with mild to moderate chronic hypertension on antihypertensive drug (methyldopa or labetalol) therapy compared to no medication." | 9.34 | Methyldopa versus labetalol or no medication for treatment of mild and moderate chronic hypertension during pregnancy: a randomized clinical trial. ( Badr, H; Dawood, R; El-Shamy, E; Emarh, M; Gamal, A; Masood, A; Rezk, M, 2020) |
| "This study aimed to evaluate the maternal and fetal results in women undergoing antihypertensive therapy (low aspirin or labetalol) with mild to severe chronic hypertension relative to women without medicines." | 9.34 | Treatment of pregnancy-induced hypertension compared with labetalol, low dose aspirin and placebo. ( Wang, F; Xiang, X; Zhao, N; Zhou, Z, 2020) |
| "To determine whether oral labetalol is associated with a shorter time to blood pressure control compared to oral extended release nifedipine for management of persistent postpartum hypertension." | 9.24 | Oral labetalol compared to oral nifedipine for postpartum hypertension: A randomized controlled trial. ( Greene, N; Kilpatrick, SJ; Sharma, KJ, 2017) |
| "This network meta-analysis aimed to compare the efficacy and safety of intravenous (IV) hydralazine, oral nifedipine, and IV labetalol with different dosage regimens in the treatment of severe hypertension during pregnancy." | 9.22 | Different dosage regimens of nifedipine, labetalol, and hydralazine for the treatment of severe hypertension during pregnancy: a network meta-analysis of randomized controlled trials. ( Cheng, Y; Jiang, YF; Li, JB; Wu, HZ; Yu, D; Zhu, ZN, 2022) |
| " Methyldopa, labetalol, and nifedipine have been perceived safe to use during pregnancy and are therefore recommended in international guidelines for treatment of hypertension." | 9.22 | Pharmacokinetics of the most commonly used antihypertensive drugs throughout pregnancy methyldopa, labetalol, and nifedipine: a systematic review. ( Allegaert, K; Flint, RB; Mian, P; Schoenmakers, S; van de Vusse, D; Versmissen, J; Visser, W, 2022) |
| "To compare pregnancy outcomes, accounting for allocated group, between methyldopa-treated and labetalol-treated women in the CHIPS Trial (ISRCTN 71416914) of 'less tight' versus 'tight' control of pregnancy hypertension." | 9.22 | Do labetalol and methyldopa have different effects on pregnancy outcome? Analysis of data from the Control of Hypertension In Pregnancy Study (CHIPS) trial. ( Asztalos, E; Gafni, A; Ganzevoort, JW; Gruslin, A; Helewa, M; Hutton, E; Koren, G; Lee, SK; Lee, T; Logan, AG; Magee, LA; Menzies, J; Moutquin, JM; Murphy, KE; Rey, E; Ross, S; Sanchez, J; Singer, J; Thornton, JG; von Dadelszen, P; Welch, R, 2016) |
| "In the present study, the efficacy and safety of oral nifedipine and intravenous labetalol for severe pre-eclampsia therapy were compared." | 9.22 | Oral nifedipine vs. intravenous labetalol for treatment of pregnancy-induced severe pre-eclampsia. ( Shi, DD; Wang, N; Yang, FZ; Zhou, L, 2016) |
| " Food and Drug Administration (FDA)-recommended doses of labetalol and nicardipine for hypertension (HTN) management in a subset of patients with renal dysfunction (RD)." | 9.19 | The management of acute hypertension in patients with renal dysfunction: labetalol or nicardipine? ( Baumann, BM; Borczuk, P; Cannon, CM; Chandra, A; Cline, DM; Diercks, DB; Hiestand, B; Hsu, A; Jois-Bilowich, P; Kaminski, B; Levy, P; Nowak, RM; Peacock, WF; Schrock, JW; Soto-Ruiz, KM; Varon, J, 2014) |
| "This is a prospective, pseudo-randomized study comparing labetalol and nicardipine for blood pressure (BP) management in acute stroke patients." | 9.17 | A prospective evaluation of labetalol versus nicardipine for blood pressure management in patients with acute stroke. ( Coplin, W; Levy, PD; Liu-DeRyke, X; Parker, D; Rhoney, DH, 2013) |
| "Our study suggests that nicardipine is a more effective antihypertensive agent than labetalol in an unselected group of patients who develop hypertension in the intensive care unit setting." | 9.16 | Intravenous labetalol compared with intravenous nicardipine in the management of hypertension in critically ill patients. ( Hilleman, DE; Malesker, MA, 2012) |
| "We evaluated 16 pregnant women with gestational age between 20 and 32 weeks in acute severe hypertension which were randomly allocated to receive either hydralazine or labetalol." | 9.15 | Changes in fetal and maternal Doppler parameters observed during acute severe hypertension treatment with hydralazine or labetalol: a randomized controlled trial. ( Baggio, MR; Berezowski, AT; Calderon, AC; Cavalli, RC; Duarte, G; Marcolin, AC; Martins, WP, 2011) |
| "The number of patients with intraoperative hypertension, number of patients receiving SNP, dose of SNP administered, and number of hypertension episodes were significantly lower in patients who received labetalol pretreatment than in control patients." | 9.12 | Labetalol pretreatment reduces blood pressure instability during surgical resection of pheochromocytoma. ( Chung, PC; Hsieh, JR; Li, AH; Ng, YT; Yang, MW, 2006) |
| "To assess the efficacy and safety of nicardipine in comparison to labetalol in the initial management of severe hypertension in pregnancy." | 9.10 | Short-term treatment of severe hypertension of pregnancy: prospective comparison of nicardipine and labetalol. ( Abroug, F; Boussarssar, M; Elatrous, S; Marghli, S; Nouira, S; Ouanes Besbes, L; Sakkouhi, M, 2002) |
| "We sought to compare the efficacies of oral nifedipine and intravenous labetalol in the acute management of hypertensive emergencies of pregnancy." | 9.09 | A randomized, double-blind trial of oral nifedipine and intravenous labetalol in hypertensive emergencies of pregnancy. ( Chauhan, SP; Newman, RB; Scardo, JA; Vermillion, ST, 1999) |
| "Our purpose was to compare the hemodynamic effects of orally administered nifedipine and intravenously administered labetalol in preeclamptic hypertensive emergencies." | 9.09 | A randomized, double-blind, hemodynamic evaluation of nifedipine and labetalol in preeclamptic hypertensive emergencies. ( Chauhan, SP; Hogg, BB; Newman, RB; Scardo, JA; Vermillion, ST, 1999) |
| "We compared the efficacy of the combination of enalaprilat/labetalol with that of enalaprilat/nicardipine to prevent emergence postcraniotomy hypertension." | 9.09 | A comparative study between a calcium channel blocker (Nicardipine) and a combined alpha-beta-blocker (Labetalol) for the control of emergence hypertension during craniotomy for tumor surgery. ( Broad, C; Ferri, E; Kross, RA; Leung, D; Melendez, JA; Pratila, M; Veronesi, M, 2000) |
| "To assess the efficacy and safety of labetalol compared with methyldopa in the management of mild and moderate cases of pregnancy-induced hypertension (PIH)." | 9.08 | Labetalol vs. methyldopa in the treatment of pregnancy-induced hypertension. ( al-Fadly, A; el-Qarmalawi, AM; Hashem, M; Morsy, AH; Obeid, A, 1995) |
| " esmolol and labetalol in the treatment of perioperative hypertension in ambulatory surgery." | 9.07 | A comparison of esmolol and labetalol for the treatment of perioperative hypertension in geriatric ambulatory surgical patients. ( Dimich, I; Sampson, I; Singh, PP; Sonnenklar, N, 1992) |
| "To determine the need for, and efficacy of, treatment with labetalol in women with mild-to-moderate pregnancy induced hypertension (PIH)." | 9.07 | A randomised placebo controlled trial of labetalol in the treatment of mild to moderate pregnancy induced hypertension. ( Broughton Pipkin, F; Pickles, CJ; Symonds, EM, 1992) |
| "This double-blind, controlled, crossover study compared the effects on blood pressure control, glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) of labetalol, methyldopa and placebo in patients with chronic renal disease and hypertension." | 9.07 | The short term effects of oral labetalol in patients with chronic renal disease and hypertension. ( Catto, GR; Edward, N; Gemmell, HG; Innes, A; Smith, FW, 1992) |
| "This study was designed to compare the clinical efficacy and safety of oral clonidine and oral labetalol in the treatment of severe hypertension in an emergency department setting." | 9.07 | Oral labetalol versus oral clonidine in the emergency treatment of severe hypertension. ( Atkin, SH; Beaty, P; Cuffie, C; Jaker, MA; Quadrel, MA; Soto-Greene, ML, 1992) |
| "Labetalol was evaluated in a multicenter, placebo-controlled study of elderly patients (greater than or equal to 60 years) with mild to moderate essential hypertension." | 9.07 | Evaluation of labetalol in elderly patients with essential hypertension. ( Bartels, DW; Burris, JF; Due, D; Giles, TD; Gregory, MC; Sirgo, MA; Weber, M, 1991) |
| "Sixty-one patients (41 men, 20 women) aged 29-73 years, with moderate to severe hypertension, were enrolled in a multicentre study to compare the efficacy, safety, and tolerability of dilevalol (D) and captopril (C)." | 9.06 | Double-blind study of dilevalol and captopril, both in combination with hydrochlorothiazide, in patients with moderate to severe hypertension. ( Fraser, I; Howes, L; Kincaid-Smith, PS; Louis, W; MacDonald, G; Matthews, PG; McGrath, BP; Rallings, M; Scheinkestel, C; Whitworth, JA, 1990) |
| "A multicenter, randomized, double-blind, parallel-group trial of 8 weeks' duration was designed to compare the efficacy and safety of once-daily carvedilol with that of twice-daily labetalol in patients with essential hypertension." | 9.06 | Safety and efficacy of once-daily carvedilol vs twice-daily labetalol in mild to moderate hypertension. ( Bussiere, JL; Durier, P; Gayet, JL; Ollivier, JP, 1990) |
| "Three hundred women with mild chronic hypertension at 6 to 13 weeks' gestation were randomly allocated to receive either methyldopa or labetalol or be in the control group." | 9.06 | A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy. ( Anderson, GD; Mabie, WC; Shamsa, F; Sibai, BM; Villar, MA, 1990) |
| "Antihypertensive therapy with labetalol was evaluated in a prospective, randomized, multicenter, double-blind study of 133 elderly patients with isolated systolic hypertension (standing systolic blood pressure [BP] greater than or equal to 160 mm Hg; diastolic BP less than 95 mm Hg)." | 9.06 | Treatment of isolated systolic hypertension with labetalol in the elderly. ( Bartels, DW; Burris, JF; Gilderman, LP; Giles, TD; Silberman, HM; Weber, M, 1990) |
| "The effects of 6 weeks of treatment with dilevalol 100 mg once daily, or carteolol 10 mg once daily, on renal blood flow (RBF), glomerular filtration rate (GFR) and total renal vascular resistance (TRR) were studied in 10 patients with mild-to-moderate essential hypertension in a randomised cross-over experiment." | 9.06 | Comparison of the renal effects of dilevalol and carteolol in patients with mild to moderate essential hypertension. ( Baba, T; Murabayashi, S; Takebe, K; Tomiyama, T, 1990) |
| "Antihypertensive effects of labetalol and nifedipine were evaluated in a double blind cross over trial in ambulatory patients with moderately severe hypertension (mean diastolic BP 101." | 9.06 | Labetalol and nifedipine in the management of essential hypertension. ( Prasad, NK, 1990) |
| "The safety and efficacy of labetalol and hydrochlorothiazide (HCTZ) were compared in a group of 34 patients aged 65 years or older with mild to moderate essential hypertension." | 9.06 | Comparison of labetalol and hydrochlorothiazide in elderly patients with hypertension using 24-hour ambulatory blood pressure monitoring. ( Due, DL; Sirgo, MA; Toth, PD; Vidt, DG; Weidler, DJ, 1990) |
| "A new non-imaging echo-Doppler cardiac output device that works on the principle of attenuated compensation volume flow (ACVF), has been used to assess the cardiovascular effects of atenolol and dilevalol in 24 patients with essential hypertension." | 9.06 | Comparison of central and peripheral haemodynamic effects of dilevalol and atenolol in essential hypertension. ( Silke, B; Taylor, SH; Tham, TC, 1990) |
| "This was a multicenter, randomized, double-blind, parallel-group study of the efficacy and safety of dilevalol, 200 mg (n = 86), compared with enalapril, 20 mg (n = 92), administered once daily to patients with mild hypertension." | 9.06 | Comparison of dilevalol and enalapril administered once daily for mild hypertension. ( Edwards, LD; Guerrero-Sierra, J; Guiducci, U; Renaud, H; Rodriguez-Saavedra, M; Sack, DW; Zannad, FM, 1989) |
| "The antihypertensive efficacy and safety of IV labetalol were evaluated and compared with the efficacy and safety of IV hydralazine in the treatment of postoperative hypertension." | 9.06 | Comparative hemodynamic effects of labetalol and hydralazine in the treatment of postoperative hypertension. ( Dimich, I; Gabrielson, G; Kaplan, JA; Lingham, R; Singh, PP, 1989) |
| "The effects of labetalol were compared with those of placebo in a multicentre randomized double-blind and prospective study of 152 patients with mild to moderate, non-proteinuric pregnancy-induced hypertension." | 9.06 | The fetal outcome in a randomized double-blind controlled trial of labetalol versus placebo in pregnancy-induced hypertension. ( Broughton Pipkin, F; Pickles, CJ; Symonds, EM, 1989) |
| " A multi-center, double-blind, parallel group study compared the safety and efficacy of labetalol to propranolol in the treatment of patients with both exertional angina and mild to moderate systemic hypertension." | 9.06 | Labetalol compared with propranolol in patients with both angina pectoris and systemic hypertension: a double-blind study. ( Charlap, S; Frishman, WH; Shapiro, W, 1989) |
| "In a six month placebo-controlled cross-over trial twenty patients with hypertension and peripheral arterial disease were randomised to captopril 25 mg twice daily, atenolol 100 mg once daily, labetalol 200 mg twice daily, or pindolol 10 mg twice daily for one month." | 9.06 | Placebo-controlled comparison of captopril, atenolol, labetalol, and pindolol in hypertension complicated by intermittent claudication. ( Breckenridge, A; McLoughlin, GA; Roberts, DH; Tsao, Y, 1987) |
| "The effects of oral dilevalol (an R, R-isomer of labetalol), a new beta-adrenoceptor blocker with beta 2-receptor stimulating and alpha-recepter blocking properties on blood pressure, renal function, plasma renin activity (PRA) and plasma aldosterone have been studied in 15 patients with mild-to-moderate essential hypertension treated with it for 6 weeks." | 9.06 | Effects of dilevalol, an R, R-isomer of labetalol, on blood pressure and renal function in patients with mild-to-moderate essential hypertension. ( Aoyagi, K; Baba, T; Ishizaki, T; Murabayashi, S, 1988) |
| "The haemodynamic impact of alpha- and beta-adrenoceptor blockade (labetalol) was compared with that of slow-calcium channel blockade (nifedipine) in 32 patients with sustained elevation of systemic arterial pressure (systolic blood pressure greater than 160; diastolic blood pressure greater than 95 mmHg) following a recent myocardial infarction (6-22 h)." | 9.06 | Sympathetic (alpha-beta) or calcium channel blockade for hypertensive myocardial infarction? A haemodynamic comparison of labetalol and nifedipine. ( Hussain, M; Nelson, GI; Reynolds, GW; Richmond, A; Silke, B; Taylor, SH; Verma, SP; Wilson, JA, 1988) |
| "Labetalol was compared with methyldopa in a randomized controlled trial involving 176 pregnant women with mild to moderate hypertension." | 9.06 | Comparison of antihypertensive efficacy and perinatal safety of labetalol and methyldopa in the treatment of hypertension in pregnancy: a randomized controlled trial. ( Breart, G; Maillard, F; Papiernik, E; Plouin, PF; Relier, JP, 1988) |
| "Labetalol was compared with methyldopa in a randomised trial involving 176 pregnant women with mild to moderate hypertension." | 9.06 | [Maternal effects and perinatal safety of labetalol in the treatment of hypertension in pregnancy. Comparison with methyldopa in a randomized cooperative trial]. ( Bréart, G; Maillard, F; Papiernik, E; Plouin, PF; Relier, JP, 1987) |
| "The results of a prospective trial to evaluate the use of diazoxide and labetalol given intravenously in the management of severe hypertensive disease in pregnancy are presented." | 9.06 | Intravenous labetalol and intravenous diazoxide in severe hypertension complicating pregnancy. ( Michael, CA, 1986) |
| "Labetalol (Trandate; Allen & Hanburys), a combined alpha- and beta-adrenergic blocking agent, was compared with the more commonly used peripheral vasodilator, dihydrallazine (Nepresol; Ciba), each administered as an infusion, in the treatment of severe hypertension in 20 primigravidas at greater than or equal to 32 weeks' gestation." | 9.06 | Comparison of labetalol and dihydralazine in hypertensive emergencies of pregnancy. ( Ashe, RG; Moodley, J; Philpott, RH; Richards, AM, 1987) |
| "1 Labetalol is an effective agent in essential hypertension as documented in open studies and controlled studies in which its efficacy has been compared with both placebo and a variety of other anti-hypertensive drugs." | 9.05 | Labetalol in essential hypertension. ( Breckenridge, A; Maciver, M; Orme, M; Serlin, MJ, 1982) |
| "The antihypertensive effects of intravenous labetalol were evaluated in 59 patients with hypertensive crises or severe hypertension in need of rapid lowering of blood pressure in a multicenter study." | 9.05 | Intravenous labetalol in the treatment of severe hypertension and hypertensive emergencies. ( Flamenbaum, W; Freis, ED; Langford, HG; Michelson, EL; Poland, MP; Vidt, DG; Vlachakis, ND; Wallin, JD; Wilson, DJ, 1983) |
| "9 years) with mild to moderate essential hypertension a comparison between equipotent beta-blocking doses of propranolol, metoprolol and labetalol was carried out." | 9.05 | Propranolol vs metoprolol vs labetalol: a comparative study in essential hypertension. ( Coote, JH; Kubik, MM, 1984) |
| "The antihypertensive effects of oral labetalol, a new alpha- and beta-adrenergic blocking agent, and metoprolol, a relatively beta1 selective adrenergic blocker, were evaluated in 91 patients with mild to moderate hypertension (standing diastolic blood pressure of 90 to 115 mm Hg) in a double-blind parallel group multicenter clinical trial." | 9.05 | Multiclinic comparison of labetalol to metoprolol in treatment of mild to moderate systemic hypertension. ( Frishman, WH; Johnson, BF; Michelson, EL; Poland, MP, 1983) |
| "Labetalol, a new alpha- and beta-adrenergic blocking agent, was administered to 57 patients with essential hypertension whose standing diastolic blood pressure was 105 to 120 mm Hg after three and four weeks of placebo therapy and greater than 90 mm Hg after three to four weeks of therapy with hydrochlorothiazide, 25 mg twice a day." | 9.05 | Step II treatment with labetalol for essential hypertension. ( Bloomfield, SS; Gantt, CL; Lucas, CP; Medakovic, M; Poland, MP, 1983) |
| "Patients with acute pregnancy-related hypertension were randomized to treatment with 200 mg oral labetalol or 10 mg intramuscular hydralazine." | 9.05 | Treatment of acute pregnancy-related hypertension: labetalol and hydralazine compared. ( Calder, AA; Greer, I; Walker, JJ, 1983) |
| "Thirty-two patients with primary hypertension were studied in a double-blind cross-over comparison between the cardioselective beta 1-blocking agent atenolol and the combined alpha- and beta-blocking agent labetalol." | 9.05 | Antihypertensive and metabolic effects of increasing doses of atenolol and labetalol. A comparative study in primary hypertension. ( Henningsen, NC; Karlberg, BE; Nilsson, OR; Thulin, T, 1982) |
| "To evaluate the role of the vasoactive prostaglandins prostacyclin and thromboxane A2 in essential hypertension, the stable metabolites 6-keto-PGF1 alpha and thromboxane B2, respectively, were measured in plasma before and after therapy in 7 patients." | 9.05 | Increased plasma concentrations of prostacyclin metabolite 6-keto-PGF1 alpha in essential hypertension. Influence of therapy with labetalol. ( Mehta, J; Mehta, P; Roy, L, 1983) |
| "Labetalol (Trandate; Allen & Hanbury) was administered to 17 hypertensive patients with angina pectoris, which had persisted despite blood pressure control on treatment including beta-blocking agents." | 9.05 | Beneficial effect of labetalol in hypertensive patients with angina pectoris. ( Lubbe, WF; White, DA, 1983) |
| "1 The effects of atenolol (100 mg), a cardioselective beta-adrenoceptor blocking agent, and labetalol (300 mg), a combined alpha- and non-selective beta-adrenoceptor blocking agent given in single doses were examined in a double-blind placebo controlled study in 11 asthmatic patients with hypertension." | 9.05 | Comparison of the effects of single doses of atenolol and labetalol on airways obstruction in patients with hypertension and asthma. ( Beevers, DG; Jackson, SH, 1983) |
| " In a double-blind cross-over study the antihypertensive action and side-effects of labetalol and propranolol were compared in 18 previously untreated outpatients with hypertension, WHO stage I--III." | 9.05 | Labetalol in the treatment of hypertension in patients with normal and impaired renal function. ( Berg, KJ; Nilsen, OG; Walstad, RA; Wessel-Aas, T, 1982) |
| "1 Labetalol has been compared with propranolol in a double-blind, double-dummy study of 24 patients with mild or moderate essential hypertension." | 9.05 | Comparison of labetalol and propranolol in hypertension. ( Bulpitt, CJ; Butler, AG; Husaini, MH; Nicholls, DP; Stephens, MD, 1980) |
| "1 Labetalol, an alpha- and beta- adrenoceptor blocking drug, was compared with acebutolol, alone or associated with dihydralazine in forty patients with moderate essential hypertension." | 9.05 | Comparative trial of labetalol and acebutolol, alone or associated with dihydralazine, in treatment of essential hypertension. ( Corvol, P; Lardoux, MD; Thibonnier, M, 1980) |
| "The hemodynamic effects of intravenous labetalol (a combined alpha- and beta-blocking agent) were studied in 11 patients during early post-open heart surgery hypertension." | 9.05 | Combined alpha- and beta-blockade with labetalol in post-open heart surgery hypertension. Reversal of hemodynamic deterioration with glucagon. ( Allonen, H; Arola, M; Laaksonen, VO; Meretoja, OA, 1980) |
| "A new alpha- and beta-blocking agent, labetalol, was used to treat 50 hypertensive patients, 34 of them with refractory hypertension." | 9.05 | The treatment of hypertension by labetalol--a new alpha- and beta-adrenoreceptor blocking agent. ( Rosenthal, T; Stern, N; Teicher, A, 1982) |
| "The clinical effects, the exercise test answer, the left ventricular function by polygraphyc test after administration at middle term of Metoprolol and Labetalol have been evaluated in 20 patients with moderate and non complicated essential hypertension." | 9.05 | [Clinical, ergometric and polygraphic evaluation of the effects of metoprolol and labetalol administration in essential arterial hypertension. Comparative study]. ( Attisano, N; Grenci, G; Martelli, G; Sarica, G; Schirripa, V, 1982) |
| "Twentysix women with pregnancy-induced hypertension have been randomly treated with either labetalol or Aldomet." | 9.05 | Comparison of the alpha and beta blocking drug, labetalol, and methyl dopa in the treatment of moderate and severe pregnancy-induced hypertension. ( Broughton Pipkin, F; Lamming, GD; Symonds, EM, 1980) |
| "In 17 patients with essential hypertension administration of labetalol alone resulted in a significant reduction in supine systolic and diastolic blood pressure of 14% and 17%, respectively." | 9.05 | Blood pressure, plasma volume, extracellular volume and glomerular filtration rate during treatment with labetalol in essential hypertension. ( Nielsen, PE; Rasmussen, S, 1980) |
| " placebo added to hydrochlorothiazide (HCTZ) for the treatment of essential hypertension." | 9.05 | Labetalol and hydrochlorothiazide in hypertension. Labetalol/Hydrochlorothiazide Multicenter Study Group. ( , 1985) |
| "The efficacy and safety of labetalol was compared in a double-blind crossover design with propranolol in 27 patients suffering from essential hypertension with a supine diastolic blood pressure of more than 100 mm Hg." | 9.05 | A double-blind crossover clinical trial of labetalol and propranolol in patients of essential hypertension. ( Aslam, S; Pandhi, P; Sharma, BK; Sharma, PL; Wahi, PL, 1985) |
| "The antihypertensive effects of labetalol infusion (2 mg/min; maximal dose 150 mg) were evaluated in 22 subjects requiring rapid lowering of blood pressure because of severe hypertension, a hypertensive crisis after surgery, or before angiographic examination." | 9.05 | Labetalol infusion in hypertensive emergencies. ( Belleau, LJ; Grose, JH; Langlois, S; Lebel, M, 1985) |
| "After screening two local populations in the northern part of The Netherlands for hypertension, patients with a diastolic pressure (DP) between 95 and 120 mmHg were treated daily either with 50 mg hydrochlorothiazide or 100 mg atenolol." | 9.05 | A comparison of labetalol and prazosin combined with atenolol in non-responders to atenolol plus hydrochlorothiazide in uncomplicated hypertension. ( Donker, AJ; May, JF; Schuurman, FH; ten Berge, BS; van der Veur, E; Wesseling, H, 1985) |
| "Previous studies have shown that labetalol, a new alpha- and beta-adrenergic antagonist, is relatively safe for the treatment of hypertension in patients with chronic obstructive pulmonary disease (COPD)." | 9.05 | Comparison of the effects of labetalol and hydrochlorothiazide on the ventilatory function of hypertensive patients with asthma and propranolol sensitivity. ( Burford, JG; Chetty, K; Conrad, SA; George, RB; Hudson, LD; Light, RW; Manocha, K, 1985) |
| "In a randomised, double-blind, cross over trial, 25 patients with mild to moderate primary hypertension were given nifedipine 20-40 mg twice daily and labetalol 200-400 mg twice daily after a 4 week period on placebo, followed by the two drugs in combination." | 9.05 | Antihypertensive and metabolic effects of nifedipine and labetalol alone and in combination in primary hypertension. ( Karlberg, BE; Ohman, KP; von Schenck, H; Weiner, L, 1985) |
| "Labetalol is a unique alpha- and beta-adrenergic-receptor blocking agent that has recently been approved for the treatment of hypertensive emergencies and urgencies." | 9.05 | Intravenous labetalol in the emergency treatment of hypertension. ( Vidt, DG, 1985) |
| " Eight hypertensive patients with angina pectoris had placebo added to their existing medications for 8 weeks, then incremental doses of active labetalol with simultaneous stepwise reduction in other medicines until blood pressure was satisfactorily controlled; after that only labetalol and thiazide (8 weeks) and finally labetalol-placebo together with previous beta-adrenoreceptor antagonists and thiazide for 4 weeks were administered." | 9.04 | Labetalol in hypertensive patients with angina pectoris: beneficial effect of combined alpha- and beta-adrenoreceptor blockade. ( Lubbe, WF; White, DA, 1978) |
| " Labetalol, a new drug combining alpha-and beta-adrenoceptor blocking properties, has been compared with placebo in a double-blind crossover study of a group of patients with mild to moderate essential hypertension (blood pressure 150/100 to 189/114 mmHg)." | 9.04 | A controlled trial of labetalol (Trandate), propranolol and placebo in the management of mild to moderate hypertension. ( Armstrong, BK; Beilin, L; Nassim, M; Pugsley, DJ, 1979) |
| "1 Twenty patients with essential hypertension completed a double-blind, dose-tritrated, cross-over comparison of methyldopa and labetalol." | 9.04 | A comparative study of methyldopa and labetalol in the treatment of hypertension. ( Davies, DM; Gales, GM; Rao, JG; Rawlins, MD; Routledge, PA; Sanders, GL, 1979) |
| "1 The effects of labetalol, bethanidine and combined treatment with both drugs were compared in a within-patient randomized cross-over study in mild essential hypertension." | 9.04 | A comparison and an investigation of a potential synergistic effect of labetalol and bethanidine in patients with mild hypertension. ( Brown, JJ; Chalmers, AG; Hunter, J; Lees, CD; Millar, JA; Robertson, JI, 1979) |
| "1 Labetalol, a new hypotensive drug combining alpha- and beta-adrenoreceptor antagonist properties, has been compared with propranolol in the treatment of severe hypertension (blood pressure 190/115-249/139 mmHg) in a double-blind trial lasting 14 weeks." | 9.04 | Controlled comparison of labetalol and propranolol in the management of severe hypertension. ( Armstrong, BK; Beilin, LJ; Nassim, MA; Pugsley, DJ, 1976) |
| " Labetalol has been compared with propranolol and placebo for the treatment of mild to moderate hypertension (150/100 to 189/114 mmHg), in a double-blind cross-over trial with three 10 week treatment periods." | 9.04 | Combined alpha- and beta-adrenoreceptor blockade in hypertension: a controlled trial of labetalol (AH 5158) compared with propranolol and placebo. ( Armstrong, B; Beilin, LJ; Nassim, M; Pugsley, D, 1976) |
| " Therefore, we analyzed the potency and side effects of two treatment options (nicardipine compared to labetalol) in order to gain insight in improved treatment of severe hypertension during pregnancy and to evaluate the feasibility of a randomised controlled trial." | 8.90 | The optimal treatment of severe hypertension in pregnancy: update of the role of nicardipine. ( de Groot, CJ; Meuleman, T; Nooij, LS; Roelofs, R; Visser, S; Vos, P, 2014) |
| " Critical care nurses who appreciate the considerations for treatment of hypertension and who can correctly and efficiently administer intravenous labetalol may save precious time and enhance outcomes for patients with stroke who have hypertension." | 8.82 | Managing hypertension in patients with stroke. Are you prepared for labetalol infusion? ( Harrington, C, 2003) |
| "To compare the efficacy of intravenous Labetalol and intravenous Hydralazine in reduction of blood pressure in patients with severe pre-eclampsia." | 8.31 | Comparison of efficacy of intravenous labetalol and intravenous hydralazine for management of pre-eclampsia in pregnant women. ( Husain, S; Hussain, R; Kausar, M, 2023) |
| "To assess whether readmission for hypertension by 6 weeks postpartum differed between patients discharged on nifedipine or labetalol." | 8.12 | Postpartum Readmission for Hypertension After Discharge on Labetalol or Nifedipine. ( Do, SC; Druzin, ML; El-Sayed, YY; Girsen, AI; Herrero, T; Kan, P; Leonard, SA; Lyell, DJ; Panelli, DM, 2022) |
| "Although considering the pathophysiology of post-coarctectomy hypertension, β-blockers should be effective, experience with labetalol for treatment is limited in the literature." | 8.12 | Treatment of Post-Coarctectomy Hypertension With Labetalol-A 9-Year Single-Center Experience. ( Brouwer, CNM; Roeleveld, PP; Siersma, C; Sojak, V; Ten Harkel, ADJ, 2022) |
| "To assess the safety and efficacy of continuous infusion (CIV)-labetalol compared to -nicardipine in controlling blood pressure (BP) in the acute stroke setting." | 8.02 | Blood Pressure Control in Acute Stroke: Labetalol or Nicardipine? ( El-Ghoroury, H; Hecht, JP; Sudekum, DM, 2021) |
| "Labetalol inhibited activation of the renin-angiotensin system and helped control paradoxical hypertension after coarctation repair in children." | 7.96 | Labetalol Infusion Attenuates Paradoxical Hypertension and Decreases Plasma Renin Activity After Repair of Coarctation of the Aorta in Children. ( Charlton, GA; Friesen, RH; Friesen, RM; Ladd, DR, 2020) |
| " Nicardipine and labetalol are commonly administered for the treatment of acute hypertension following stroke." | 7.91 | Nicardipine Associated Risk of Short-Term Mortality in Critically Ill Patients with Ischemic Stroke. ( Desai, A; Hanni, C; Mohamed, W; Parker, D; Saber, H; Sadeghi, M; Singh, A, 2019) |
| "Labetalol and nicardipine are antihypertensives commonly used in the management of elevated blood pressure (BP) following an acute stroke, but there is limited evidence to suggest which agent as a continuous infusion should be used preferentially in this setting." | 7.88 | Continuous-Infusion Labetalol vs Nicardipine for Hypertension Management in Stroke Patients. ( Hecht, JP; Richards, PG, 2018) |
| "The aim of this study was to evaluate the use of as-needed (PRN) labetalol and hydralazine [intravenous (IV) or oral] in hospitalized medicine patients for the treatment of severe asymptomatic hypertension and to examine the potential negative outcomes associated with their use." | 7.88 | Retrospective review of the use of as-needed hydralazine and labetalol for the treatment of acute hypertension in hospitalized medicine patients. ( Gaynor, MF; Vondracek, S; Wright, GC, 2018) |
| "The study was performed to assess the response & side effects of injectable Labetalol in the treatment of pregnancy induced severe hypertension." | 7.85 | Response & Side Effects of Injectable Labetalol in Pregnancy Induced Severe Hypertension. ( Ahmed, MU; Akter, FA; Alom, M; Begum, F; Biswas, D; Ferdousi, RA; Hossain, MZ; Nahar, K; Rahman, MM; Razi, RZ, 2017) |
| "Topical cocaine is sometimes used for the treatment of epistaxis, as it has both potent anesthetic and vasoconstrictive properties." | 7.85 | Acute Toxicity from Topical Cocaine for Epistaxis: Treatment with Labetalol. ( Lange, RA; Laurin, EG; Richards, JR; Tabish, N, 2017) |
| " Persistent bradycardia and hypotension, unresponsive to epinephrine and norepinephrine, were suspected to have been exacerbated by chronic labetalol therapy for resistant arterial hypertension." | 7.81 | Use of enoximone in management of anaphylaxis complicated by labetalol use. ( Conway Morris, A; Hayhoe, S; Navapurkar, V, 2015) |
| "This study aimed to compare the effects of labetalol, nicardipine, or hydralazine on time to target blood pressure before alteplase administration in patients with acute ischemic stroke." | 7.81 | Time to Blood Pressure Control Before Thrombolytic Therapy in Patients With Acute Ischemic Stroke: Comparison of Labetalol, Nicardipine, and Hydralazine. ( Cortes, J; Hall, AB; McKay, C, 2015) |
| "The use of antihypertensive drugs in pregnancy is relatively common and is increasing, with the liberal use of methyldopa and (especially) labetalol contributing appreciably to this increase." | 7.79 | Trends in using beta-blockers and methyldopa for hypertensive disorders during pregnancy in a Canadian population. ( Guo, Y; Krewski, D; Mattison, D; Nerenberg, K; Walker, MC; Wen, SW; Xie, RH, 2013) |
| "Nicardipine and labetalol are two commonly used antihypertensives for treating elevated blood pressures in the setting of intracerebral hemorrhage (ICH) and subarachnoid hemorrhage (SAH)." | 7.79 | Effectiveness and safety of nicardipine and labetalol infusion for blood pressure management in patients with intracerebral and subarachnoid hemorrhage. ( Agarwal, S; Badjatia, N; Carpenter, AM; Claassen, J; Lantigua, H; Lee, K; Lesch, C; Li, M; Mayer, SA; Ortega-Gutierrez, S; Reccius, A; Schmidt, JM; Thomas, J, 2013) |
| "American Heart Association/American Stroke Association guidelines for management of aneurysmal subarachnoid hemorrhage (aSAH) recommend blood pressure (BP) control, utilizing labetalol or nicardipine, but do not differentiate efficacy between the two agents." | 7.78 | Retrospective evaluation of nicardipine versus labetalol for blood pressure control in aneurysmal subarachnoid hemorrhage. ( Barletta, JF; DeShane, RS; Figueroa, BE; McAllen, KJ; Woloszyn, AV, 2012) |
| "We investigated the effects of labetalol and pindolol on uterine, placental, and fetal hemodynamics following norepinephrine-induced maternal hypertension in a sheep model of increased placental vascular resistance." | 7.75 | Placental and fetal hemodynamics after labetalol or pindolol in a sheep model of increased placental vascular resistance and maternal hypertension. ( Acharya, G; Alahuhta, S; Erkinaro, T; Haapsamo, M; Kavasmaa, T; Mäkikallio, K; Ohtonen, P; Räsänen, J; Ylikauma, L, 2009) |
| "Evaluate the ease of use and tolerability of labetalol (L) and nicardipine (N) for hypertension management in patients with acute stroke." | 7.74 | A comparison of nicardipine and labetalol for acute hypertension management following stroke. ( Coplin, WM; Janisse, J; Liu-Deryke, X; Norris, G; Parker, D; Rhoney, DH, 2008) |
| "This case highlights the possibility of a more rapid perioperative control of pheochromocytoma using high doses of labetolol and a magnesium sulfate infusion to achieve stable intraoperative hemodynamics during laparoscopic resection of pheochromocytoma." | 7.71 | Rapid preparation of a patient with pheochromocytoma with labetolol and magnesium sulfate. ( Chin, EY; Poopalalingam, R, 2001) |
| "Our report describes the outcome of a twin pregnancy in a woman who was maintained on tacrolimus after a living related renal transplant." | 7.70 | Outcome of twin pregnancy in a renal transplant recipient treated with tacrolimus. ( Anderson, V; Baqi, N; Hidalgo, G; Kumar, A; Markell, MS; Piecuch, S; Singh, A; Vyas, S, 1999) |
| "The aim of the study was to investigate cord blood leptin concentrations and their relationship to birth weight and gender in term pregnancies complicated by pre-eclampsia." | 7.70 | Serum leptin concentration in cord blood: relationship to birth weight and gender in pregnancies complicated by pre-eclampsia. ( Hartmann, BW; Laml, T; Preyer, O; Ruecklinger, E; Soeregi, G; Wagenbichler, P, 2000) |
| "The hypotensive effect, kinetics, and concentration-response relationship of labetalol, alpha beta- and alpha 1-adrenoceptor blocking drug, were studied in seven women with a moderate-to-severe hypertension (averaged diastolic blood pressure [DBP] of 100 to 120 mm Hg measured during a 1- to 2-day hospitalization period) during the third trimester of pregnancy who received the oral twice-daily doses of 150 to 450 mg." | 7.68 | Labetalol in hypertension during the third trimester of pregnancy: its antihypertensive effect and pharmacokinetic-dynamic analysis. ( Echizen, H; Ishizaki, T; Minoura, S; Saotome, T; Sato, T; Terashi, K, 1993) |
| "Although labetalol (LAB), the combination of an alpha- and beta-adrenergic blocking agent, is thought to be effective and safe for the control of postoperative hypertension, no study has focused on changes in left ventricular (LV) function when this drug was used to control postoperative hypertension." | 7.68 | Transesophageal echocardiographic assessment of left ventricular function in response to labetalol for control of postoperative hypertension. ( Baron, JF; Coriat, P; Gosgnach, M; Le Bret, F; Reiz, S; Viars, P, 1992) |
| "7 years, mean +/- SD) received intravenous doses of labetalol, an alpha 1- and beta-adrenergic blocker, on 15 separate occasions for treatment of hypertension." | 7.68 | Intravenously administered labetalol for treatment of hypertension in children. ( Bunchman, TE; Lynch, RE; Wood, EG, 1992) |
| "8 mg/kg of an intravenous bolus of labetalol on maternal and fetal hemodynamics was investigated in ten women with pregnancy-induced hypertension." | 7.68 | Single dose of labetalol in hypertensive pregnancy: effects on maternal hemodynamics and uterine and fetal flow velocity waveforms. ( Ekblad, UU; Erkkola, RU; Mäkinen, JI; Pirhonen, JP, 1991) |
| " This patient with Marfan syndrome whose case is reported herein presented with chest pain, hypertensive crisis, and aortic insufficiency; labetalol was used successfully to treat the acute hypertensive crisis and magnetic resonance imaging (MRI) was used to differentiate between aortic dissection and an expanding aortic aneurysm." | 7.68 | Labetalol and MRI as initial medical and diagnostic modalities in a marfanoid patient with expanding ascending aortic aneurysm. ( Baciewicz, FA; Grubb, B; Laden, N, 1990) |
| "Pharmacokinetic parameters of oral labetalol were studied in eight women with pregnancy-induced hypertension in the third trimester of pregnancy." | 7.68 | Labetalol pharmacokinetics in pregnancy-induced hypertension. ( Rogers, RC; Sibai, BM; Whybrew, WD, 1990) |
| "Three renal transplant recipients developed potentially life-threatening hyperkalemia after receiving intravenous labetalol for postoperative hypertension." | 7.68 | Hyperkalemia associated with intravenous labetalol therapy for acute hypertension in renal transplant recipients. ( Arthur, S; Greenberg, A, 1990) |
| "Forty-one patients (21 males and 20 females) suffering from arterial hypertension associated with peripheral and cerebral vascular distress were treated for a period of 60 days with an extempore combination of labetalol (an antihypertensive drug with an alpha- and beta-blocking action) and flunarizine (a calcium-antagonist)." | 7.67 | Combined labetalol plus flunarizine treatment for arterial hypertension. ( Bonavita, E, 1984) |
| "We determined echocardiographic (M-mode) indices of left ventricular mass and function serially at 1-month intervals in 10 patients with uncomplicated mild or moderate essential hypertension, before and after adequate control of blood pressure with labetalol, a combined alpha- and beta-receptor blocking agent." | 7.67 | Effects of labetalol on left ventricular mass and function in hypertension--an assessment by serial echocardiography. ( Bhatia, ML; Kaul, U; Mohan, JC, 1984) |
| "The intravenous administration of labetalol, a combined alpha- and beta-adrenergic receptor blocking agent, reduced diastolic blood pressure by 30 mm Hg or more in 15 of 17 patients with severe hypertension (supine diastolic blood pressure greater than or equal to 125 mm Hg)." | 7.67 | Intravenous labetalol in the management of severe hypertension and hypertensive emergencies. ( Cressman, MD; Gifford, RW; Moore, WS; Vidt, DG; Wilson, DJ, 1984) |
| "To investigate the safety of labetalol in the treatment of hypertension in patients with heart failure, sixteen hypertensive patients with a history of congestive heart failure and an ejection fraction at rest less than 45%, had measurements of ejection fraction and cardiac output by first pass radionuclide angiography at baseline, at the end of 2 weeks maintenance with labetalol (titrated to the effective antihypertensive dose of 200-1600 mg daily), and in the post-treatment placebo period." | 7.67 | Hemodynamic effects of labetalol in patients with combined hypertension and left ventricular failure. ( Berger, H; Cubbon, J; Escala, E; Johnson, LL; Jones, RH; Ramanathan, KB; Sciacca, R, 1988) |
| "Intravenous labetalol is commonly used in the management of hypertensive emergencies or urgencies as well as postoperative hypertension." | 7.67 | The safety of cumulative doses of labetalol in perioperative hypertension. ( Cosentino, F; Little, JR; Orlowski, JP; Shiesley, D; Vidt, DG, 1989) |
| "The efficacy and safety of labetalol therapy were evaluated in 20 patients 60 years and older with isolated systolic or diastolic hypertension and 19 patients aged younger than 60 years with diastolic hypertension." | 7.67 | Labetalol in the treatment of hypertension in elderly and younger patients. ( Abernethy, DR; Bartos, P; Plachetka, JR, 1987) |
| "Dilevalol hydrochloride, the R-R optical isomer of labetalol hydrochloride, was administered intravenously to subjects with severe hypertension." | 7.67 | Intravenous dilevalol. Effects of the R-R optical isomer of labetalol in patients with severe hypertension. ( Blasucci, DJ; Clifton, GG; Cook, ME; Poland, M; Wallin, JD, 1988) |
| "22 patients with untreated, essential hypertension (diastolic blood-pressure greater than or equal to 140 mmHg) and in most cases also showing neurological symptoms were given a single oral dose of 400 mg labetalol." | 7.67 | Treatment of severe hypertension with peroral labetalol. ( Frithz, G, 1987) |
| "This study documents our experience with labetalol administered by continuous intravenous infusion for severe hypertension." | 7.67 | Labetalol by continuous intravenous infusion in severe hypertension. ( Goodman, RP; Minisi, AJ; Wilson, DJ; Wright, JT, 1986) |
| "The effects of labetalol on serum lipoproteins, the intravenous fat tolerance test (IVFTT) and lipoprotein lipase (LPL) and hepatic lipase (HL) activities were studied in 16 patients with mild hypertension before and after 6 months of therapy." | 7.67 | Effects of long-term therapy with labetalol on lipoprotein metabolism in patients with mild hypertension. ( Eliasson, K; Hylander, B; Nilsson-Ehle, P; Rössner, S, 1985) |
| "In 14 patients with essential hypertension, the influence of the alpha- and beta-adrenoceptor blocking drug labetalol on blood pressure, heart rate, plasma renin, plasma noradrenaline and pressor effect of exogenous noradrenaline was investigated during long-term treatment." | 7.66 | Sympathetic nervous activity and the pressor effect of noradrenaline under chronic alpha-beta-adrenoceptor blockade with labetalol in hypertension. ( Distler, A; Lüth, JB; Neurohr, W; Philipp, T; Zschiedrich, H, 1983) |
| "This study reports the results that were obtained in 56 cases of arterial hypertension in pregnancy solely by beta-blocking with Atenolol or Labetalol." | 7.66 | [Effect of 2 beta-blockers on arterial hypertension during pregnancy. Results of a prospective study on 56 pregnant hypertensive women treated with atenolol and labetalol]. ( Beauséjour, B; Blazquez, G; Faurie, C; Flouvat, B; Gérard, J; Lardoux, H; Rousset, D, 1983) |
| "Labetalol, an alpha and beta adrenergic blocking drug, was used during anesthesia for removal of a very large pheochromocytoma which was predominantly epinephrine secreting." | 7.66 | Use of labetalol during anesthesia for pheochromocytoma removal. ( de Rood, M; Lambilliotte, JP; Levarlet, M; Lignian, H; Van Stratum, M, 1983) |
| "Labetalol was used to treat systemic hypertension (systolic blood pressure above 150 mmHg) in 11 patients with acute myocardial infarction; its haemodynamic effects and tolerance were studied." | 7.66 | Treatment of hypertension in acute stage of myocardial infarction. Haemodynamic effects of labetalol. ( Bernard, R; Jacobs, P; Renard, M; Rivière, A, 1983) |
| "1 Labetalol pharmacokinetics and concentration-effect relationships following intravenous administration have been studied in 10 women during the last trimester of pregnancies complicated by hypertension, in seven of these women postpartum (when normotensive) and in 10 normotensive female volunteers." | 7.66 | Labetalol disposition and concentration-effect relationships during pregnancy. ( Butters, L; Fitzsimons, C; Kelman, AW; Reid, JL; Rubin, PC, 1983) |
| "In 12 patients with resistant hypertension labetalol was added to existing therapy." | 7.66 | Labetalol in resistant hypertension. ( Hedstrand, H, 1982) |
| "Labetalol was given to women with hypertension of pregnancy in their last trimester to study its acute effect on circulation and metabolism." | 7.66 | Labetalol, a combined alpha- and beta-blocker, in hypertension of pregnancy. ( Fredholm, B; Hjemdahl, P; Lewander, R; Lunell, NO; Nisell, H; Nylund, L; Persson, B; Sarby, B; Wager, J, 1982) |
| "The effects of labetalol, an alpha- and beta-adrenoceptor blocking drug, on blood pressure, heart rate, plasma renin activity (PRA) and plasma aldosterone were studied in 17 adult patients with essential hypertension." | 7.66 | [Essential arterial hypertension. Effects of labetalol on blood pressure and renin-angiotensin system (author's transl)]. ( Corvol, P; Lardoux, H; Martinand, A; Milliez, P, 1980) |
| "Arterial blood pressure and plasma catecholamines, renin activity and aldosterone concentration in 12 patients with severe essential hypertension were studied before and after combined alpha- and beta- adrenoceptor blockade induced by oral labetalol treatment for 2 months." | 7.66 | Plasma catecholamines, renin and aldosterone during combined alpha- and beta- adrenoceptor blockade in patients with severe arterial hypertension. ( Christensen, NJ; Kornerup, HJ; Pedersen, A; Pedersen, EB; Pedersen, G, 1980) |
| "2-Hydroxy-(1-hydroxy-[(1-methyl-3-phenylpropyl)amino]-2-ethyl)-5-benzamide (labetalol), a new alpha- and beta-adrenergic blocking agent, was employed in 21 patients with severe hypertension by slow (6 patients) and rapid (15 patients) i." | 7.66 | Intravenous labetalol in severe hypertension. Effects on blood pressure, plasma renin activity and catecholamines. ( Cesura, AM; Covi, G; Danti, G; Lechi, A; Mattioli, M; Pedrolli, E; Picotti, GB; Pomari, S, 1981) |
| "The effect of labetalol on blood pressure, heart rate and the renin-angiotensin system was evaluated in 12 patients with severe essential hypertension (diastolic blood pressure greater than or equal to 120 mmHg, WHO: Phase I and II) who had been resistant to other therapeutic regimens." | 7.66 | Treatment of severe essential hypertension with labetalol: effect on active and inactive renin. ( Hauger-Klevene, JH, 1981) |
| "1 Eighty-five women with severe hypertension complicating pregnancy were treated with oral labetalol (Trandate)." | 7.66 | The evaluation of labetalol in the treatment of hypertension complicating pregnancy. ( Michael, CA, 1982) |
| "1 Labetalol was administered by intravenous infusion or by the combination of intravenous bolus injection plus infusion to 15 patients with severe essential hypertension and to one with phaeochromocytoma." | 7.66 | Intravenous labetalol in severe hypertension. ( Dal Palu, C; Hlede, M; Morandin, F; Palatini, P; Pessina, AC; Rossi, GP; Semplicini, A; Sperti, G, 1982) |
| "1 We have compared, in patients with severe hypertension, the administration of intravenous labetalol by single rapid injection, by repeated bolus injections, and by incremental infusion." | 7.66 | Intravenous labetalol in the treatment of severe hypertension. ( Brown, JJ; Cumming, AM; Lever, AF; Robertson, JI, 1982) |
| "The effectiveness of repeated intravenous injections of labetalol in reducing blood pressure (BP) was evaluated in patients with severe hypertension." | 7.66 | Treatment of severe hypertension with intravenous labetalol. ( Freis, ED; Khatri, IM; Notargiacomo, AV; Papademetriou, V, 1982) |
| " doses of labetalol were evaluated in 10 normovolaemic sedated patients presenting with hypertension and tachycardia in the early period after myocardial revascularization." | 7.66 | I.v. labetalol in the treatment of hypertension following coronary-artery surgery. ( Forster, A; Morel, DR; Suter, PM, 1982) |
| "Intracranial pressure measurements and ventricular volume pressure response curves were made during induced hypotension with labetalol, a combined alpha- and beta-adrenoceptor antagonist, in dogs without (group I) and with (group II) intracranial hypertension." | 7.66 | Effect of labetalol on intracranial pressure in dogs with and without intracranial hypertension. ( Heinecke, A; Puchstein, C; Schweppe, ML; Van Aken, H, 1982) |
| "Eleven patients suffering from WHO stage II essential arterial hypertension were treated with the combination of labetalol plus chlorthalidone in the reciprocal ratio of 10:1 in the form of once-a-day administration in the morning." | 7.66 | Use of the the combination labetalol plus chlorthalidone in essential arterial hypertension therapy. ( Rossi, AG, 1981) |
| "1 Seven women with hypertension of pregnancy were given the combined alpha- and beta-adrenoceptor blocking drug labetalol (50 mg i." | 7.66 | Circulatory and metabolic effects of a combined alpha- and beta-adrenoceptor blocker (labetalol) in hypertension of pregnancy. ( Fredholm, BB; Hjemdahl, P; Lunell, NO; Nisell, H; Persson, B; Wager, J, 1981) |
| "1 In a single blind study seventeen patients with mild or moderate essential hypertension and normal renal function were treated with labetalol alone in increasing doses from 300 via 600 to 1200 mg daily." | 7.66 | Blood pressure, body fluid volumes and glomerular filtration rate during treatment with labetalol in essential hypertension. ( Nielsen, PE; Rasmussen, S, 1981) |
| "A study was carried out in 73 patients with mild or moderate hypertension to assess the effectiveness of treatment with labetalol." | 7.66 | Experience with labetalol in essential hypertension. ( Elo, J; Nissinen, A; Tuomilehto, J, 1980) |
| "Plasma catecholamines and renal function were evaluated in 18 patients with essential hypertension treated with the alpha and beta adrenoceptor blocking agent, labetalol." | 7.66 | Effects of chronic alpha and beta adrenoceptor blockade with labetalol on plasma catecholamines and renal function in hypertension. ( de Châtel, R; Keusch, G; Reubi, FC; Weidmann, P; Ziegler, WH, 1980) |
| "An open study was undertaken in 31 patients with moderate to severe hypertension to compare labetalol (a competitive antagonist of both alpha-adrenoreceptors and beta-adrenoreceptors) alone and in combination with a thiazide diuretic, with a combination of thiazide, beta-adrenergic blocking agent and the alpha-adrenoreceptor blocker prazosin." | 7.66 | Use of labetalol in moderate to severe hypertension. ( Hua, AS; Kincaid-Smith, P; Macdonald, I; Thomas, GW; Whitworth, JA; Woo, KT, 1980) |
| "The haemodynamic effects of labetalol were studied in patients with essential hypertension after acute and long-term administration." | 7.66 | Sequential haemodynamic effects of labetalol at rest and during exercise in essential hypertension. ( Hartling, OJ; Nielsen, PE; Rasmussen, S; Svendsen, TL; Trap-Jensen, J, 1980) |
| "Arterial blood pressure and plasma catecholamines, renin activity and aldosterone concentration in 12 patients with severe essential hypertension were studied before and after combined alpha- and beta-adrenergic receptor blockage induced by oral labetalol treatment for 2 months." | 7.66 | Effect of oral labetalol on plasma catecholamines, renin and aldosterone in patients with severe arterial hypertension. ( Christensen, NJ; Kornerup, HJ; Pedersen, A; Pedersen, EB; Pedersen, G, 1979) |
| "Diazoxide, clonidine and labetalol, administered intravenously in fixed doses, were used to treat 30 episodes of severe hypertension in 27 patients." | 7.66 | Comparison of labetalol, clonidine and diazoxide intravenously administered in severe hypertension. ( Kincaid-Smith, P; Thomas, GW; Whitworth, JA; Yeung, CK, 1979) |
| "1 The efficacy of labetalol in the treatment of severe hypertension (diastolic greater than or equal to 115 mm Hg) was studied retrospectively." | 7.66 | Labetalol in severe and resistant hypertension. ( Murphy, MJ; Parsons, V; Williams, LC, 1979) |
| "1 Six previously untreated emergency admissions to hospital with severe hypertension were given oral treatment with labetalol." | 7.66 | Acute management of severe hypertension with oral labetalol. ( Ghose, RR, 1979) |
| "1 Labetalol, a hypotensive agent combining alpha- and beta-adrenoceptor antagonist properties, was used to treat severe hypertensive disease complicating pregnancy." | 7.66 | Use of labetalol in the treatment of severe hypertension during pregnancy. ( Michael, CA, 1979) |
| "1 In nine hypertensive subjects with angina pectoris, labetalol diminished the incidence of chest pain occurring spontaneously or induced by exercise." | 7.66 | Open evaluation of labetalol in the treatment of angina pectoris occurring in hypertensive patients. ( Besterman, EM; Spencer, M, 1979) |
| "1 Fifteen patients with suspected acute myocardial infarction and systemic BP of greater than 160/110 mmHg were treated with an incremental infusion of labetalol." | 7.66 | Labetalol infusion in acute myocardial infarction with systemic hypertension. ( Marx, PG; Reid, DS, 1979) |
| "The effects of intravenously administered labetalol on blood pressure and pulse rate were examined in 17 patients with severe hypertension." | 7.66 | Emergency treatment of severe hypertension with intravenous labetalol. ( Johnston, CI; Matthews, PG; Maydom, BW; McGrath, BP; Walter, NM, 1978) |
| "1 Labetalol, a beta- and alpha-adrenoreceptor-blocking drug, has been used in the treatment of hypertension in a total of 32 patients for over 4." | 7.65 | Labetalol in long-term treatment of hypertension. ( Boakes, AJ; Prichard, BN, 1976) |
| "Labetalol, a new antihypertensive drug which combines alpha- and beta-blocking properties, was used in an open clinical trial in a mixed group of 47 adult patients with mainly essential hypertension, many of whom had been poorly controlled on other drugs." | 7.65 | Treatment of hypertension with labetalol. ( Bolli, P; Seeman, HM; Simpson, FO; Waal-Manning, HJ, 1977) |
| "1 The efficacy of labetalol in lowering blood pressure has been assessed in a group of 16 patients with severe hypertension whose blood pressure was inadequately controlled (supine diastolic blood pressure greater than 110 mmHg on two consecutive occasions) on existing therapy or in whom severe side-effects necessitated a change in therapy." | 7.65 | Labetalol in resistant hypertension. ( Daniel, J; Dargie, HJ; Dollery, CT, 1976) |
| "Labetalol is a good alternative drug to control hypertensive response during emergence from anesthesia for post-craniotomy." | 6.80 | An Equivalence Trial Comparing Labetalol and Diltiazem in Controlling Emergence Hypertension after Supratentorial Tumor Surgery. ( Punkla, W; Raksamani, K; Rushatamukayanunt, P; Sakaew, A; Sirivanasandha, B; Sutthivaiyakit, K; Waitayawinyu, P, 2015) |
| " Full-text, English-language articles describing IV labetalol and/or hydralazine use for non-emergent HTN in an inpatient setting that focused on clinical outcomes (ie vitals, adverse effects, healthcare utilisation) were included." | 6.72 | Safety and efficacy of intravenous hydralazine and labetalol for the treatment of asymptomatic hypertension in hospitalised patients: A systematic review. ( Cawoski, JR; Covvey, JR; DeBiasio, KA; Donnachie, SW; Guarascio, AJ; Montepara, CA; Nemecek, BD; Timanus, EA; Zimmerman, DE, 2021) |
| "Labetalol was started at 50 mg bid and as necessary increased by 50 mg bid every 2 weeks." | 6.68 | A dose-ranging study of labetalol in moderate to moderately severe hypertension. ( Anggraeni, E; Bahry, B; Darmansjah, I; Jusman, J; Parsoedi, I; Prabowo, P; Setiawati, A; Sukandar, E, 1995) |
| "Labetalol was well tolerated and no significant maternal toxicity was noted." | 6.67 | Does labetalol influence the development of proteinuria in pregnancy hypertension? A randomised controlled study. ( Campbell, DM; Cruickshank, DJ; MacGillivray, I; Robertson, AA, 1992) |
| "The labetalol-treated patients were significantly less often above their diastolic BP goal throughout the 24-hour ABPM period (p less than 0." | 6.67 | Comparison of labetalol versus enalapril as monotherapy in elderly patients with hypertension: results of 24-hour ambulatory blood pressure monitoring. ( Applegate, WB; Borhani, N; DeQuattro, V; Due, DL; Kaihlanen, PM; Oishi, S; Sirgo, MA, 1991) |
| "This randomized multicentre study in elderly hypertensives with two unbalanced groups (2 patients under labetalol for 1 patient under nifedipine) compared the efficacy and safety of labetalol, whose dosage could be adjusted (1, 2, then 3 tablets/day) according to blood pressure level (BP greater than or equal to 160/95 mmHg), to that of nifedipine given at its recommended dosage (2 tablets/day)." | 6.67 | [Hypertension in the elderly. Comparison of the efficacy and tolerability of labetalol and nifedipine. A multicenter, randomized, single-blind study]. ( d'Allens, H; Decoulx, M; Godon, P; Pappo, M, 1990) |
| "Hypertension is common following coronary artery bypass surgery." | 6.66 | Intravenous labetalol versus sodium nitroprusside for treatment of hypertension postcoronary bypass surgery. ( Cruise, CJ; David, TE; Marquez-Julio, A; Skrobik, Y; Webster, RE, 1989) |
| "02; 2--A more frequent adjustment of daily dosage with MD (n = 15) than with ACE (n = 10) or LAB (n = 7); 3--The absence of any significant difference for uricemia level, platelet counts, foetal cardiac rythm, and occurrence of pre-eclampsia (MD = 4; ACE = 3; LAB = 4; 4--An equivalent birth-weight (MD = 3110 +/- 628 g; ACE = 3115 +/- 645." | 6.66 | [Randomized, comparative study on the treatment of moderate arterial hypertension during pregnancy: methyldopa, acebutolol, labetalol]. ( Blazquez, G; Gérard, J; Lardoux, H; Leperlier, E, 1988) |
| "Labetalol therapy was then initiated at 100 mg twice a day in a single-blind manner and increased weekly by 100 mg twice a day until blood pressure control was obtained or a maximum dosage of 400 mg twice a day was reached." | 6.66 | Labetalol blunts morning pressor surge in systolic hypertension. ( Allen, J; DeQuattro, V; Lee, DD; Plachetka, J; Sirgo, M, 1988) |
| " The duration of action also varied in the labetalol group, with the shortest duration occurring in those patients who required the highest dosage for BP control." | 6.66 | A comparative trial of labetalol and hydralazine in the acute management of severe hypertension complicating pregnancy. ( Amon, E; Gonzalez, AR; Mabie, WC; Sibai, BM, 1987) |
| "Twenty-five women with preeclampsia who were scheduled to undergo cesarean section under general anesthesia were randomly assigned to either a labetalol pretreatment group (n = 15) or a control group (n = 10) who did not receive any antihypertensive therapy before the induction of anesthesia." | 6.66 | The use of labetalol for attenuation of the hypertensive response to endotracheal intubation in preeclampsia. ( Chauhan, D; Mabie, WC; Ramanathan, J; Ruiz, AG; Sibai, BM, 1988) |
| "Verapamil was devoid of any such effect." | 6.66 | Evaluation of verapamil in the treatment of hypertension. ( Anavekar, SN; Doyle, AE, 1986) |
| ", following the initial dose of active treatment) and on each visit when the dosage was increased." | 6.66 | The effects of treatments with labetalol and hydrochlorothiazide on ventilatory function of asthmatic hypertensive patients with demonstrated bronchosensitivity to propranolol. ( Blasucci, DJ; Falliers, CJ; Maloy, JW; Medakovic, M; Vrchota, J, 1985) |
| "Labetalol is a competitive, nonselective antagonist of both beta 1 and beta 2 adrenoceptors." | 6.66 | Concomitant therapy with labetalol and hydrochlorothiazide in moderate to moderately severe essential hypertension. ( Kalbfleisch, JH; Kochar, MS; Tyson, J, 1985) |
| "Labetalol and atenolol were equivalent in control of blood pressure at rest, exercise tolerance and use of nitroglycerin; however, heart rates at rest and during exercise were higher with labetalol (p less than 0." | 6.66 | Double-blind trial comparing labetalol with atenolol in the treatment of systemic hypertension with angina pectoris. ( Jee, LD; Opie, LH, 1985) |
| "Labetalol is a safe and effective treatment for patients with mild hypertension." | 6.65 | Monotherapy with labetalol in the treatment of mild hypertension: a double-blind study. ( Davidov, ME; Maloy, J; Medakovic, M; Moir, GD; Poland, MP, 1983) |
| "Treatment with labetalol alone or in combination with furosemide, as well as methyldopa plus furosemide, was associated with significant reductions in supine and standing blood pressure levels." | 6.65 | Treatment of severe hypertension with labetalol compared with methyldopa and furosemide. Results of a long-term, double-blind, multicenter trial. ( Langford, H; Maloy, J; Maronde, RF; Michelson, EL; Poland, M; Wallin, JD; Wilson, D; Winer, N, 1983) |
| "Diazoxide did not increase the heart rate as much as expected (P greater than 0." | 6.65 | Diazoxide vs labetalol: a cross-over comparison of short-term effects in hypertension. ( Bagatin, J; Rumboldt, Z; Vidovic, A, 1983) |
| " The dosage was first titrated out and assessed in a double-blind cross-over trial." | 6.65 | Treatment of hypertension in the elderly with labetalol. ( Eisalo, A; Virta, P, 1982) |
| "Labetalol was used in a multicentre open clinical trial in 128 patients in 10 centres." | 6.65 | A multicentre study of labetalol in hypertension. New Zealand Hypertension Study Group. ( , 1981) |
| "Labetalol is a useful hypotensive drug with effect similar to that of a combination of a beta-adrenoceptor blocking drug and a vasodilator." | 6.64 | Labetalol compared with prindolol plus hydraliazine in the treatment of hypertension: a double-blind cross-over study. ( Barnett, AJ; Guest, C; Kalowski, S, 1978) |
| "Labetalol was more effective in lowering blood pressure but less effective in reducing pulse rate of plasma angiotensin II concentration." | 6.64 | Effect of blood pressure angiotensin II and aldosterone concentrations during treatment of severe hypertension with intravenous labetalol: comparison with propranolol. ( Brown, JJ; Fraser, R; Lever, AF; Morton, JJ; Robertson, JI; Rosei, EA; Trust, PM, 1976) |
| "Labetalol is an adrenoceptor blocking drug with combined alpha- and beta-blocking properties." | 6.38 | Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease. ( Benfield, P; Goa, KL; Sorkin, EM, 1989) |
| "In the elderly, hypertension is generally characterized by elevated peripheral vascular resistance and decreased cardiac output." | 6.38 | Treatment of hypertension in the elderly with labetalol. ( Applegate, WB; Boyd, BK; Sirgo, MA, 1989) |
| "Labetalol is an orally active adrenoceptor blocking drug which is a competitive antagonist at both alpha- and beta-adrenoceptor sites." | 6.36 | Labetalol: a review of its pharmacology and therapeutic use in hypertension. ( Avery, GS; Brogden, RN; Heel, RC; Speight, TM, 1978) |
| "The efficacy and the clinical and biological safety of labetalol were assessed, in primary care, in an ambulatory hypertensive elderly population, with systolo-diastolic hypertension (mean 175 +/- 14/100 +/- 7 mmHg) monitored during a 6 month period by general practitioners." | 6.16 | [Evaluation of labetalol in general medicine in aged patients with hypertension. Compliance, efficacy and safety in long-term treatment]. ( Herrero, G; Hugonot, L; Hugonot, R, 1990) |
| "The present review shows that labetalol has many advantageous properties in the treatment of patients suffering from angina pectoris with or without hypertension." | 6.16 | Labetalol in the treatment of angina pectoris. ( Kanto, JH, 1987) |
| "The cost effectiveness of labetalol and propranolol in the treatment of black adults with mild to moderate hypertension was assessed using published reports from US clinical trials of these agents among such patients." | 6.16 | Cost effectiveness of labetalol and propranolol in the treatment of hypertension among blacks. ( Colditz, GA; Delea, TE; Huse, DM; Oster, G; Savage, DD, 1987) |
| " Therapy success: systolic blood pressure ~140 mm Hg and diastolic blood pressure ~90 mm Hg, therapy failure: persistent systolic blood pressure ≥ 160 or diastolic blood pressure ≥ 110 mm Hg after maximum dosage of therapy (EL)." | 5.91 | Comparison of outcomes following intravenous magnesium compared with intravenous labetalol and oral nifedipine in 355 pregnant Han Chinese women with preeclampsia. ( Dong, W; Peng, Z; Xiao, Y; Zhang, J, 2023) |
| "The Giant PANDA study is a pragmatic, open-label, multicentre, randomised controlled trial of a treatment initiation strategy with nifedipine (calcium channel blocker), versus labetalol (mixed alpha/beta blocker) in 2300 women with pregnancy hypertension." | 5.69 | A treatment strategy with nifedipine versus labetalol for women with pregnancy hypertension: study protocol for a randomised controlled trial (Giant PANDA). ( Ashworth, D; Battersby, C; Bick, D; Chappell, LC; Green, M; Hardy, P; Leighton, L; Magee, LA; Maher, A; McManus, RJ; Moakes, C; Morris, RK; Myers, J; Nelson-Piercy, C; Rivero-Arias, O; Sparkes, J; Webb, A; Wilson, H, 2023) |
| "Magnesium sulfate was promptly administered on admission to every woman to prevent seizure." | 5.56 | Clinical Experiences of Intravenous Hydralazine and Labetalol for Acute Treatment of Severe Hypertension in Pregnant Thai Women. ( Chera-Aree, P; Leetheeragul, J; Sampaojarean, U; Surasereewong, S; Tengtrakulcharoen, P; Wataganara, T, 2020) |
| "The objectives were to compare the efficacy and safety of intravenous hydralazine and labetalol for acutely lowering severe hypertension in pregnancy." | 5.51 | Comparison of intravenous labetalol and hydralazine for severe hypertension in pregnancy in Northeastern Nigeria: A randomized controlled trial. ( Bako, B; Dawha, YM; Muhammad, S; Usman, H; Yahya, A; Yekeen, A, 2022) |
| "The purpose is to investigate the influence of nifedipine, labetalol, and magnesium sulfate on blood pressure control, blood coagulation, and maternal and infant outcome in those suffering from pregnancy-induced hypertension (PIH)." | 5.51 | Effects of Nifedipine and Labetalol Combined with Magnesium Sulfate on Blood Pressure Control, Blood Coagulation Function, and Maternal and Infant Outcome in Patients with Pregnancy-Induced Hypertension. ( Gu, S; Shao, Y; Zhang, X, 2022) |
| "Recent studies have shown a benefit to more aggressive treatment of mild chronic hypertension to a blood pressure goal of <140/90 with oral labetalol and nifedipine remaining first-line agents." | 5.41 | Cardiac medications in obstetric patients. ( Albert-Stone, E; Davis, MB; Spehar, SM, 2023) |
| "Pheochromocytoma is a catecholamine-producing tumor but rarely delayingly diagnosed until during pregnancy." | 5.37 | Cardiovascular collapse after labetalol for hypertensive crisis in an undiagnosed pheochromocytoma during cesarean section. ( Huang, CS; Ko, YP; Kuok, CH; Tsai, PS; Yen, CR, 2011) |
| "to assess the maternal and fetal outcome in women with mild to moderate chronic hypertension on antihypertensive drug (methyldopa or labetalol) therapy compared to no medication." | 5.34 | Methyldopa versus labetalol or no medication for treatment of mild and moderate chronic hypertension during pregnancy: a randomized clinical trial. ( Badr, H; Dawood, R; El-Shamy, E; Emarh, M; Gamal, A; Masood, A; Rezk, M, 2020) |
| "This study aimed to evaluate the maternal and fetal results in women undergoing antihypertensive therapy (low aspirin or labetalol) with mild to severe chronic hypertension relative to women without medicines." | 5.34 | Treatment of pregnancy-induced hypertension compared with labetalol, low dose aspirin and placebo. ( Wang, F; Xiang, X; Zhao, N; Zhou, Z, 2020) |
| "This was a nested cohort study of women with chronic hypertension and a singleton pregnancy recruited to the PANDA (Pregnancy And chronic hypertension: NifeDipine vs lAbetalol as antihypertensive treatment) study at one of three UK maternity units." | 5.30 | Longitudinal changes in vascular function parameters in pregnant women with chronic hypertension and association with adverse outcome: a cohort study. ( Chappell, LC; Cruickshank, JK; Khalil, A; Mills, C; Myers, JE; Nelson-Piercy, C; Seed, PT; Watt-Coote, I; Webster, LM, 2019) |
| "Fetal tachycardia was present as well." | 5.30 | Intrapartum labetalol for the treatment of maternal and fetal thyrotoxicosis. ( Bergmann, M; Bowman, ML; Smith, JF, 1998) |
| "Hypertension is due to disturbance of the complex interplay between numerous known and unknown mechanisms that normally control blood pressure." | 5.29 | Long-term hemodynamic effects at rest and during exercise of newer antihypertensive agents and salt restriction in essential hypertension: review of epanolol, doxazosin, amlodipine, felodipine, diltiazem, lisinopril, dilevalol, carvedilol, and ketanserin. ( Lund-Johansen, P; Omvik, P, 1993) |
| "And we considered left ventricular hypertrophy as left ventricular mass index greater than 120 g/m2." | 5.28 | [Action of labetalol on norepinephrine myocardial content in left ventricular hypertrophy in hypertensive patients]. ( Boutelant, S; de Gaudemaris, R; Fagret, D; Mallion, JM; Schwebel, C; Siché, JP; Tremel, F, 1992) |
| "Both esmolol and labetalol were equally effective in controlling systolic blood pressure on emergence and in the recovery room in patients undergoing intracranial surgery." | 5.28 | Labetalol and esmolol in the control of hypertension after intracranial surgery. ( Black, S; Cucchiara, RF; Losasso, TJ; Muzzi, DA, 1990) |
| "Labetalol was administered at the conclusion of surgery as a 20-mg bolus over two minutes followed by 40 mg every 10 minutes until the desired BP was achieved (BP less than or equal to 10% above average preoperative BP or less than 150 mmHg, systolic) or 300 mg had been given." | 5.28 | Intravenous labetalol for the treatment of hypertension after carotid endarterectomy. ( Azad, SS; Goldberg, ME; Larijani, GE; Marr, AT; Seltzer, JL; Smullens, SN, 1989) |
| "Labetalol is an antihypertensive agent with combined alpha- and beta-blocking properties that has been used to manage patients with suspected pheochromocytomas." | 5.28 | Labetalol reduces iodine-131 MIBG uptake by pheochromocytoma and normal tissues. ( Fig, LM; Khafagi, FA; Mallette, S; Shapiro, B; Sisson, JC, 1989) |
| "The results of the treatment in hypertension with pregnancy by a alpha-beta blocker in 58 women show: the good tolerance of the drug and its lack of teratogenic effect, its quasi-constant efficiency (91%) in hypertension, its benefit repercussion on neonatal weight." | 5.27 | [Treatment of arterial hypertension in pregnancy with an alpha-beta blocker. 58 Cases treated with labetalol]. ( Blazquez, G; Gérard, J; Giraud, P; Jeuffroy, A; Lardoux, H; Mounac, M, 1984) |
| "Beta blockers are now widely used to treat hypertension during pregnancy." | 5.27 | [Treatment of arterial hypertension in the pregnant woman with labetalol. A propos of 24 cases]. ( Dubois, D; Klepper, A; Leboullenger, P; Petitcolas, J; Temperville, B, 1984) |
| "When clonidine was given in a dose of 0." | 5.27 | Interaction of clonidine and labetalol in hypertension. ( Lilja, M, 1983) |
| " The average daily dosage was 144." | 5.27 | Hypertension in pregnancy: evaluation of two beta blockers atenolol and labetalol. ( Blazquez, G; Chouty, F; Flouvat, B; Gerard, J; Lardoux, H, 1983) |
| "Labetalol seems to be suitable to treat hypertension perioperatively in neurosurgical patients but it is not a suitable drug for induced hypotension." | 5.27 | Treatment of hypertension with labetalol in neurosurgical practice. Influence of labetalol on cerebral perfusion pressure in dogs without and with intracranial mass lesions. ( Anger, C; Hidding, J; Lawin, P; Puchstein, C; van Aken, H, 1983) |
| "Severe hypertension may be a difficult management issue, and it often requires therapy with multiple drugs at frequent dosing intervals." | 5.27 | Clinical experience with labetalol and enalapril in combination in patients with severe essential and renovascular hypertension. ( Aydelotte, ME; White, WB, 1988) |
| "Paradoxical hypertension is a relatively common complication of surgical repair of coarctation of the aorta." | 5.27 | Intravenous labetalol for the control of hypertension following repair of coarctation of the aorta. ( Bojar, RM; Cleveland, RJ; Weiner, B, 1988) |
| "Labetalol is a combined alpha- and beta-adrenoreceptor blocking agent." | 5.27 | Continuous i.v. infusion of labetalol for postoperative hypertension. Haemodynamic effects and plasma kinetics. ( Chauvin, M; Deriaz, H; Viars, P, 1987) |
| "One hundred and fifty-seven hypertensive patients (1st and 2nd degree of the WHO classification) studied in 15 hospitals were treated with labetalol at a dosage of 300-600 mg a day for 3 months." | 5.26 | [Treatment of arterial hypertension with labetalol. A polycentric study]. ( , 1982) |
| " Initial dosage was 300 mg per day." | 5.26 | Labetalol ('trandate') in hypertension: a multicentre study in general practice. ( Gomez, G; Phillips, LA, 1980) |
| "Labetalol was used in a mean daily dose of 1356 mg (range 400-3000 mg) either as mono-therapy or in combination with other drugs." | 5.26 | Long-term treatment of hypertension with labetalol. ( Andersson, E; Erichs, M; Rothgardt, NP, 1980) |
| " The resting heart rate is faster with labetalol than with an equivalent dosage of propranolol." | 5.26 | Comparison of labetalol and propranolol in treatment of hypertension. ( Harvald, B, 1980) |
| "1Labetalol is a new compound with antagonistic effects at both alpha- and beta-adrenoreceptor sites." | 5.26 | Labetalol, a new alpha- and beta-adrenoreceptor blocking agent, in hypertension. ( Hänel, B; Hansson, L, 1976) |
| " We have studied the variations brought about by effective hypotensive therapy with an alpha and beta blocking agent (Labetalol) in 15 patients over a period of 90 days, with an average dosage of 420 mg/day in three divided doses." | 5.26 | [Systolic time intervals in essential hypertension. II. Variations produced by treatment with labetalol]. ( Lomanto, B; Rossi, A; Ziacchi, V, 1979) |
| "Labetalol was given as replacement for a beta-blocking drug providing less than satisfactory control." | 5.26 | A pilot trial of labetalol (AH 5158A): a combined alpha and beta blocker in treatment of hypertension. ( Dent, R; Kellaway, GS, 1977) |
| "1." | 5.26 | Blood pressure reduction by incremental infusion of labetalol in patients with severe hypertension. ( Brown, JJ; Cummings, AM; Fraser, R; Lever, AF; Morton, JJ; Richards, DA; Robertson, JI, 1979) |
| "6 Labetalol is a useful addition to the medical treatment of phaeochromocytoma." | 5.26 | Treatment of phaeochromocytoma and of clonidine withdrawal hypertension with labetalol. ( Brown, JJ; Lever, AF; Robertson, AS; Robertson, JI; Rosei, EA; Trust, PM, 1976) |
| "To determine whether oral labetalol is associated with a shorter time to blood pressure control compared to oral extended release nifedipine for management of persistent postpartum hypertension." | 5.24 | Oral labetalol compared to oral nifedipine for postpartum hypertension: A randomized controlled trial. ( Greene, N; Kilpatrick, SJ; Sharma, KJ, 2017) |
| " Randomized controlled trials or comparative observational studies that evaluated clevidipine, nicardipine, labetalol, esmolol, or nitroprusside for acute neurologic emergencies were included." | 5.22 | Comparison of Intravenous Antihypertensives on Blood Pressure Control in Acute Neurovascular Emergencies: A Systematic Review. ( Brown, CS; Cabrera, D; Farrell, K; Gerberi, DJ; Mattson, AE; Oliveira J E Silva, L; Rabinstein, AA, 2022) |
| "This network meta-analysis aimed to compare the efficacy and safety of intravenous (IV) hydralazine, oral nifedipine, and IV labetalol with different dosage regimens in the treatment of severe hypertension during pregnancy." | 5.22 | Different dosage regimens of nifedipine, labetalol, and hydralazine for the treatment of severe hypertension during pregnancy: a network meta-analysis of randomized controlled trials. ( Cheng, Y; Jiang, YF; Li, JB; Wu, HZ; Yu, D; Zhu, ZN, 2022) |
| " In the setting of hypertensive disorders of pregnancy, oral antihypertensive medications should be initiated when systolic blood pressure is greater than 160 mm Hg or when diastolic blood pressure is greater than 110 mm Hg, with the most ideal agents being labetalol or nifedipine." | 5.22 | Hypertensive Disorders of Pregnancy: Common Clinical Conundrums. ( Dotters-Katz, S; Kuller, JA; Lim, SL; Ohamadike, O; Siegel, A; Zemtsov, G, 2022) |
| " Methyldopa, labetalol, and nifedipine have been perceived safe to use during pregnancy and are therefore recommended in international guidelines for treatment of hypertension." | 5.22 | Pharmacokinetics of the most commonly used antihypertensive drugs throughout pregnancy methyldopa, labetalol, and nifedipine: a systematic review. ( Allegaert, K; Flint, RB; Mian, P; Schoenmakers, S; van de Vusse, D; Versmissen, J; Visser, W, 2022) |
| "To compare pregnancy outcomes, accounting for allocated group, between methyldopa-treated and labetalol-treated women in the CHIPS Trial (ISRCTN 71416914) of 'less tight' versus 'tight' control of pregnancy hypertension." | 5.22 | Do labetalol and methyldopa have different effects on pregnancy outcome? Analysis of data from the Control of Hypertension In Pregnancy Study (CHIPS) trial. ( Asztalos, E; Gafni, A; Ganzevoort, JW; Gruslin, A; Helewa, M; Hutton, E; Koren, G; Lee, SK; Lee, T; Logan, AG; Magee, LA; Menzies, J; Moutquin, JM; Murphy, KE; Rey, E; Ross, S; Sanchez, J; Singer, J; Thornton, JG; von Dadelszen, P; Welch, R, 2016) |
| "In the present study, the efficacy and safety of oral nifedipine and intravenous labetalol for severe pre-eclampsia therapy were compared." | 5.22 | Oral nifedipine vs. intravenous labetalol for treatment of pregnancy-induced severe pre-eclampsia. ( Shi, DD; Wang, N; Yang, FZ; Zhou, L, 2016) |
| " Food and Drug Administration (FDA)-recommended doses of labetalol and nicardipine for hypertension (HTN) management in a subset of patients with renal dysfunction (RD)." | 5.19 | The management of acute hypertension in patients with renal dysfunction: labetalol or nicardipine? ( Baumann, BM; Borczuk, P; Cannon, CM; Chandra, A; Cline, DM; Diercks, DB; Hiestand, B; Hsu, A; Jois-Bilowich, P; Kaminski, B; Levy, P; Nowak, RM; Peacock, WF; Schrock, JW; Soto-Ruiz, KM; Varon, J, 2014) |
| "This is a prospective, pseudo-randomized study comparing labetalol and nicardipine for blood pressure (BP) management in acute stroke patients." | 5.17 | A prospective evaluation of labetalol versus nicardipine for blood pressure management in patients with acute stroke. ( Coplin, W; Levy, PD; Liu-DeRyke, X; Parker, D; Rhoney, DH, 2013) |
| "Our study suggests that nicardipine is a more effective antihypertensive agent than labetalol in an unselected group of patients who develop hypertension in the intensive care unit setting." | 5.16 | Intravenous labetalol compared with intravenous nicardipine in the management of hypertension in critically ill patients. ( Hilleman, DE; Malesker, MA, 2012) |
| " In parts I and II, the number of patients who required additional doses of the study drug because of persistent hypertension was lower in the nicardipine groups than in the labetalol groups (P < 0." | 5.16 | Comparative prophylactic and therapeutic effects of intravenous labetalol 0.4 mg/kg and nicardipine 20 μg/kg on hypertensive responses to endotracheal intubation in patients undergoing elective surgeries with general anesthesia: a prospective, randomized, ( Apfel, CC; Do, SH; Hwang, JW; Jeon, YT; Kim, CS; Ro, YJ; Ryu, JH; Whelan, R, 2012) |
| "We evaluated 16 pregnant women with gestational age between 20 and 32 weeks in acute severe hypertension which were randomly allocated to receive either hydralazine or labetalol." | 5.15 | Changes in fetal and maternal Doppler parameters observed during acute severe hypertension treatment with hydralazine or labetalol: a randomized controlled trial. ( Baggio, MR; Berezowski, AT; Calderon, AC; Cavalli, RC; Duarte, G; Marcolin, AC; Martins, WP, 2011) |
| "Our purpose was to compare the safety and efficacy of food and drug administration (FDA) recommended dosing of IV nicardipine versus IV labetalol for the management of acute hypertension." | 5.15 | CLUE: a randomized comparative effectiveness trial of IV nicardipine versus labetalol use in the emergency department. ( Baumann, BM; Borczuk, P; Cannon, CM; Chandra, A; Cline, DM; Diercks, D; Hiestand, B; Hsu, A; Jois-Bilowich, P; Kaminski, B; Levy, P; Nowak, RM; Peacock, WF; Schrock, JW; Varon, J, 2011) |
| "Labetalol and lisinopril are effective antihypertensive drugs in acute stroke that do not increase serious adverse events." | 5.14 | Controlling hypertension and hypotension immediately post-stroke (CHHIPS): a randomised, placebo-controlled, double-blind pilot trial. ( Chernova, J; Ford, GA; Jagger, C; James, M; Mistri, A; Potter, JF; Robinson, TG, 2009) |
| "The number of patients with intraoperative hypertension, number of patients receiving SNP, dose of SNP administered, and number of hypertension episodes were significantly lower in patients who received labetalol pretreatment than in control patients." | 5.12 | Labetalol pretreatment reduces blood pressure instability during surgical resection of pheochromocytoma. ( Chung, PC; Hsieh, JR; Li, AH; Ng, YT; Yang, MW, 2006) |
| "To assess the efficacy and safety of nicardipine in comparison to labetalol in the initial management of severe hypertension in pregnancy." | 5.10 | Short-term treatment of severe hypertension of pregnancy: prospective comparison of nicardipine and labetalol. ( Abroug, F; Boussarssar, M; Elatrous, S; Marghli, S; Nouira, S; Ouanes Besbes, L; Sakkouhi, M, 2002) |
| "We sought to compare the efficacies of oral nifedipine and intravenous labetalol in the acute management of hypertensive emergencies of pregnancy." | 5.09 | A randomized, double-blind trial of oral nifedipine and intravenous labetalol in hypertensive emergencies of pregnancy. ( Chauhan, SP; Newman, RB; Scardo, JA; Vermillion, ST, 1999) |
| "Our purpose was to compare the hemodynamic effects of orally administered nifedipine and intravenously administered labetalol in preeclamptic hypertensive emergencies." | 5.09 | A randomized, double-blind, hemodynamic evaluation of nifedipine and labetalol in preeclamptic hypertensive emergencies. ( Chauhan, SP; Hogg, BB; Newman, RB; Scardo, JA; Vermillion, ST, 1999) |
| "We compared the efficacy of the combination of enalaprilat/labetalol with that of enalaprilat/nicardipine to prevent emergence postcraniotomy hypertension." | 5.09 | A comparative study between a calcium channel blocker (Nicardipine) and a combined alpha-beta-blocker (Labetalol) for the control of emergence hypertension during craniotomy for tumor surgery. ( Broad, C; Ferri, E; Kross, RA; Leung, D; Melendez, JA; Pratila, M; Veronesi, M, 2000) |
| "To assess the efficacy and safety of labetalol compared with methyldopa in the management of mild and moderate cases of pregnancy-induced hypertension (PIH)." | 5.08 | Labetalol vs. methyldopa in the treatment of pregnancy-induced hypertension. ( al-Fadly, A; el-Qarmalawi, AM; Hashem, M; Morsy, AH; Obeid, A, 1995) |
| "In a randomized double-blind crossover study in 42 patients with essential hypertension, the metabolic effects of a beta-adrenergic blocker with a pronounced beta 2-agonistic effect, dilevalol 400 mg x 1, were compared with those of metoprolol succinate 200 mg x 1." | 5.07 | Treatment with a beta-blocker with beta 2-agonism improves glucose and lipid metabolism in essential hypertension. ( Haenni, A; Lithell, H, 1994) |
| "Adverse alterations in lipid profile suggesting higher atherogenicity were observed following 12 weeks treatment with atenolol in patients of hypertension." | 5.07 | Effect of atenolol and labetalol on serum lipids. ( Dahiya, SS; Seth, RK; Seth, S; Sharma, D; Siwach, SB, 1993) |
| " esmolol and labetalol in the treatment of perioperative hypertension in ambulatory surgery." | 5.07 | A comparison of esmolol and labetalol for the treatment of perioperative hypertension in geriatric ambulatory surgical patients. ( Dimich, I; Sampson, I; Singh, PP; Sonnenklar, N, 1992) |
| "To determine the need for, and efficacy of, treatment with labetalol in women with mild-to-moderate pregnancy induced hypertension (PIH)." | 5.07 | A randomised placebo controlled trial of labetalol in the treatment of mild to moderate pregnancy induced hypertension. ( Broughton Pipkin, F; Pickles, CJ; Symonds, EM, 1992) |
| "This double-blind, controlled, crossover study compared the effects on blood pressure control, glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) of labetalol, methyldopa and placebo in patients with chronic renal disease and hypertension." | 5.07 | The short term effects of oral labetalol in patients with chronic renal disease and hypertension. ( Catto, GR; Edward, N; Gemmell, HG; Innes, A; Smith, FW, 1992) |
| "This study was designed to compare the clinical efficacy and safety of oral clonidine and oral labetalol in the treatment of severe hypertension in an emergency department setting." | 5.07 | Oral labetalol versus oral clonidine in the emergency treatment of severe hypertension. ( Atkin, SH; Beaty, P; Cuffie, C; Jaker, MA; Quadrel, MA; Soto-Greene, ML, 1992) |
| "To evaluate the ex-vivo effects of labetalol, at effective vasodepressor doses, on platelet aggregation in hypertension, 30 hypertensive patients were randomized to either a labetalol or control group in a ratio of two to one." | 5.07 | Lack of effect of labetalol on platelet aggregation in hypertensive patients. ( Huang, CS; Lin, MS, 1991) |
| "Labetalol and hydrochlorothiazide (HCTZ) were compared for their efficacy in controlling hypertension of blacks in a prospective, double-blind study." | 5.07 | The effectiveness of labetalol compared to hydrochlorothiazide in hypertensive black patients. ( Due, D; Forbes, WP; Jenkins, P; Lucas, C; Mendels, J; Sirgo, MA, 1991) |
| "Labetalol was evaluated in a multicenter, placebo-controlled study of elderly patients (greater than or equal to 60 years) with mild to moderate essential hypertension." | 5.07 | Evaluation of labetalol in elderly patients with essential hypertension. ( Bartels, DW; Burris, JF; Due, D; Giles, TD; Gregory, MC; Sirgo, MA; Weber, M, 1991) |
| "In this randomised double-blind parallel study, we compared the efficacy of labetalol and atenolol in a group of black (n = 33) and white (n = 34) hypertensives with uncomplicated essential hypertension after obtaining pretreatment renin profiles." | 5.07 | Renin profile, race, and antihypertensive efficacy with atenolol and labetalol. ( DiPette, DJ; Goodman, RP; McKenney, JM; Townsend, R; Wright, JT, 1991) |
| "Sixty-one patients (41 men, 20 women) aged 29-73 years, with moderate to severe hypertension, were enrolled in a multicentre study to compare the efficacy, safety, and tolerability of dilevalol (D) and captopril (C)." | 5.06 | Double-blind study of dilevalol and captopril, both in combination with hydrochlorothiazide, in patients with moderate to severe hypertension. ( Fraser, I; Howes, L; Kincaid-Smith, PS; Louis, W; MacDonald, G; Matthews, PG; McGrath, BP; Rallings, M; Scheinkestel, C; Whitworth, JA, 1990) |
| "A multicenter, randomized, double-blind, parallel-group trial of 8 weeks' duration was designed to compare the efficacy and safety of once-daily carvedilol with that of twice-daily labetalol in patients with essential hypertension." | 5.06 | Safety and efficacy of once-daily carvedilol vs twice-daily labetalol in mild to moderate hypertension. ( Bussiere, JL; Durier, P; Gayet, JL; Ollivier, JP, 1990) |
| "Three hundred women with mild chronic hypertension at 6 to 13 weeks' gestation were randomly allocated to receive either methyldopa or labetalol or be in the control group." | 5.06 | A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy. ( Anderson, GD; Mabie, WC; Shamsa, F; Sibai, BM; Villar, MA, 1990) |
| "Antihypertensive therapy with labetalol was evaluated in a prospective, randomized, multicenter, double-blind study of 133 elderly patients with isolated systolic hypertension (standing systolic blood pressure [BP] greater than or equal to 160 mm Hg; diastolic BP less than 95 mm Hg)." | 5.06 | Treatment of isolated systolic hypertension with labetalol in the elderly. ( Bartels, DW; Burris, JF; Gilderman, LP; Giles, TD; Silberman, HM; Weber, M, 1990) |
| "The effects of 6 weeks of treatment with dilevalol 100 mg once daily, or carteolol 10 mg once daily, on renal blood flow (RBF), glomerular filtration rate (GFR) and total renal vascular resistance (TRR) were studied in 10 patients with mild-to-moderate essential hypertension in a randomised cross-over experiment." | 5.06 | Comparison of the renal effects of dilevalol and carteolol in patients with mild to moderate essential hypertension. ( Baba, T; Murabayashi, S; Takebe, K; Tomiyama, T, 1990) |
| " In this double-blind randomized study, after a 4-weeks placebo period, 18 patients with mild to moderate primary hypertension were assigned to treatment with either dilevalol (n = 9) daily or atenolol (n = 9) over a period of 3 months." | 5.06 | Comparative effects of dilevalol and atenolol on lung function and airway response to methacholine in hypertensive subjects. ( Boulet, LP; Lacourcière, Y; Lampron, N; Milot, J, 1990) |
| "The purpose of this multicenter investigation was to determine the efficacy and safety of the alpha/beta-blocker labetalol versus the beta 1-selective beta-blocker atenolol in white and black patients with essential hypertension." | 5.06 | Combined alpha/beta-blockade versus beta 1-selective blockade in essential hypertension in black and white patients. ( Blumfield, D; Cronin, R; DiPette, DJ; Goodman, R; Gradman, A; Katz, LA; McCarthy, EP; Sopko, G; Townsend, RR, 1990) |
| "Labetalol, a drug with alpha- and beta-adrenergic receptor blocking effects, was used to attenuate hypertension and tachycardia associated with electroconvulsive therapy (ECT) in a series of 11 elderly patients with refractory depression and cardiovascular disease in a placebo-controlled, double-blind crossover study design." | 5.06 | Labetalol in the control of cardiovascular responses to electroconvulsive therapy in high-risk depressed medical patients. ( Cooper, R; Gladson, M; Knos, G; Markwalter, H; Morris, R; Stoudemire, A; Sung, YF, 1990) |
| "Antihypertensive effects of labetalol and nifedipine were evaluated in a double blind cross over trial in ambulatory patients with moderately severe hypertension (mean diastolic BP 101." | 5.06 | Labetalol and nifedipine in the management of essential hypertension. ( Prasad, NK, 1990) |
| "Dilevalol (100 mg) or atenolol (50 mg) was given orally in 13 subjects with essential hypertension." | 5.06 | Clinical pharmacology of dilevalol (i.v.). Influence of hepatic and renal functions on the disposition of dilevalol and atenolol in hypertensive subjects. ( Ebihara, A; Fujimura, A; Kotegawa, T, 1990) |
| "The safety and efficacy of labetalol and hydrochlorothiazide (HCTZ) were compared in a group of 34 patients aged 65 years or older with mild to moderate essential hypertension." | 5.06 | Comparison of labetalol and hydrochlorothiazide in elderly patients with hypertension using 24-hour ambulatory blood pressure monitoring. ( Due, DL; Sirgo, MA; Toth, PD; Vidt, DG; Weidler, DJ, 1990) |
| "A new non-imaging echo-Doppler cardiac output device that works on the principle of attenuated compensation volume flow (ACVF), has been used to assess the cardiovascular effects of atenolol and dilevalol in 24 patients with essential hypertension." | 5.06 | Comparison of central and peripheral haemodynamic effects of dilevalol and atenolol in essential hypertension. ( Silke, B; Taylor, SH; Tham, TC, 1990) |
| "Left ventricular diastolic filling was investigated in 12 black and 15 white subjects before and after double-blinded randomized treatment of mild to moderate hypertension with combined alpha- and beta-adrenergic receptor blockade (labetalol) and beta-blockade alone (atenolol)." | 5.06 | Left ventricular filling in hypertensive blacks and whites following adrenergic blockade. ( Cornman, C; Dianzumba, SB; DiPette, D; Joyner, CR; Mauro, K; Theobald, T; Townsend, R; Weber, E, 1990) |
| "This was a multicenter, randomized, double-blind, parallel-group study of the efficacy and safety of dilevalol, 200 mg (n = 86), compared with enalapril, 20 mg (n = 92), administered once daily to patients with mild hypertension." | 5.06 | Comparison of dilevalol and enalapril administered once daily for mild hypertension. ( Edwards, LD; Guerrero-Sierra, J; Guiducci, U; Renaud, H; Rodriguez-Saavedra, M; Sack, DW; Zannad, FM, 1989) |
| "The antihypertensive efficacy and safety of IV labetalol were evaluated and compared with the efficacy and safety of IV hydralazine in the treatment of postoperative hypertension." | 5.06 | Comparative hemodynamic effects of labetalol and hydralazine in the treatment of postoperative hypertension. ( Dimich, I; Gabrielson, G; Kaplan, JA; Lingham, R; Singh, PP, 1989) |
| "The effects of labetalol were compared with those of placebo in a multicentre randomized double-blind and prospective study of 152 patients with mild to moderate, non-proteinuric pregnancy-induced hypertension." | 5.06 | The fetal outcome in a randomized double-blind controlled trial of labetalol versus placebo in pregnancy-induced hypertension. ( Broughton Pipkin, F; Pickles, CJ; Symonds, EM, 1989) |
| " A multi-center, double-blind, parallel group study compared the safety and efficacy of labetalol to propranolol in the treatment of patients with both exertional angina and mild to moderate systemic hypertension." | 5.06 | Labetalol compared with propranolol in patients with both angina pectoris and systemic hypertension: a double-blind study. ( Charlap, S; Frishman, WH; Shapiro, W, 1989) |
| "1 To compare the haemodynamic effects of secondary characteristics of beta-adrenoceptor blockers with an angiotensin converting enzyme inhibitor forty patients with previously untreated mild to moderate hypertension were prescribed either atenolol 50-100 mg day-1, labetalol 200-800 mg day-1, pindolol 10-30 mg day-1 or captopril 25-100 mg day-1 and observed for 6 months." | 5.06 | Haemodynamic effects of atenolol, labetalol, pindolol and captopril: a comparison in hypertensive patients with special reference to changes in limb blood flow, heart rate and left ventricular function. ( Breckenridge, AM; Grimmer, SF; Orme, ML; Roberts, DH; Tsao, Y; Winstanley, PA, 1987) |
| "In a six month placebo-controlled cross-over trial twenty patients with hypertension and peripheral arterial disease were randomised to captopril 25 mg twice daily, atenolol 100 mg once daily, labetalol 200 mg twice daily, or pindolol 10 mg twice daily for one month." | 5.06 | Placebo-controlled comparison of captopril, atenolol, labetalol, and pindolol in hypertension complicated by intermittent claudication. ( Breckenridge, A; McLoughlin, GA; Roberts, DH; Tsao, Y, 1987) |
| "The effects of oral dilevalol (an R, R-isomer of labetalol), a new beta-adrenoceptor blocker with beta 2-receptor stimulating and alpha-recepter blocking properties on blood pressure, renal function, plasma renin activity (PRA) and plasma aldosterone have been studied in 15 patients with mild-to-moderate essential hypertension treated with it for 6 weeks." | 5.06 | Effects of dilevalol, an R, R-isomer of labetalol, on blood pressure and renal function in patients with mild-to-moderate essential hypertension. ( Aoyagi, K; Baba, T; Ishizaki, T; Murabayashi, S, 1988) |
| "The haemodynamic impact of alpha- and beta-adrenoceptor blockade (labetalol) was compared with that of slow-calcium channel blockade (nifedipine) in 32 patients with sustained elevation of systemic arterial pressure (systolic blood pressure greater than 160; diastolic blood pressure greater than 95 mmHg) following a recent myocardial infarction (6-22 h)." | 5.06 | Sympathetic (alpha-beta) or calcium channel blockade for hypertensive myocardial infarction? A haemodynamic comparison of labetalol and nifedipine. ( Hussain, M; Nelson, GI; Reynolds, GW; Richmond, A; Silke, B; Taylor, SH; Verma, SP; Wilson, JA, 1988) |
| "Labetalol was compared with methyldopa in a randomized controlled trial involving 176 pregnant women with mild to moderate hypertension." | 5.06 | Comparison of antihypertensive efficacy and perinatal safety of labetalol and methyldopa in the treatment of hypertension in pregnancy: a randomized controlled trial. ( Breart, G; Maillard, F; Papiernik, E; Plouin, PF; Relier, JP, 1988) |
| "Labetalol was compared with methyldopa in a randomised trial involving 176 pregnant women with mild to moderate hypertension." | 5.06 | [Maternal effects and perinatal safety of labetalol in the treatment of hypertension in pregnancy. Comparison with methyldopa in a randomized cooperative trial]. ( Bréart, G; Maillard, F; Papiernik, E; Plouin, PF; Relier, JP, 1987) |
| "A double-blind parallel group study was conducted to examine the effects of oral labetalol, in doses from 100 to 800 mg BID, and propranolol, 40 to 320 mg, in patients with mild to moderate hypertension." | 5.06 | Labetalol compared with propranolol in the treatment of black hypertensive patients. ( Curry, C; Hinds, J; Kong, BW; Medakovic, M; Poland, M; Roper, K; Saunders, E, 1987) |
| "Twenty young (45 years or younger) and 20 older (55 years or older) adult patients with mild hypertension were enrolled in this study to compare the hemodynamic effects of labetalol versus placebo in two age groups." | 5.06 | Hemodynamic effects of labetalol in young and older adult hypertensives. ( Buell, JC; Eliot, RS; Little, MR; Plachetka, JR, 1988) |
| "The results of a prospective trial to evaluate the use of diazoxide and labetalol given intravenously in the management of severe hypertensive disease in pregnancy are presented." | 5.06 | Intravenous labetalol and intravenous diazoxide in severe hypertension complicating pregnancy. ( Michael, CA, 1986) |
| "Labetalol (Trandate; Allen & Hanburys), a combined alpha- and beta-adrenergic blocking agent, was compared with the more commonly used peripheral vasodilator, dihydrallazine (Nepresol; Ciba), each administered as an infusion, in the treatment of severe hypertension in 20 primigravidas at greater than or equal to 32 weeks' gestation." | 5.06 | Comparison of labetalol and dihydralazine in hypertensive emergencies of pregnancy. ( Ashe, RG; Moodley, J; Philpott, RH; Richards, AM, 1987) |
| "The pharmacodynamic effects of single oral doses of atenolol (100 mg), labetalol (300 mg), and propranolol (80 mg) were compared with those of placebo in a randomized, double-blind, Latin square design in 12 patients with hypertension." | 5.06 | The effects of single-dose atenolol, labetalol, and propranolol on cardiac and vascular function. ( Berry, DA; Finley, D; Holtzman, JL; Johnson, B; Sirgo, MA, 1986) |
| "1 Labetalol is an effective agent in essential hypertension as documented in open studies and controlled studies in which its efficacy has been compared with both placebo and a variety of other anti-hypertensive drugs." | 5.05 | Labetalol in essential hypertension. ( Breckenridge, A; Maciver, M; Orme, M; Serlin, MJ, 1982) |
| "The antihypertensive effects of intravenous labetalol were evaluated in 59 patients with hypertensive crises or severe hypertension in need of rapid lowering of blood pressure in a multicenter study." | 5.05 | Intravenous labetalol in the treatment of severe hypertension and hypertensive emergencies. ( Flamenbaum, W; Freis, ED; Langford, HG; Michelson, EL; Poland, MP; Vidt, DG; Vlachakis, ND; Wallin, JD; Wilson, DJ, 1983) |
| "9 years) with mild to moderate essential hypertension a comparison between equipotent beta-blocking doses of propranolol, metoprolol and labetalol was carried out." | 5.05 | Propranolol vs metoprolol vs labetalol: a comparative study in essential hypertension. ( Coote, JH; Kubik, MM, 1984) |
| " The effects of labetalol and hydrochlorothiazide on the hypertension and ventilatory function of patients with both hypertension and mild reversible chronic pulmonary disease were compared." | 5.05 | Comparison of the effects of labetalol and hydrochlorothiazide on the ventilatory function of hypertensive patients with mild chronic obstructive pulmonary disease. ( Chetty, KG; Light, RW; Stansbury, DW, 1983) |
| "This was an open-label, two-phase crossover study of labetalol in 11 patients with mild to moderate hypertension." | 5.05 | Study of single and multiple dose pharmacokinetic/pharmacodynamic modeling of the antihypertensive effects of labetalol. ( Barr, JW; Chung, M; Maronde, RF; Medakovic, M; Robinson, D; Vlachakis, ND; Zampaglione, N, 1983) |
| "The antihypertensive effects of oral labetalol, a new alpha- and beta-adrenergic blocking agent, and metoprolol, a relatively beta1 selective adrenergic blocker, were evaluated in 91 patients with mild to moderate hypertension (standing diastolic blood pressure of 90 to 115 mm Hg) in a double-blind parallel group multicenter clinical trial." | 5.05 | Multiclinic comparison of labetalol to metoprolol in treatment of mild to moderate systemic hypertension. ( Frishman, WH; Johnson, BF; Michelson, EL; Poland, MP, 1983) |
| "Labetalol, a new alpha- and beta-adrenergic blocking agent, was administered to 57 patients with essential hypertension whose standing diastolic blood pressure was 105 to 120 mm Hg after three and four weeks of placebo therapy and greater than 90 mm Hg after three to four weeks of therapy with hydrochlorothiazide, 25 mg twice a day." | 5.05 | Step II treatment with labetalol for essential hypertension. ( Bloomfield, SS; Gantt, CL; Lucas, CP; Medakovic, M; Poland, MP, 1983) |
| "The drug albetol (labetalol) was used in 97 patients with stage I-III essential hypertension (according to the WHO classification) and 13 patients with stable arterial hypertension of renal genesis." | 5.05 | [Use of Albetol for treating hypertension patients]. ( Evsikov, EM; Kharchenko, VI; Savenkov, PM, 1984) |
| "A randomized double-blind crossover trial was conducted in 20 patients with moderate to severe hypertension to compare the efficacy of labetalol, which combines alpha- and beta-adrenoceptor blocking properties, with that of metoprolol alone or in combination with prazosin." | 5.05 | On the combination of alpha- and beta-adrenoceptor blockade in hypertension. ( Gellatly, R; Hill, A; Mennie, BA; Stokes, GS, 1983) |
| "Patients with acute pregnancy-related hypertension were randomized to treatment with 200 mg oral labetalol or 10 mg intramuscular hydralazine." | 5.05 | Treatment of acute pregnancy-related hypertension: labetalol and hydralazine compared. ( Calder, AA; Greer, I; Walker, JJ, 1983) |
| "Thirty-two patients with primary hypertension were studied in a double-blind cross-over comparison between the cardioselective beta 1-blocking agent atenolol and the combined alpha- and beta-blocking agent labetalol." | 5.05 | Antihypertensive and metabolic effects of increasing doses of atenolol and labetalol. A comparative study in primary hypertension. ( Henningsen, NC; Karlberg, BE; Nilsson, OR; Thulin, T, 1982) |
| "To evaluate the role of the vasoactive prostaglandins prostacyclin and thromboxane A2 in essential hypertension, the stable metabolites 6-keto-PGF1 alpha and thromboxane B2, respectively, were measured in plasma before and after therapy in 7 patients." | 5.05 | Increased plasma concentrations of prostacyclin metabolite 6-keto-PGF1 alpha in essential hypertension. Influence of therapy with labetalol. ( Mehta, J; Mehta, P; Roy, L, 1983) |
| "Labetalol (Trandate; Allen & Hanbury) was administered to 17 hypertensive patients with angina pectoris, which had persisted despite blood pressure control on treatment including beta-blocking agents." | 5.05 | Beneficial effect of labetalol in hypertensive patients with angina pectoris. ( Lubbe, WF; White, DA, 1983) |
| "1 The effects of atenolol (100 mg), a cardioselective beta-adrenoceptor blocking agent, and labetalol (300 mg), a combined alpha- and non-selective beta-adrenoceptor blocking agent given in single doses were examined in a double-blind placebo controlled study in 11 asthmatic patients with hypertension." | 5.05 | Comparison of the effects of single doses of atenolol and labetalol on airways obstruction in patients with hypertension and asthma. ( Beevers, DG; Jackson, SH, 1983) |
| " In a double-blind cross-over study the antihypertensive action and side-effects of labetalol and propranolol were compared in 18 previously untreated outpatients with hypertension, WHO stage I--III." | 5.05 | Labetalol in the treatment of hypertension in patients with normal and impaired renal function. ( Berg, KJ; Nilsen, OG; Walstad, RA; Wessel-Aas, T, 1982) |
| "Eleven patients with essential hypertension participated in a double-blind cross-over comparison of labetalol (L) and propranolol (P)." | 5.05 | Effects of labetalol and propranolol on the peripheral circulation in hypertensive patients. ( Berglund, G; Nyberg, G, 1982) |
| "1 Labetalol has been compared with propranolol in a double-blind, double-dummy study of 24 patients with mild or moderate essential hypertension." | 5.05 | Comparison of labetalol and propranolol in hypertension. ( Bulpitt, CJ; Butler, AG; Husaini, MH; Nicholls, DP; Stephens, MD, 1980) |
| "1 Labetalol, an alpha- and beta- adrenoceptor blocking drug, was compared with acebutolol, alone or associated with dihydralazine in forty patients with moderate essential hypertension." | 5.05 | Comparative trial of labetalol and acebutolol, alone or associated with dihydralazine, in treatment of essential hypertension. ( Corvol, P; Lardoux, MD; Thibonnier, M, 1980) |
| "The hemodynamic effects of intravenous labetalol (a combined alpha- and beta-blocking agent) were studied in 11 patients during early post-open heart surgery hypertension." | 5.05 | Combined alpha- and beta-blockade with labetalol in post-open heart surgery hypertension. Reversal of hemodynamic deterioration with glucagon. ( Allonen, H; Arola, M; Laaksonen, VO; Meretoja, OA, 1980) |
| "A new alpha- and beta-blocking agent, labetalol, was used to treat 50 hypertensive patients, 34 of them with refractory hypertension." | 5.05 | The treatment of hypertension by labetalol--a new alpha- and beta-adrenoreceptor blocking agent. ( Rosenthal, T; Stern, N; Teicher, A, 1982) |
| "An open crossover study was carried out in 10 Arab patients with mild to moderate hypertension to compare the effectiveness and tolerability of labetalol with alpha-methyldopa." | 5.05 | A controlled comparison of the antihypertensive effects of labetalol and alpha-methyldopa. ( Al-Damluji, SF; Al-Khalidi, A; Shaarbaf, H; Tawfiq, NH, 1982) |
| "The clinical effects, the exercise test answer, the left ventricular function by polygraphyc test after administration at middle term of Metoprolol and Labetalol have been evaluated in 20 patients with moderate and non complicated essential hypertension." | 5.05 | [Clinical, ergometric and polygraphic evaluation of the effects of metoprolol and labetalol administration in essential arterial hypertension. Comparative study]. ( Attisano, N; Grenci, G; Martelli, G; Sarica, G; Schirripa, V, 1982) |
| "Twentysix women with pregnancy-induced hypertension have been randomly treated with either labetalol or Aldomet." | 5.05 | Comparison of the alpha and beta blocking drug, labetalol, and methyl dopa in the treatment of moderate and severe pregnancy-induced hypertension. ( Broughton Pipkin, F; Lamming, GD; Symonds, EM, 1980) |
| "In 17 patients with essential hypertension administration of labetalol alone resulted in a significant reduction in supine systolic and diastolic blood pressure of 14% and 17%, respectively." | 5.05 | Blood pressure, plasma volume, extracellular volume and glomerular filtration rate during treatment with labetalol in essential hypertension. ( Nielsen, PE; Rasmussen, S, 1980) |
| " placebo added to hydrochlorothiazide (HCTZ) for the treatment of essential hypertension." | 5.05 | Labetalol and hydrochlorothiazide in hypertension. Labetalol/Hydrochlorothiazide Multicenter Study Group. ( , 1985) |
| "The efficacy and safety of labetalol was compared in a double-blind crossover design with propranolol in 27 patients suffering from essential hypertension with a supine diastolic blood pressure of more than 100 mm Hg." | 5.05 | A double-blind crossover clinical trial of labetalol and propranolol in patients of essential hypertension. ( Aslam, S; Pandhi, P; Sharma, BK; Sharma, PL; Wahi, PL, 1985) |
| "The antihypertensive effects of labetalol infusion (2 mg/min; maximal dose 150 mg) were evaluated in 22 subjects requiring rapid lowering of blood pressure because of severe hypertension, a hypertensive crisis after surgery, or before angiographic examination." | 5.05 | Labetalol infusion in hypertensive emergencies. ( Belleau, LJ; Grose, JH; Langlois, S; Lebel, M, 1985) |
| "After screening two local populations in the northern part of The Netherlands for hypertension, patients with a diastolic pressure (DP) between 95 and 120 mmHg were treated daily either with 50 mg hydrochlorothiazide or 100 mg atenolol." | 5.05 | A comparison of labetalol and prazosin combined with atenolol in non-responders to atenolol plus hydrochlorothiazide in uncomplicated hypertension. ( Donker, AJ; May, JF; Schuurman, FH; ten Berge, BS; van der Veur, E; Wesseling, H, 1985) |
| "Previous studies have shown that labetalol, a new alpha- and beta-adrenergic antagonist, is relatively safe for the treatment of hypertension in patients with chronic obstructive pulmonary disease (COPD)." | 5.05 | Comparison of the effects of labetalol and hydrochlorothiazide on the ventilatory function of hypertensive patients with asthma and propranolol sensitivity. ( Burford, JG; Chetty, K; Conrad, SA; George, RB; Hudson, LD; Light, RW; Manocha, K, 1985) |
| "In a randomised, double-blind, cross over trial, 25 patients with mild to moderate primary hypertension were given nifedipine 20-40 mg twice daily and labetalol 200-400 mg twice daily after a 4 week period on placebo, followed by the two drugs in combination." | 5.05 | Antihypertensive and metabolic effects of nifedipine and labetalol alone and in combination in primary hypertension. ( Karlberg, BE; Ohman, KP; von Schenck, H; Weiner, L, 1985) |
| "Labetalol is a unique alpha- and beta-adrenergic-receptor blocking agent that has recently been approved for the treatment of hypertensive emergencies and urgencies." | 5.05 | Intravenous labetalol in the emergency treatment of hypertension. ( Vidt, DG, 1985) |
| "1 The effect of intravenous injections of labetalol at doses of 1 and 2 mg/kg was studied in 15 patients with severe hypertension inadequately controlled by beta-adrenoreceptor-blocking drugs." | 5.04 | Intravenous labetalol in hypertensive patients treated with beta-adrenoreceptor-blocking drugs. ( Havard, CW; Pearson, RM, 1976) |
| "Atenolol was compared with five other beta-blockers and a thiazide diuretic in a randomised cross-over trial of once-daily treatment of essential hypertension." | 5.04 | Randomised study of six beta-blockers and a thiazide diuretic in essential hypertension. ( Wilcox, RG, 1978) |
| " Eight hypertensive patients with angina pectoris had placebo added to their existing medications for 8 weeks, then incremental doses of active labetalol with simultaneous stepwise reduction in other medicines until blood pressure was satisfactorily controlled; after that only labetalol and thiazide (8 weeks) and finally labetalol-placebo together with previous beta-adrenoreceptor antagonists and thiazide for 4 weeks were administered." | 5.04 | Labetalol in hypertensive patients with angina pectoris: beneficial effect of combined alpha- and beta-adrenoreceptor blockade. ( Lubbe, WF; White, DA, 1978) |
| "20 patients (12 female) with moderately severe essential hypertension [blood pressure during placebo treatment 181 +/- 6 (systolic), 107 +/- 3 (diastolic)] completed a double-blind, cross-over dose-titrated comparison of labetalol and methyldopa." | 5.04 | Labetalol, a cross-over double blind controlled trial. ( Davies, DM; Gales, GM; Rao, JG; Rawlins, MD; Routledge, PA; Sanders, GL, 1978) |
| " Labetalol, a new drug combining alpha-and beta-adrenoceptor blocking properties, has been compared with placebo in a double-blind crossover study of a group of patients with mild to moderate essential hypertension (blood pressure 150/100 to 189/114 mmHg)." | 5.04 | A controlled trial of labetalol (Trandate), propranolol and placebo in the management of mild to moderate hypertension. ( Armstrong, BK; Beilin, L; Nassim, M; Pugsley, DJ, 1979) |
| "A randomized double-blind crossover trial of labetalol, bendrofluazide and placebo was carried out in 18 patients with mild to moderate hypertension." | 5.04 | Labetalol and bendrofluazide: comparison of their antihypertensive effects. ( Caterson, RJ; Collett, P; Duggin, GG; Horvath, JS; Kelly, DH; Tiller, DJ, 1979) |
| "1 Twenty patients with essential hypertension completed a double-blind, dose-tritrated, cross-over comparison of methyldopa and labetalol." | 5.04 | A comparative study of methyldopa and labetalol in the treatment of hypertension. ( Davies, DM; Gales, GM; Rao, JG; Rawlins, MD; Routledge, PA; Sanders, GL, 1979) |
| " Four different doses of labetalol (150, 300, 600 and 900 mg/day) were given for 1 week to each of four groups of patients with essential hypertension (six patients for each group)." | 5.04 | Effect of increasing doses of labetalol on blood pressure, plasma renin activity and aldosterone in hypertensive patients. ( Arzilli, F; Pedrinelli, R; Salvetti, A; Sassano, P, 1979) |
| "Seventeen outpatients suffering from essential hypertension were treated in a double-blind cross-over study with labetalol or with a combination of propranolol and dihydrallazine." | 5.04 | Antihypertensive effect and plasma levels of labetalol. A comparison with propranolol and dihydrallazine. ( Allonen, H; Kleimola, T; Lehtonen, A, 1979) |
| "1 The effects of labetalol, bethanidine and combined treatment with both drugs were compared in a within-patient randomized cross-over study in mild essential hypertension." | 5.04 | A comparison and an investigation of a potential synergistic effect of labetalol and bethanidine in patients with mild hypertension. ( Brown, JJ; Chalmers, AG; Hunter, J; Lees, CD; Millar, JA; Robertson, JI, 1979) |
| "1 Diazoxide 300 mg and labetalol 150 mg were each injected intravenously on separate occasions into five patients with essentail hypertension." | 5.04 | Comparison of effects on cerebral blood flow of rapid reduction in systemic arterial pressure by diazoxide and labetalol in hypertensive patients: preliminary findings. ( Griffith, DN; Havard, CW; James, IM; Pearson, RM; Woollard, M, 1979) |
| "1 Labetalol, a new hypotensive drug combining alpha- and beta-adrenoreceptor antagonist properties, has been compared with propranolol in the treatment of severe hypertension (blood pressure 190/115-249/139 mmHg) in a double-blind trial lasting 14 weeks." | 5.04 | Controlled comparison of labetalol and propranolol in the management of severe hypertension. ( Armstrong, BK; Beilin, LJ; Nassim, MA; Pugsley, DJ, 1976) |
| " Labetalol has been compared with propranolol and placebo for the treatment of mild to moderate hypertension (150/100 to 189/114 mmHg), in a double-blind cross-over trial with three 10 week treatment periods." | 5.04 | Combined alpha- and beta-adrenoreceptor blockade in hypertension: a controlled trial of labetalol (AH 5158) compared with propranolol and placebo. ( Armstrong, B; Beilin, LJ; Nassim, M; Pugsley, D, 1976) |
| " Oral nifedipine is now considered an alternative first-line therapy, along with intravenous hydralazine and labetalol for women presenting with pre-eclampsia." | 4.98 | Focused Update on Pharmacologic Management of Hypertensive Emergencies. ( Broscious, R; Devabhakthuni, S; Noel, ZR; Watson, K, 2018) |
| "The present evidence suggests similar efficacy between nifedipine, hydralazine and labetalol in the treatment of severe hypertension in pregnancy." | 4.98 | Drugs for treating severe hypertension in pregnancy: a network meta-analysis and trial sequential analysis of randomized clinical trials. ( Sequeira, RP; Sridharan, K, 2018) |
| " Therefore, we analyzed the potency and side effects of two treatment options (nicardipine compared to labetalol) in order to gain insight in improved treatment of severe hypertension during pregnancy and to evaluate the feasibility of a randomised controlled trial." | 4.90 | The optimal treatment of severe hypertension in pregnancy: update of the role of nicardipine. ( de Groot, CJ; Meuleman, T; Nooij, LS; Roelofs, R; Visser, S; Vos, P, 2014) |
| " Critical care nurses who appreciate the considerations for treatment of hypertension and who can correctly and efficiently administer intravenous labetalol may save precious time and enhance outcomes for patients with stroke who have hypertension." | 4.82 | Managing hypertension in patients with stroke. Are you prepared for labetalol infusion? ( Harrington, C, 2003) |
| " Hydralazine has been widely used in treatment of hypertension in eclampsia and preeclampsia, and its safety has been demonstrated in these patients." | 4.79 | Management of hypertensive urgencies and emergencies. ( Abdelwahab, W; Frishman, W; Landau, A, 1995) |
| "We report the specifics of 12 cases of severe hypertension after the intraoperative use of topical phenylephrine, submucosal epinephrine, or both." | 4.79 | Cardiopulmonary compromise after use of topical and submucosal alpha-agonists: possible added complication by the use of beta-blocker therapy. ( Carpenter, RL; Guertin, SR; Kalyanaraman, M; McGlew, MJ, 1997) |
| " However, their therapeutic potential in the management of essential hypertension was not realized until prazosin, a highly selective alpha 1-adrenergic antagonist, became available." | 4.76 | Selective alpha 1-adrenergic antagonists: therapeutically relevant antihypertensive agents. ( Graham, RM, 1984) |
| " It has also been used intravenously in phaeochromocytoma, tetanus, clonidine withdrawal, and as an adjunct to halothane to produce hypotensive anaesthesia." | 4.76 | Combined alpha- and beta-receptor inhibition in the treatment of hypertension. ( Prichard, BN, 1984) |
| "To compare the risk of readmission in those receiving no treatment, labetalol, nifedipine or both at hospital discharge following delivery complicated by presence of hypertension." | 4.31 | Postpartum medical management of hypertension and risk of readmission for hypertensive complications. ( Connealy, B; D Dahlke, J; Lovgren, T; Yao, R, 2023) |
| "To compare the efficacy of intravenous Labetalol and intravenous Hydralazine in reduction of blood pressure in patients with severe pre-eclampsia." | 4.31 | Comparison of efficacy of intravenous labetalol and intravenous hydralazine for management of pre-eclampsia in pregnant women. ( Husain, S; Hussain, R; Kausar, M, 2023) |
| "A retrospective cohort study of patients with severe peripartum hypertension (systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 110 mm Hg confirmed within 15 min) to determine whether the effectiveness of blood pressure control using nationally recommended medications (hydralazine, labetalol, nifedipine) differed by race/ethnicity." | 4.12 | Race/ethnicity differences in response to acute antihypertensive treatment of peripartum severe hypertension. ( Greene, NH; Kilpatrick, SJ; Pon, FF, 2022) |
| "To assess whether readmission for hypertension by 6 weeks postpartum differed between patients discharged on nifedipine or labetalol." | 4.12 | Postpartum Readmission for Hypertension After Discharge on Labetalol or Nifedipine. ( Do, SC; Druzin, ML; El-Sayed, YY; Girsen, AI; Herrero, T; Kan, P; Leonard, SA; Lyell, DJ; Panelli, DM, 2022) |
| "Although considering the pathophysiology of post-coarctectomy hypertension, β-blockers should be effective, experience with labetalol for treatment is limited in the literature." | 4.12 | Treatment of Post-Coarctectomy Hypertension With Labetalol-A 9-Year Single-Center Experience. ( Brouwer, CNM; Roeleveld, PP; Siersma, C; Sojak, V; Ten Harkel, ADJ, 2022) |
| "To assess the safety and efficacy of continuous infusion (CIV)-labetalol compared to -nicardipine in controlling blood pressure (BP) in the acute stroke setting." | 4.02 | Blood Pressure Control in Acute Stroke: Labetalol or Nicardipine? ( El-Ghoroury, H; Hecht, JP; Sudekum, DM, 2021) |
| " The American College of Obstetricians and Gynecologists recommends that acute-onset, severe hypertension be treated with first line-therapy (intravenous labetalol, intravenous hydralazine or oral nifedipine) within 60 minutes to reduce risk of maternal morbidity and death." | 3.96 | Identification of factors associated with delayed treatment of obstetric hypertensive emergencies. ( Akerman, MB; Elsayad, A; Halpern, TA; Heiselman, CJ; Heo, HJ; Kantorowska, A; Muscat, JC; Sicuranza, GB; Vintzileos, AM, 2020) |
| "Labetalol inhibited activation of the renin-angiotensin system and helped control paradoxical hypertension after coarctation repair in children." | 3.96 | Labetalol Infusion Attenuates Paradoxical Hypertension and Decreases Plasma Renin Activity After Repair of Coarctation of the Aorta in Children. ( Charlton, GA; Friesen, RH; Friesen, RM; Ladd, DR, 2020) |
| "To evaluate the effect on arterial blood pressure (ABP) of labetalol infusion as treatment for perioperative non nociceptive acute hypertension in dogs." | 3.96 | Retrospective evaluation of labetalol as antihypertensive agent in dogs. ( Corletto, F; De Gennaro, C; Zublena, F, 2020) |
| "Intravenous (IV) hydralazine, enalapril and labetalol are oftentimes used without indication for the treatment of asymptomatic hypertension in the hospital setting and have been shown to have substantial adverse effects that are associated with increased morbidity and mortality, as well as longer length of stay." | 3.91 | Improving the use of intravenous antihypertensive medications in the hospital setting: a quality improvement initiative for patient safety. ( Chams, N; Gjeka, R; Kumar, S; Peterson, D; Ross, I; Salman, A; Salman, J; Tegeltija, V, 2019) |
| " Nicardipine and labetalol are commonly administered for the treatment of acute hypertension following stroke." | 3.91 | Nicardipine Associated Risk of Short-Term Mortality in Critically Ill Patients with Ischemic Stroke. ( Desai, A; Hanni, C; Mohamed, W; Parker, D; Saber, H; Sadeghi, M; Singh, A, 2019) |
| " labetalol hydrochloride with doses greater than 300 mg in 24 hours observed a high rate of bradycardia and hypotension, but the study found that these events rarely caused clinically significant hemodynamic compromise and was not statistically associated with adverse events." | 3.91 | Safety of high-dose intravenous labetalol in hypertensive crisis. ( Brandt, MM; Hecht, JP; Mahmood, SM, 2019) |
| " Hypertension failed to be controlled with multiple doses of oral clonidine and intravenous labetalol." | 3.91 | Hypertensive Urgency: An Undesirable Complication of a "Male Performance" Herbal Product. ( Prescott, A; Smereck, J, 2019) |
| "Labetalol and nicardipine are antihypertensives commonly used in the management of elevated blood pressure (BP) following an acute stroke, but there is limited evidence to suggest which agent as a continuous infusion should be used preferentially in this setting." | 3.88 | Continuous-Infusion Labetalol vs Nicardipine for Hypertension Management in Stroke Patients. ( Hecht, JP; Richards, PG, 2018) |
| "The aim of this study was to evaluate the use of as-needed (PRN) labetalol and hydralazine [intravenous (IV) or oral] in hospitalized medicine patients for the treatment of severe asymptomatic hypertension and to examine the potential negative outcomes associated with their use." | 3.88 | Retrospective review of the use of as-needed hydralazine and labetalol for the treatment of acute hypertension in hospitalized medicine patients. ( Gaynor, MF; Vondracek, S; Wright, GC, 2018) |
| "The study was performed to assess the response & side effects of injectable Labetalol in the treatment of pregnancy induced severe hypertension." | 3.85 | Response & Side Effects of Injectable Labetalol in Pregnancy Induced Severe Hypertension. ( Ahmed, MU; Akter, FA; Alom, M; Begum, F; Biswas, D; Ferdousi, RA; Hossain, MZ; Nahar, K; Rahman, MM; Razi, RZ, 2017) |
| "Topical cocaine is sometimes used for the treatment of epistaxis, as it has both potent anesthetic and vasoconstrictive properties." | 3.85 | Acute Toxicity from Topical Cocaine for Epistaxis: Treatment with Labetalol. ( Lange, RA; Laurin, EG; Richards, JR; Tabish, N, 2017) |
| "Hypertensive pregnant women who do not respond to treatment with labetalol to control blood pressure (BP), but require vasodilatory therapy, progress rapidly to severe hypertension." | 3.85 | Longitudinal hemodynamics in acute phase of treatment with labetalol in hypertensive pregnant women to predict need for vasodilatory therapy. ( Bolten, M; Chambers, JB; Kametas, NA; Papastefanou, I; Paraschiv, D; Stott, D, 2017) |
| "Our findings suggest that neonates born to mothers exposed to β blockers in late pregnancy, including labetalol, are at elevated risk for neonatal hypoglycemia and bradycardia." | 3.83 | Late Pregnancy β Blocker Exposure and Risks of Neonatal Hypoglycemia and Bradycardia. ( Bateman, BT; Desai, RJ; Fischer, MA; Hernandez-Diaz, S; Huybrechts, KF; Maeda, A; Mogun, H; Patorno, E; Seely, EW, 2016) |
| " Persistent bradycardia and hypotension, unresponsive to epinephrine and norepinephrine, were suspected to have been exacerbated by chronic labetalol therapy for resistant arterial hypertension." | 3.81 | Use of enoximone in management of anaphylaxis complicated by labetalol use. ( Conway Morris, A; Hayhoe, S; Navapurkar, V, 2015) |
| "This study aimed to compare the effects of labetalol, nicardipine, or hydralazine on time to target blood pressure before alteplase administration in patients with acute ischemic stroke." | 3.81 | Time to Blood Pressure Control Before Thrombolytic Therapy in Patients With Acute Ischemic Stroke: Comparison of Labetalol, Nicardipine, and Hydralazine. ( Cortes, J; Hall, AB; McKay, C, 2015) |
| " Antenatally, her blood pressure was controlled with labetalol, and blood tests including serum creatinine were within normal limits for pregnancy." | 3.81 | Fulminant antenatal pulmonary oedema in a woman with hypertension and superimposed preeclampsia. ( Kubota-Sjogren, Y; Nelson-Piercy, C, 2015) |
| "We identified a cohort of 9750 patients with outpatient prescriptions for CCBs, methyldopa, or labetalol for pre-existing or gestational hypertension whose days of supply overlapped with delivery; 1226 were exposed to CCBs." | 3.79 | Outpatient calcium-channel blockers and the risk of postpartum haemorrhage: a cohort study. ( Bateman, BT; Ecker, JL; Fischer, MA; Hernandez-Diaz, S; Huybrechts, KF; Mogun, H; Palmsten, K; Seely, EW, 2013) |
| "The use of antihypertensive drugs in pregnancy is relatively common and is increasing, with the liberal use of methyldopa and (especially) labetalol contributing appreciably to this increase." | 3.79 | Trends in using beta-blockers and methyldopa for hypertensive disorders during pregnancy in a Canadian population. ( Guo, Y; Krewski, D; Mattison, D; Nerenberg, K; Walker, MC; Wen, SW; Xie, RH, 2013) |
| "Nicardipine and labetalol are two commonly used antihypertensives for treating elevated blood pressures in the setting of intracerebral hemorrhage (ICH) and subarachnoid hemorrhage (SAH)." | 3.79 | Effectiveness and safety of nicardipine and labetalol infusion for blood pressure management in patients with intracerebral and subarachnoid hemorrhage. ( Agarwal, S; Badjatia, N; Carpenter, AM; Claassen, J; Lantigua, H; Lee, K; Lesch, C; Li, M; Mayer, SA; Ortega-Gutierrez, S; Reccius, A; Schmidt, JM; Thomas, J, 2013) |
| " A diagnosis of Raynaud's phenomenon of the nipple was made after she began taking labetalol for pregnancy-induced hypertension." | 3.79 | Raynaud's phenomenon of the nipple associated with labetalol use. ( Cording, V; McGuinness, N, 2013) |
| "American Heart Association/American Stroke Association guidelines for management of aneurysmal subarachnoid hemorrhage (aSAH) recommend blood pressure (BP) control, utilizing labetalol or nicardipine, but do not differentiate efficacy between the two agents." | 3.78 | Retrospective evaluation of nicardipine versus labetalol for blood pressure control in aneurysmal subarachnoid hemorrhage. ( Barletta, JF; DeShane, RS; Figueroa, BE; McAllen, KJ; Woloszyn, AV, 2012) |
| "Preoperative alpha- and beta-adrenergic receptor block with phenoxybenzamine and labetalol, the intraoperative course of a 4-month-old infant with neuroblastoma and elevated catecholamines causing sweating, hypertension, and tachycardia, are presented." | 3.75 | Catecholamine-secreting neuroblastoma in a 4-month-old infant: perioperative management. ( Hernandez, MR; Seefelder, C; Shamberger, RC, 2009) |
| "We investigated the effects of labetalol and pindolol on uterine, placental, and fetal hemodynamics following norepinephrine-induced maternal hypertension in a sheep model of increased placental vascular resistance." | 3.75 | Placental and fetal hemodynamics after labetalol or pindolol in a sheep model of increased placental vascular resistance and maternal hypertension. ( Acharya, G; Alahuhta, S; Erkinaro, T; Haapsamo, M; Kavasmaa, T; Mäkikallio, K; Ohtonen, P; Räsänen, J; Ylikauma, L, 2009) |
| "Evaluate the ease of use and tolerability of labetalol (L) and nicardipine (N) for hypertension management in patients with acute stroke." | 3.74 | A comparison of nicardipine and labetalol for acute hypertension management following stroke. ( Coplin, WM; Janisse, J; Liu-Deryke, X; Norris, G; Parker, D; Rhoney, DH, 2008) |
| "We report a case of a large labetalol overdose in an eight-month-old infant that was being treated for hypertension following surgery for coarctation of the aorta." | 3.74 | Severe labetalol overdose in an 8-month-old infant. ( Eiríksson, H; Helgason, H; Johannesdottir, A; Thorsteinsson, A, 2008) |
| " In response to moderate hypertension the patient received intravenous labetalol hydrochloride 20 mg." | 3.73 | Inadvertent intrathecal injection of labetalol in a patient undergoing post-partum tubal ligation. ( Balestrieri, PJ; Blank, RS; Grubb, CT; Hamza, MS; Ting, PH, 2005) |
| "To research the cerebral hemodynamic effects of labetalol in pregnant women with hypertension." | 3.71 | Labetalol decreases cerebral perfusion pressure without negatively affecting cerebral blood flow in hypertensive gravidas. ( Allen, JC; Belfort, MA; Dizon-Townson, D; Tooke-Miller, C; Varner, MA, 2002) |
| "This case highlights the possibility of a more rapid perioperative control of pheochromocytoma using high doses of labetolol and a magnesium sulfate infusion to achieve stable intraoperative hemodynamics during laparoscopic resection of pheochromocytoma." | 3.71 | Rapid preparation of a patient with pheochromocytoma with labetolol and magnesium sulfate. ( Chin, EY; Poopalalingam, R, 2001) |
| "In 21 pregnancies complicated by pregnancy-induced hypertension (PIH) which was treated by antihypertensive drugs (labetalol, nifedipine), fetal behavioural recordings (quiet state, C1F; active state, C2F; no coincidence, NOC) and Doppler measurements of blood flow velocity in the umbilical artery (UA) (resistance index, RI) were made on two occasions (27-32 and 33-36 weeks of gestation)." | 3.70 | Pregnancy-induced hypertension, antihypertensive drugs and the development of fetal behavioural states. ( Bruschettini, PL; Gazzolo, D; Russo, A; Santi, F; Scopesi, F; Visser, GH, 1998) |
| "An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0." | 3.70 | An unusual toxic reaction to axillary block by mepivacaine with adrenaline. ( Koscielniak-Nielsen, ZJ, 1998) |
| "Our report describes the outcome of a twin pregnancy in a woman who was maintained on tacrolimus after a living related renal transplant." | 3.70 | Outcome of twin pregnancy in a renal transplant recipient treated with tacrolimus. ( Anderson, V; Baqi, N; Hidalgo, G; Kumar, A; Markell, MS; Piecuch, S; Singh, A; Vyas, S, 1999) |
| "The aim of the study was to investigate cord blood leptin concentrations and their relationship to birth weight and gender in term pregnancies complicated by pre-eclampsia." | 3.70 | Serum leptin concentration in cord blood: relationship to birth weight and gender in pregnancies complicated by pre-eclampsia. ( Hartmann, BW; Laml, T; Preyer, O; Ruecklinger, E; Soeregi, G; Wagenbichler, P, 2000) |
| "A 22-year-old woman diagnosed with pheochromocytoma was medically managed at 33 weeks gestation with oral phenoxybenzamine and labetalol until delivery 26 days later." | 3.69 | Phenoxybenzamine placental transfer during the third trimester. ( Santeiro, ML; Stromquist, C; Wyble, L, 1996) |
| "The effect of intravenously-administered labetalol (1 mg/kg) on uterine and fetal hemodynamics and fetal cardiac function was studied in 13 women with pregnancy-induced hypertension." | 3.68 | Effect of labetalol infusion on uterine and fetal hemodynamics and fetal cardiac function. ( Jouppila, P; Räsänen, J, 1993) |
| "Eleven patients with moderate to severe hypertension were pre-treated with oral labetalol 800-1200 mg/day for one week, prior to receiving two i." | 3.68 | Effect of intravenous dopamine on blood pressure and plasma insulin in hypertensive patients. ( Forte, P; Hernandez Pieretti, O; Luchsinger, A; Martin, G; Mendoza, F; Romero, E; Urbina-Quintana, A; Velasco, M, 1993) |
| "The hypotensive effect, kinetics, and concentration-response relationship of labetalol, alpha beta- and alpha 1-adrenoceptor blocking drug, were studied in seven women with a moderate-to-severe hypertension (averaged diastolic blood pressure [DBP] of 100 to 120 mm Hg measured during a 1- to 2-day hospitalization period) during the third trimester of pregnancy who received the oral twice-daily doses of 150 to 450 mg." | 3.68 | Labetalol in hypertension during the third trimester of pregnancy: its antihypertensive effect and pharmacokinetic-dynamic analysis. ( Echizen, H; Ishizaki, T; Minoura, S; Saotome, T; Sato, T; Terashi, K, 1993) |
| "Hypertension develops in most patients after transplantation when immunosuppression is based on cyclosporine and prednisone." | 3.68 | De novo hypertension after liver transplantation. ( Textor, SC, 1993) |
| "Forty eight neonates, born to mothers suffering from pregnancy induced hypertension and receiving labetalol for control of blood pressure, were studied for the possible adverse effects of the drug." | 3.68 | Effects of maternal labetalol on the newborn infant. ( Deorari, AK; Munshi, UK; Paul, VK; Singh, M, 1992) |
| "Although labetalol (LAB), the combination of an alpha- and beta-adrenergic blocking agent, is thought to be effective and safe for the control of postoperative hypertension, no study has focused on changes in left ventricular (LV) function when this drug was used to control postoperative hypertension." | 3.68 | Transesophageal echocardiographic assessment of left ventricular function in response to labetalol for control of postoperative hypertension. ( Baron, JF; Coriat, P; Gosgnach, M; Le Bret, F; Reiz, S; Viars, P, 1992) |
| "7 years, mean +/- SD) received intravenous doses of labetalol, an alpha 1- and beta-adrenergic blocker, on 15 separate occasions for treatment of hypertension." | 3.68 | Intravenously administered labetalol for treatment of hypertension in children. ( Bunchman, TE; Lynch, RE; Wood, EG, 1992) |
| "8 mg/kg of an intravenous bolus of labetalol on maternal and fetal hemodynamics was investigated in ten women with pregnancy-induced hypertension." | 3.68 | Single dose of labetalol in hypertensive pregnancy: effects on maternal hemodynamics and uterine and fetal flow velocity waveforms. ( Ekblad, UU; Erkkola, RU; Mäkinen, JI; Pirhonen, JP, 1991) |
| " This patient with Marfan syndrome whose case is reported herein presented with chest pain, hypertensive crisis, and aortic insufficiency; labetalol was used successfully to treat the acute hypertensive crisis and magnetic resonance imaging (MRI) was used to differentiate between aortic dissection and an expanding aortic aneurysm." | 3.68 | Labetalol and MRI as initial medical and diagnostic modalities in a marfanoid patient with expanding ascending aortic aneurysm. ( Baciewicz, FA; Grubb, B; Laden, N, 1990) |
| "Pharmacokinetic parameters of oral labetalol were studied in eight women with pregnancy-induced hypertension in the third trimester of pregnancy." | 3.68 | Labetalol pharmacokinetics in pregnancy-induced hypertension. ( Rogers, RC; Sibai, BM; Whybrew, WD, 1990) |
| "Three renal transplant recipients developed potentially life-threatening hyperkalemia after receiving intravenous labetalol for postoperative hypertension." | 3.68 | Hyperkalemia associated with intravenous labetalol therapy for acute hypertension in renal transplant recipients. ( Arthur, S; Greenberg, A, 1990) |
| "Forty-one patients (21 males and 20 females) suffering from arterial hypertension associated with peripheral and cerebral vascular distress were treated for a period of 60 days with an extempore combination of labetalol (an antihypertensive drug with an alpha- and beta-blocking action) and flunarizine (a calcium-antagonist)." | 3.67 | Combined labetalol plus flunarizine treatment for arterial hypertension. ( Bonavita, E, 1984) |
| "We determined echocardiographic (M-mode) indices of left ventricular mass and function serially at 1-month intervals in 10 patients with uncomplicated mild or moderate essential hypertension, before and after adequate control of blood pressure with labetalol, a combined alpha- and beta-receptor blocking agent." | 3.67 | Effects of labetalol on left ventricular mass and function in hypertension--an assessment by serial echocardiography. ( Bhatia, ML; Kaul, U; Mohan, JC, 1984) |
| "A single oral dose of 300 mg labetalol was given to 10 subjects with uncomplicated primary hypertension; its effects on blood pressure, heart rate (HR), plasma renin activity (PRA), and plasma concentration of catecholamines and of their major metabolites, octopamine ( OTP ), and dopamine-beta hydroxylase (DbH) were investigated." | 3.67 | Acute effect of labetalol on blood pressure in relation to the sympathetic nervous system and plasma renin activity. ( Alexander, N; Barr, J; Maronde, R; Velasquez, M; Vlachakis, ND, 1984) |
| "The intravenous administration of labetalol, a combined alpha- and beta-adrenergic receptor blocking agent, reduced diastolic blood pressure by 30 mm Hg or more in 15 of 17 patients with severe hypertension (supine diastolic blood pressure greater than or equal to 125 mm Hg)." | 3.67 | Intravenous labetalol in the management of severe hypertension and hypertensive emergencies. ( Cressman, MD; Gifford, RW; Moore, WS; Vidt, DG; Wilson, DJ, 1984) |
| "To investigate the safety of labetalol in the treatment of hypertension in patients with heart failure, sixteen hypertensive patients with a history of congestive heart failure and an ejection fraction at rest less than 45%, had measurements of ejection fraction and cardiac output by first pass radionuclide angiography at baseline, at the end of 2 weeks maintenance with labetalol (titrated to the effective antihypertensive dose of 200-1600 mg daily), and in the post-treatment placebo period." | 3.67 | Hemodynamic effects of labetalol in patients with combined hypertension and left ventricular failure. ( Berger, H; Cubbon, J; Escala, E; Johnson, LL; Jones, RH; Ramanathan, KB; Sciacca, R, 1988) |
| "Dilevalol, the stereoisomer of labetalol, was given in repeated incremental intravenous bolus injections to 10 patients with severe hypertension requiring urgent blood pressure lowering." | 3.67 | Intravenous dilevalol in the treatment of severe hypertension. ( Blasucci, DJ; Bursztyn, M; Gavras, H; Gavras, I, 1989) |
| "Labetalol is an alpha 1- and beta-adrenergic antagonist currently used in the treatment of hypertension." | 3.67 | Effects of age on the elimination of labetalol. ( Rocci, ML; Sirgo, MA; Valiquett, T, 1989) |
| " The mother had been treated with adequate doses of labetalol because of pregnancy-induced hypertension and her plasma concentration was found to be 89 micrograms/l one day after delivery." | 3.67 | Half-life of maternal labetalol in a premature infant. ( Geven, W; Haraldsson, A, 1989) |
| "Intravenous labetalol is commonly used in the management of hypertensive emergencies or urgencies as well as postoperative hypertension." | 3.67 | The safety of cumulative doses of labetalol in perioperative hypertension. ( Cosentino, F; Little, JR; Orlowski, JP; Shiesley, D; Vidt, DG, 1989) |
| "The effect of long-term treatment with propranolol (45 patients), trasicor (15), visken (23) and combinations thereof with phentolamine and labetalol (12) on submaximum exercise tolerance was studied in patients with second-stage essential hypertension." | 3.67 | [Effect of beta-adrenergic blockaders and their combination with an alpha-adrenergic blockader on physical exertion tolerance in patients with hypertension]. ( Smirnov, GB, 1986) |
| "The aim of this study was a comparison between the hypotensive effects of two fixed combinations (atenolol + chlorthalidone and labetalol + chlorthalidone) in patients suffering from untreated mild to moderate hypertension." | 3.67 | Antihypertensive therapy with diuretics and beta-blockers at fixed dosage: comparison between the combinations labetalol plus chlorthalidone and atenolol plus chlorthalidone. ( Cumetti, C; De Cristofaro, A; Montanari, C; Roja, M; Vergani, A, 1985) |
| "The antihypertensive effect of labetalol was evaluated in 18 adult black patients with mild to moderate essential hypertension previously controlled with a combination of a diuretic and a beta blocker." | 3.67 | Labetalol as monotherapy in hypertensive black patients. ( Cubberley, RB, 1985) |
| "The efficacy and safety of labetalol therapy were evaluated in 20 patients 60 years and older with isolated systolic or diastolic hypertension and 19 patients aged younger than 60 years with diastolic hypertension." | 3.67 | Labetalol in the treatment of hypertension in elderly and younger patients. ( Abernethy, DR; Bartos, P; Plachetka, JR, 1987) |
| "Dilevalol hydrochloride, the R-R optical isomer of labetalol hydrochloride, was administered intravenously to subjects with severe hypertension." | 3.67 | Intravenous dilevalol. Effects of the R-R optical isomer of labetalol in patients with severe hypertension. ( Blasucci, DJ; Clifton, GG; Cook, ME; Poland, M; Wallin, JD, 1988) |
| "Forearm arterial hemodynamics, including measurements of brachial artery diameter and compliance with pulsed Doppler velocimetry, were determined before and after acute administration of labetalol in patients with sustained essential hypertension." | 3.67 | Acute effect of labetalol on hypertensive brachial artery. ( Cournot, AX; Georges, DR; Pappo, M; Pithois-Merli, IM; Safar, ME, 1987) |
| "22 patients with untreated, essential hypertension (diastolic blood-pressure greater than or equal to 140 mmHg) and in most cases also showing neurological symptoms were given a single oral dose of 400 mg labetalol." | 3.67 | Treatment of severe hypertension with peroral labetalol. ( Frithz, G, 1987) |
| "Five patients with essential hypertension who were receiving treatment with the beta- and alpha-adrenoreceptor-blocking drug labetalol had elevated urinary excretion of catecholamines." | 3.67 | Falsely elevated urinary excretion of catecholamines and metanephrines in patients receiving labetalol therapy. ( Feldman, JM, 1987) |
| "Labetalol, a drug possessing both alpha- and beta-adrenergic blocking activities, is used in the treatment of hypertension." | 3.67 | Rising multiple-dose pharmacokinetics of labetalol in hypertensive patients. ( Chung, M; Gural, RP; Leitz, FH; Maier, G; Patrick, JE; Symchowicz, S, 1986) |
| "This study documents our experience with labetalol administered by continuous intravenous infusion for severe hypertension." | 3.67 | Labetalol by continuous intravenous infusion in severe hypertension. ( Goodman, RP; Minisi, AJ; Wilson, DJ; Wright, JT, 1986) |
| " The hypertension, which peaked at 200/160 mm Hg and was associated with severe headache and diaphoresis, responded expeditiously to two initial intravenous doses of labetalol." | 3.67 | Pseudoephedrine-induced hypertensive emergency: treatment with labetalol. ( Mariani, PJ, 1986) |
| "The transfer of labetalol into human breast milk and amniotic fluid was studied in women with pregnancy hypertension." | 3.67 | Transfer of labetalol into amniotic fluid and breast milk in lactating women. ( Kulas, J; Lunell, NO; Rane, A, 1985) |
| "The effects of labetalol on serum lipoproteins, the intravenous fat tolerance test (IVFTT) and lipoprotein lipase (LPL) and hepatic lipase (HL) activities were studied in 16 patients with mild hypertension before and after 6 months of therapy." | 3.67 | Effects of long-term therapy with labetalol on lipoprotein metabolism in patients with mild hypertension. ( Eliasson, K; Hylander, B; Nilsson-Ehle, P; Rössner, S, 1985) |
| "The effectiveness, safety, and pharmacodynamics of repeated doses of intravenous labetalol for rapid reduction of severe hypertension and of subsequent oral labetalol dosing were studied." | 3.67 | Pharmacodynamics of intravenous labetalol and follow-up therapy with oral labetalol. ( Kassem, N; Maloy, JW; Maronde, RF; Medakovic, M; Vlachakis, ND, 1985) |
| " To verify whether or not this is due to reduction in alpha-blocking activity, phenylephrine-induced increase in blood pressure was studied in six subjects with mild essential hypertension before and after 3 and 6 days and 1 and 6 mo of continuous treatment with 200 mg labetalol three times a day by mouth." | 3.66 | Alpha-adrenoceptor blockade by labetalol during long-term dosing. ( Hlede, M; Morandin, F; Pessina, AC; Rossi, GP; Semplicini, A, 1983) |
| "Labetalol, a new beta-adrenoceptor blocking drug with ancillary alpha-adrenoceptor blocking and vasodilating activity, will soon be available in the United States for the treatment of hypertension." | 3.66 | Labetalol: an alpha- and beta-adrenoceptor blocking drug. ( Frishman, WH; Michelson, EL, 1983) |
| "Labetalol was administered as the sole antihypertensive agent to 20 ambulatory patients with mild to moderate hypertension." | 3.66 | Labetalol: potent antihypertensive agent that blocks both alpha- and beta-adrenergic receptors. ( Logan, AG; Milne, BJ, 1980) |
| "In 14 patients with essential hypertension, the influence of the alpha- and beta-adrenoceptor blocking drug labetalol on blood pressure, heart rate, plasma renin, plasma noradrenaline and pressor effect of exogenous noradrenaline was investigated during long-term treatment." | 3.66 | Sympathetic nervous activity and the pressor effect of noradrenaline under chronic alpha-beta-adrenoceptor blockade with labetalol in hypertension. ( Distler, A; Lüth, JB; Neurohr, W; Philipp, T; Zschiedrich, H, 1983) |
| "26 patients with moderate hypertension and no signs of heart failure were treated with metoprolol, labetalol or prazosin." | 3.66 | The use of systolic time intervals in the evaluation of antihypertensive treatment with metoprolol, labetalol and prazosin. ( Buch, J; Rasmussen, S, 1983) |
| "This study reports the results that were obtained in 56 cases of arterial hypertension in pregnancy solely by beta-blocking with Atenolol or Labetalol." | 3.66 | [Effect of 2 beta-blockers on arterial hypertension during pregnancy. Results of a prospective study on 56 pregnant hypertensive women treated with atenolol and labetalol]. ( Beauséjour, B; Blazquez, G; Faurie, C; Flouvat, B; Gérard, J; Lardoux, H; Rousset, D, 1983) |
| "Labetalol, an alpha and beta adrenergic blocking drug, was used during anesthesia for removal of a very large pheochromocytoma which was predominantly epinephrine secreting." | 3.66 | Use of labetalol during anesthesia for pheochromocytoma removal. ( de Rood, M; Lambilliotte, JP; Levarlet, M; Lignian, H; Van Stratum, M, 1983) |
| "Labetalol has been successful in treating hypertension, and few side effects have been reported, although there have been cases of muscle pain during treatment." | 3.66 | Labetalol-induced toxic myopathy. ( Kissin, E; Rosenthal, T; Sarova, I; Teicher, A, 1981) |
| "Labetalol was used to treat systemic hypertension (systolic blood pressure above 150 mmHg) in 11 patients with acute myocardial infarction; its haemodynamic effects and tolerance were studied." | 3.66 | Treatment of hypertension in acute stage of myocardial infarction. Haemodynamic effects of labetalol. ( Bernard, R; Jacobs, P; Renard, M; Rivière, A, 1983) |
| "1 Labetalol pharmacokinetics and concentration-effect relationships following intravenous administration have been studied in 10 women during the last trimester of pregnancies complicated by hypertension, in seven of these women postpartum (when normotensive) and in 10 normotensive female volunteers." | 3.66 | Labetalol disposition and concentration-effect relationships during pregnancy. ( Butters, L; Fitzsimons, C; Kelman, AW; Reid, JL; Rubin, PC, 1983) |
| "In 12 patients with resistant hypertension labetalol was added to existing therapy." | 3.66 | Labetalol in resistant hypertension. ( Hedstrand, H, 1982) |
| "Labetalol was given to women with hypertension of pregnancy in their last trimester to study its acute effect on circulation and metabolism." | 3.66 | Labetalol, a combined alpha- and beta-blocker, in hypertension of pregnancy. ( Fredholm, B; Hjemdahl, P; Lewander, R; Lunell, NO; Nisell, H; Nylund, L; Persson, B; Sarby, B; Wager, J, 1982) |
| "1 Labetalol has been used to treat 163 patients at the Dunedin Hypertension Clinic for periods up to 6." | 3.66 | Review of long-term treatment with labetalol. ( Simpson, FO; Waal-Manning, HJ, 1982) |
| "The effects of labetalol, an alpha- and beta-adrenoceptor blocking drug, on blood pressure, heart rate, plasma renin activity (PRA) and plasma aldosterone were studied in 17 adult patients with essential hypertension." | 3.66 | [Essential arterial hypertension. Effects of labetalol on blood pressure and renin-angiotensin system (author's transl)]. ( Corvol, P; Lardoux, H; Martinand, A; Milliez, P, 1980) |
| "Arterial blood pressure and plasma catecholamines, renin activity and aldosterone concentration in 12 patients with severe essential hypertension were studied before and after combined alpha- and beta- adrenoceptor blockade induced by oral labetalol treatment for 2 months." | 3.66 | Plasma catecholamines, renin and aldosterone during combined alpha- and beta- adrenoceptor blockade in patients with severe arterial hypertension. ( Christensen, NJ; Kornerup, HJ; Pedersen, A; Pedersen, EB; Pedersen, G, 1980) |
| "Labetalol, a blocker of alpha- and beta-adrenoreceptors, was tried on 45 patients with severe (29 cases) or mild to moderate (16 cases) hypertension." | 3.66 | [Effects of labetalol, a new alpha- and beta-adrenoreceptor blocking drug, on arterial pressure, renal function and renin activity (author's transl)]. ( Pozet, N; Sassard, J; Vincent, M; Zech, P, 1980) |
| "2-Hydroxy-(1-hydroxy-[(1-methyl-3-phenylpropyl)amino]-2-ethyl)-5-benzamide (labetalol), a new alpha- and beta-adrenergic blocking agent, was employed in 21 patients with severe hypertension by slow (6 patients) and rapid (15 patients) i." | 3.66 | Intravenous labetalol in severe hypertension. Effects on blood pressure, plasma renin activity and catecholamines. ( Cesura, AM; Covi, G; Danti, G; Lechi, A; Mattioli, M; Pedrolli, E; Picotti, GB; Pomari, S, 1981) |
| "The effect of labetalol on blood pressure, heart rate and the renin-angiotensin system was evaluated in 12 patients with severe essential hypertension (diastolic blood pressure greater than or equal to 120 mmHg, WHO: Phase I and II) who had been resistant to other therapeutic regimens." | 3.66 | Treatment of severe essential hypertension with labetalol: effect on active and inactive renin. ( Hauger-Klevene, JH, 1981) |
| "1 Eighty-five women with severe hypertension complicating pregnancy were treated with oral labetalol (Trandate)." | 3.66 | The evaluation of labetalol in the treatment of hypertension complicating pregnancy. ( Michael, CA, 1982) |
| "1 The anti-hypertensive effect of labetalol given twice or three times daily was evaluated in ambulant subjects with essential hypertension by recording blood pressure directly for 24 h before and after 15 d of labetalol administration (daily dose 600-1800 mg)." | 3.66 | Blood pressure response to labetalol in twice and three times daily administration during a 24-hour period. ( Bertinieri, G; Ferrari, A; Grassi, G; Gregorini, L; Mancia, G; Navone, F; Parati, G; Pomidossi, G; Zanchetti, A, 1982) |
| "1 Labetalol 100 mg was given intravenously to 27 patients with essential hypertension (12 males, 15 females; WHO I-II; age range 30-66 yr; on average, a significant reduction of blood pressure was observed within 5 min (P less than 0." | 3.66 | The acute and chronic hypotensive effect of labetalol and the relationship with pretreatment plasma noradrenaline levels. ( Agabiti-Rosei, E; Alicandri, CL; Beschi, M; Castellano, M; Fariello, R; Montini, E; Muiesan, G; Muiesan, ML; Romanelli, G, 1982) |
| "1 Labetalol was administered by intravenous infusion or by the combination of intravenous bolus injection plus infusion to 15 patients with severe essential hypertension and to one with phaeochromocytoma." | 3.66 | Intravenous labetalol in severe hypertension. ( Dal Palu, C; Hlede, M; Morandin, F; Palatini, P; Pessina, AC; Rossi, GP; Semplicini, A; Sperti, G, 1982) |
| "1 We have compared, in patients with severe hypertension, the administration of intravenous labetalol by single rapid injection, by repeated bolus injections, and by incremental infusion." | 3.66 | Intravenous labetalol in the treatment of severe hypertension. ( Brown, JJ; Cumming, AM; Lever, AF; Robertson, JI, 1982) |
| "Basal hemodynamics and plasma catecholamines were measured in 10 patients with systolic hypertension, 7 males and 3 females, aged 38-69 years (Group 1), and in 10 patients with systolic and diastolic hypertension, 7 males and 3 females, aged 40-65 years (Group 2); the same measurements were repeated after acute pharmacological alpha and beta-blockade with Labetalol, 100 mg iv, or Propranolol, 10 mg iv, plus Phentolamine, 10 mg iv." | 3.66 | Adrenergic activity in systolic hypertension. ( Agabiti-Rosei, E; Alicandri, C; Beschi, M; Boni, E; Castellano, M; Fariello, R; Muiesan, G; Muiesan, ML; Romanelli, G, 1982) |
| "The effectiveness of repeated intravenous injections of labetalol in reducing blood pressure (BP) was evaluated in patients with severe hypertension." | 3.66 | Treatment of severe hypertension with intravenous labetalol. ( Freis, ED; Khatri, IM; Notargiacomo, AV; Papademetriou, V, 1982) |
| " doses of labetalol were evaluated in 10 normovolaemic sedated patients presenting with hypertension and tachycardia in the early period after myocardial revascularization." | 3.66 | I.v. labetalol in the treatment of hypertension following coronary-artery surgery. ( Forster, A; Morel, DR; Suter, PM, 1982) |
| "Intracranial pressure measurements and ventricular volume pressure response curves were made during induced hypotension with labetalol, a combined alpha- and beta-adrenoceptor antagonist, in dogs without (group I) and with (group II) intracranial hypertension." | 3.66 | Effect of labetalol on intracranial pressure in dogs with and without intracranial hypertension. ( Heinecke, A; Puchstein, C; Schweppe, ML; Van Aken, H, 1982) |
| "Renal function studies were performed in subjects with mild hypertension treated with labetalol (n = 5) and moderate to moderately severe hypertension treated in a random double-blind fashion with either labetalol (n = 6) or methyldopa (n = 6)." | 3.66 | Effects of labetalol and methyldopa on renal function. ( Clifton, G; Cruz, F; O'Neill, WM; Wallin, JD, 1981) |
| "Eleven patients suffering from WHO stage II essential arterial hypertension were treated with the combination of labetalol plus chlorthalidone in the reciprocal ratio of 10:1 in the form of once-a-day administration in the morning." | 3.66 | Use of the the combination labetalol plus chlorthalidone in essential arterial hypertension therapy. ( Rossi, AG, 1981) |
| "1 Seven women with hypertension of pregnancy were given the combined alpha- and beta-adrenoceptor blocking drug labetalol (50 mg i." | 3.66 | Circulatory and metabolic effects of a combined alpha- and beta-adrenoceptor blocker (labetalol) in hypertension of pregnancy. ( Fredholm, BB; Hjemdahl, P; Lunell, NO; Nisell, H; Persson, B; Wager, J, 1981) |
| "1 In a single blind study seventeen patients with mild or moderate essential hypertension and normal renal function were treated with labetalol alone in increasing doses from 300 via 600 to 1200 mg daily." | 3.66 | Blood pressure, body fluid volumes and glomerular filtration rate during treatment with labetalol in essential hypertension. ( Nielsen, PE; Rasmussen, S, 1981) |
| " Six weeks' treatment with labetalol (600 mg/day) significantly reduced systolic and diastolic blood pressures in 24 patients with essential hypertension." | 3.66 | Effects of combined alpha- and beta-receptor blockade on peripheral circulation in essential hypertension. ( Heck, I; Stumpe, KO; Trübestein, G, 1981) |
| "A study was carried out in 73 patients with mild or moderate hypertension to assess the effectiveness of treatment with labetalol." | 3.66 | Experience with labetalol in essential hypertension. ( Elo, J; Nissinen, A; Tuomilehto, J, 1980) |
| "Plasma catecholamines and renal function were evaluated in 18 patients with essential hypertension treated with the alpha and beta adrenoceptor blocking agent, labetalol." | 3.66 | Effects of chronic alpha and beta adrenoceptor blockade with labetalol on plasma catecholamines and renal function in hypertension. ( de Châtel, R; Keusch, G; Reubi, FC; Weidmann, P; Ziegler, WH, 1980) |
| "An open study was undertaken in 31 patients with moderate to severe hypertension to compare labetalol (a competitive antagonist of both alpha-adrenoreceptors and beta-adrenoreceptors) alone and in combination with a thiazide diuretic, with a combination of thiazide, beta-adrenergic blocking agent and the alpha-adrenoreceptor blocker prazosin." | 3.66 | Use of labetalol in moderate to severe hypertension. ( Hua, AS; Kincaid-Smith, P; Macdonald, I; Thomas, GW; Whitworth, JA; Woo, KT, 1980) |
| "Labetalol has been used in 83 patients with severe hypertension resistant to a wide number of drugs." | 3.66 | Long-term experiences with labetalol. ( Adam, W; Hodgson, M; Morgan, T; Myers, J; Waga, S, 1980) |
| "The haemodynamic effects of labetalol were studied in patients with essential hypertension after acute and long-term administration." | 3.66 | Sequential haemodynamic effects of labetalol at rest and during exercise in essential hypertension. ( Hartling, OJ; Nielsen, PE; Rasmussen, S; Svendsen, TL; Trap-Jensen, J, 1980) |
| "The haemodynamic reaction to an acute emotional stress was tested in nine patients with essential and eleven with renal hypertension after an intravenous bolus of labetalol (0." | 3.66 | [The effect of combined alpha and beta blockade with labetalol on the haemodynamics of stress reaction in hypertensives (author's transl)]. ( Bahlmann, J; Brod, J; Hubrich, W; Pretschner, P, 1980) |
| "The efficacy of labetalol in lowering blood pressure was assessed in 18 patients with chronic renal failure and hypertension." | 3.66 | Labetalol in the treatment of hypertensive renal patients. ( Craswell, PW; De Voss, K; Williams, JG, 1978) |
| "1 The pharmacological and therapeutic effects of labetalol were investigated during an 8 h interdose period of chronic oral therapy in six patients with essential hypertension." | 3.66 | Interdose control of beta-blockade and arterial blood pressure during chronic oral labetalol treatment. ( Murray, A; Rawlins, MD; Sanders, GL, 1979) |
| "1 Forty-one patients with mild to moderate hypertension have been treated with labetalol for up to 5 years." | 3.66 | A long-term study of labetalol in general practice. ( Gregg, I; Kane, J; Stephens, MD, 1979) |
| "Three renal patients with transplant kidneys and uncontrolled hypertension were treated with intravenous doses of labetalol." | 3.66 | Poor hypotensive response and tachyphylaxis following intravenous labetalol. ( Anderson, CC; Gabriel, R, 1978) |
| "A patient treated for hypertension with labetalol developed left ventricular failure." | 3.66 | Left ventricular failure with labetalol. ( Bayley, TJ; Frais, MA, 1979) |
| "Arterial blood pressure and plasma catecholamines, renin activity and aldosterone concentration in 12 patients with severe essential hypertension were studied before and after combined alpha- and beta-adrenergic receptor blockage induced by oral labetalol treatment for 2 months." | 3.66 | Effect of oral labetalol on plasma catecholamines, renin and aldosterone in patients with severe arterial hypertension. ( Christensen, NJ; Kornerup, HJ; Pedersen, A; Pedersen, EB; Pedersen, G, 1979) |
| "Diazoxide, clonidine and labetalol, administered intravenously in fixed doses, were used to treat 30 episodes of severe hypertension in 27 patients." | 3.66 | Comparison of labetalol, clonidine and diazoxide intravenously administered in severe hypertension. ( Kincaid-Smith, P; Thomas, GW; Whitworth, JA; Yeung, CK, 1979) |
| "1 The efficacy of labetalol in the treatment of severe hypertension (diastolic greater than or equal to 115 mm Hg) was studied retrospectively." | 3.66 | Labetalol in severe and resistant hypertension. ( Murphy, MJ; Parsons, V; Williams, LC, 1979) |
| "1 Six previously untreated emergency admissions to hospital with severe hypertension were given oral treatment with labetalol." | 3.66 | Acute management of severe hypertension with oral labetalol. ( Ghose, RR, 1979) |
| "1 Labetalol, a hypotensive agent combining alpha- and beta-adrenoceptor antagonist properties, was used to treat severe hypertensive disease complicating pregnancy." | 3.66 | Use of labetalol in the treatment of severe hypertension during pregnancy. ( Michael, CA, 1979) |
| "1 In nine hypertensive subjects with angina pectoris, labetalol diminished the incidence of chest pain occurring spontaneously or induced by exercise." | 3.66 | Open evaluation of labetalol in the treatment of angina pectoris occurring in hypertensive patients. ( Besterman, EM; Spencer, M, 1979) |
| "1 Fifteen patients with suspected acute myocardial infarction and systemic BP of greater than 160/110 mmHg were treated with an incremental infusion of labetalol." | 3.66 | Labetalol infusion in acute myocardial infarction with systemic hypertension. ( Marx, PG; Reid, DS, 1979) |
| "Patients with essential hypertension were treated for four weeks with the alpha- and beta-adreno-receptor blocking agent labetalol." | 3.66 | Increased catecholamine excretion after labetalol therapy: a spurious effect of drug metabolites. ( De Quattro, V; Kolloch, R; Miano, L, 1979) |
| "The effects of intravenously administered labetalol on blood pressure and pulse rate were examined in 17 patients with severe hypertension." | 3.66 | Emergency treatment of severe hypertension with intravenous labetalol. ( Johnston, CI; Matthews, PG; Maydom, BW; McGrath, BP; Walter, NM, 1978) |
| "1 Labetalol, a beta- and alpha-adrenoreceptor-blocking drug, has been used in the treatment of hypertension in a total of 32 patients for over 4." | 3.65 | Labetalol in long-term treatment of hypertension. ( Boakes, AJ; Prichard, BN, 1976) |
| "Labetalol, a new antihypertensive drug which combines alpha- and beta-blocking properties, was used in an open clinical trial in a mixed group of 47 adult patients with mainly essential hypertension, many of whom had been poorly controlled on other drugs." | 3.65 | Treatment of hypertension with labetalol. ( Bolli, P; Seeman, HM; Simpson, FO; Waal-Manning, HJ, 1977) |
| "1 The efficacy of labetalol in lowering blood pressure has been assessed in a group of 16 patients with severe hypertension whose blood pressure was inadequately controlled (supine diastolic blood pressure greater than 110 mmHg on two consecutive occasions) on existing therapy or in whom severe side-effects necessitated a change in therapy." | 3.65 | Labetalol in resistant hypertension. ( Daniel, J; Dargie, HJ; Dollery, CT, 1976) |
| "1 Seventeen men, aged 45-57 yr, with essential hypertension showed obvious and, in the standing position, dose-related reductions in blood pressure during treatment with oral labetalol with weekly dose increments." | 3.65 | Anti-hypertensive action, time of onset and effects on carbohydrate metabolism of labetalol. ( Andersson, O; Berglund, G; Hansson, L, 1976) |
| " Initial dosing with nicardipine lowered acute diastolic BP than labetalol (least square mean difference (labetalol-nicardipine)=5." | 3.11 | Initial antihypertensive agent effects on acute blood pressure after intracerebral haemorrhage. ( Behymer, TP; Bettin, M; Christianson, T; Coleman, ER; Divani, A; Flaherty, ML; Gilkerson, LA; James, ML; King, NKK; Krishnamoorthy, V; Langefeld, CD; McCauley, JL; Ng, Y; Qi, W; Shah, S; Testai, FD; Walsh, KB; Woo, D, 2022) |
| "Labetalol is a good alternative drug to control hypertensive response during emergence from anesthesia for post-craniotomy." | 2.80 | An Equivalence Trial Comparing Labetalol and Diltiazem in Controlling Emergence Hypertension after Supratentorial Tumor Surgery. ( Punkla, W; Raksamani, K; Rushatamukayanunt, P; Sakaew, A; Sirivanasandha, B; Sutthivaiyakit, K; Waitayawinyu, P, 2015) |
| "This is a substudy of the multicenter safety and efficacy Evaluation of intravenous Cardene (nicardipine) and Labetalol Use in the Emergency department (CLUE) trial that randomized patients to Food and Drug Administration-recommended intravenous dosing of nicardipine or labetalol to reach a physician predefined systolic BP (SBP) and target range (TR) of ±20 mm Hg within 30 minutes." | 2.79 | Impact of initial blood pressure on antihypertensive response in patients with acute hypertension. ( Farias, S; Gonzalez, M; Levy, PD; Peacock, WF, 2014) |
| "Hypertension and tachycardia are common during fiber-optic bronchoscopy (FOB), and this may lead to cardiac ischemia." | 2.73 | Benzodiazepine and opioid sedation attenuate the sympathetic response to fiberoptic bronchoscopy. Prophylactic labetalol gave no additional benefit. Results of a randomized double-blind placebo-controlled study. ( Ben-Zvi, I; Fox, BD; Kramer, MR; Krylov, Y; Leon, P; Peled, N; Shitrit, D, 2008) |
| " Full-text, English-language articles describing IV labetalol and/or hydralazine use for non-emergent HTN in an inpatient setting that focused on clinical outcomes (ie vitals, adverse effects, healthcare utilisation) were included." | 2.72 | Safety and efficacy of intravenous hydralazine and labetalol for the treatment of asymptomatic hypertension in hospitalised patients: A systematic review. ( Cawoski, JR; Covvey, JR; DeBiasio, KA; Donnachie, SW; Guarascio, AJ; Montepara, CA; Nemecek, BD; Timanus, EA; Zimmerman, DE, 2021) |
| "Urapidil seems to be a good alternative to labetalol for attenuating the hypertensive response to ECT in cases where there is a contraindication to beta-antagonists." | 2.70 | Comparative hemodynamic effects of urapidil and labetalol after electroconvulsive therapy. ( Arcega, JM; Bernardo, M; Blanch, J; Faulí, A; Gomar, C; Imaz, ML; Martínez-Pallí, G; Navinés, R; Santos, P, 2001) |
| "Labetalol was started at 50 mg bid and as necessary increased by 50 mg bid every 2 weeks." | 2.68 | A dose-ranging study of labetalol in moderate to moderately severe hypertension. ( Anggraeni, E; Bahry, B; Darmansjah, I; Jusman, J; Parsoedi, I; Prabowo, P; Setiawati, A; Sukandar, E, 1995) |
| "Labetalol was well tolerated in this group of patients who had preserved ventricular function." | 2.68 | Effect of antihypertensive agents on the arterial partial pressure of oxygen and venous admixture after cardiac surgery. ( Wood, G, 1997) |
| "The dosage of urinary catecholamines and their metabolites is a main element of diagnosis in the research of a pheochromocytoma in patients with high blood pressure." | 2.67 | [Absence of labetalol interference on urine metanephrine determination in hypertensive patients]. ( Billaud, EM; Girerd, X; Laurent, S; Ropers, J; Safar, M; Safavian, A; Sorrel-Dejerine, A, 1992) |
| "Labetalol was well tolerated and no significant maternal toxicity was noted." | 2.67 | Does labetalol influence the development of proteinuria in pregnancy hypertension? A randomised controlled study. ( Campbell, DM; Cruickshank, DJ; MacGillivray, I; Robertson, AA, 1992) |
| " There were no significant age-related changes in pharmacokinetics for either acute or chronic treatment with dilevalol, although there were significant changes in elimination half-life from 7." | 2.67 | The effects of age on the pharmacokinetics, antihypertensive efficacy and general tolerability of dilevalol. ( Elliott, HL; Howie, CA; Macphee, GJ; Meredith, PA, 1991) |
| "The labetalol-treated patients were significantly less often above their diastolic BP goal throughout the 24-hour ABPM period (p less than 0." | 2.67 | Comparison of labetalol versus enalapril as monotherapy in elderly patients with hypertension: results of 24-hour ambulatory blood pressure monitoring. ( Applegate, WB; Borhani, N; DeQuattro, V; Due, DL; Kaihlanen, PM; Oishi, S; Sirgo, MA, 1991) |
| " Although 28 patients required no further labetalol in the maintenance period, in the others dosage varied from 5 to 400 mg." | 2.67 | Labetalol for the control of elevated blood pressure following coronary artery bypass grafting. ( Goldberg, JS; Klamerus, KJ; Leslie, JB; Levitsky, S; Mann, HJ; Mills, SA; Molina, JE; Prough, DS; Sladen, RN; Swafford, MW, 1990) |
| "This randomized multicentre study in elderly hypertensives with two unbalanced groups (2 patients under labetalol for 1 patient under nifedipine) compared the efficacy and safety of labetalol, whose dosage could be adjusted (1, 2, then 3 tablets/day) according to blood pressure level (BP greater than or equal to 160/95 mmHg), to that of nifedipine given at its recommended dosage (2 tablets/day)." | 2.67 | [Hypertension in the elderly. Comparison of the efficacy and tolerability of labetalol and nifedipine. A multicenter, randomized, single-blind study]. ( d'Allens, H; Decoulx, M; Godon, P; Pappo, M, 1990) |
| " Blood pressure and heart rate were measured at rest and during bicycle exercise tests 4 ("peak") and 24 hours ("trough") after dosing in the dilevalol group and 4 ("peak") and 12 hours ("trough") after dosing in the captopril group." | 2.67 | Antihypertensive activity and duration of action of dilevalol in hypertensive patients at rest and during exercise. A comparison with captopril. ( Cesana, B; Fogari, R; Poletti, L; Savonitto, S; Tettamanti, F, 1990) |
| " A randomized, double-blind, placebo-controlled, cross-over trial with two 4 week treatment periods was used to compare the efficacy of once daily dosing with dilevalol (in the range of 100-400 mg daily) against placebo." | 2.67 | A comparison of dilevalol and placebo in the management of isolated systolic hypertension using ambulatory monitoring. ( Farish, S; McGrath, BP; McNeil, JJ; Silagy, CA, 1990) |
| "More metoprolol-treated patients withdrew because of depression (6 vs less than 1%; p = 0." | 2.66 | Influence of beta 2 agonism and beta 1 and beta 2 antagonism on adverse effects and plasma lipoproteins: results of a multicenter comparison of dilevalol and metoprolol. ( Ahmad, S; Glasser, SP; Lucas, C; Lutz, LJ; Materson, BJ; Morledge, JH; Ramanathan, KB; Saunders, E; Schnaper, HW; Vlachakis, ND, 1989) |
| "Hypertension is common following coronary artery bypass surgery." | 2.66 | Intravenous labetalol versus sodium nitroprusside for treatment of hypertension postcoronary bypass surgery. ( Cruise, CJ; David, TE; Marquez-Julio, A; Skrobik, Y; Webster, RE, 1989) |
| " In both study populations renal function tests commenced two hours after dosing at expected peak plasma levels of dilevalol." | 2.66 | The renal function and blood pressure effects of dilevalol in the normotensive and hypertensive elderly. ( Clifton, GG; Cook, ME; Poland, M; Wallin, JD, 1989) |
| "Treatment with labetalol, on the other hand, led to an improvement in respiratory function." | 2.66 | Respiratory effects of four adrenergic blocking agents combined with a diuretic in treating hypertension with concurrent chronic obstructive lung disease. ( Dal Negro, RW; Pomari, C; Trevisan, F; Turco, P; Zoccatelli, O, 1986) |
| "02; 2--A more frequent adjustment of daily dosage with MD (n = 15) than with ACE (n = 10) or LAB (n = 7); 3--The absence of any significant difference for uricemia level, platelet counts, foetal cardiac rythm, and occurrence of pre-eclampsia (MD = 4; ACE = 3; LAB = 4; 4--An equivalent birth-weight (MD = 3110 +/- 628 g; ACE = 3115 +/- 645." | 2.66 | [Randomized, comparative study on the treatment of moderate arterial hypertension during pregnancy: methyldopa, acebutolol, labetalol]. ( Blazquez, G; Gérard, J; Lardoux, H; Leperlier, E, 1988) |
| "Labetalol therapy was then initiated at 100 mg twice a day in a single-blind manner and increased weekly by 100 mg twice a day until blood pressure control was obtained or a maximum dosage of 400 mg twice a day was reached." | 2.66 | Labetalol blunts morning pressor surge in systolic hypertension. ( Allen, J; DeQuattro, V; Lee, DD; Plachetka, J; Sirgo, M, 1988) |
| " The duration of action also varied in the labetalol group, with the shortest duration occurring in those patients who required the highest dosage for BP control." | 2.66 | A comparative trial of labetalol and hydralazine in the acute management of severe hypertension complicating pregnancy. ( Amon, E; Gonzalez, AR; Mabie, WC; Sibai, BM, 1987) |
| " Dilevalol, in doses of 200-800 mg/day, is a safe and effective drug for the treatment of patients with mild hypertension." | 2.66 | The safety and efficacy of once-daily dilevalol in patients with mild hypertension: a placebo-controlled study. ( Frishman, W; Greenberg, S; Soberman, J, 1987) |
| "Twenty-five women with preeclampsia who were scheduled to undergo cesarean section under general anesthesia were randomly assigned to either a labetalol pretreatment group (n = 15) or a control group (n = 10) who did not receive any antihypertensive therapy before the induction of anesthesia." | 2.66 | The use of labetalol for attenuation of the hypertensive response to endotracheal intubation in preeclampsia. ( Chauhan, D; Mabie, WC; Ramanathan, J; Ruiz, AG; Sibai, BM, 1988) |
| "Verapamil was devoid of any such effect." | 2.66 | Evaluation of verapamil in the treatment of hypertension. ( Anavekar, SN; Doyle, AE, 1986) |
| ", following the initial dose of active treatment) and on each visit when the dosage was increased." | 2.66 | The effects of treatments with labetalol and hydrochlorothiazide on ventilatory function of asthmatic hypertensive patients with demonstrated bronchosensitivity to propranolol. ( Blasucci, DJ; Falliers, CJ; Maloy, JW; Medakovic, M; Vrchota, J, 1985) |
| "Labetalol is a competitive, nonselective antagonist of both beta 1 and beta 2 adrenoceptors." | 2.66 | Concomitant therapy with labetalol and hydrochlorothiazide in moderate to moderately severe essential hypertension. ( Kalbfleisch, JH; Kochar, MS; Tyson, J, 1985) |
| "Labetalol and atenolol were equivalent in control of blood pressure at rest, exercise tolerance and use of nitroglycerin; however, heart rates at rest and during exercise were higher with labetalol (p less than 0." | 2.66 | Double-blind trial comparing labetalol with atenolol in the treatment of systemic hypertension with angina pectoris. ( Jee, LD; Opie, LH, 1985) |
| "Propranolol was the only drug that significantly increased airways obstruction (FEV1, specific airways resistance)." | 2.65 | Labetalol, beta blockers, and acute deterioration of chronic airway obstruction. ( Adam, WR; Barter, CE; Meagher, EJ, 1982) |
| "Verapamil was devoid of any such effect." | 2.65 | A double-blind comparison of verapamil and labetalol in hypertensive patients with coexisting chronic obstructive airways disease. ( Adam, WR; Anavekar, SN; Barter, C; Doyle, AE, 1982) |
| " 4 Efficacy of labetalol as a beta-adrenoceptor antagonist and anti-hypertensive drug was assessed 2 h after an oral dose during chronic eight hourly dosage in sixteen hypertensive patients." | 2.65 | Pharmacokinetics, beta-adrenoceptor blockade and anti-hypertensive action of labetalol during chronic oral treatment. ( Davies, DM; Rawlins, MD; Sanders, GL, 1980) |
| "Labetalol is a new adrenergic antagonist with both alpha- and beta-blocking effects." | 2.65 | Effects of labetalol in hypertensive patients with chronic obstructive pulmonary disease. ( Burford, JG; Conrad, SA; George, RB; Kinasewitz, GT; Manocha, K, 1983) |
| "Labetalol is a safe and effective treatment for patients with mild hypertension." | 2.65 | Monotherapy with labetalol in the treatment of mild hypertension: a double-blind study. ( Davidov, ME; Maloy, J; Medakovic, M; Moir, GD; Poland, MP, 1983) |
| "Treatment with labetalol alone or in combination with furosemide, as well as methyldopa plus furosemide, was associated with significant reductions in supine and standing blood pressure levels." | 2.65 | Treatment of severe hypertension with labetalol compared with methyldopa and furosemide. Results of a long-term, double-blind, multicenter trial. ( Langford, H; Maloy, J; Maronde, RF; Michelson, EL; Poland, M; Wallin, JD; Wilson, D; Winer, N, 1983) |
| "Atenolol was withdrawn in those allocated to labetalol, and minoxidil was given only to men." | 2.65 | "Third drug" trial: comparative study of antihypertensive agents added to treatment when blood pressure remains uncontrolled by a beta blocker plus thiazide diuretic. ( Latham, L; Lorimer, AR; McAreavey, D; McLaren, AD; Ramsey, LE; Reid, JL; Robertson, JI; Robertson, MP; Weir, RJ, 1984) |
| "Diazoxide did not increase the heart rate as much as expected (P greater than 0." | 2.65 | Diazoxide vs labetalol: a cross-over comparison of short-term effects in hypertension. ( Bagatin, J; Rumboldt, Z; Vidovic, A, 1983) |
| " The dosage was first titrated out and assessed in a double-blind cross-over trial." | 2.65 | Treatment of hypertension in the elderly with labetalol. ( Eisalo, A; Virta, P, 1982) |
| "Labetalol was used in a multicentre open clinical trial in 128 patients in 10 centres." | 2.65 | A multicentre study of labetalol in hypertension. New Zealand Hypertension Study Group. ( , 1981) |
| "Labetalol pre-treatment especially seemed to enhance the effect of subsequent propranolol/hydralazine administration." | 2.65 | Comparison of labetalol, propranolol and hydralazine in hypertensive out-patients. ( Donker, AJ; May, JF; ten Berge, BS; van der Veur, E; Wesseling, H, 1982) |
| " The mean elimination half-life was 3." | 2.65 | Pharmacokinetics and pharmacodynamic studies of labetalol in hypertensive subjects. ( Anderson, AE; Louis, WJ; McNeil, JJ; Morgan, DJ, 1979) |
| "Labetalol was administered to six hypertensive subjects in increasing doses for seven days." | 2.64 | Hemodynamic effects of labetalol, an alpha and beta adrenergic blocking agent, in hypertensive subjects. ( Cohn, JN; Mehta, J, 1977) |
| "Labetalol is a useful hypotensive drug with effect similar to that of a combination of a beta-adrenoceptor blocking drug and a vasodilator." | 2.64 | Labetalol compared with prindolol plus hydraliazine in the treatment of hypertension: a double-blind cross-over study. ( Barnett, AJ; Guest, C; Kalowski, S, 1978) |
| "Labetalol was more effective in lowering blood pressure but less effective in reducing pulse rate of plasma angiotensin II concentration." | 2.64 | Effect of blood pressure angiotensin II and aldosterone concentrations during treatment of severe hypertension with intravenous labetalol: comparison with propranolol. ( Brown, JJ; Fraser, R; Lever, AF; Morton, JJ; Robertson, JI; Rosei, EA; Trust, PM, 1976) |
| "Neonatal hypertension is increasingly recognized as dramatic improvements in neonatal intensive care, advancements in our understanding of neonatal physiology, and implementation of new therapies have led to improved survival of premature infants." | 2.61 | Neonatal hypertension: cases, causes, and clinical approach. ( Flynn, JT; Starr, MC, 2019) |
| "Pregnancy-induced hypertension is a major cause of maternal and fetal morbidity and mortality." | 2.61 | Hypertension and Pregnancy: Management and Future Risks. ( Jim, B; Reddy, S, 2019) |
| "Women with chronic hypertension are at significant risk for maternal and fetal morbidity and mortality, yet it remains unclear whether antihypertensive treatment during pregnancy lowers these risks." | 2.55 | New Evidence in the Management of Chronic Hypertension in Pregnancy. ( August, P; Podymow, T, 2017) |
| "Perioperative hypertension is commonly encountered in patients that undergo surgery." | 2.44 | Perioperative hypertension management. ( Marik, PE; Varon, J, 2008) |
| "Hypertension that complicates preeclampsia in pregnancy is a disorder that requires special consideration in both prevention and pharmacologic treatment." | 2.43 | Pathophysiology and medical management of systemic hypertension in preeclampsia. ( Frishman, WH; Schlocker, SJ; Tejani, N; Veresh, M, 2006) |
| "While nitroprusside is commonly used to treat severe hypertension, it is an extremely toxic drug that should only be used in rare circumstances." | 2.41 | The diagnosis and management of hypertensive crises. ( Marik, PE; Varon, J, 2000) |
| "The etiology of preeclampsia is still unknown." | 2.41 | Pharmacological treatment of severe hypertension in pregnancy and the role of serotonin(2)-receptor blockers. ( Bolte, AC; Dekker, GA; van Geijn, HP, 2001) |
| "Carvedilol is a new beta-blocker antihypertensive agent with vasodilating properties secondary to alpha 1-blocking activity." | 2.40 | Results of therapy with carvedilol, a beta-blocker vasodilator with antioxidant properties, in hypertensive patients. ( Frishman, W; Moser, M, 1998) |
| " The current drug classes are reviewed with respect to dosage guidelines, adverse effects and potential drug-drug interactions." | 2.39 | Pharmacological management of hypertension in paediatric patients. A comprehensive review of the efficacy, safety and dosage guidelines of the available agents. ( Miller, K, 1994) |
| " More controlled trials with less aggressive dosing regimens and placebo controls need to be performed to assess the most appropriate treatment for HUs with the fewest adverse effects." | 2.39 | Oral antihypertensives for hypertensive urgencies. ( Gales, MA, 1994) |
| "The drug has a place in the chronic treatment of hypertension and in the therapy of hypertensive emergencies." | 2.38 | Clinical experience with dual-acting drugs in hypertension. ( Rahn, KH, 1992) |
| "Antihypertensive agents have been associated with adverse reactions that, if unrecognized by health practitioners, may have devastating consequences." | 2.38 | Fatal hepatotoxicity induced by hydralazine or labetalol. ( Stumpf, JL, 1991) |
| " The recommended dosage range of dilevalol, of 200-400 mg once-daily, has generally been shown to be at least as effective at lowering raised blood pressure as established antihypertensive agents given according to their recommended doses." | 2.38 | Overview of clinical trials of dilevalol in essential hypertension. ( Glover, DR; Tarbit, WJ, 1990) |
| "Labetalol is an adrenoceptor blocking drug with combined alpha- and beta-blocking properties." | 2.38 | Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease. ( Benfield, P; Goa, KL; Sorkin, EM, 1989) |
| "In the elderly, hypertension is generally characterized by elevated peripheral vascular resistance and decreased cardiac output." | 2.38 | Treatment of hypertension in the elderly with labetalol. ( Applegate, WB; Boyd, BK; Sirgo, MA, 1989) |
| "Hypertension in pregnancy has implications for both maternal and fetal welfare." | 2.37 | Hypertension in pregnancy. Pathophysiology and management. ( Lubbe, WF, 1984) |
| "Labetalol is a unique antihypertensive agent which induces both alpha- and beta-blockade." | 2.37 | Pharmacology of combined alpha-beta-blockade. II. Haemodynamic effects of labetalol. ( Lund-Johansen, P, 1984) |
| "Carvedilol is a new compound that combines beta-receptor blockade and vasodilation in one molecule." | 2.37 | Antihypertensive compounds with combined actions. ( Rahn, KH, 1987) |
| "Labetalol is a unique antihypertensive agent which is a competitive peripheral antagonist at both alpha- and beta-adrenoceptor sites." | 2.37 | Current status of labetalol, the first alpha- and beta-blocking agent. ( Kanto, JH, 1985) |
| "The chronic use of propranolol is characterized by 10%-20% decrements of renal plasma flow (RPF) and glomerular filtration rate (GFR)." | 2.37 | Beta blockers and renal function: a reappraisal. ( Epstein, M; Oster, JR, 1985) |
| "Urapidil appears to be an effective antihypertensive drug with a wide spectrum of action and few side effects." | 2.37 | Do hybrid drugs offer an additional benefit over pure alpha 1-blockade for hypertensive patients? ( Doyle, AE, 1988) |
| "Labetalol is a competitive antagonist of alpha 1-, beta 1-, and beta 2-adrenergic receptors." | 2.36 | Labetalol. ( Carter, BL, 1983) |
| "Labetalol is an orally active adrenoceptor blocking drug which is a competitive antagonist at both alpha- and beta-adrenoceptor sites." | 2.36 | Labetalol: a review of its pharmacology and therapeutic use in hypertension. ( Avery, GS; Brogden, RN; Heel, RC; Speight, TM, 1978) |
| "Labetalol was 6-10 times less potent than phentolamine in blocking alpha-adrenoreceptors and 1." | 2.35 | A review of the animal pharmacology of labetalol, a combined alpha- and beta-adrenoceptor-blocking drug. ( Brittain, RT; Levy, GP, 1976) |
| "Giant pheochromocytomas are rare tumors, with the majority being clinically silent." | 1.91 | A Giant Pheochromocytoma Presenting in Pheochromocytoma Crisis: A Case Report. ( Baniya, S; Bogati, K; Karki, N; Pokhrel, M; Regmi, UK; Thapa, S, 2023) |
| " Therapy success: systolic blood pressure ~140 mm Hg and diastolic blood pressure ~90 mm Hg, therapy failure: persistent systolic blood pressure ≥ 160 or diastolic blood pressure ≥ 110 mm Hg after maximum dosage of therapy (EL)." | 1.91 | Comparison of outcomes following intravenous magnesium compared with intravenous labetalol and oral nifedipine in 355 pregnant Han Chinese women with preeclampsia. ( Dong, W; Peng, Z; Xiao, Y; Zhang, J, 2023) |
| "Labetalol was safe and associated with higher neurological recovery." | 1.72 | Efficacy and Safety of Intravenous Labetalol in Acute Hypertensive Crisis in Children. ( Angurana, SK; Bansal, A; Baranwal, A; Jayashree, M; Lad, S; Nallasamy, K; Patil, M, 2022) |
| "Severe hypertension is a risk factor for sustained hypertension after pregnancy." | 1.62 | Severe hypertension in pregnancy. ( Damodaram, M; Frise, C; Wiles, K, 2021) |
| "Magnesium sulfate was promptly administered on admission to every woman to prevent seizure." | 1.56 | Clinical Experiences of Intravenous Hydralazine and Labetalol for Acute Treatment of Severe Hypertension in Pregnant Thai Women. ( Chera-Aree, P; Leetheeragul, J; Sampaojarean, U; Surasereewong, S; Tengtrakulcharoen, P; Wataganara, T, 2020) |
| "Labetalol treatment was appropriately initiated in many cases; however, protocol adherence could greatly improve." | 1.48 | Management of Hypertension on the Labor and Delivery Unit: Delivering Care in the Era of Protocols and Algorithms. ( Duong, J; Haring, A; Kuhlmann, Z; O'brien, L; Winterton, T, 2018) |
| "The dilemmas involved in treating hypertension caused by dexmedetomidine are discussed." | 1.43 | Intravenous labetolol in treating hypertensive crisis following dexmedetomidine infusion for procedural sedation. ( Balaji, S; Mathews, L; Moni, A; Muthiah, T, 2016) |
| "Postpartum preeclampsia/eclampsia is the presence of hypertension and proteinuria, with or without seizures, occurring up to 4 weeks after delivery." | 1.37 | Postpartum preeclampsia: emergency department presentation and management. ( Abbott, J; Bakes, K; Withers, E; Yancey, LM, 2011) |
| " Aside from patients presenting with ischemic or traumatic brain injury, labetalol was safe to use in this population for hypertensive emergencies and had a satisfactory adverse effect profile." | 1.37 | Safety and efficacy of intravenous labetalol for hypertensive crisis in infants and small children. ( Feig, DI; Moffett, BS; Mott, AR; Thomas, CA; Wagner, JL, 2011) |
| "Efforts to increase the awareness and treatment of hypertension in the population at large may lower the incidence of hypertensive crisis and its complications." | 1.37 | Dutch guideline for the management of hypertensive crisis -- 2010 revision. ( Beutler, JJ; de Gooijer, A; Gaillard, CA; Kroon, AA; van den Born, BJ; van den Meiracker, AH, 2011) |
| "Pheochromocytoma is a catecholamine-producing tumor but rarely delayingly diagnosed until during pregnancy." | 1.37 | Cardiovascular collapse after labetalol for hypertensive crisis in an undiagnosed pheochromocytoma during cesarean section. ( Huang, CS; Ko, YP; Kuok, CH; Tsai, PS; Yen, CR, 2011) |
| "Differentiation from acute cerebral ischemia is important in order to prevent permanent vision loss due to delay in initiating prompt and vigorous treatment of exacerbating factors, such as intermittent hypertension." | 1.36 | Postoperative blindness associated with posterior reversible encephalopathy syndrome: a case report. ( Kim, TK; Kim, WS; Lee, HJ; Park, SC; Yoon, JU; Yoon, JY, 2010) |
| "Treatment with labetalol was only partially successful in controlling the elevated blood pressure." | 1.32 | Autonomic dysreflexia manifested by severe hypertension. ( Assadi, F; Czech, K; Palmisano, JL, 2004) |
| "Fetal tachycardia was present as well." | 1.30 | Intrapartum labetalol for the treatment of maternal and fetal thyrotoxicosis. ( Bergmann, M; Bowman, ML; Smith, JF, 1998) |
| "This was manifested clinically by a seizure which began focally and became generalised." | 1.30 | Autonomic instability and hypertension resulting in subarachnoid haemorrhage in the Guillain-Barré syndrome. ( Gande, AR; Nolan, KM; Taylor, IR, 1999) |
| "Amosulalol was approximately threefold more potent than labetalol and arotinolol in decreasing blood pressure (BP) in conscious SHR." | 1.29 | Characterization of the adrenoceptor antagonistic and antihypertensive activity of oral amosulalol, a combined alpha- and beta-adrenoceptor antagonist, in hypertensive rats. ( Honda, K; Inagaki, O; Nakagawa, C; Shibasaki, M; Sudoh, K, 1994) |
| "To assess the influence of intrauterine growth retardation on heart rate (HR) and HR variability during sleep, we performed polygraphic recordings in 10 small-for-gestational age (SGA) and 16 appropriate-for-gestational age (AGA) newborns." | 1.29 | Heart rate and heart rate variability during sleep in small-for-gestational age newborns. ( Clairambault, J; Curzi-Dascalova, L; Eiselt, M; Kauffmann, F; Médigue, C; Peirano, P; Spassov, L, 1994) |
| "Felodipine was equally effective at both time points." | 1.29 | Time-dependent efficacy of antihypertensive agents in spontaneously hypertensive rats. ( Janssen, BJ; Oosting, J; Struyker-Boudier, HA; Tyssen, CM, 1993) |
| "Hypertension is due to disturbance of the complex interplay between numerous known and unknown mechanisms that normally control blood pressure." | 1.29 | Long-term hemodynamic effects at rest and during exercise of newer antihypertensive agents and salt restriction in essential hypertension: review of epanolol, doxazosin, amlodipine, felodipine, diltiazem, lisinopril, dilevalol, carvedilol, and ketanserin. ( Lund-Johansen, P; Omvik, P, 1993) |
| "The episodes of acute secondary erythermalgia were transient in all and did not recur after a mean follow up period of 1." | 1.29 | Acute secondary erythermalgia and hypertension in children. Erythermalgia Multidisciplinary Study Group. ( Drenth, JP; Michiels, JJ; Ozsoylu, S, 1995) |
| "And we considered left ventricular hypertrophy as left ventricular mass index greater than 120 g/m2." | 1.28 | [Action of labetalol on norepinephrine myocardial content in left ventricular hypertrophy in hypertensive patients]. ( Boutelant, S; de Gaudemaris, R; Fagret, D; Mallion, JM; Schwebel, C; Siché, JP; Tremel, F, 1992) |
| "Labetalol has been advocated to rapidly decrease blood pressure in preeclamptic women and to blunt the hemodynamic response to tracheal intubation." | 1.28 | Maternal and fetal effects of labetalol in pregnant ewes. ( Dewan, DM; Eisenach, JC; Mandell, G, 1991) |
| " At dosage levels similar to arotinolol, both pindolol and labetalol were less effective in preventing cerebral lesions despite lower blood pressure." | 1.28 | Prevention of cerebral stroke by arotinolol in salt-loaded SHRSP. ( Hara, Y; Maniwa, T; Miyagishi, A; Noguchi, T, 1991) |
| "Both esmolol and labetalol were equally effective in controlling systolic blood pressure on emergence and in the recovery room in patients undergoing intracranial surgery." | 1.28 | Labetalol and esmolol in the control of hypertension after intracranial surgery. ( Black, S; Cucchiara, RF; Losasso, TJ; Muzzi, DA, 1990) |
| "Labetalol was effective and well tolerated in both groups." | 1.28 | Pharmacokinetics and pharmacodynamics of labetalol in elderly and young hypertensive patients following single and multiple doses. ( Cressman, MD; Plachetka, JR; Rocci, ML; Sirgo, MA; Vlasses, PH, 1990) |
| " Values of Cmax, Tmax, half-life or renal elimination did not significantly change with decreased renal function." | 1.28 | The pharmacokinetics of dilevalol in renal impairment. ( Donohue, J; Doyle, GD; Kelly, JG; Laher, MS, 1990) |
| " Doses were calculated to produce plasma levels approximating those achieved after oral dosing (0." | 1.28 | Effects of dilevalol on forearm circulation in essential hypertension. ( Cleroux, J; Giannattasio, C; Grassi, G; Mancia, G; Seravalle, G; Zanchetti, A, 1989) |
| " Blood samples for plasma dilevalol concentrations were taken during an 8-hour post-drug period following the first and eighth dosages, and the time to maximum concentration (tmax), maximum plasma concentration (Cmax), distribution half-life (t1/2 alpha), elimination half-life (t1/2 beta) and area under the plasma concentration-time curve (AUC) were determined." | 1.28 | Clinical pharmacology of dilevalol (III). A pharmacokinetic study of dilevalol in elderly subjects with essential hypertension. ( Ebihara, A; Fujimura, A; Kumagai, Y; Nakashima, H; Sugimoto, K, 1989) |
| "Labetalol was administered at the conclusion of surgery as a 20-mg bolus over two minutes followed by 40 mg every 10 minutes until the desired BP was achieved (BP less than or equal to 10% above average preoperative BP or less than 150 mmHg, systolic) or 300 mg had been given." | 1.28 | Intravenous labetalol for the treatment of hypertension after carotid endarterectomy. ( Azad, SS; Goldberg, ME; Larijani, GE; Marr, AT; Seltzer, JL; Smullens, SN, 1989) |
| " Studies of dilevalol's pharmacokinetics in normotensive and hypertensive volunteers have demonstrated that (1) it is rapidly and well absorbed; (2) because of extensive first-pass metabolism its absolute oral bioavailability is about 12%; (3) its mean elimination half-life is 8 to 12 hours after administration of single oral or intravenous doses to normal volunteers, a value consistent with once-daily dosing; and (4) food does not appear to alter its bioavailability or pharmacokinetics." | 1.28 | Pharmacokinetics of dilevalol in normotensive and hypertensive volunteers. ( Affrime, MB; Kramer, WG; Patrick, JE; Perentesis, G, 1989) |
| "Labetalol is an antihypertensive agent with combined alpha- and beta-blocking properties that has been used to manage patients with suspected pheochromocytomas." | 1.28 | Labetalol reduces iodine-131 MIBG uptake by pheochromocytoma and normal tissues. ( Fig, LM; Khafagi, FA; Mallette, S; Shapiro, B; Sisson, JC, 1989) |
| " SCH 19927 produced a competitive alpha 1- and beta 1-blockade in vitro as indicated by the parallel shift to the right of the dose-response curves for norepinephrine and isoprenaline, respectively." | 1.27 | Effects of the R, R-isomer of labetalol, SCH 19927, in isolated tissues and in spontaneously hypertensive rats during a repeated treatment. ( Bamonte, F; Forlani, A; Monopoli, A; Ongini, E; Parravicini, L, 1984) |
| "The results of the treatment in hypertension with pregnancy by a alpha-beta blocker in 58 women show: the good tolerance of the drug and its lack of teratogenic effect, its quasi-constant efficiency (91%) in hypertension, its benefit repercussion on neonatal weight." | 1.27 | [Treatment of arterial hypertension in pregnancy with an alpha-beta blocker. 58 Cases treated with labetalol]. ( Blazquez, G; Gérard, J; Giraud, P; Jeuffroy, A; Lardoux, H; Mounac, M, 1984) |
| "Beta blockers are now widely used to treat hypertension during pregnancy." | 1.27 | [Treatment of arterial hypertension in the pregnant woman with labetalol. A propos of 24 cases]. ( Dubois, D; Klepper, A; Leboullenger, P; Petitcolas, J; Temperville, B, 1984) |
| "When clonidine was given in a dose of 0." | 1.27 | Interaction of clonidine and labetalol in hypertension. ( Lilja, M, 1983) |
| " The average daily dosage was 144." | 1.27 | Hypertension in pregnancy: evaluation of two beta blockers atenolol and labetalol. ( Blazquez, G; Chouty, F; Flouvat, B; Gerard, J; Lardoux, H, 1983) |
| " Dosage ranged from 100 to 2400 mg per day (mean 654 mg per day) and treatment was continued for between 6 and 18 months (mean 7." | 1.27 | Side-effects with long-term labetalol: an open study of 251 patients in a single centre. ( Tcherdakoff, P, 1983) |
| "Labetalol seems to be suitable to treat hypertension perioperatively in neurosurgical patients but it is not a suitable drug for induced hypotension." | 1.27 | Treatment of hypertension with labetalol in neurosurgical practice. Influence of labetalol on cerebral perfusion pressure in dogs without and with intracranial mass lesions. ( Anger, C; Hidding, J; Lawin, P; Puchstein, C; van Aken, H, 1983) |
| "Severe hypertension may be a difficult management issue, and it often requires therapy with multiple drugs at frequent dosing intervals." | 1.27 | Clinical experience with labetalol and enalapril in combination in patients with severe essential and renovascular hypertension. ( Aydelotte, ME; White, WB, 1988) |
| " Labetalol and prazosin also significantly shifted the dose-response curve to the right for phenylephrine but not for angiotensin II." | 1.27 | Analysis of the mechanism underlying the vasodilator action of carvedilol in pithed spontaneously hypertensive rats. ( Akashi, A; Hashimoto, H; Kanda, A; Tanaka, M, 1988) |
| "Paradoxical hypertension is a relatively common complication of surgical repair of coarctation of the aorta." | 1.27 | Intravenous labetalol for the control of hypertension following repair of coarctation of the aorta. ( Bojar, RM; Cleveland, RJ; Weiner, B, 1988) |
| "Urgent hypertension is defined by severe elevations of blood pressure without associated end-organ damage." | 1.27 | Management of urgent hypertension: a comparison of oral treatment regimens in the emergency department. ( Catapano, MS; Marx, JA, 1986) |
| "Labetalol is a combined alpha- and beta-adrenoreceptor blocking agent." | 1.27 | Continuous i.v. infusion of labetalol for postoperative hypertension. Haemodynamic effects and plasma kinetics. ( Chauvin, M; Deriaz, H; Viars, P, 1987) |
| "1 Labetalol was administered to 18 hypertensive patients for an average duration of 2." | 1.26 | Response of the systemic pulmonary circulation to labetalol at rest and during exercise. ( Amery, A; Fagard, R; Lijnen, P, 1982) |
| "1 During chronic treatment of hypertensive patients observed mean steady-state plasma labetalol levels in ten patients were consistently and significantly higher than predicted from initial acute pharmacokinetic analysis." | 1.26 | Labetalol steady-state pharmacokinetics in hypertensive patients. ( Anderson, AE; Louis, WJ; McNeil, JJ; Raymond, K, 1982) |
| "One hundred and fifty-seven hypertensive patients (1st and 2nd degree of the WHO classification) studied in 15 hospitals were treated with labetalol at a dosage of 300-600 mg a day for 3 months." | 1.26 | [Treatment of arterial hypertension with labetalol. A polycentric study]. ( , 1982) |
| "Labetalol, which is a combined alpha- and beta-blocking agent, reduces mean blood pressure levels at all times." | 1.26 | Effects of treatment on circadian rhythms of blood pressure. ( Balasubramanian, V; Mann, S; Millar-Craig, MW; Raftery, EB, 1981) |
| "Minoxidil is an extremely potent hypotensive drug." | 1.26 | Minoxidil and labetalol: very effective antihypertensive combination. ( Bett, N; Boyle, P; Craswell, P; Whiting, G, 1980) |
| " Initial dosage was 300 mg per day." | 1.26 | Labetalol ('trandate') in hypertension: a multicentre study in general practice. ( Gomez, G; Phillips, LA, 1980) |
| "Labetalol was used in a mean daily dose of 1356 mg (range 400-3000 mg) either as mono-therapy or in combination with other drugs." | 1.26 | Long-term treatment of hypertension with labetalol. ( Andersson, E; Erichs, M; Rothgardt, NP, 1980) |
| " The resting heart rate is faster with labetalol than with an equivalent dosage of propranolol." | 1.26 | Comparison of labetalol and propranolol in treatment of hypertension. ( Harvald, B, 1980) |
| "A case of acute dissecting aneurysm of the aorta in a seriously hypertensive woman was treated for 9 days with continuously infused labetalol hydrochloride, initially at 1 mg/min and later at 125 mg/min." | 1.26 | [Use of labetalol hydrochloride by continuous infusion in managing the hypertensive state; a clinical case]. ( Garavini, L; Mereto, GC, 1980) |
| "During hyperreflexia the pre-ejection period/left ventricular ejection time (PEP/LVET) ratio and the PEP and electromechanical systole (QS2) reduced, suggesting positive inotropic effects." | 1.26 | Sympathetic hyperreflexia in tetraplegics. The value of systolic time intervals in assessing drug effects. ( Sommers, DK, 1980) |
| "1Labetalol is a new compound with antagonistic effects at both alpha- and beta-adrenoreceptor sites." | 1.26 | Labetalol, a new alpha- and beta-adrenoreceptor blocking agent, in hypertension. ( Hänel, B; Hansson, L, 1976) |
| " We have studied the variations brought about by effective hypotensive therapy with an alpha and beta blocking agent (Labetalol) in 15 patients over a period of 90 days, with an average dosage of 420 mg/day in three divided doses." | 1.26 | [Systolic time intervals in essential hypertension. II. Variations produced by treatment with labetalol]. ( Lomanto, B; Rossi, A; Ziacchi, V, 1979) |
| "1." | 1.26 | Effects of labetalol on systemic and pulmonary haemodynamics at rest and during exercise in hypertensive patients. ( Amery, A; Billiet, L; Fagard, R; Lijnen, P; Reybrouck, T, 1978) |
| "Labetalol was given as replacement for a beta-blocking drug providing less than satisfactory control." | 1.26 | A pilot trial of labetalol (AH 5158A): a combined alpha and beta blocker in treatment of hypertension. ( Dent, R; Kellaway, GS, 1977) |
| "1." | 1.26 | Blood pressure reduction by incremental infusion of labetalol in patients with severe hypertension. ( Brown, JJ; Cummings, AM; Fraser, R; Lever, AF; Morton, JJ; Richards, DA; Robertson, JI, 1979) |
| "5 Labetalol treatment reduced the variation in systolic BP from the lowest observed quarter-hourly mean as compared with pre-treatment values." | 1.26 | Effect of labetalol on continuous ambulatory blood pressure. ( Altman, D; Balasubramanian, V; Mann, S; Millar-Craig, MW; Raftery, EB, 1979) |
| "1 Labetalol was given to 41 hypertensive patients in a divided dosage of 150--2,400 mg daily for periods ranging from 1--64 months." | 1.26 | Monotherapy with labetalol for hypertensive patients with normal and impaired renal function. ( Hussein, MM; Joekes, AM; Thompson, FD, 1979) |
| "6 Labetalol is a useful addition to the medical treatment of phaeochromocytoma." | 1.26 | Treatment of phaeochromocytoma and of clonidine withdrawal hypertension with labetalol. ( Brown, JJ; Lever, AF; Robertson, AS; Robertson, JI; Rosei, EA; Trust, PM, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 576 (64.65) | 18.7374 |
| 1990's | 133 (14.93) | 18.2507 |
| 2000's | 53 (5.95) | 29.6817 |
| 2010's | 85 (9.54) | 24.3611 |
| 2020's | 44 (4.94) | 2.80 |
| Authors | Studies |
|---|---|
| Wiles, K | 1 |
| Damodaram, M | 1 |
| Frise, C | 1 |
| Pearlman, B | 1 |
| Lodebo, BT | 1 |
| Brown, CS | 1 |
| Oliveira J E Silva, L | 1 |
| Mattson, AE | 1 |
| Cabrera, D | 1 |
| Farrell, K | 1 |
| Gerberi, DJ | 1 |
| Rabinstein, AA | 1 |
| Bastian, IN | 1 |
| Antony, KM | 1 |
| Wu, HZ | 1 |
| Cheng, Y | 1 |
| Yu, D | 1 |
| Li, JB | 1 |
| Jiang, YF | 1 |
| Zhu, ZN | 1 |
| Ohamadike, O | 1 |
| Lim, SL | 1 |
| Siegel, A | 1 |
| Zemtsov, G | 1 |
| Kuller, JA | 1 |
| Dotters-Katz, S | 1 |
| Ng, Y | 1 |
| Qi, W | 1 |
| King, NKK | 1 |
| Christianson, T | 1 |
| Krishnamoorthy, V | 1 |
| Shah, S | 1 |
| Divani, A | 1 |
| Bettin, M | 1 |
| Coleman, ER | 1 |
| Flaherty, ML | 1 |
| Walsh, KB | 1 |
| Testai, FD | 1 |
| McCauley, JL | 1 |
| Gilkerson, LA | 1 |
| Langefeld, CD | 1 |
| Behymer, TP | 1 |
| Woo, D | 1 |
| James, ML | 1 |
| Muhammad, S | 1 |
| Usman, H | 1 |
| Dawha, YM | 1 |
| Yahya, A | 1 |
| Yekeen, A | 1 |
| Bako, B | 1 |
| Rednic, R | 1 |
| Marcovici, I | 1 |
| Dragoi, R | 1 |
| Pinzaru, I | 1 |
| Dehelean, CA | 1 |
| Tomescu, M | 1 |
| Arnautu, DA | 1 |
| Craina, M | 1 |
| Gluhovschi, A | 1 |
| Valcovici, M | 1 |
| Manea, A | 1 |
| Greene, NH | 1 |
| Pon, FF | 1 |
| Kilpatrick, SJ | 2 |
| Do, SC | 1 |
| Leonard, SA | 1 |
| Kan, P | 1 |
| Panelli, DM | 1 |
| Girsen, AI | 1 |
| Lyell, DJ | 1 |
| El-Sayed, YY | 1 |
| Druzin, ML | 1 |
| Herrero, T | 1 |
| van de Vusse, D | 1 |
| Mian, P | 1 |
| Schoenmakers, S | 1 |
| Flint, RB | 1 |
| Visser, W | 1 |
| Allegaert, K | 1 |
| Versmissen, J | 1 |
| Wautlet, CK | 1 |
| Hoffman, MC | 1 |
| Shao, Y | 1 |
| Gu, S | 1 |
| Zhang, X | 1 |
| Siersma, C | 1 |
| Brouwer, CNM | 1 |
| Sojak, V | 1 |
| Ten Harkel, ADJ | 1 |
| Roeleveld, PP | 1 |
| Lovgren, T | 3 |
| Connealy, B | 2 |
| Yao, R | 2 |
| D Dahlke, J | 2 |
| Kim, MK | 1 |
| Choe, KR | 1 |
| Jeong, DE | 1 |
| Lee, KN | 1 |
| Cho, I | 1 |
| Kim, HJ | 1 |
| Park, JY | 1 |
| Trahan, MJ | 1 |
| Plourde, M | 1 |
| Wou, K | 1 |
| Huroy, M | 1 |
| Itani, R | 1 |
| Pavilanis, A | 1 |
| Flannery, A | 1 |
| Haas, S | 1 |
| Aucoin, G | 1 |
| Monast, PO | 1 |
| Koolian, M | 1 |
| Hassan, N | 1 |
| Suarthana, E | 1 |
| Daskalopoulou, SS | 1 |
| Malhamé, I | 1 |
| Kou, X | 1 |
| Yang, J | 2 |
| Spehar, SM | 1 |
| Albert-Stone, E | 1 |
| Davis, MB | 1 |
| Bogati, K | 1 |
| Baniya, S | 1 |
| Thapa, S | 1 |
| Regmi, UK | 1 |
| Karki, N | 1 |
| Pokhrel, M | 1 |
| Wasif, U | 1 |
| Al-Shehab, U | 1 |
| Lo, DF | 1 |
| Cífková, R | 1 |
| Kausar, M | 1 |
| Husain, S | 1 |
| Hussain, R | 1 |
| Ashworth, D | 1 |
| Battersby, C | 1 |
| Bick, D | 1 |
| Green, M | 1 |
| Hardy, P | 1 |
| Leighton, L | 1 |
| Magee, LA | 6 |
| Maher, A | 1 |
| McManus, RJ | 2 |
| Moakes, C | 1 |
| Morris, RK | 1 |
| Nelson-Piercy, C | 4 |
| Sparkes, J | 1 |
| Rivero-Arias, O | 1 |
| Webb, A | 1 |
| Wilson, H | 1 |
| Myers, J | 3 |
| Chappell, LC | 4 |
| Farley, TM | 1 |
| Peng, Z | 1 |
| Zhang, J | 1 |
| Xiao, Y | 1 |
| Dong, W | 1 |
| Webster, LM | 2 |
| Reed, K | 1 |
| Myers, JE | 2 |
| Burns, A | 1 |
| Gupta, P | 1 |
| Patel, P | 1 |
| Wiesender, C | 1 |
| Seed, PT | 2 |
| Salman, J | 1 |
| Salman, A | 1 |
| Kumar, S | 1 |
| Gjeka, R | 1 |
| Tegeltija, V | 1 |
| Peterson, D | 1 |
| Chams, N | 1 |
| Ross, I | 1 |
| Carrera, JF | 1 |
| Sorace, BJ | 1 |
| Worrall, BB | 1 |
| Southerland, AM | 1 |
| Chiota-McCollum, NA | 1 |
| Singer, J | 4 |
| Lee, T | 3 |
| Lay-Flurrie, S | 1 |
| Rey, E | 4 |
| Logan, AG | 5 |
| von Dadelszen, P | 4 |
| Kantorowska, A | 1 |
| Heiselman, CJ | 1 |
| Halpern, TA | 1 |
| Akerman, MB | 1 |
| Elsayad, A | 1 |
| Muscat, JC | 1 |
| Sicuranza, GB | 1 |
| Vintzileos, AM | 1 |
| Heo, HJ | 1 |
| Miller, J | 1 |
| McNaughton, C | 1 |
| Joyce, K | 1 |
| Binz, S | 1 |
| Levy, P | 3 |
| Charlton, GA | 1 |
| Ladd, DR | 1 |
| Friesen, RM | 1 |
| Friesen, RH | 2 |
| Chera-Aree, P | 1 |
| Tengtrakulcharoen, P | 1 |
| Leetheeragul, J | 1 |
| Sampaojarean, U | 1 |
| Surasereewong, S | 1 |
| Wataganara, T | 1 |
| Cluver, CA | 1 |
| Herbst, P | 1 |
| Griffith-Richards, S | 1 |
| Hassan, M | 1 |
| Allwood, B | 1 |
| Rezk, M | 1 |
| Emarh, M | 1 |
| Masood, A | 1 |
| Dawood, R | 1 |
| El-Shamy, E | 1 |
| Gamal, A | 1 |
| Badr, H | 1 |
| Zublena, F | 1 |
| De Gennaro, C | 1 |
| Corletto, F | 1 |
| Zhu, X | 1 |
| Machovec, KA | 1 |
| Ames, WA | 1 |
| Cawoski, JR | 1 |
| DeBiasio, KA | 1 |
| Donnachie, SW | 1 |
| Timanus, EA | 1 |
| Zimmerman, DE | 1 |
| Guarascio, AJ | 1 |
| Montepara, CA | 1 |
| Covvey, JR | 1 |
| Nemecek, BD | 1 |
| Lad, S | 1 |
| Patil, M | 1 |
| Jayashree, M | 1 |
| Bansal, A | 1 |
| Baranwal, A | 1 |
| Nallasamy, K | 1 |
| Angurana, SK | 1 |
| Xiang, X | 1 |
| Wang, F | 1 |
| Zhao, N | 1 |
| Zhou, Z | 1 |
| El-Ghoroury, H | 1 |
| Sudekum, DM | 1 |
| Hecht, JP | 3 |
| Bordlee, JW | 1 |
| Beakley, BD | 1 |
| Mody, R | 1 |
| McConville, AP | 1 |
| Weed, JT | 1 |
| McClure, BP | 1 |
| Foldes, PJ | 1 |
| Ma, JG | 1 |
| Kaye, AD | 1 |
| Eskander, JP | 1 |
| Duan, L | 1 |
| Ng, A | 1 |
| Chen, W | 1 |
| Spencer, HT | 1 |
| Nguyen, J | 1 |
| Shen, AY | 1 |
| Lee, MS | 1 |
| Podymow, T | 1 |
| August, P | 1 |
| Starr, JB | 1 |
| Tirschwell, DL | 1 |
| Becker, KJ | 1 |
| Akter, FA | 1 |
| Nahar, K | 1 |
| Rahman, MM | 1 |
| Ferdousi, RA | 1 |
| Ahmed, MU | 1 |
| Begum, F | 1 |
| Biswas, D | 1 |
| Alom, M | 1 |
| Hossain, MZ | 1 |
| Razi, RZ | 1 |
| Richards, PG | 1 |
| Gaynor, MF | 1 |
| Wright, GC | 1 |
| Vondracek, S | 1 |
| Mills, C | 1 |
| Watt-Coote, I | 1 |
| Khalil, A | 1 |
| Cruickshank, JK | 1 |
| Starr, MC | 1 |
| Flynn, JT | 1 |
| Watson, K | 1 |
| Broscious, R | 1 |
| Devabhakthuni, S | 1 |
| Noel, ZR | 1 |
| Sridharan, K | 1 |
| Sequeira, RP | 1 |
| O'brien, L | 1 |
| Duong, J | 1 |
| Winterton, T | 1 |
| Haring, A | 1 |
| Kuhlmann, Z | 1 |
| Lichtenstein, SJ | 1 |
| Herring, MJ | 1 |
| Baxi, PV | 1 |
| Abrams, RI | 1 |
| Korbet, SM | 1 |
| Singla, D | 1 |
| Parashar, A | 1 |
| Pandey, V | 1 |
| Mangla, M | 1 |
| Sadeghi, M | 1 |
| Saber, H | 1 |
| Singh, A | 2 |
| Hanni, C | 1 |
| Parker, D | 3 |
| Desai, A | 1 |
| Mohamed, W | 1 |
| Mahmood, SM | 1 |
| Brandt, MM | 1 |
| Jacobs, ZG | 1 |
| Najafi, N | 1 |
| Fang, MC | 1 |
| Prasad, PA | 1 |
| Abe-Jones, Y | 1 |
| Auerbach, AD | 1 |
| Patel, S | 1 |
| Pasik, SD | 1 |
| Chiu, S | 1 |
| Sinfield, C | 1 |
| Zubizarreta, N | 1 |
| Ramkeesoon, R | 1 |
| Cho, HJ | 1 |
| Krouss, M | 1 |
| Reddy, S | 1 |
| Jim, B | 1 |
| Prescott, A | 1 |
| Smereck, J | 1 |
| Walasek, A | 1 |
| Gupta, S | 1 |
| Fine, S | 1 |
| Russo, P | 1 |
| Lemoine, ER | 1 |
| Karumanchi, SA | 1 |
| Liu-DeRyke, X | 2 |
| Levy, PD | 3 |
| Coplin, W | 1 |
| Rhoney, DH | 3 |
| Bateman, BT | 2 |
| Hernandez-Diaz, S | 2 |
| Huybrechts, KF | 2 |
| Palmsten, K | 1 |
| Mogun, H | 2 |
| Ecker, JL | 1 |
| Seely, EW | 2 |
| Fischer, MA | 2 |
| Xie, RH | 1 |
| Guo, Y | 1 |
| Krewski, D | 1 |
| Mattison, D | 1 |
| Nerenberg, K | 1 |
| Walker, MC | 1 |
| Wen, SW | 1 |
| Mondel, PK | 1 |
| Udare, AS | 1 |
| Anand, S | 1 |
| Kulkarni, AV | 1 |
| Kapadia, FN | 1 |
| Modhe, JM | 1 |
| Limaye, US | 1 |
| Nooij, LS | 1 |
| Visser, S | 1 |
| Meuleman, T | 1 |
| Vos, P | 1 |
| Roelofs, R | 1 |
| de Groot, CJ | 1 |
| Farias, S | 1 |
| Peacock, WF | 5 |
| Gonzalez, M | 1 |
| Kissel, M | 1 |
| Phoon, CK | 1 |
| Kahn, PJ | 1 |
| Varon, J | 5 |
| Soto-Ruiz, KM | 1 |
| Baumann, BM | 2 |
| Borczuk, P | 2 |
| Cannon, CM | 2 |
| Chandra, A | 3 |
| Cline, DM | 2 |
| Diercks, DB | 1 |
| Hiestand, B | 2 |
| Hsu, A | 2 |
| Jois-Bilowich, P | 2 |
| Kaminski, B | 2 |
| Nowak, RM | 2 |
| Schrock, JW | 2 |
| Vadhera, RB | 1 |
| Simon, M | 1 |
| Malaty, J | 1 |
| Malaty, IA | 1 |
| Rolfes, L | 1 |
| de Swart-Ruijter, I | 1 |
| van Hunsel, F | 1 |
| Shi, Q | 1 |
| Leng, W | 1 |
| Yao, Q | 1 |
| Mi, C | 1 |
| Xing, A | 1 |
| Freiermuth, CE | 1 |
| Ross, S | 3 |
| Asztalos, E | 2 |
| Murphy, KE | 2 |
| Menzies, J | 2 |
| Sanchez, J | 2 |
| Gafni, A | 3 |
| Gruslin, A | 3 |
| Helewa, M | 3 |
| Hutton, E | 2 |
| Koren, G | 4 |
| Lee, SK | 3 |
| Ganzevoort, JW | 2 |
| Welch, R | 2 |
| Thornton, JG | 2 |
| Moutquin, JM | 3 |
| Wong, GW | 1 |
| Laugerotte, A | 1 |
| Wright, JM | 1 |
| Sibai, BM | 7 |
| Hayhoe, S | 1 |
| Navapurkar, V | 1 |
| Conway Morris, A | 1 |
| McKay, C | 1 |
| Hall, AB | 1 |
| Cortes, J | 1 |
| Olson-Chen, C | 1 |
| Seligman, NS | 1 |
| Kubota-Sjogren, Y | 1 |
| Jones, R | 1 |
| Redler, K | 1 |
| Witherick, J | 1 |
| Fuller, G | 1 |
| Mahajan, T | 1 |
| Wakerley, BR | 1 |
| Sirivanasandha, B | 1 |
| Sakaew, A | 1 |
| Sutthivaiyakit, K | 1 |
| Raksamani, K | 1 |
| Waitayawinyu, P | 1 |
| Rushatamukayanunt, P | 1 |
| Punkla, W | 1 |
| Muthiah, T | 1 |
| Moni, A | 1 |
| Mathews, L | 1 |
| Balaji, S | 1 |
| Chhabra, R | 1 |
| Magee, C | 1 |
| Patorno, E | 1 |
| Desai, RJ | 1 |
| Maeda, A | 1 |
| Shi, DD | 1 |
| Yang, FZ | 1 |
| Zhou, L | 1 |
| Wang, N | 1 |
| Richards, JR | 1 |
| Laurin, EG | 1 |
| Tabish, N | 1 |
| Lange, RA | 1 |
| Stott, D | 1 |
| Bolten, M | 1 |
| Paraschiv, D | 1 |
| Papastefanou, I | 1 |
| Chambers, JB | 1 |
| Kametas, NA | 1 |
| Sharma, KJ | 1 |
| Greene, N | 1 |
| Legler, A | 1 |
| Kim, RK | 1 |
| Chawla, N | 1 |
| Barton, JR | 1 |
| Yancey, LM | 1 |
| Withers, E | 1 |
| Bakes, K | 1 |
| Abbott, J | 1 |
| Marik, PE | 3 |
| Grassi, D | 1 |
| O'Flaherty, M | 1 |
| Pellizzari, M | 1 |
| Bendersky, M | 1 |
| Rodriguez, P | 1 |
| Turri, D | 1 |
| Forcada, P | 1 |
| Ferdinand, KC | 2 |
| Kotliar, C | 1 |
| Martin-Schild, S | 1 |
| Potter, JF | 1 |
| Robinson, TG | 1 |
| Ford, GA | 1 |
| Mistri, A | 2 |
| James, M | 2 |
| Chernova, J | 2 |
| Jagger, C | 2 |
| Potter, J | 1 |
| Brodie, F | 1 |
| Wilson, E | 1 |
| Ford, G | 1 |
| Robinson, T | 1 |
| Hernandez, MR | 1 |
| Shamberger, RC | 1 |
| Seefelder, C | 1 |
| Asencio Moreno, A | 1 |
| Alamán Orbañanos, B | 1 |
| Moro Velasco, MC | 1 |
| Erkinaro, T | 1 |
| Kavasmaa, T | 1 |
| Ylikauma, L | 1 |
| Mäkikallio, K | 1 |
| Haapsamo, M | 1 |
| Acharya, G | 1 |
| Ohtonen, P | 1 |
| Alahuhta, S | 1 |
| Räsänen, J | 2 |
| Bakris, G | 1 |
| Lee, MR | 1 |
| Chuang, YM | 1 |
| Chen, WJ | 1 |
| Lin, CP | 1 |
| Manrique, C | 1 |
| Giles, TD | 3 |
| Sowers, JR | 1 |
| Weder, AB | 1 |
| Erickson, S | 1 |
| Dennis, A | 1 |
| Walker, S | 1 |
| Drinkwater, P | 1 |
| Crowhurst, J | 1 |
| Thomas, CA | 1 |
| Moffett, BS | 1 |
| Wagner, JL | 1 |
| Mott, AR | 1 |
| Feig, DI | 1 |
| Merino, JL | 1 |
| Espejo, B | 1 |
| Ferreiro, P | 1 |
| Bueno, B | 1 |
| Paraíso, V | 1 |
| Chan, WS | 1 |
| Barrera, M | 1 |
| Rezvani, M | 1 |
| Knittel-Keren, D | 1 |
| Nulman, I | 1 |
| Kim, TK | 1 |
| Yoon, JU | 1 |
| Park, SC | 1 |
| Lee, HJ | 1 |
| Kim, WS | 1 |
| Yoon, JY | 1 |
| Kujal, P | 1 |
| Chábová, VČ | 1 |
| Vernerová, Z | 1 |
| Walkowska, A | 1 |
| Kompanowska-Jezierska, E | 1 |
| Sadowski, J | 1 |
| Vaňourková, Z | 1 |
| Husková, Z | 1 |
| Opočenský, M | 1 |
| Skaroupková, P | 1 |
| Schejbalová, S | 1 |
| Kramer, HJ | 1 |
| Rakušan, D | 1 |
| Malý, J | 1 |
| Netuka, I | 1 |
| Vaněčková, I | 1 |
| Kopkan, L | 1 |
| Cervenka, L | 1 |
| Santos Nores, J | 1 |
| Bravo López, JJ | 1 |
| Borrajo Prol, MP | 1 |
| Iglesias Forneiro, A | 1 |
| Baggio, MR | 1 |
| Martins, WP | 1 |
| Calderon, AC | 1 |
| Berezowski, AT | 1 |
| Marcolin, AC | 1 |
| Duarte, G | 1 |
| Cavalli, RC | 1 |
| van den Born, BJ | 1 |
| Beutler, JJ | 1 |
| Gaillard, CA | 1 |
| de Gooijer, A | 1 |
| van den Meiracker, AH | 1 |
| Kroon, AA | 1 |
| Diercks, D | 1 |
| Campbell, P | 1 |
| Singh, KP | 1 |
| Schuchard, G | 1 |
| Jain, K | 1 |
| White, WB | 3 |
| Kuok, CH | 1 |
| Yen, CR | 1 |
| Huang, CS | 2 |
| Ko, YP | 1 |
| Tsai, PS | 1 |
| Dueñas-Garcia, OF | 1 |
| Hilleman, DE | 2 |
| Koucký, M | 1 |
| Rivera, R | 1 |
| Malesker, MA | 1 |
| Ryu, JH | 1 |
| Apfel, CC | 1 |
| Whelan, R | 1 |
| Jeon, YT | 1 |
| Hwang, JW | 1 |
| Do, SH | 1 |
| Ro, YJ | 1 |
| Kim, CS | 1 |
| Woloszyn, AV | 1 |
| McAllen, KJ | 1 |
| Figueroa, BE | 1 |
| DeShane, RS | 1 |
| Barletta, JF | 1 |
| Wu, CS | 1 |
| Sung, SF | 1 |
| Tong, SH | 1 |
| Ong, CT | 1 |
| Ortega-Gutierrez, S | 1 |
| Thomas, J | 1 |
| Reccius, A | 1 |
| Agarwal, S | 1 |
| Lantigua, H | 1 |
| Li, M | 1 |
| Carpenter, AM | 1 |
| Mayer, SA | 1 |
| Schmidt, JM | 1 |
| Lee, K | 1 |
| Claassen, J | 1 |
| Badjatia, N | 1 |
| Lesch, C | 1 |
| Daskas, N | 1 |
| Crowne, E | 1 |
| Shield, JP | 1 |
| Liu, QQ | 1 |
| Yu, YH | 1 |
| Gong, SP | 1 |
| Huang, LP | 1 |
| McGuinness, N | 1 |
| Cording, V | 1 |
| Odunukan, OW | 1 |
| Abudiab, MM | 1 |
| Sinak, LJ | 1 |
| Elatrous, S | 1 |
| Nouira, S | 1 |
| Ouanes Besbes, L | 1 |
| Marghli, S | 1 |
| Boussarssar, M | 1 |
| Sakkouhi, M | 1 |
| Abroug, F | 1 |
| Belfort, MA | 1 |
| Tooke-Miller, C | 1 |
| Allen, JC | 1 |
| Dizon-Townson, D | 1 |
| Varner, MA | 1 |
| Mok, CC | 1 |
| Kwan, TH | 1 |
| Chow, L | 1 |
| De Conti, F | 1 |
| Da Cortà, R | 1 |
| Del Monte, D | 1 |
| Catena, V | 1 |
| Berton, G | 1 |
| Mormino, P | 2 |
| Pecoraro, L | 1 |
| Piovesana, P | 1 |
| Harrington, C | 1 |
| Kai, H | 1 |
| Imaizumi, T | 2 |
| Assadi, F | 1 |
| Czech, K | 1 |
| Palmisano, JL | 1 |
| Zhang, Y | 1 |
| White, PF | 1 |
| Thornton, L | 1 |
| Perdue, L | 1 |
| Downing, M | 1 |
| Semplicini, A | 6 |
| Calò, L | 1 |
| Fynn, J | 1 |
| Venyo, AK | 1 |
| Stählin, P | 1 |
| Gremmelmaier, D | 1 |
| Handler, J | 1 |
| Balestrieri, PJ | 1 |
| Hamza, MS | 1 |
| Ting, PH | 1 |
| Blank, RS | 1 |
| Grubb, CT | 1 |
| Diamond, AL | 1 |
| Callison, RC | 1 |
| Shokri, J | 1 |
| Cruz-Flores, S | 1 |
| Kinsella, LJ | 1 |
| Weber, MA | 2 |
| Chung, PC | 1 |
| Ng, YT | 1 |
| Hsieh, JR | 1 |
| Yang, MW | 1 |
| Li, AH | 1 |
| Moser, M | 2 |
| Izzo, JL | 1 |
| Bisognano, J | 1 |
| Lewis, S | 1 |
| Dirnhuber, M | 1 |
| Soar, J | 1 |
| Aruny, JE | 1 |
| Perazella, MA | 1 |
| Mizuta, Y | 1 |
| Frishman, WH | 11 |
| Veresh, M | 1 |
| Schlocker, SJ | 1 |
| Tejani, N | 1 |
| Gray, RJ | 1 |
| Long, RC | 1 |
| Wofford, MR | 1 |
| Harkins, KG | 1 |
| Minor, DS | 1 |
| Chan, S | 1 |
| Hewson, S | 1 |
| Kavuma, E | 1 |
| McKay, D | 1 |
| Ohlsson, A | 1 |
| Willan, AR | 1 |
| Hannah, ME | 1 |
| Hatfield, T | 1 |
| Steiger, R | 1 |
| Wing, DA | 1 |
| Janisse, J | 1 |
| Coplin, WM | 1 |
| Norris, G | 1 |
| van der Starre, PJ | 1 |
| Lemmens, HJ | 1 |
| Chandel, A | 1 |
| Brock-Utne, JG | 2 |
| Solvason, HB | 1 |
| Thorsteinsson, A | 1 |
| Johannesdottir, A | 1 |
| Eiríksson, H | 1 |
| Helgason, H | 1 |
| Roberts, J | 1 |
| Isenberg, DL | 1 |
| Fox, BD | 1 |
| Krylov, Y | 1 |
| Leon, P | 1 |
| Ben-Zvi, I | 1 |
| Peled, N | 1 |
| Shitrit, D | 1 |
| Kramer, MR | 1 |
| Noppers, IM | 1 |
| Zijlstra, JG | 1 |
| Jack, DB | 1 |
| Dean, S | 1 |
| Kendall, MJ | 1 |
| Laugher, S | 1 |
| Wilson, JD | 1 |
| Booth, RJ | 1 |
| Bullock, JY | 1 |
| Campbell, DG | 1 |
| Staughton, R | 1 |
| Sutton, R | 1 |
| Farrell, M | 1 |
| McGonigle, RJ | 1 |
| Williams, L | 1 |
| Murphy, MJ | 2 |
| Parsons, V | 3 |
| Rossano, P | 1 |
| Saffiotti, O | 1 |
| Mayer, MC | 1 |
| Blasich, M | 1 |
| Rossano, G | 1 |
| Bellotti, P | 1 |
| Nami, R | 1 |
| Pizzuti, M | 1 |
| Nardi, PL | 1 |
| D'Ascenzo, G | 1 |
| Maioli, E | 1 |
| Gennari, C | 1 |
| Strom, JA | 3 |
| Kirschner, M | 2 |
| Poland, M | 6 |
| Klein, N | 1 |
| Halprin, S | 3 |
| LeJemtel, TH | 1 |
| Kram, M | 1 |
| Sonnenblick, EH | 1 |
| O'Hare, JA | 1 |
| Murnaghan, DJ | 1 |
| Bernard, D | 1 |
| Lagrue, G | 1 |
| Erina, EV | 3 |
| Charyev, KhE | 3 |
| Beliakova, EV | 1 |
| Tverskaia, LV | 1 |
| Kukharchuk, VV | 1 |
| Breckenridge, A | 3 |
| Orme, M | 1 |
| Serlin, MJ | 2 |
| Maciver, M | 2 |
| Prichard, BN | 7 |
| Richards, DA | 7 |
| Walker, JJ | 5 |
| Erwin, L | 1 |
| Lang, G | 1 |
| Prentice, CR | 1 |
| Belch, JJ | 2 |
| McLaren, M | 2 |
| Forbes, CD | 3 |
| Calder, AA | 5 |
| Russell, WJ | 1 |
| Kaines, AH | 1 |
| Hooper, MJ | 1 |
| Frewin, DB | 1 |
| Adam, WR | 2 |
| Meagher, EJ | 1 |
| Barter, CE | 1 |
| Lund-Johansen, P | 8 |
| Baum, T | 2 |
| Sybertz, EJ | 2 |
| Koch, G | 8 |
| Pessina, AC | 7 |
| Rossi, GP | 3 |
| Hlede, M | 5 |
| Morandin, F | 3 |
| Smith, AM | 1 |
| Walker, H | 1 |
| Bonduelle, M | 1 |
| Greer, I | 2 |
| Rubin, PC | 2 |
| Reid, JL | 4 |
| Anand, MP | 1 |
| Glezer, GA | 1 |
| Smolenskiĭ, VS | 1 |
| Porotikov, VI | 1 |
| Meĭler, SM | 1 |
| Khodzhamirova, VS | 1 |
| Scriven, AJ | 1 |
| Lewis, PJ | 1 |
| Michelson, EL | 7 |
| Frohlich, ED | 2 |
| Dunn, FG | 2 |
| Messerli, FH | 4 |
| Wilson, DJ | 3 |
| Wallin, JD | 12 |
| Vlachakis, ND | 5 |
| Freis, ED | 3 |
| Vidt, DG | 9 |
| Langford, HG | 1 |
| Flamenbaum, W | 4 |
| Poland, MP | 9 |
| Lardoux, H | 8 |
| Gerard, J | 6 |
| Blazquez, G | 6 |
| Flouvat, B | 3 |
| De Leeuw, PW | 2 |
| Birkenhäger, WH | 1 |
| Graham, RM | 1 |
| Kubik, MM | 1 |
| Coote, JH | 1 |
| Eliasson, K | 2 |
| Danielson, M | 1 |
| Hylander, B | 2 |
| Lindblad, LE | 1 |
| Johns, VJ | 1 |
| Lubbe, WF | 4 |
| Drayer, JI | 1 |
| Monopoli, A | 1 |
| Bamonte, F | 1 |
| Forlani, A | 1 |
| Ongini, E | 1 |
| Parravicini, L | 1 |
| Bonavita, E | 1 |
| Mounac, M | 1 |
| Giraud, P | 1 |
| Jeuffroy, A | 1 |
| van Hasselt, G | 1 |
| MacKenzie, I | 1 |
| Edwards, JC | 1 |
| Ferrari, A | 2 |
| Buccino, N | 1 |
| Di Rienzo, M | 2 |
| Pedotti, A | 1 |
| Mancia, G | 6 |
| Zanchetti, A | 4 |
| Riley, AJ | 1 |
| Meredith, PA | 3 |
| Elliott, HL | 3 |
| Anavekar, SN | 2 |
| Barter, C | 1 |
| Doyle, AE | 4 |
| Mathisen, R | 1 |
| Sveen, K | 1 |
| Kaul, U | 1 |
| Mohan, JC | 1 |
| Bhatia, ML | 1 |
| Sanders, GL | 5 |
| Davies, DM | 4 |
| Rawlins, MD | 5 |
| Milne, BJ | 1 |
| Holzgreve, H | 1 |
| Rosenthal, T | 5 |
| Rabinowitz, B | 1 |
| Boichis, H | 1 |
| Elazar, E | 1 |
| Brauner, A | 1 |
| Neufeld, HN | 1 |
| Zschiedrich, H | 1 |
| Neurohr, W | 1 |
| Lüth, JB | 1 |
| Philipp, T | 1 |
| Distler, A | 1 |
| Lediashova, GA | 1 |
| Smolenskiĭ, AV | 1 |
| George, RB | 3 |
| Manocha, K | 2 |
| Burford, JG | 3 |
| Conrad, SA | 3 |
| Kinasewitz, GT | 1 |
| Andrén, L | 1 |
| Hansson, L | 4 |
| Eggertsen, R | 1 |
| Hedner, T | 1 |
| Karlberg, BE | 3 |
| O'Neill, WM | 2 |
| Maharaj, RJ | 1 |
| Thompson, M | 1 |
| Williamson, R | 1 |
| Downing, JW | 1 |
| Broughton Pipkin, F | 4 |
| Symonds, EM | 4 |
| Lamming, GD | 3 |
| Jadoul, FA | 1 |
| Rahn, KH | 4 |
| Scannapieco, G | 2 |
| Pauletto, P | 2 |
| Dario, C | 1 |
| Vescovo, G | 2 |
| Mazzucato, A | 2 |
| Angelini, A | 1 |
| Carter, BL | 1 |
| Sassard, J | 2 |
| Zech, PY | 1 |
| Pozet, N | 2 |
| Cuisinaud, G | 1 |
| Vincent, M | 2 |
| Light, RW | 3 |
| Chetty, KG | 1 |
| Stansbury, DW | 1 |
| Maronde, RF | 3 |
| Robinson, D | 1 |
| Barr, JW | 1 |
| Chung, M | 2 |
| Zampaglione, N | 1 |
| Medakovic, M | 7 |
| Davidov, ME | 3 |
| Moir, GD | 1 |
| Maloy, J | 2 |
| Johnson, BF | 6 |
| Lewis, JE | 1 |
| Edwards, WT | 1 |
| Flanigan, WJ | 1 |
| Bloomfield, SS | 2 |
| Lucas, C | 3 |
| Finnerty, FA | 1 |
| Lucas, CP | 1 |
| Gantt, CL | 1 |
| Wilson, D | 1 |
| Winer, N | 3 |
| Langford, H | 1 |
| Hammerle, AF | 2 |
| Agabiti-Rosei, E | 6 |
| Alicandri, C | 3 |
| Beschi, M | 4 |
| Castellano, M | 4 |
| Corea, L | 1 |
| Beggi, P | 1 |
| Motolese, M | 1 |
| Muiesan, G | 6 |
| Barr, J | 1 |
| Velasquez, M | 1 |
| Alexander, N | 1 |
| Maronde, R | 1 |
| Lifshits, NL | 1 |
| Ermolenko, VM | 1 |
| Rozhdestvenskaia, TM | 1 |
| Tatsievskiĭ, VA | 1 |
| Panasiuk, VV | 1 |
| Kharchenko, VI | 4 |
| Savenkov, PM | 2 |
| Evsikov, EM | 3 |
| Ram, CV | 5 |
| Greer, IA | 2 |
| McAreavey, D | 1 |
| Ramsey, LE | 1 |
| Latham, L | 1 |
| McLaren, AD | 1 |
| Lorimer, AR | 1 |
| Robertson, JI | 13 |
| Robertson, MP | 1 |
| Weir, RJ | 1 |
| Domenighetti, GM | 2 |
| Savary, G | 2 |
| Stricker, H | 1 |
| Song, YC | 1 |
| Sugano, O | 1 |
| Hirano, J | 1 |
| Hirano, K | 1 |
| Kubota, Y | 1 |
| Numasawa, K | 1 |
| Kawamura, S | 1 |
| Dziekański, S | 3 |
| Adamska-Dyniewska, H | 3 |
| Słomka, S | 1 |
| Tkaczewski, W | 1 |
| Navaratnarajah, M | 1 |
| White, DC | 1 |
| Gill, D | 1 |
| Ward, A | 2 |
| Bridges-Webb, C | 1 |
| Breen, EG | 1 |
| Lombard, M | 1 |
| Watson, A | 2 |
| Keogh, JA | 2 |
| Enoki, N | 1 |
| Satoh, Z | 1 |
| Ogata, A | 1 |
| Yukioka, H | 1 |
| Nishimura, K | 1 |
| Fujimori, M | 1 |
| Belogi, M | 1 |
| Ansuini, R | 1 |
| Pupita, G | 1 |
| Campolucci, G | 1 |
| Pupita, F | 1 |
| Dubois, D | 1 |
| Petitcolas, J | 1 |
| Temperville, B | 1 |
| Klepper, A | 1 |
| Leboullenger, P | 1 |
| Fagard, R | 6 |
| Reybrouck, T | 5 |
| Vanhees, L | 1 |
| Cattaert, A | 1 |
| Vanmeenen, T | 1 |
| Grauwels, R | 1 |
| Amery, A | 6 |
| Nylund, L | 3 |
| Lunell, NO | 5 |
| Lewander, R | 3 |
| Sarby, B | 2 |
| Thornström, S | 2 |
| Mamoun, I | 1 |
| Sarby, S | 1 |
| Wajngarten, M | 1 |
| Antunes, JE | 1 |
| Pereyra, PL | 1 |
| Godoy, M | 1 |
| Dauar, D | 1 |
| Martinelli Filho, M | 1 |
| Pereira Barretto, AC | 1 |
| Pileggi, F | 1 |
| Woods, DL | 1 |
| Malan, AF | 1 |
| Lin, MS | 2 |
| McNay, JL | 1 |
| Shepherd, AM | 1 |
| Keeton, TK | 1 |
| Mulac, KD | 1 |
| Meryn, S | 1 |
| Lilja, M | 2 |
| Stokes, GS | 2 |
| Mennie, BA | 1 |
| Gellatly, R | 1 |
| Hill, A | 1 |
| Mehta, J | 4 |
| Feldman, RL | 1 |
| Marx, JD | 1 |
| Kelly, GA | 1 |
| Romanova, LV | 1 |
| Arkhipov, SN | 1 |
| Borisova, GG | 1 |
| Buch, J | 1 |
| Rasmussen, S | 8 |
| Keusch, G | 2 |
| Schiffl, H | 1 |
| Binswanger, U | 1 |
| Chouty, F | 3 |
| Beauséjour, B | 1 |
| Faurie, C | 1 |
| Rousset, D | 1 |
| Van Stratum, M | 1 |
| Levarlet, M | 1 |
| Lambilliotte, JP | 1 |
| Lignian, H | 1 |
| de Rood, M | 1 |
| Rumboldt, Z | 2 |
| Bagatin, J | 2 |
| Vidovic, A | 2 |
| Cressman, MD | 2 |
| Gifford, RW | 2 |
| Moore, WS | 1 |
| Morel, DR | 2 |
| Forster, A | 2 |
| Suter, PM | 2 |
| Rossi, A | 3 |
| Ziacchi, V | 3 |
| Lomanto, B | 3 |
| Bellamy, GR | 2 |
| Hunyor, SN | 3 |
| Roffe, D | 2 |
| Massang, J | 2 |
| Nilsson, OR | 1 |
| Henningsen, NC | 1 |
| Thulin, T | 1 |
| Benchimol, AB | 1 |
| Sbissa, AS | 1 |
| Benchimol, CB | 1 |
| Saad, EA | 1 |
| Barbosa, ET | 1 |
| Albanesi Filho, FM | 1 |
| Pillegi, F | 1 |
| da Cunha, GP | 1 |
| Maranhão, MF | 1 |
| Batlouni, M | 1 |
| Schlesinger, P | 1 |
| Duprat, R | 1 |
| Maciel, R | 1 |
| Lijnen, P | 5 |
| de Schaepdryver, A | 1 |
| Moerman, E | 1 |
| Clémenty, J | 2 |
| Dallocchio, M | 2 |
| Bricaud, H | 1 |
| Teicher, A | 3 |
| Kissin, E | 1 |
| Sarova, I | 1 |
| Stewart, PA | 1 |
| Oigman, W | 1 |
| Dreslinski, GR | 1 |
| Reisin, E | 1 |
| Roy, L | 1 |
| Mehta, P | 1 |
| Tcherdakoff, P | 1 |
| Puchstein, C | 2 |
| van Aken, H | 2 |
| Hidding, J | 1 |
| Anger, C | 1 |
| Lawin, P | 1 |
| White, DA | 2 |
| Renard, M | 2 |
| Rivière, A | 1 |
| Jacobs, P | 2 |
| Bernard, R | 2 |
| Butters, L | 1 |
| Kelman, AW | 1 |
| Fitzsimons, C | 1 |
| Jackson, SH | 1 |
| Beevers, DG | 1 |
| Liusov, VA | 2 |
| Istomina, IA | 1 |
| Rifai, MA | 1 |
| Palatini, P | 3 |
| Sperti, G | 2 |
| Ventura, E | 1 |
| Agnoletto, V | 1 |
| Gava, R | 1 |
| Dal Palù, C | 4 |
| Oates, HF | 1 |
| Bauer, GE | 1 |
| Ross, M | 1 |
| Larkin, H | 1 |
| Tötterman, KJ | 2 |
| Eisalo, A | 2 |
| Zilcher, H | 1 |
| Weber, H | 1 |
| Glogar, D | 1 |
| Holzer, H | 1 |
| Pogglitsch, H | 1 |
| Katschnig, H | 1 |
| Korthals, C | 1 |
| Mutz, N | 1 |
| Duma, S | 1 |
| Barousch, R | 1 |
| Prohaska, H | 1 |
| Honetz, N | 1 |
| Hedstrand, H | 1 |
| Virta, P | 1 |
| Walstad, RA | 2 |
| Berg, KJ | 2 |
| Wessel-Aas, T | 2 |
| Nilsen, OG | 1 |
| Fredholm, B | 1 |
| Hjemdahl, P | 2 |
| Nisell, H | 2 |
| Persson, B | 2 |
| Wager, J | 2 |
| Nyberg, G | 1 |
| Berglund, G | 2 |
| Waal-Manning, HJ | 2 |
| Simpson, FO | 3 |
| Nicholls, DP | 1 |
| Husaini, MH | 1 |
| Bulpitt, CJ | 1 |
| Stephens, MD | 3 |
| Butler, AG | 1 |
| West, MJ | 1 |
| Wing, LM | 2 |
| Mulligan, J | 1 |
| Walkley, J | 1 |
| Grygiel, JJ | 1 |
| Graham, JR | 1 |
| Chalmers, JP | 1 |
| Thibonnier, M | 1 |
| Lardoux, MD | 1 |
| Corvol, P | 2 |
| Nontak, MA | 1 |
| Ahmad, S | 2 |
| Maheendran, KK | 1 |
| Abdullah, Z | 1 |
| Martinand, A | 1 |
| Milliez, P | 1 |
| Kornerup, HJ | 3 |
| Pedersen, EB | 5 |
| Pedersen, A | 3 |
| Pedersen, G | 3 |
| Christensen, NJ | 5 |
| Kofod, P | 1 |
| Kjaer, K | 1 |
| Vejlø, S | 1 |
| Hvidt, S | 1 |
| Meretoja, OA | 1 |
| Allonen, H | 2 |
| Arola, M | 1 |
| Laaksonen, VO | 1 |
| Zech, P | 1 |
| Lechi, A | 3 |
| Picotti, GB | 1 |
| Covi, G | 2 |
| Pomari, S | 3 |
| Pedrolli, E | 2 |
| Cesura, AM | 1 |
| Danti, G | 2 |
| Mattioli, M | 2 |
| Novo, S | 2 |
| Pinto, A | 2 |
| Davì, G | 1 |
| Riolo, F | 1 |
| Gullotti, D | 1 |
| Baratta, L | 1 |
| Florio, P | 1 |
| Guerrieri, P | 1 |
| Lanciotti, G | 1 |
| Mastrocola, C | 1 |
| Petrosillo, N | 1 |
| Scarfò, G | 1 |
| Avella, A | 1 |
| Gyimesi, A | 1 |
| Hanyecz, V | 1 |
| Pocsay, G | 1 |
| Iványi, J | 1 |
| Hauger-Klevene, JH | 1 |
| Bar-Andziak, E | 1 |
| Chlewicka, I | 1 |
| Demarchi, PG | 1 |
| Mancini, A | 1 |
| Brignole, M | 1 |
| Astengo, D | 1 |
| Bertulla, A | 1 |
| Cybulska, I | 2 |
| Sznajderman, M | 2 |
| Brym, E | 2 |
| Czerniewska, E | 2 |
| Stern, N | 2 |
| Greminger, P | 1 |
| Minder, F | 1 |
| Schärer, HU | 1 |
| van der Veur, E | 3 |
| ten Berge, BS | 3 |
| Donker, AJ | 2 |
| May, JF | 2 |
| Wesseling, H | 3 |
| Takeda, T | 1 |
| Kaneko, Y | 1 |
| Omae, T | 1 |
| Yoshinaga, K | 1 |
| Masuyama, Y | 1 |
| Nukada, T | 1 |
| Shigiya, R | 1 |
| Al-Damluji, SF | 1 |
| Al-Khalidi, A | 1 |
| Shaarbaf, H | 1 |
| Tawfiq, NH | 1 |
| Berto, R | 1 |
| Buniotto, P | 1 |
| Parrinello, A | 1 |
| Marini, F | 1 |
| Cogo, L | 1 |
| Tomasi, A | 1 |
| Baretta, G | 1 |
| Schirripa, V | 2 |
| Attisano, N | 2 |
| Sarica, G | 2 |
| Grenci, G | 2 |
| Martelli, G | 2 |
| Jounela, AJ | 1 |
| Karppanen, H | 1 |
| Davies, AB | 1 |
| Bala Subramanian, V | 1 |
| Gould, B | 1 |
| Raftery, EB | 8 |
| Opie, LH | 4 |
| White, D | 1 |
| Lee, J | 1 |
| Malini, PL | 1 |
| Strocchi, E | 1 |
| Negroni, S | 1 |
| Ambrosioni, E | 1 |
| Magnani, B | 1 |
| Scott, DB | 1 |
| Michael, CA | 4 |
| Cohn, JN | 2 |
| Francis, GS | 1 |
| McNeil, JJ | 6 |
| Anderson, AE | 3 |
| Louis, WJ | 6 |
| Raymond, K | 1 |
| Pomidossi, G | 1 |
| Parati, G | 2 |
| Bertinieri, G | 1 |
| Grassi, G | 3 |
| Navone, F | 1 |
| Gregorini, L | 1 |
| Kane, JA | 1 |
| Alicandri, CL | 3 |
| Fariello, R | 5 |
| Montini, E | 2 |
| Muiesan, ML | 2 |
| Romanelli, G | 4 |
| Cumming, AM | 3 |
| Brown, JJ | 11 |
| Lever, AF | 10 |
| Gomez, G | 2 |
| Barbieri, C | 1 |
| Larovere, MT | 1 |
| Mariotti, G | 1 |
| Ferrari, C | 1 |
| Caldara, R | 1 |
| Boni, E | 2 |
| Zaninelli, A | 1 |
| Papademetriou, V | 1 |
| Notargiacomo, AV | 1 |
| Khatri, IM | 1 |
| Vas, A | 1 |
| Gachályi, B | 1 |
| Káldor, A | 1 |
| Visonà, A | 1 |
| Schweppe, ML | 1 |
| Heinecke, A | 1 |
| Carré, AG | 1 |
| Bertrand, ME | 1 |
| Libersa, CC | 1 |
| Lekieffre, JP | 1 |
| Fea, F | 1 |
| Salvioli, G | 1 |
| Planca, E | 1 |
| Pelliccioli, I | 1 |
| Foti, F | 1 |
| Colombo, G | 1 |
| Kane, J | 3 |
| Gregg, I | 3 |
| Cruz, F | 1 |
| Clifton, G | 1 |
| Cantelli, I | 1 |
| Lombardi, G | 1 |
| Naccarella, F | 1 |
| Pavesi, PC | 1 |
| Bracchetti, D | 1 |
| Rossi, AG | 1 |
| Timmis, AD | 1 |
| Fowler, MB | 1 |
| Jaggarao, NS | 1 |
| Chamberlain, DA | 1 |
| Maher, K | 1 |
| Piterman, L | 1 |
| Nakagawa, Y | 1 |
| Takeda, K | 1 |
| Sakurai, H | 1 |
| Mitomi, A | 1 |
| Imai, S | 1 |
| Lüben, V | 1 |
| Rieder, W | 1 |
| Zierski, J | 1 |
| Hempelmann, G | 1 |
| Fredholm, BB | 1 |
| Nielsen, PE | 7 |
| Millar-Craig, MW | 3 |
| Mann, S | 3 |
| Balasubramanian, V | 3 |
| Krechnáková, A | 1 |
| Danĕková, H | 1 |
| Nandoryová, M | 1 |
| Niederland, TR | 1 |
| Heck, I | 1 |
| Trübestein, G | 1 |
| Stumpe, KO | 1 |
| Wocial, B | 1 |
| Frishman, W | 5 |
| Strom, J | 1 |
| Tuomilehto, J | 1 |
| Nissinen, A | 1 |
| Elo, J | 1 |
| Svendsen, TL | 5 |
| Hartling, OJ | 3 |
| Trap-Jensen, J | 6 |
| Weidmann, P | 2 |
| Ziegler, WH | 2 |
| de Châtel, R | 2 |
| Reubi, FC | 1 |
| Whiting, G | 1 |
| Craswell, P | 1 |
| Boyle, P | 1 |
| Bett, N | 1 |
| Macdonald, I | 1 |
| Hua, AS | 1 |
| Thomas, GW | 2 |
| Woo, KT | 1 |
| Whitworth, JA | 3 |
| Kincaid-Smith, P | 2 |
| Morgan, T | 2 |
| Waga, S | 1 |
| Hodgson, M | 1 |
| Adam, W | 2 |
| Turco, P | 2 |
| Dal Negro, R | 1 |
| Phillips, LA | 1 |
| Zacharias, FJ | 1 |
| Larsen, JS | 2 |
| Clausen, JP | 1 |
| Krogsgaard, AR | 1 |
| Carlsen, JE | 1 |
| Erichs, M | 1 |
| Rothgardt, NP | 1 |
| Andersson, E | 2 |
| Kristensen, BO | 2 |
| la Cour Petersen, E | 2 |
| Harvald, B | 1 |
| Douglas-Jones, AP | 1 |
| Mereto, GC | 1 |
| Garavini, L | 1 |
| Sommers, DK | 2 |
| Zannini, G | 1 |
| Bahlmann, J | 2 |
| Brod, J | 2 |
| Hubrich, W | 2 |
| Pretschner, P | 2 |
| Sternon, J | 1 |
| Melot, C | 1 |
| Contu, E | 1 |
| Omvik, P | 2 |
| Palla, R | 1 |
| Bionda, A | 1 |
| Carmassi, F | 1 |
| Giusti, R | 1 |
| Marchitiello, M | 1 |
| Stoudemire, A | 3 |
| Inagaki, O | 1 |
| Sudoh, K | 1 |
| Shibasaki, M | 1 |
| Nakagawa, C | 1 |
| Honda, K | 1 |
| Miller, K | 1 |
| Zigmont, EA | 1 |
| Connelly, JF | 1 |
| Handa, SP | 1 |
| Wong, J | 1 |
| Wolf, HK | 1 |
| Darmansjah, I | 1 |
| Setiawati, A | 1 |
| Prabowo, P | 1 |
| Sukandar, E | 1 |
| Parsoedi, I | 1 |
| Bahry, B | 1 |
| Jusman, J | 1 |
| Anggraeni, E | 1 |
| el-Qarmalawi, AM | 1 |
| Morsy, AH | 1 |
| al-Fadly, A | 1 |
| Obeid, A | 1 |
| Hashem, M | 1 |
| Remme, WJ | 1 |
| von Schelven, D | 1 |
| Bartels, GL | 1 |
| Kruijssen, HA | 1 |
| Apeldoorn, L | 1 |
| Voerman, HJ | 1 |
| Hoefnagel, CA | 1 |
| Morgenstern, BZ | 1 |
| Mutti, E | 1 |
| Frattola, A | 1 |
| Castiglioni, P | 1 |
| Bilello, K | 1 |
| Schultz, S | 1 |
| Powell, C | 1 |
| Jaffin, J | 1 |
| Cole, F | 1 |
| Malcolm, D | 1 |
| Spassov, L | 1 |
| Curzi-Dascalova, L | 1 |
| Clairambault, J | 1 |
| Kauffmann, F | 1 |
| Eiselt, M | 1 |
| Médigue, C | 1 |
| Peirano, P | 1 |
| Kantola, I | 1 |
| Kaila, T | 1 |
| Erkkola, R | 1 |
| Janssen, BJ | 1 |
| Oosting, J | 1 |
| Tyssen, CM | 1 |
| Struyker-Boudier, HA | 1 |
| Jouppila, P | 1 |
| Martin, G | 2 |
| Forte, P | 2 |
| Luchsinger, A | 2 |
| Mendoza, F | 2 |
| Urbina-Quintana, A | 2 |
| Hernandez Pieretti, O | 2 |
| Romero, E | 2 |
| Velasco, M | 3 |
| Haenni, A | 1 |
| Lithell, H | 1 |
| Montolivo, M | 2 |
| Gemma, M | 2 |
| Regi, B | 2 |
| Coffano, B | 1 |
| Giannini, A | 1 |
| Grandi, L | 1 |
| Fiacchino, F | 2 |
| Eriksson, S | 1 |
| Andersson, B | 1 |
| Gunnarsson, U | 1 |
| Rundgren, M | 1 |
| Gales, MA | 1 |
| Saotome, T | 1 |
| Minoura, S | 1 |
| Terashi, K | 1 |
| Sato, T | 1 |
| Echizen, H | 1 |
| Ishizaki, T | 2 |
| Siwach, SB | 1 |
| Dahiya, SS | 1 |
| Seth, S | 1 |
| Seth, RK | 1 |
| Sharma, D | 1 |
| Walley, T | 1 |
| Tsao, Y | 3 |
| Scott, A | 2 |
| Mackay, E | 1 |
| Vandenburg, M | 1 |
| Textor, SC | 1 |
| McDonald, AJ | 1 |
| Yealy, DM | 1 |
| Jacobson, S | 1 |
| Morgan, MA | 1 |
| Silavin, SL | 1 |
| Dormer, KJ | 1 |
| Fishburne, BC | 1 |
| Fishburne, JI | 1 |
| Abdelwahab, W | 1 |
| Landau, A | 1 |
| Hurst, JA | 1 |
| Houlston, RS | 1 |
| Roberts, A | 1 |
| Gould, SJ | 1 |
| Tingey, WG | 1 |
| Drenth, JP | 1 |
| Michiels, JJ | 1 |
| Ozsoylu, S | 1 |
| Trejo Gabriel y Galán, JM | 1 |
| Groshong, T | 1 |
| Santeiro, ML | 1 |
| Stromquist, C | 1 |
| Wyble, L | 1 |
| Kalyanaraman, M | 1 |
| Carpenter, RL | 1 |
| McGlew, MJ | 1 |
| Guertin, SR | 1 |
| Wood, G | 1 |
| Gazzolo, D | 1 |
| Visser, GH | 1 |
| Russo, A | 1 |
| Scopesi, F | 1 |
| Santi, F | 1 |
| Bruschettini, PL | 1 |
| Fagan, SC | 1 |
| Bowes, MP | 1 |
| Lyden, PD | 1 |
| Zivin, JA | 1 |
| Drop, L | 1 |
| Castelli, I | 1 |
| Kaufmann, M | 1 |
| Koscielniak-Nielsen, ZJ | 1 |
| Bowman, ML | 1 |
| Bergmann, M | 1 |
| Smith, JF | 1 |
| Vyas, S | 1 |
| Kumar, A | 1 |
| Piecuch, S | 1 |
| Hidalgo, G | 1 |
| Anderson, V | 1 |
| Markell, MS | 1 |
| Baqi, N | 1 |
| Blanco, M | 1 |
| Gomez, J | 1 |
| Negrín, C | 1 |
| Blanco, G | 1 |
| Rodriguez, M | 1 |
| Torres, M | 1 |
| Vásquez, M | 1 |
| Alcalá, I | 1 |
| Vargas, R | 1 |
| Armero, R | 1 |
| Vicente, R | 1 |
| Alepuz, R | 1 |
| Boulton, DW | 1 |
| Dakers, JM | 1 |
| Fawcett, JP | 1 |
| Fiddes, TM | 1 |
| Vermillion, ST | 2 |
| Scardo, JA | 2 |
| Newman, RB | 2 |
| Chauhan, SP | 2 |
| Hogg, BB | 1 |
| Gande, AR | 1 |
| Taylor, IR | 1 |
| Nolan, KM | 1 |
| Kross, RA | 1 |
| Ferri, E | 1 |
| Leung, D | 1 |
| Pratila, M | 1 |
| Broad, C | 1 |
| Veronesi, M | 1 |
| Melendez, JA | 1 |
| Fischberg, GM | 1 |
| Lozano, E | 1 |
| Rajamani, K | 1 |
| Ameriso, S | 1 |
| Fisher, MJ | 1 |
| Bull, SB | 1 |
| Logan, A | 1 |
| Laml, T | 1 |
| Hartmann, BW | 1 |
| Preyer, O | 1 |
| Ruecklinger, E | 1 |
| Soeregi, G | 1 |
| Wagenbichler, P | 1 |
| Bolte, AC | 1 |
| van Geijn, HP | 1 |
| Dekker, GA | 1 |
| Hussein, M | 1 |
| Mooij, JM | 1 |
| Roujouleh, H | 1 |
| Poopalalingam, R | 1 |
| Chin, EY | 1 |
| Blanch, J | 1 |
| Martínez-Pallí, G | 1 |
| Navinés, R | 1 |
| Arcega, JM | 1 |
| Imaz, ML | 1 |
| Santos, P | 1 |
| Faulí, A | 1 |
| Bernardo, M | 1 |
| Gomar, C | 1 |
| Rollins, G | 1 |
| Oparil, S | 1 |
| Spierings, EL | 1 |
| Brittain, RT | 1 |
| Levy, GP | 2 |
| Hänel, B | 2 |
| Pearson, RM | 4 |
| Havard, CW | 4 |
| Rosei, EA | 7 |
| Fraser, R | 5 |
| Morton, JJ | 5 |
| Trust, PM | 7 |
| Wollam, GL | 1 |
| Tarazi, RC | 1 |
| Brogden, RN | 1 |
| Heel, RC | 1 |
| Speight, TM | 1 |
| Avery, GS | 1 |
| Williams, JG | 1 |
| De Voss, K | 1 |
| Craswell, PW | 1 |
| Wilcox, RG | 1 |
| Harris, D | 1 |
| Blakeley, AG | 1 |
| Summers, RJ | 1 |
| Hayduk, K | 1 |
| Billiet, L | 2 |
| Kaplan, NM | 1 |
| Drew, GM | 1 |
| Hilditch, A | 1 |
| Murray, A | 1 |
| Boakes, AJ | 3 |
| Bailey, RR | 3 |
| Brignell, MJ | 1 |
| Christophidis, N | 2 |
| Vajda, FJ | 2 |
| Briggs, RS | 1 |
| Birtwell, AJ | 1 |
| Pohl, JE | 1 |
| FitzGerald, GA | 1 |
| Davies, DL | 1 |
| Branford, WA | 1 |
| Hunter, JA | 1 |
| Muir, AL | 1 |
| Pagnan, A | 1 |
| Zanetti, G | 1 |
| Dal Palu', C | 1 |
| Lysbo Svendsen, T | 1 |
| Hartling, O | 1 |
| Brignell, M | 1 |
| Vijayasekaran, V | 1 |
| McNeil, J | 1 |
| Dent, R | 1 |
| Kellaway, GS | 1 |
| Bolli, P | 2 |
| Seeman, HM | 1 |
| Ghose, RR | 3 |
| Sampson, A | 1 |
| Flammer, J | 1 |
| Reubi, F | 1 |
| Barnett, AJ | 1 |
| Kalowski, S | 1 |
| Guest, C | 1 |
| Anderson, CC | 1 |
| Gabriel, R | 2 |
| Routledge, PA | 3 |
| Rao, JG | 2 |
| Gales, GM | 2 |
| Pugsley, DJ | 2 |
| Nassim, M | 2 |
| Armstrong, BK | 2 |
| Beilin, L | 1 |
| Steiner, JA | 1 |
| Cooper, R | 2 |
| Gear, JS | 1 |
| Ledingham, JG | 1 |
| Dawson, A | 1 |
| Smith, IK | 1 |
| Munro-Faure, AD | 3 |
| Horvath, JS | 1 |
| Caterson, RJ | 1 |
| Collett, P | 1 |
| Duggin, GG | 1 |
| Kelly, DH | 1 |
| Tiller, DJ | 1 |
| Forsell, P | 1 |
| O'Sullivan, J | 1 |
| Carson, N | 1 |
| Mackay, A | 1 |
| Salvetti, A | 1 |
| Pedrinelli, R | 1 |
| Sassano, P | 1 |
| Arzilli, F | 1 |
| Romo, M | 1 |
| Halttunen, P | 1 |
| Saarinen, P | 1 |
| Sarna, S | 1 |
| Petralito, A | 1 |
| Lunetta, M | 1 |
| Mangiafico, RA | 1 |
| Liuzzo, A | 1 |
| Fiore, CE | 1 |
| Manderson, WS | 1 |
| Lehtonen, A | 1 |
| Kleimola, T | 1 |
| Hurley, DM | 1 |
| Vandongen, R | 1 |
| Beilin, LJ | 3 |
| Cummings, AM | 1 |
| Robinson, IG | 1 |
| Allen, B | 1 |
| Frais, MA | 1 |
| Bayley, TJ | 1 |
| Yeung, CK | 1 |
| Cachovan, M | 1 |
| Altman, D | 1 |
| Thompson, FD | 2 |
| Joekes, AM | 3 |
| Hussein, MM | 1 |
| Williams, LC | 1 |
| Morgan, DJ | 1 |
| Hernández, R | 1 |
| Chalmers, AG | 1 |
| Hunter, J | 1 |
| Lees, CD | 1 |
| Millar, JA | 1 |
| Griffith, DN | 1 |
| Woollard, M | 1 |
| James, IM | 1 |
| Besterman, EM | 1 |
| Spencer, M | 1 |
| Symonds, EB | 1 |
| Marx, PG | 1 |
| Reid, DS | 1 |
| Miano, L | 1 |
| Kolloch, R | 1 |
| De Quattro, V | 1 |
| Raffo, M | 2 |
| Cherchi, A | 2 |
| Sau, F | 2 |
| Pirisi, R | 2 |
| Seguro, C | 2 |
| Pisano, MR | 1 |
| Mathur, YB | 1 |
| Upadhyay, M | 1 |
| Morgan, WD | 1 |
| Khan, S | 1 |
| Gillies, A | 1 |
| Morgan, G | 1 |
| MacCarthy, EP | 2 |
| Frost, GW | 1 |
| Good, CS | 1 |
| Maidment, CG | 1 |
| Davies, R | 1 |
| Harris, C | 1 |
| McGrath, BP | 3 |
| Matthews, PG | 2 |
| Walter, NM | 1 |
| Maydom, BW | 1 |
| Johnston, CI | 1 |
| Orme, MC | 1 |
| Green, GJ | 1 |
| Macnee, CM | 2 |
| Breckenridge, AM | 3 |
| Bakke, OM | 1 |
| Frick, MH | 1 |
| Pörsti, P | 1 |
| Edwards, RC | 1 |
| Waal-Manning, J | 1 |
| Wood, AJ | 1 |
| Nassim, MA | 1 |
| LaBrooy, J | 2 |
| Thompson, FO | 1 |
| Orme, NL | 1 |
| Sterlin, MJ | 1 |
| Crofton, M | 1 |
| Dargie, HJ | 1 |
| Dollery, CT | 2 |
| Daniel, J | 1 |
| Jennings, K | 1 |
| Ronne-Rasmussen, JO | 1 |
| Andersen, GS | 1 |
| Jensen, NB | 1 |
| Robertson, AS | 2 |
| Andersson, O | 1 |
| Pugsley, D | 1 |
| Armstrong, B | 1 |
| Munshi, UK | 1 |
| Deorari, AK | 1 |
| Paul, VK | 1 |
| Singh, M | 1 |
| Singh, PP | 2 |
| Dimich, I | 2 |
| Sampson, I | 1 |
| Sonnenklar, N | 1 |
| Giannattasio, C | 2 |
| Seravalle, G | 2 |
| Cattaneo, BM | 1 |
| Perondi, R | 1 |
| Foster, E | 1 |
| Plehn, JF | 1 |
| Bernard, SA | 1 |
| Battinelli, NJ | 1 |
| Huntington-Coats, M | 1 |
| Apstein, CS | 1 |
| Deal, JE | 1 |
| Barratt, TM | 1 |
| Dillon, MJ | 1 |
| Etzel, R | 1 |
| Pickles, CJ | 2 |
| Schwebel, C | 1 |
| Fagret, D | 1 |
| Tremel, F | 1 |
| Siché, JP | 2 |
| Boutelant, S | 1 |
| de Gaudemaris, R | 3 |
| Mallion, JM | 3 |
| Girerd, X | 1 |
| Billaud, EM | 1 |
| Sorrel-Dejerine, A | 1 |
| Ropers, J | 1 |
| Safavian, A | 1 |
| Safar, M | 2 |
| Laurent, S | 1 |
| Le Bret, F | 2 |
| Coriat, P | 2 |
| Gosgnach, M | 1 |
| Baron, JF | 1 |
| Reiz, S | 1 |
| Viars, P | 3 |
| Hauswald, M | 1 |
| Baba, T | 3 |
| Takebe, K | 2 |
| Tomiyama, T | 2 |
| Stronkhorst, A | 1 |
| Bosma, A | 1 |
| van Leeuwen, DJ | 1 |
| Cruickshank, DJ | 2 |
| Robertson, AA | 1 |
| Campbell, DM | 2 |
| MacGillivray, I | 1 |
| Pastore, JC | 1 |
| Bricchi, M | 1 |
| Vescovi, A | 1 |
| Innes, A | 1 |
| Gemmell, HG | 1 |
| Smith, FW | 1 |
| Edward, N | 1 |
| Catto, GR | 1 |
| Eisenach, JC | 1 |
| Mandell, G | 1 |
| Dewan, DM | 1 |
| Fransson, L | 1 |
| Drici, MD | 2 |
| Roux, M | 1 |
| Candito, M | 2 |
| Rimailho, A | 1 |
| Morand, P | 2 |
| Lapalus, P | 2 |
| Louis, W | 1 |
| Howes, L | 1 |
| Kincaid-Smith, PS | 1 |
| Fraser, I | 1 |
| Scheinkestel, C | 1 |
| MacDonald, G | 1 |
| Rallings, M | 1 |
| Miyagishi, A | 1 |
| Maniwa, T | 1 |
| Noguchi, T | 1 |
| Hara, Y | 1 |
| Atkin, SH | 1 |
| Jaker, MA | 1 |
| Beaty, P | 1 |
| Quadrel, MA | 1 |
| Cuffie, C | 1 |
| Soto-Greene, ML | 1 |
| Bunchman, TE | 1 |
| Lynch, RE | 1 |
| Wood, EG | 1 |
| Stumpf, JL | 1 |
| Pirhonen, JP | 1 |
| Erkkola, RU | 1 |
| Mäkinen, JI | 1 |
| Ekblad, UU | 1 |
| Fairlie, FM | 2 |
| Jenkins, P | 1 |
| Mendels, J | 1 |
| Due, D | 2 |
| Forbes, WP | 1 |
| Sirgo, MA | 10 |
| Abrignani, MG | 1 |
| Liquori, M | 1 |
| Corda, M | 1 |
| Cosentino, F | 2 |
| Strano, A | 1 |
| Weber, M | 2 |
| Bartels, DW | 2 |
| Gregory, MC | 1 |
| Burris, JF | 3 |
| Mutch, WA | 1 |
| Ringaert, KR | 1 |
| Ewert, FJ | 1 |
| White, IW | 1 |
| Donen, N | 1 |
| Hudson, RJ | 1 |
| Wright, JT | 2 |
| DiPette, DJ | 2 |
| Goodman, RP | 2 |
| Townsend, R | 3 |
| McKenney, JM | 1 |
| Pasini, FL | 1 |
| Pecchi, S | 1 |
| Guideri, F | 1 |
| DeFranco, V | 1 |
| Damiani, P | 1 |
| Galigani, C | 1 |
| Saletti, M | 1 |
| Verzuri, MS | 1 |
| Blardi, P | 1 |
| Di Perri, T | 1 |
| Ferrari, E | 1 |
| Jacomet, Y | 1 |
| Macphee, GJ | 2 |
| Howie, CA | 1 |
| Muzzi, DA | 1 |
| Black, S | 1 |
| Losasso, TJ | 1 |
| Cucchiara, RF | 1 |
| Ollivier, JP | 1 |
| Durier, P | 1 |
| Bussiere, JL | 1 |
| Gayet, JL | 1 |
| van Zwieten, PA | 1 |
| Markowsky, SJ | 1 |
| Eyer, SD | 1 |
| Troyer, SD | 1 |
| Vaughan, LM | 1 |
| Sudduth, CD | 1 |
| Sahn, SA | 1 |
| Zell-Kanter, M | 1 |
| Leikin, JB | 1 |
| Applegate, WB | 2 |
| Borhani, N | 1 |
| DeQuattro, V | 2 |
| Kaihlanen, PM | 1 |
| Oishi, S | 1 |
| Due, DL | 4 |
| Gonzalez, ER | 1 |
| Peterson, MA | 1 |
| Racht, EM | 1 |
| Ornato, JP | 1 |
| Feit, A | 2 |
| Cohen, M | 2 |
| Dimino, L | 1 |
| el-Sherif, N | 2 |
| Holtzman, R | 2 |
| Venkata, C | 1 |
| Ram, S | 1 |
| Gaffeny, D | 1 |
| Heller, J | 1 |
| Kaplan, N | 1 |
| Malsch, E | 1 |
| Katonah, J | 1 |
| Gratz, I | 1 |
| Abate, MA | 1 |
| Neely, JL | 1 |
| Layne, RD | 1 |
| D'Alessandri, R | 1 |
| Harper, A | 1 |
| Murnaghan, GA | 1 |
| Sandler, MA | 1 |
| Jacobs, LE | 1 |
| Kotler, MN | 1 |
| Sladen, RN | 1 |
| Klamerus, KJ | 1 |
| Swafford, MW | 1 |
| Prough, DS | 1 |
| Mann, HJ | 1 |
| Leslie, JB | 3 |
| Goldberg, JS | 1 |
| Levitsky, S | 1 |
| Molina, JE | 1 |
| Mills, SA | 1 |
| Glover, DR | 1 |
| Tarbit, WJ | 1 |
| Lalonde, RL | 1 |
| Tenero, DM | 1 |
| Kazierad, DJ | 1 |
| Mabie, WC | 4 |
| Shamsa, F | 1 |
| Villar, MA | 1 |
| Anderson, GD | 2 |
| Chrisp, P | 1 |
| Goa, KL | 2 |
| Silberman, HM | 2 |
| Gilderman, LP | 1 |
| Murabayashi, S | 2 |
| Decoulx, M | 1 |
| Godon, P | 1 |
| Pappo, M | 5 |
| d'Allens, H | 4 |
| Fogari, R | 1 |
| Poletti, L | 1 |
| Tettamanti, F | 1 |
| Cesana, B | 1 |
| Savonitto, S | 1 |
| Boulet, LP | 1 |
| Lacourcière, Y | 1 |
| Milot, J | 1 |
| Lampron, N | 1 |
| Wright, SW | 1 |
| Hedges, JR | 1 |
| Wright, MB | 1 |
| Chudnofsky, CR | 1 |
| Laden, N | 1 |
| Baciewicz, FA | 1 |
| Grubb, B | 1 |
| Townsend, RR | 1 |
| Goodman, R | 1 |
| Blumfield, D | 1 |
| Cronin, R | 1 |
| Gradman, A | 1 |
| Katz, LA | 1 |
| McCarthy, EP | 1 |
| Sopko, G | 1 |
| Knos, G | 1 |
| Gladson, M | 1 |
| Markwalter, H | 1 |
| Sung, YF | 1 |
| Morris, R | 1 |
| Prasad, NK | 1 |
| Silagy, CA | 1 |
| Farish, S | 1 |
| Hugonot, R | 1 |
| Hugonot, L | 1 |
| Herrero, G | 1 |
| Rogers, RC | 1 |
| Whybrew, WD | 1 |
| Goldsmith, TL | 1 |
| Barker, DE | 1 |
| Strodel, WE | 1 |
| Kotegawa, T | 1 |
| Fujimura, A | 2 |
| Ebihara, A | 2 |
| Rocci, ML | 2 |
| Vlasses, PH | 2 |
| Plachetka, JR | 8 |
| Weidler, DJ | 1 |
| Toth, PD | 1 |
| Kelly, JG | 1 |
| Laher, MS | 1 |
| Donohue, J | 1 |
| Doyle, GD | 1 |
| Tham, TC | 1 |
| Silke, B | 2 |
| Taylor, SH | 2 |
| Arthur, S | 1 |
| Greenberg, A | 1 |
| Geniton, DJ | 1 |
| Dianzumba, SB | 2 |
| DiPette, D | 2 |
| Joyner, CR | 2 |
| Cornman, C | 2 |
| Mauro, K | 2 |
| Weber, E | 2 |
| Theobald, T | 1 |
| Johnson, LL | 2 |
| Cubbon, J | 5 |
| Escala, E | 1 |
| Sciacca, R | 1 |
| Ramanathan, KB | 3 |
| Berger, H | 1 |
| Jones, RH | 1 |
| Bursztyn, M | 1 |
| Gavras, I | 1 |
| Blasucci, DJ | 4 |
| Gavras, H | 2 |
| Carre, A | 1 |
| Petetin, N | 1 |
| Jouvent, R | 1 |
| Baruch, P | 1 |
| Lee, SC | 1 |
| Fung, ST | 1 |
| Lee, JH | 1 |
| Grossman, E | 1 |
| Oren, S | 1 |
| MacPhee, AA | 1 |
| Rodriguez-Saavedra, M | 1 |
| Zannad, FM | 1 |
| Guerrero-Sierra, J | 1 |
| Sack, DW | 1 |
| Renaud, H | 1 |
| Guiducci, U | 1 |
| Edwards, LD | 1 |
| Bugni, WJ | 1 |
| Ayers, CW | 1 |
| Ashby, R | 1 |
| Bittle, PA | 1 |
| Ramirez, G | 1 |
| Cleroux, J | 1 |
| Glasser, SP | 3 |
| Schoenberger, JA | 4 |
| Liebson, P | 1 |
| Materson, BJ | 2 |
| Morledge, JH | 1 |
| Saunders, E | 2 |
| Lutz, LJ | 1 |
| Schnaper, HW | 1 |
| Mabadeje, AF | 1 |
| Adebayo, GI | 1 |
| Koehn, DK | 1 |
| Powell, R | 1 |
| Mikami, H | 1 |
| Ogihara, T | 1 |
| Sugimoto, K | 1 |
| Kumagai, Y | 1 |
| Nakashima, H | 1 |
| Goldberg, ME | 1 |
| Seltzer, JL | 1 |
| Azad, SS | 1 |
| Smullens, SN | 1 |
| Marr, AT | 1 |
| Larijani, GE | 1 |
| Mitchell, D | 1 |
| Sirgo, M | 2 |
| Valiquett, T | 1 |
| Turki, S | 1 |
| Mouren, S | 1 |
| Arthaud, M | 1 |
| Haraldsson, A | 1 |
| Geven, W | 1 |
| Higgins, TL | 1 |
| Estafanous, FG | 1 |
| Kalayjian, RW | 2 |
| McLoughlin, TM | 1 |
| Lingham, R | 1 |
| Gabrielson, G | 1 |
| Kaplan, JA | 1 |
| Farry, JP | 1 |
| Fischl, SJ | 1 |
| Tighe, MJ | 1 |
| Krell, MJ | 1 |
| Gorwit, J | 1 |
| Bedsole, GD | 2 |
| Benfield, P | 1 |
| Sorkin, EM | 1 |
| Shapiro, W | 1 |
| Charlap, S | 1 |
| Boyd, BK | 1 |
| Cruise, CJ | 1 |
| Skrobik, Y | 1 |
| Webster, RE | 1 |
| Marquez-Julio, A | 1 |
| David, TE | 1 |
| Gorwit, JI | 3 |
| Cook, ME | 5 |
| Fletcher, E | 1 |
| Holtzman, JL | 2 |
| Grim, CE | 1 |
| Inada, E | 1 |
| Cullen, DJ | 1 |
| Nemeskal, AR | 1 |
| Teplick, R | 1 |
| Lambeth, MA | 1 |
| Barnes, RW | 1 |
| Given, BD | 2 |
| Affrime, MB | 3 |
| Perentesis, G | 2 |
| Christopher, JD | 1 |
| Herron, J | 1 |
| Patrick, JE | 3 |
| Kramer, WG | 2 |
| Bugni, W | 1 |
| Atkins, J | 1 |
| Fouad-Tarazi, F | 1 |
| Kinhal, V | 1 |
| Kulkarni, A | 1 |
| Pozderac, R | 1 |
| Clifton, GG | 4 |
| Kelly, R | 1 |
| Daley, J | 1 |
| Avolio, A | 1 |
| O'Rourke, M | 1 |
| Khafagi, FA | 1 |
| Shapiro, B | 1 |
| Fig, LM | 1 |
| Mallette, S | 1 |
| Sisson, JC | 1 |
| Orlowski, JP | 2 |
| Shiesley, D | 2 |
| Little, JR | 2 |
| Graves, JW | 1 |
| Douglas, DD | 1 |
| Yang, RD | 1 |
| Jensen, P | 1 |
| Thiele, DL | 1 |
| Lavies, NG | 1 |
| Meiklejohn, BH | 1 |
| May, AE | 1 |
| Achola, KJ | 1 |
| Fell, D | 1 |
| Haehn, KD | 1 |
| Hotan, W | 1 |
| Moerchel, J | 1 |
| Müller, J | 1 |
| Gonzalez, DG | 1 |
| Aydelotte, ME | 1 |
| Rietbrock, N | 1 |
| Woodcock, BG | 1 |
| Carrageta, MO | 1 |
| Steinrauf, LK | 1 |
| Schulz, AR | 1 |
| Ryder, KW | 1 |
| Brunn, PW | 1 |
| Cook, D | 1 |
| Judy, W | 1 |
| Naden, RP | 1 |
| Redman, CW | 1 |
| Lepäntalo, M | 2 |
| Kanto, JH | 2 |
| Durando, C | 1 |
| Leidi, L | 1 |
| Margaria, E | 1 |
| Medaglia, M | 1 |
| Gessa, M | 1 |
| Maina, G | 1 |
| Anderson, RJ | 1 |
| Reed, WG | 1 |
| Smirnov, GB | 1 |
| Roja, M | 1 |
| Cumetti, C | 1 |
| Vergani, A | 1 |
| Montanari, C | 1 |
| De Cristofaro, A | 1 |
| Epstein, M | 1 |
| Oster, JR | 1 |
| Cubberley, RB | 2 |
| Cook, CA | 1 |
| Modrak, JB | 1 |
| Pruszczyński, J | 1 |
| Dal Negro, RW | 1 |
| Zoccatelli, O | 1 |
| Pomari, C | 1 |
| Trevisan, F | 1 |
| Roberts, DH | 2 |
| Grimmer, SF | 1 |
| Winstanley, PA | 1 |
| Orme, ML | 1 |
| McLoughlin, GA | 1 |
| Abernethy, DR | 2 |
| Bartos, P | 1 |
| McGarry-Myers, RJ | 1 |
| Franciosa, JA | 1 |
| Stone, JG | 1 |
| Foëx, P | 1 |
| Sear, JW | 1 |
| Khambatta, HJ | 1 |
| Triner, L | 1 |
| Aoyagi, K | 1 |
| Widimský, J | 1 |
| Lefflerová, K | 1 |
| Warren, JB | 1 |
| Verma, SP | 1 |
| Hussain, M | 1 |
| Nelson, GI | 1 |
| Wilson, JA | 1 |
| Reynolds, GW | 1 |
| Richmond, A | 1 |
| Hashimoto, H | 1 |
| Tanaka, M | 1 |
| Kanda, A | 1 |
| Akashi, A | 1 |
| Ahokas, RA | 1 |
| Karch, SB | 1 |
| Leperlier, E | 2 |
| Acciaro, E | 1 |
| Acciaro, L | 1 |
| La Scala, G | 1 |
| Giuseppini, S | 1 |
| Valentini, A | 1 |
| Zanozdra, NS | 1 |
| Kupchinskaia, EG | 1 |
| Svishchenko, EP | 1 |
| Chernoguz, LS | 1 |
| Malyshko, LN | 1 |
| Ferguson, RK | 1 |
| Plouin, PF | 2 |
| Breart, G | 2 |
| Maillard, F | 2 |
| Papiernik, E | 2 |
| Relier, JP | 2 |
| Vaisse, B | 1 |
| Asmar, R | 1 |
| Poggi, L | 1 |
| Liebens, I | 1 |
| Abou Hamdam, B | 1 |
| Oster, G | 1 |
| Huse, DM | 1 |
| Delea, TE | 1 |
| Savage, DD | 1 |
| Colditz, GA | 1 |
| Harrier, HD | 1 |
| Ayuso Gatell, A | 1 |
| Martínez Ferrer, JR | 1 |
| Trenchs Verdaguer, X | 1 |
| Pujol Colomer, J | 1 |
| Gal, J | 1 |
| Zirrolli, JA | 1 |
| Lichtenstein, PS | 1 |
| Kravchenko, IG | 1 |
| Pedan, NV | 1 |
| Minina, EM | 1 |
| Lapshina, LA | 1 |
| Bojar, RM | 1 |
| Weiner, B | 1 |
| Cleveland, RJ | 1 |
| Lee, DD | 1 |
| Allen, J | 1 |
| Plachetka, J | 1 |
| Gray, JM | 1 |
| Gonzalez, AR | 1 |
| Amon, E | 1 |
| Soberman, J | 1 |
| Greenberg, S | 1 |
| Curry, C | 1 |
| Hinds, J | 1 |
| Kong, BW | 1 |
| Roper, K | 1 |
| Schamaun, O | 1 |
| Westheim, A | 1 |
| Qvigstad, EK | 1 |
| Teisberg, P | 1 |
| Gay, GR | 2 |
| Loper, KA | 2 |
| Nugent, CA | 1 |
| Bleicher, JM | 1 |
| Foster, S | 1 |
| Ries, R | 1 |
| Prys-Roberts, C | 1 |
| Dagnino, J | 1 |
| Buell, JC | 1 |
| Eliot, RS | 1 |
| Little, MR | 1 |
| Barnett, GH | 1 |
| Huey, J | 1 |
| Thomas, JP | 1 |
| Hendricks, DR | 1 |
| Wehmeyer, AE | 1 |
| Johns, LJ | 1 |
| MacCosbe, PE | 1 |
| Ramanathan, J | 1 |
| Chauhan, D | 1 |
| Ruiz, AG | 1 |
| Leys, D | 1 |
| Pasquier, F | 1 |
| Vermersch, P | 1 |
| Gosset, D | 1 |
| Michiels, H | 1 |
| Kassiotis, P | 1 |
| Petit, H | 1 |
| Pithois-Merli, IM | 1 |
| Cournot, AX | 1 |
| Georges, DR | 1 |
| Safar, ME | 1 |
| Chou, YP | 1 |
| Hwang, SJ | 1 |
| Wong, CS | 1 |
| Chang, CL | 1 |
| Lin, CY | 1 |
| Goto, Y | 1 |
| Shiina, Y | 1 |
| Tamachi, H | 1 |
| Honma, Y | 1 |
| Halperin, AK | 1 |
| Cubeddu, LX | 1 |
| Rouffy, J | 1 |
| Bakir, R | 1 |
| Chanu, B | 1 |
| Djian, F | 1 |
| Goy-Loeper, J | 1 |
| Henry Amar, M | 1 |
| Renon, D | 1 |
| Catapano, MS | 1 |
| Marx, JA | 1 |
| Ashe, RG | 1 |
| Moodley, J | 1 |
| Richards, AM | 1 |
| Philpott, RH | 1 |
| Cagatay, G | 1 |
| Soydan, I | 1 |
| Mart'ianova, II | 1 |
| Shcheplikova, TM | 1 |
| Frithz, G | 1 |
| Rasmussen, K | 1 |
| Ngole, PM | 1 |
| Watkins, WD | 1 |
| Wang, HM | 1 |
| Datta, SR | 1 |
| Schwartz, JB | 1 |
| Todd, EL | 1 |
| Egan, JM | 1 |
| Chauvin, M | 1 |
| Deriaz, H | 1 |
| Feldman, JM | 1 |
| Leitz, FH | 1 |
| Maier, G | 1 |
| Gural, RP | 1 |
| Symchowicz, S | 1 |
| Debache, N | 1 |
| Bleinc, D | 1 |
| Touboul, A | 1 |
| Haquin, G | 1 |
| Minisi, AJ | 1 |
| Lindström, BL | 1 |
| Finley, D | 1 |
| Johnson, B | 1 |
| Berry, DA | 1 |
| Sheikh, A | 1 |
| Giguere, GC | 1 |
| Mehta, JL | 1 |
| Lopez, LM | 1 |
| Forette, F | 1 |
| Henry-Amar, M | 1 |
| Hervy, MP | 1 |
| Bouchacourt, P | 1 |
| Henry, JF | 1 |
| Falliers, CJ | 1 |
| Vrchota, J | 1 |
| Maloy, JW | 2 |
| Hudson, L | 1 |
| Manocha, KL | 1 |
| De Cesaris, R | 1 |
| Grimaldi, A | 1 |
| Balestrazzi, M | 1 |
| Ranieri, G | 1 |
| Chiarappa, R | 1 |
| Avantaggiato, F | 1 |
| Pandhi, P | 1 |
| Aslam, S | 1 |
| Sharma, BK | 1 |
| Sharma, PL | 1 |
| Wahi, PL | 1 |
| Lebel, M | 1 |
| Langlois, S | 1 |
| Belleau, LJ | 1 |
| Grose, JH | 1 |
| Schuurman, FH | 1 |
| Meese, RB | 1 |
| Kochar, MS | 1 |
| Tyson, J | 1 |
| Kalbfleisch, JH | 1 |
| Hudson, LD | 1 |
| Chetty, K | 1 |
| Ohman, KP | 1 |
| Weiner, L | 1 |
| von Schenck, H | 1 |
| Jee, LD | 1 |
| Mariani, PJ | 1 |
| Olowoyeye, JO | 1 |
| Okoro, EO | 1 |
| Omotosho, AB | 1 |
| Wouda, AA | 1 |
| Abrams, JH | 1 |
| Schulman, P | 1 |
| Bouloux, PM | 1 |
| Featherstone, RM | 1 |
| Clement-Jones, V | 1 |
| Rees, LH | 1 |
| Goligher, JE | 1 |
| Valenta, LJ | 1 |
| Kern, J | 1 |
| Kulas, J | 1 |
| Rane, A | 1 |
| Nilsson-Ehle, P | 1 |
| Rössner, S | 1 |
| Kassem, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Ethnic/Racial Variations of Intracerebral Hemorrhage (ERICH)[NCT01202864] | 6,000 participants (Actual) | Observational | 2010-08-01 | Completed | |||
| The CHIPS Trial (Control of Hypertension In Pregnancy Study)[NCT01192412] | 987 participants (Actual) | Interventional | 2009-04-30 | Completed | |||
| A Randomized Control Trial of Furosemide or Placebo With Usual Antihypertensives in the Antepartum Management of Severe Hypertension With Wide Pulse Pressure[NCT04615624] | Phase 3 | 65 participants (Actual) | Interventional | 2021-01-04 | Completed | ||
| A Phase IV, Randomized Trial to Determine the Efficacy and Safety of Cardene Intravenous (I.V.) Versus Labetalol for Management of Hypertensive Emergencies in the Emergency Department Setting[NCT00765648] | Phase 4 | 226 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| Comparison of Oral Nifedipine to Oral Labetolol for the Management of Severe Postpartum Hypertension[NCT02168309] | 50 participants (Actual) | Interventional | 2014-06-30 | Completed | |||
| Amlodipine Versus Nifedipine ER for the Management of Postpartum Hypertension: A Randomized Controlled Noninferiority Trial[NCT04790279] | Phase 4 | 132 participants (Actual) | Interventional | 2021-04-09 | Completed | ||
| A Multi-center Randomised Controlled Trial to Explore the Ideal Individualized Anti-hypertension Strategies in Patients With Severe Stroke at Acute Stage[NCT02982655] | 500 participants (Anticipated) | Interventional | 2017-01-31 | Completed | |||
| [NCT01041066] | 70 participants (Anticipated) | Interventional | 2009-09-30 | Recruiting | |||
| Labetalol Versus MgSO4 for the Prevention of Eclampsia Trial (LAMPET)[NCT00293735] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2015-06-30 | Withdrawn (stopped due to Lack of funding) | ||
| Alternative in Beta Blocker Intolerance; the ABBI Trial[NCT00893984] | Phase 4 | 6 participants (Actual) | Interventional | 2009-05-31 | Terminated (stopped due to Lack of patient recruitment) | ||
| Safety and Efficacy of Sedation for Flexible Fiberoptic Bronchoscopy: Comparison of Propofol/Alfentanil With Propofol/Ketamine[NCT02000206] | 80 participants (Anticipated) | Interventional | 2014-02-28 | Not yet recruiting | |||
| [NCT00394537] | Phase 4 | 72 participants (Anticipated) | Interventional | Completed | |||
| A Comparison of Fetal Hemodynamic Measurements Between Pregnant Women Taking Anti-hypertensive Medication and Controls[NCT00759278] | 0 participants (Actual) | Observational | 2008-08-31 | Withdrawn (stopped due to No participants) | |||
| Efficiency of Intravenous Lidocaine to Reduce Coughing and the Hemodynamic Changes Associated to Tracheal Extubation[NCT03731429] | Phase 4 | 144 participants (Anticipated) | Interventional | 2019-04-05 | Recruiting | ||
| Nicardipine Versus Esmolol for Management of Emergence Hypertension After Craniotomy[NCT01951950] | Phase 1 | 40 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Metabolic Phenotyping and Systems Biology in Surgery[NCT01378013] | 50 participants (Actual) | Observational | 2011-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Pregnancy loss or NICU admission for greater than 48 hours, as recorded in the maternal and infant medical records immediately following the birth (or pregnancy loss), and then again after the mothers' and infants' discharge home. Supplemental information, about potential post-discharge maternal or neonatal morbidities in the 6 weeks following birth for the mother, or 28 days of life for the baby, will be obtained by contacting women at 6 weeks postpartum and/or from medical records. (NCT01192412)
Timeframe: 6 weeks
| Intervention | participants (Number) |
|---|---|
| 'Less Tight' Control. | 155 |
| 'Tight' Control. | 150 |
"Serious maternal complications measured up to 6 weeks postpartum. Death or one or more life-threatening maternal complications:~Adverse neurological complications (stroke, eclampsia, and/or blindness), and/or~End-organ failure (uncontrolled hypertension, inotropic support, pulmonary oedema, respiratory failure, myocardial ischaemia/infarction, renal failure, coagulopathy, and/or transfusion)" (NCT01192412)
Timeframe: 6 weeks
| Intervention | participants (Number) |
|---|---|
| 'Less Tight' Control. | 18 |
| 'Tight' Control. | 10 |
Calculated as the mean (± standard deviation) number of titrations over 30 minutes for each treatment group (NCT00765648)
Timeframe: 30 minutes
| Intervention | number of titrations (Mean) |
|---|---|
| Nicardipine | 2.2 |
| Labetalol | 1.3 |
Median number of hours from hospital admission until Emergency Department(ED)disposition (NCT00765648)
Timeframe: 6 hours
| Intervention | hours (Median) |
|---|---|
| Nicardipine | 4.6 |
| Labetalol | 4.6 |
Percentage of subjects achieving a pre-defined target systolic blood pressure (BP) range defined as a systolic blood pressure that is within +/- 20 mmHg of the target as established by the investigator. (NCT00765648)
Timeframe: 30 minutes after initiation of therapy
| Intervention | percentage of participants (Number) |
|---|---|
| Nicardipine | 91.7 |
| Labetalol | 82.5 |
The percent of subjects requiring the use of intravenous rescue medications (NCT00765648)
Timeframe: 6 hours
| Intervention | percentage of participants (Number) |
|---|---|
| Nicardipine | 15.5 |
| Labetalol | 22.4 |
The median transition time (in hours) to oral medication (NCT00765648)
Timeframe: 6 hours
| Intervention | hours (Median) |
|---|---|
| Nicardipine | 4.9 |
| Labetalol | 6.4 |
Treatment failure is defined as admission to the hospital or observation unit for BP management (NCT00765648)
Timeframe: 6 hours
| Intervention | percentage of participants (Number) |
|---|---|
| Nicardipine | 43.1 |
| Labetalol | 37.4 |
Primary outcome (NCT02168309)
Timeframe: 24 hours
| Intervention | hours (Mean) |
|---|---|
| Labetalol | 37.6 |
| Nifedipine | 38.2 |
Secondary outcome (NCT02168309)
Timeframe: 0-10 days
| Intervention | days (Mean) |
|---|---|
| Labetalol | 4.0 |
| Nifedipine | 4.3 |
(NCT00893984)
Timeframe: 30 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Nebivolol | 0 |
(NCT00893984)
Timeframe: 30 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Nebivolol | 0 |
Mild symptoms include weight gain, edema, and headaches (NCT00893984)
Timeframe: 30 Days
| Intervention | participants (Number) |
|---|---|
| Nebivolol | 1 |
(NCT00893984)
Timeframe: 30 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Nebivolol | 0 |
(NCT01951950)
Timeframe: 1 hour postoperatively
| Intervention | participants (Number) |
|---|---|
| Nicardipine | 1 |
| Esmolol | 11 |
97 reviews available for labetalol and Hypertension
| Article | Year |
|---|---|
Comparison of Intravenous Antihypertensives on Blood Pressure Control in Acute Neurovascular Emergencies: A Systematic Review.
Topics: Antihypertensive Agents; Blood Pressure; Emergencies; Humans; Hypertension; Labetalol; Nicardipine; | 2022 |
Different dosage regimens of nifedipine, labetalol, and hydralazine for the treatment of severe hypertension during pregnancy: a network meta-analysis of randomized controlled trials.
Topics: Antihypertensive Agents; Blood Pressure; Female; Humans; Hydralazine; Hypertension; Hypertension, Pr | 2022 |
Hypertensive Disorders of Pregnancy: Common Clinical Conundrums.
Topics: Antihypertensive Agents; Female; Humans; Hypertension; Hypertension, Pregnancy-Induced; Labetalol; P | 2022 |
Pharmacokinetics of the most commonly used antihypertensive drugs throughout pregnancy methyldopa, labetalol, and nifedipine: a systematic review.
Topics: Antihypertensive Agents; Female; Humans; Hypertension; Hypertension, Pregnancy-Induced; Labetalol; M | 2022 |
Hypertensive Crisis in Pregnancy.
Topics: Antihypertensive Agents; Female; Humans; Hydralazine; Hypertension; Labetalol; Nifedipine; Pregnancy | 2022 |
Cardiac medications in obstetric patients.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Agents; Female; Hematologic Agents; Humans; Hyperte | 2023 |
Hypertension in Pregnancy: A Diagnostic and Therapeutic Overview.
Topics: Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Hypertension, Pregnancy-Induc | 2023 |
Hypertensive Emergency: Parenteral Antihypertensives and Population Data.
Topics: Antihypertensive Agents; Emergencies; Humans; Hypertension; Hypertensive Encephalopathy; Labetalol; | 2023 |
Hypertension Management in Emergency Departments.
Topics: Acute Disease; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyper | 2020 |
Safety and efficacy of intravenous hydralazine and labetalol for the treatment of asymptomatic hypertension in hospitalised patients: A systematic review.
Topics: Administration, Intravenous; Antihypertensive Agents; Humans; Hydralazine; Hypertension; Labetalol | 2021 |
New Evidence in the Management of Chronic Hypertension in Pregnancy.
Topics: Algorithms; Antihypertensive Agents; Blood Pressure; Chronic Disease; Female; Humans; Hypertension; | 2017 |
Neonatal hypertension: cases, causes, and clinical approach.
Topics: Administration, Intravenous; Antihypertensive Agents; Birth Weight; Blood Pressure; Blood Pressure D | 2019 |
Focused Update on Pharmacologic Management of Hypertensive Emergencies.
Topics: Administration, Oral; Antihypertensive Agents; Blood Pressure; Brain Ischemia; Emergencies; Enalapri | 2018 |
Drugs for treating severe hypertension in pregnancy: a network meta-analysis and trial sequential analysis of randomized clinical trials.
Topics: Antihypertensive Agents; Dose-Response Relationship, Drug; Female; Headache; Humans; Hydralazine; Hy | 2018 |
Hypertension and Pregnancy: Management and Future Risks.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Chronic Disease; Diuretics; Female; Human | 2019 |
The optimal treatment of severe hypertension in pregnancy: update of the role of nicardipine.
Topics: Antihypertensive Agents; Female; Humans; Hypertension; Hypotension; Infant, Newborn; Labetalol; Nica | 2014 |
Hypertensive emergencies in pregnancy.
Topics: Antihypertensive Agents; Eclampsia; Emergencies; Female; Humans; Hydralazine; Hypertension; Hyperten | 2014 |
Oral nifedipine versus intravenous labetalol for the treatment of severe hypertension in pregnancy.
Topics: Administration, Oral; Antihypertensive Agents; Female; Humans; Hypertension; Infusions, Intravenous; | 2015 |
Blood pressure lowering efficacy of dual alpha and beta blockers for primary hypertension.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Blood | 2015 |
Hypertensive Emergencies in Pregnancy.
Topics: Antihypertensive Agents; Cesarean Section; Chronic Disease; Congenital Abnormalities; Emergencies; E | 2016 |
Perioperative hypertension management.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Enalaprilat; Fenoldopam; Hemodynamics; Humans; | 2008 |
An in-depth analysis of vasodilation in the management of hypertension: focus on adrenergic blockade.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Benzopyrans; Blood Pressure; Carbazoles; Cardi | 2009 |
Realities of newer beta-blockers for the management of hypertension.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Benzopyrans; Carbazoles; Carvedilol; Ethanolam | 2009 |
A systematic review of nicardipine vs labetalol for the management of hypertensive crises.
Topics: Acute Disease; Antihypertensive Agents; Humans; Hypertension; Labetalol; Nicardipine | 2012 |
[Current perspective of treating hypertension in pregnancy].
Topics: Antihypertensive Agents; Calcium Channel Blockers; Female; Humans; Hypertension; Hypertension, Pregn | 2011 |
Hypertensive emergencies: an update.
Topics: Acute Disease; Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Pressure; Critical Care; | 2011 |
[Clinical efficacy and perinatal outcome of nifedipine for severe preeclampsia: meta-analysis].
Topics: Antihypertensive Agents; Blood Pressure; Female; Humans; Hydralazine; Hypertension; Infant, Newborn; | 2012 |
Managing hypertension in patients with stroke. Are you prepared for labetalol infusion?
Topics: Aged; Antihypertensive Agents; Cerebrovascular Circulation; Contraindications; Critical Care; Dose-R | 2003 |
[Protective effect of alpha beta-blockers on hypertensive target-organ damage].
Topics: Adrenal Gland Neoplasms; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antihypertensive | 2004 |
The role of the new beta-blockers in treating cardiovascular disease.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Benzopyrans | 2005 |
[Alpha beta-blockers for patients with hypertension].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Carbazoles; Carv | 2006 |
Pathophysiology and medical management of systemic hypertension in preeclampsia.
Topics: Adrenergic beta-Antagonists; Aspirin; Calcium; Calcium Channel Blockers; Cerebral Hemorrhage; Female | 2006 |
Postcardiac surgical hypertension.
Topics: Cardiac Surgical Procedures; Heart Rate; Humans; Hypertension; Labetalol; Nitroprusside; Norepinephr | 1988 |
Goodpasture's disease in pregnancy: case report and review of the literature.
Topics: Adult; Anti-Glomerular Basement Membrane Disease; Antihypertensive Agents; Female; Humans; Hypertens | 2007 |
Comparison of labetalol with other anti-hypertensive drugs.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Diuretics; Drug Therapy, Combination; Ethanola | 1982 |
Rationale for combined alpha-beta-adrenoceptor blockade: haemodynamic considerations.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Cardiac Output; Female; Hemodyna | 1982 |
Hypertension--drug management.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Calcium Channel Blockers; Captopril; Diaz | 1982 |
Beta-adrenergic blocking drugs in the treatment of hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aging; Black People; Drug Interactions; Heart; Hemodynamic | 1983 |
Alpha-adrenergic blockade in the treatment of essential hypertension.
Topics: Adrenergic alpha-Antagonists; Biomechanical Phenomena; Hemodynamics; Humans; Hypertension; Indoramin | 1983 |
Selective alpha 1-adrenergic antagonists: therapeutically relevant antihypertensive agents.
Topics: Adrenergic alpha-Antagonists; Ethanolamines; Humans; Hypertension; Indoramin; Labetalol; Prazosin; R | 1984 |
Beta-blocking drugs for arrhythmias, hypertension, and ischemic heart disease.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Animals; Arrhythmias, Cardiac; Atenolol; Blood Pressur | 1984 |
Hypertension in pregnancy. Pathophysiology and management.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Calcium Channel Blockers; Captopril; Clon | 1984 |
Central and peripheral blockade of the sympathetic nervous system.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Pressure; | 1984 |
Pharmacology of combined alpha-beta-blockade. II. Haemodynamic effects of labetalol.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Cerebro | 1984 |
Combined alpha- and beta-receptor inhibition in the treatment of hypertension.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Anesthesia; Antihyp | 1984 |
The pharmacological basis for the use of labetalol in the treatment of hypertension.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Electric Stimulation; Ethanolamines; Huma | 1981 |
Hemodynamic changes after acute and long-term combined alpha--beta-adrenoceptor blockade with labetalol as compared with beta-receptor blockade.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Aging; Ethanolam | 1981 |
Clinical pharmacology of labetalol in pregnancy.
Topics: Ethanolamines; Female; Fetus; Heart Rate; Humans; Hypertension; Infant, Newborn; Kidney; Labetalol; | 1981 |
Labetalol and the management of hypertension.
Topics: Adrenal Gland Neoplasms; Clonidine; Ethanolamines; Humans; Hypertension; Labetalol; Pheochromocytoma | 1981 |
Labetalol. Current research and therapeutic status.
Topics: Adult; Aged; Ethanolamines; Female; Hemodynamics; Humans; Hypertension; Labetalol; Male; Middle Aged | 1983 |
Labetalol.
Topics: Drug Interactions; Ethanolamines; Humans; Hypertension; Intestinal Absorption; Kinetics; Labetalol; | 1983 |
Hypertensive crisis.
Topics: Antihypertensive Agents; Brain Diseases; Cerebrovascular Disorders; Clonidine; Coronary Disease; Dia | 1984 |
Hypertension and calcium antagonists.
Topics: Airway Resistance; Antihypertensive Agents; Calcium Channel Blockers; Humans; Hypertension; Labetalo | 1982 |
[Comparison of metroprolol and labetalol. Antihypertensive activity at rest and during exertion and effect on some noninvasive parameters of cardiovascular function].
Topics: Adult; Clinical Trials as Topic; Ethanolamines; Female; Hemodynamics; Humans; Hypertension; Labetalo | 1981 |
Pharmacological management of hypertension in paediatric patients. A comprehensive review of the efficacy, safety and dosage guidelines of the available agents.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angiotensin-Co | 1994 |
Oral antihypertensives for hypertensive urgencies.
Topics: Administration, Oral; Antihypertensive Agents; Blood Pressure; Captopril; Clonidine; Female; Humans; | 1994 |
Management of hypertensive urgencies and emergencies.
Topics: Administration, Oral; Antihypertensive Agents; Emergencies; Enalaprilat; Female; Humans; Hydralazine | 1995 |
[Treatment of medical complications: hypertension/hypotension, hyperglycemia, hyperthermia, hypoxia, cardiac complications and pulmonary embolism].
Topics: Administration, Oral; Antihypertensive Agents; Arrhythmias, Cardiac; Cerebrovascular Disorders; Hear | 1995 |
Cardiopulmonary compromise after use of topical and submucosal alpha-agonists: possible added complication by the use of beta-blocker therapy.
Topics: Administration, Intranasal; Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Child; Epinephri | 1997 |
Results of therapy with carvedilol, a beta-blocker vasodilator with antioxidant properties, in hypertensive patients.
Topics: Adrenergic beta-Antagonists; Aging; Antioxidants; Blood Pressure; Carbazoles; Carvedilol; Humans; Hy | 1998 |
The diagnosis and management of hypertensive crises.
Topics: Antihypertensive Agents; Aortic Aneurysm; Aortic Dissection; Clonidine; Diazoxide; Enalaprilat; Fema | 2000 |
The generalizability of trial data; a comparison of beta-blocker trial participants with a prospective cohort of women taking beta-blockers in pregnancy.
Topics: Adrenergic beta-Antagonists; Adult; Cohort Studies; Databases as Topic; Diabetes, Gestational; Femal | 2001 |
Pharmacological treatment of severe hypertension in pregnancy and the role of serotonin(2)-receptor blockers.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Diureti | 2001 |
The effect of antihypertensive drugs on the fetus.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; An | 2002 |
A review of the animal pharmacology of labetalol, a combined alpha- and beta-adrenoceptor-blocking drug.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Autonomic Fibers, Preganglionic; | 1976 |
Antihypertensive drugs: clinical pharmacology and therapeutic use.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertens | 1977 |
Labetalol: a review of its pharmacology and therapeutic use in hypertension.
Topics: Adrenal Gland Neoplasms; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angiotensin II; | 1978 |
The pharmacology of labetalol, an alpha- and beta-adrenoceptor blocking agent.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Coronary Circulation; Ethanolami | 1978 |
[New antihypertensive agents].
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertens | 1979 |
Clinical experience with dual-acting drugs in hypertension.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; Celipr | 1992 |
The influence of vasodilating beta-blockers on cardiac function and vascular resistance in essential hypertension.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiac Output; Carvedilol; Hemodynamics; Humans; Hypertens | 1992 |
Fatal hepatotoxicity induced by hydralazine or labetalol.
Topics: Aged; Chemical and Drug Induced Liver Injury; Humans; Hydralazine; Hypertension; Labetalol; Male | 1991 |
Management of hypertensive emergencies: changing therapeutic options.
Topics: Emergencies; Humans; Hydralazine; Hypertension; Labetalol; Nicardipine; Nitroprusside | 1991 |
Doppler flow velocimetry in hypertension in pregnancy.
Topics: Female; Fetus; Hemodynamics; Humans; Hypertension; Labetalol; Mass Screening; Nifedipine; Placenta; | 1991 |
Overview of clinical trials of dilevalol in essential hypertension.
Topics: Humans; Hypertension; Labetalol; Lipoproteins, HDL; Meta-Analysis as Topic | 1990 |
Dilevalol: an overview of its clinical pharmacology and therapeutic use in hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Dogs; Heart; Hemodynamics; Humans; Hypertension; | 1990 |
Dilevalol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension.
Topics: Animals; Dogs; Female; Guinea Pigs; Humans; Hypertension; Labetalol; Pregnancy; Randomized Controlle | 1990 |
[Evaluation of labetalol in general medicine in aged patients with hypertension. Compliance, efficacy and safety in long-term treatment].
Topics: Aged; Ambulatory Care; Female; Follow-Up Studies; Humans; Hypertension; Labetalol; Male; Middle Aged | 1990 |
Hemodynamic and cardiac adaptation in essential hypertension. Consequences for therapy.
Topics: Adaptation, Physiological; Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aging; Black People | 1985 |
Antihypertensive compounds with combined actions.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Carbazoles; Carvedilol; Celiprolol; Humans; Hy | 1987 |
Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease.
Topics: Coronary Disease; Humans; Hypertension; Labetalol | 1989 |
Treatment of hypertension in the elderly with labetalol.
Topics: Aged; Blood Pressure; Cardiac Output; Humans; Hypertension; Labetalol; Posture; Vascular Resistance | 1989 |
Dilevalol: a selective beta-2 adrenergic agonist vasodilator with beta adrenergic blocking activity.
Topics: Animals; Catecholamines; Hemodynamics; Humans; Hypertension; Kidney; Labetalol; Renin | 1989 |
Hypertension and beta-blockers. Are they all the same?
Topics: Adrenergic beta-Antagonists; Atenolol; Blood Pressure; Circadian Rhythm; Humans; Hypertension; Labet | 1985 |
Antihypertensive drugs in pregnancy.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Diazoxide; Diuretics; Female; Fetus; Humans; H | 1985 |
Current status of labetalol, the first alpha- and beta-blocking agent.
Topics: Adrenal Gland Neoplasms; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Anesthesia; Biot | 1985 |
Adverse effects of antihypertensive treatment.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Calcium Channel Blockers; Diuretics; Enzyme In | 1986 |
Beta blockers and renal function: a reappraisal.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Blood Urea Nitrogen; Cardiac Output; Creatinine; Dog | 1985 |
Labetalol in the treatment of angina pectoris.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angina Pectoris; Clinical Trials as Topic | 1987 |
Betablockers in the treatment of hypertension (with special emphasis on betablockers with ISA). A review.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Celiprolol; Humans; Hypertension; Labetal | 1988 |
Do hybrid drugs offer an additional benefit over pure alpha 1-blockade for hypertensive patients?
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Humans; Hypertension; Ketanserin; Labetalol; | 1988 |
The usefulness of alpha-adrenoceptor blockade in the treatment of hypertension.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Humans; Hypertension; Indoramin; Labetalol; P | 1988 |
Hypertensive emergencies and urgencies.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; | 1986 |
Cost effectiveness of labetalol and propranolol in the treatment of hypertension among blacks.
Topics: Aged; Black People; Clinical Trials as Topic; Cost-Benefit Analysis; Female; Humans; Hypertension; L | 1987 |
Role of vasodilation in the antihypertensive and antianginal effects of labetalol: implications for therapy of combined hypertension and angina.
Topics: Angina Pectoris; Antihypertensive Agents; Humans; Hypertension; Labetalol; Vasodilation | 1988 |
The role of calcium channel blockers in the treatment of hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Clinical Trials as Topic; Diltiaz | 1986 |
Hypertensive cardiovascular emergencies.
Topics: Antihypertensive Agents; Brain Diseases; Cerebrovascular Disorders; Clonidine; Coronary Disease; Dia | 1985 |
271 trials available for labetalol and Hypertension
| Article | Year |
|---|---|
Initial antihypertensive agent effects on acute blood pressure after intracerebral haemorrhage.
Topics: Antihypertensive Agents; Blood Pressure; Cerebral Hemorrhage; Humans; Hydralazine; Hypertension; Lab | 2022 |
Comparison of intravenous labetalol and hydralazine for severe hypertension in pregnancy in Northeastern Nigeria: A randomized controlled trial.
Topics: Antihypertensive Agents; Blood Pressure; Female; Humans; Hydralazine; Hypertension; Infant; Infant, | 2022 |
Effects of Nifedipine and Labetalol Combined with Magnesium Sulfate on Blood Pressure Control, Blood Coagulation Function, and Maternal and Infant Outcome in Patients with Pregnancy-Induced Hypertension.
Topics: Antihypertensive Agents; Blood Coagulation; Blood Pressure; Female; Humans; Hypertension; Hypertensi | 2022 |
Labetalol, Low-dose Aspirin, and Vitamin E and Calcium for Gestational Hypertension and Influence on MicroRNA-126 and PLGF Levels.
Topics: Aspirin; Calcium; Female; Humans; Hypertension; Hypertension, Pregnancy-Induced; Labetalol; MicroRNA | 2023 |
A treatment strategy with nifedipine versus labetalol for women with pregnancy hypertension: study protocol for a randomised controlled trial (Giant PANDA).
Topics: Animals; Antihypertensive Agents; Female; Humans; Hypertension; Infant; Infant, Newborn; Labetalol; | 2023 |
Quantifying adherence to antihypertensive medication for chronic hypertension during pregnancy.
Topics: Adult; Antihypertensive Agents; Blood Pressure Determination; Chromatography, High Pressure Liquid; | 2019 |
Are blood pressure level and variability related to pregnancy outcome? Analysis of control of hypertension in pregnancy study data.
Topics: Adult; Antihypertensive Agents; Birth Weight; Female; Humans; Hypertension; Hypertension, Pregnancy- | 2020 |
Methyldopa versus labetalol or no medication for treatment of mild and moderate chronic hypertension during pregnancy: a randomized clinical trial.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Labetalol; Methyldopa; | 2020 |
Treatment of pregnancy-induced hypertension compared with labetalol, low dose aspirin and placebo.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; Blood Pressure; Do | 2020 |
Longitudinal changes in vascular function parameters in pregnant women with chronic hypertension and association with adverse outcome: a cohort study.
Topics: Adult; Antihypertensive Agents; Birth Weight; Black People; Blood Pressure; Chronic Disease; Cohort | 2019 |
Comparative evaluation of dexmedetomidine and labetalol for attenuating hemodynamic stress responses during laparoscopic cholecystectomy in borderline hypertensive patients.
Topics: Adrenergic alpha-2 Receptor Agonists; Adult; Blood Pressure; Bradycardia; Cholecystectomy, Laparosco | 2019 |
A prospective evaluation of labetalol versus nicardipine for blood pressure management in patients with acute stroke.
Topics: Aged; Antihypertensive Agents; APACHE; Blood Pressure; Female; Hospital Mortality; Humans; Hypertens | 2013 |
Impact of initial blood pressure on antihypertensive response in patients with acute hypertension.
Topics: Acute Disease; Antihypertensive Agents; Blood Pressure; Creatinine; Emergency Service, Hospital; Hum | 2014 |
The management of acute hypertension in patients with renal dysfunction: labetalol or nicardipine?
Topics: Acute Disease; Antihypertensive Agents; Comorbidity; Double-Blind Method; Female; Humans; Hypertensi | 2014 |
Characteristics of patients that do not initially respond to intravenous antihypertensives in the emergency department: subanalysis of the CLUE trial.
Topics: Antihypertensive Agents; Emergency Service, Hospital; Emergency Treatment; Female; Humans; Hypertens | 2015 |
Control of Hypertension In Pregnancy Study randomised controlled trial-are the results dependent on the choice of labetalol or methyldopa?
Topics: Adult; Antihypertensive Agents; Blood Pressure; Clinical Decision-Making; Female; Humans; Hypertensi | 2016 |
Do labetalol and methyldopa have different effects on pregnancy outcome? Analysis of data from the Control of Hypertension In Pregnancy Study (CHIPS) trial.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Hypertension, Pregnanc | 2016 |
An Equivalence Trial Comparing Labetalol and Diltiazem in Controlling Emergence Hypertension after Supratentorial Tumor Surgery.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Diltiazem; Female; Humans; Hypertension; La | 2015 |
Oral nifedipine vs. intravenous labetalol for treatment of pregnancy-induced severe pre-eclampsia.
Topics: Administration, Intravenous; Administration, Oral; Adult; Antihypertensive Agents; Blood Pressure; D | 2016 |
Oral labetalol compared to oral nifedipine for postpartum hypertension: A randomized controlled trial.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Labetalol; Nifedipine; | 2017 |
Oral labetalol compared to oral nifedipine for postpartum hypertension: A randomized controlled trial.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Labetalol; Nifedipine; | 2017 |
Oral labetalol compared to oral nifedipine for postpartum hypertension: A randomized controlled trial.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Labetalol; Nifedipine; | 2017 |
Oral labetalol compared to oral nifedipine for postpartum hypertension: A randomized controlled trial.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Labetalol; Nifedipine; | 2017 |
Hypertensive urgencies in the emergency department: evaluating blood pressure response to rest and to antihypertensive drugs with different profiles.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Combined Modality Therapy; Emergencies; Emergen | 2008 |
Controlling hypertension and hypotension immediately post-stroke (CHHIPS): a randomised, placebo-controlled, double-blind pilot trial.
Topics: Acute Disease; Aged; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Female; Humans; H | 2009 |
Controlling hypertension and hypotension immediately post stroke (CHHIPS)--a randomised controlled trial.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Cardiotonic Agents; Cost-Benefit Analysis; Deg | 2009 |
Changes in fetal and maternal Doppler parameters observed during acute severe hypertension treatment with hydralazine or labetalol: a randomized controlled trial.
Topics: Acute Disease; Adult; Antihypertensive Agents; Female; Humans; Hydralazine; Hypertension; Labetalol; | 2011 |
CLUE: a randomized comparative effectiveness trial of IV nicardipine versus labetalol use in the emergency department.
Topics: Acute Disease; Adult; Aged; Antihypertensive Agents; Blood Pressure; Emergency Service, Hospital; Fe | 2011 |
Intravenous labetalol compared with intravenous nicardipine in the management of hypertension in critically ill patients.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Critical Illness; Female; Hospital Charges; Humans; H | 2012 |
Comparative prophylactic and therapeutic effects of intravenous labetalol 0.4 mg/kg and nicardipine 20 μg/kg on hypertensive responses to endotracheal intubation in patients undergoing elective surgeries with general anesthesia: a prospective, randomized,
Topics: Adult; Anesthesia, General; Antihypertensive Agents; Dose-Response Relationship, Drug; Double-Blind | 2012 |
Short-term treatment of severe hypertension of pregnancy: prospective comparison of nicardipine and labetalol.
Topics: Adult; Antihypertensive Agents; Female; Humans; Hypertension; Labetalol; Nicardipine; Pre-Eclampsia; | 2002 |
The use of nicardipine for electroconvulsive therapy: a dose-ranging study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Calcium Channe | 2005 |
Labetalol pretreatment reduces blood pressure instability during surgical resection of pheochromocytoma.
Topics: Adult; Antihypertensive Agents; Drug Therapy, Combination; Female; Humans; Hypertension; Infusions, | 2006 |
The Control of Hypertension In Pregnancy Study pilot trial.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Labetalol; Patient Sat | 2007 |
The effects of esmolol and labetalol on cerebral blood flow velocity during electroconvulsive therapy.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Blood Flow Velocity; Blood Pressure; Ce | 2008 |
Benzodiazepine and opioid sedation attenuate the sympathetic response to fiberoptic bronchoscopy. Prophylactic labetalol gave no additional benefit. Results of a randomized double-blind placebo-controlled study.
Topics: Adrenergic beta-Antagonists; Alfentanil; Analgesics, Opioid; Antihypertensive Agents; Benzodiazepine | 2008 |
Benzodiazepine and opioid sedation attenuate the sympathetic response to fiberoptic bronchoscopy. Prophylactic labetalol gave no additional benefit. Results of a randomized double-blind placebo-controlled study.
Topics: Adrenergic beta-Antagonists; Alfentanil; Analgesics, Opioid; Antihypertensive Agents; Benzodiazepine | 2008 |
Benzodiazepine and opioid sedation attenuate the sympathetic response to fiberoptic bronchoscopy. Prophylactic labetalol gave no additional benefit. Results of a randomized double-blind placebo-controlled study.
Topics: Adrenergic beta-Antagonists; Alfentanil; Analgesics, Opioid; Antihypertensive Agents; Benzodiazepine | 2008 |
Benzodiazepine and opioid sedation attenuate the sympathetic response to fiberoptic bronchoscopy. Prophylactic labetalol gave no additional benefit. Results of a randomized double-blind placebo-controlled study.
Topics: Adrenergic beta-Antagonists; Alfentanil; Analgesics, Opioid; Antihypertensive Agents; Benzodiazepine | 2008 |
Labetalol and lipids.
Topics: Cholesterol; Clinical Trials as Topic; Ethanolamines; Humans; Hypertension; Labetalol; Random Alloca | 1981 |
Labetalol in essential hypertension.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Clinical Trials as Topic; Diuretics; Ethanolamines; Hum | 1982 |
Labetalol and platelet function in pre-eclampsia.
Topics: Blood Platelets; Clinical Trials as Topic; Ethanolamines; Female; Humans; Hypertension; Labetalol; P | 1982 |
Labetalol, beta blockers, and acute deterioration of chronic airway obstruction.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Ethanolamines; Humans; Hypertension; Labetalol; Lung Di | 1982 |
Antihypertensive therapy in pregnancy.
Topics: Atenolol; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Hypertension; Labetalol; Ma | 1983 |
Intravenous labetalol in the treatment of severe hypertension and hypertensive emergencies.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Clinical Trials as Topic; Emergencies; Eth | 1983 |
[Comparative evaluation of the therapeutic effect of various classes of beta-blockaders in patients with hypertension].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Clinical Trials as Topic; Echocardiography; Hear | 1983 |
Propranolol vs metoprolol vs labetalol: a comparative study in essential hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Blood Pressure; Double-Blind Method; Female; Humans; Hypertensio | 1984 |
A double-blind comparison of verapamil and labetalol in hypertensive patients with coexisting chronic obstructive airways disease.
Topics: Aged; Blood Pressure; Calcium Channel Blockers; Clinical Trials as Topic; Double-Blind Method; Ethan | 1982 |
[Clinical trial of labetalol (Tranedate) in general practice].
Topics: Adult; Aged; Clinical Trials as Topic; Diarrhea; Drug Eruptions; Ethanolamines; Female; Humans; Hype | 1983 |
Pharmacokinetics, beta-adrenoceptor blockade and anti-hypertensive action of labetalol during chronic oral treatment.
Topics: Administration, Oral; Adult; Blood Pressure; Ethanolamines; Humans; Hypertension; Kinetics; Labetalo | 1980 |
Effects of labetalol in hypertensive patients with chronic obstructive pulmonary disease.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Ethanolamines; Exercise | 1983 |
Circulatory effects of noise.
Topics: Adult; Catecholamines; Female; Hemodynamics; Humans; Hypertension; Labetalol; Male; Middle Aged; Noi | 1983 |
Treatment of hypertension following endotracheal intubation. A study comparing the efficacy of labetalol, practolol and placebo.
Topics: Blood Pressure; Clinical Trials as Topic; Diastole; Ethanolamines; Heart Rate; Humans; Hypertension; | 1983 |
Comparison of the effects of labetalol and hydrochlorothiazide on the ventilatory function of hypertensive patients with mild chronic obstructive pulmonary disease.
Topics: Aged; Clinical Trials as Topic; Double-Blind Method; Ethanolamines; Forced Expiratory Volume; Humans | 1983 |
Study of single and multiple dose pharmacokinetic/pharmacodynamic modeling of the antihypertensive effects of labetalol.
Topics: Adult; Blood Pressure; Clinical Trials as Topic; Drug Administration Schedule; Ethanolamines; Female | 1983 |
Monotherapy with labetalol in the treatment of mild hypertension: a double-blind study.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Ethanolamines; Female; H | 1983 |
Multiclinic comparison of labetalol to metoprolol in treatment of mild to moderate systemic hypertension.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Ethanolamines; Female; H | 1983 |
Multicenter clinical evaluation of long-term efficacy and safety of labetalol in treatment of hypertension.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Ethanolamines; Female; H | 1983 |
Step II treatment with labetalol for essential hypertension.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Ethanolamines; Female; H | 1983 |
Treatment of severe hypertension with labetalol compared with methyldopa and furosemide. Results of a long-term, double-blind, multicenter trial.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combinatio | 1983 |
[Use of Albetol for treating hypertension patients].
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Dose-Response Relationship, Drug; Ethanolamin | 1984 |
"Third drug" trial: comparative study of antihypertensive agents added to treatment when blood pressure remains uncontrolled by a beta blocker plus thiazide diuretic.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Atenolol; Bendroflumethiazide; Blood Pressure; Cli | 1984 |
On the combination of alpha- and beta-adrenoceptor blockade in hypertension.
Topics: Adult; Double-Blind Method; Drug Evaluation; Drug Therapy, Combination; Ethanolamines; Female; Human | 1983 |
Treatment of acute pregnancy-related hypertension: labetalol and hydralazine compared.
Topics: Ethanolamines; Female; Heart Rate; Humans; Hydralazine; Hypertension; Labetalol; Pregnancy; Pregnanc | 1983 |
Diazoxide and labetalol in acute hypertension during haemodialysis.
Topics: Adult; Aged; Blood Pressure; Diazoxide; Ethanolamines; Female; Humans; Hypertension; Labetalol; Male | 1983 |
Diazoxide vs labetalol: a cross-over comparison of short-term effects in hypertension.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Diazoxide; Drug Evaluation; Ethanolamines; Female; Heart | 1983 |
The hypotensive effect of a single daily dose of labetalol: a preliminary study.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Ethanolamines; Female; Humans; Hypertension; | 1982 |
Anti-hypertensive action of labetalol: a detailed profile.
Topics: Adult; Blood Pressure; Blood Pressure Determination; Circadian Rhythm; Clinical Trials as Topic; Eth | 1982 |
Antihypertensive and metabolic effects of increasing doses of atenolol and labetalol. A comparative study in primary hypertension.
Topics: Adult; Aged; Aldosterone; Atenolol; Blood Pressure; Double-Blind Method; Drug Evaluation; Ethanolami | 1982 |
[Labetalol in the treatment of arterial hypertension. A Brazilian multicenter study].
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therap | 1982 |
Increased plasma concentrations of prostacyclin metabolite 6-keto-PGF1 alpha in essential hypertension. Influence of therapy with labetalol.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Ethanolamines; Hemodynamics; Humans; Hypertension | 1983 |
Beneficial effect of labetalol in hypertensive patients with angina pectoris.
Topics: Adult; Aged; Angina Pectoris; Blood Pressure; Ethanolamines; Female; Heart Rate; Humans; Hypertensio | 1983 |
Comparison of the effects of single doses of atenolol and labetalol on airways obstruction in patients with hypertension and asthma.
Topics: Adult; Asthma; Atenolol; Blood Pressure; Ethanolamines; Female; Forced Expiratory Volume; Humans; Hy | 1983 |
Labetalol and propranolol in mild hypertensives: comparison of blood pressure and plasma volume effects.
Topics: Adult; Aged; Blood Pressure; Body Weight; Drug Therapy, Combination; Ethanolamines; Female; Humans; | 1980 |
Treatment of hypertension in the elderly with labetalol.
Topics: Aged; Blood Pressure; Double-Blind Method; Drug Evaluation; Ethanolamines; Female; Humans; Hypertens | 1982 |
Labetalol in the treatment of hypertension in patients with normal and impaired renal function.
Topics: Adult; Aged; Double-Blind Method; Ethanolamines; Female; Half-Life; Humans; Hypertension; Kidney Dis | 1982 |
Effects of labetalol and propranolol on the peripheral circulation in hypertensive patients.
Topics: Adult; Aged; Blood Pressure; Double-Blind Method; Ethanolamines; Extremities; Female; Humans; Hypert | 1982 |
Comparison of labetalol and propranolol in hypertension.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Ethanolamines; Female; H | 1980 |
Comparison of labetalol, hydrallazine, and propranolol in the therapy of moderate hypertension.
Topics: Antihypertensive Agents; Clinical Trials as Topic; Drug Therapy, Combination; Ethanolamines; Female; | 1980 |
Comparative trial of labetalol and acebutolol, alone or associated with dihydralazine, in treatment of essential hypertension.
Topics: Acebutolol; Adult; Clinical Trials as Topic; Dihydralazine; Drug Therapy, Combination; Ethanolamines | 1980 |
A double-blind study with oral labetalol (Trandate)--a new hypotensive agent.
Topics: Adult; Clinical Trials as Topic; Double-Blind Method; Ethanolamines; Humans; Hypertension; Labetalol | 1980 |
Labetalol and alprenolol. A comparative investigation of antihypertensive effect.
Topics: Adult; Aged; Alprenolol; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Ethanolamine | 1980 |
Labetalol in mild and moderate hypertension. A report from the General Practitioner Research Group.
Topics: Adult; Aged; Bendroflumethiazide; Clinical Trials as Topic; Double-Blind Method; Ethanolamines; Fema | 1980 |
Combined alpha- and beta-blockade with labetalol in post-open heart surgery hypertension. Reversal of hemodynamic deterioration with glucagon.
Topics: Adult; Blood Pressure; Cardiac Output; Cardiac Surgical Procedures; Clinical Trials as Topic; Depres | 1980 |
[Cardiovascular effects of acute administration of labetalol in hypertensive patients].
Topics: Adult; Blood Pressure; Clinical Trials as Topic; Electrocardiography; Ethanolamines; Female; Heart R | 1980 |
A multicentre study of labetalol in hypertension. New Zealand Hypertension Study Group.
Topics: Adolescent; Adult; Aged; Blood Pressure; Child; Clinical Trials as Topic; Ethanolamines; Female; Hum | 1981 |
[Diazoxide vs. labetalol: a cross-over comparison of acute effects in hypertensive patients (author's transl)].
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Diazoxide; Ethanolamines; Female; Humans; Hyperte | 1980 |
[Open clinical trial of labetalol in ambulatory patients with arterial hypertension].
Topics: Adult; Aged; Ambulatory Care; Clinical Trials as Topic; Ethanolamines; Female; Humans; Hypertension; | 1981 |
[Labetalol: a new alpha/beta-adrenergic receptor blocking agent].
Topics: Clinical Trials as Topic; Ethanolamines; Humans; Hypertension; Labetalol | 1981 |
[Comparison of metroprolol and labetalol. Antihypertensive activity at rest and during exertion and effect on some noninvasive parameters of cardiovascular function].
Topics: Adult; Clinical Trials as Topic; Ethanolamines; Female; Hemodynamics; Humans; Hypertension; Labetalo | 1981 |
[Own experience with labetalol - a new adrenergic alpha and beta receptor blockader - in the treatment of arterial hypertension].
Topics: Adult; Blood Pressure; Clinical Trials as Topic; Ethanolamines; Female; Humans; Hypertension; Labeta | 1981 |
The treatment of hypertension by labetalol--a new alpha- and beta-adrenoreceptor blocking agent.
Topics: Adolescent; Adult; Aged; Blood Pressure; Child; Child, Preschool; Clinical Trials as Topic; Ethanola | 1982 |
[Labetalol: a field study in essential hypertension (author's transl)].
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Drug Therapy, Combination; Ethanolamines; Female; | 1982 |
Comparison of labetalol, propranolol and hydralazine in hypertensive out-patients.
Topics: Adult; Clinical Trials as Topic; Drug Therapy, Combination; Ethanolamines; Female; Humans; Hydralazi | 1982 |
The use of labetalol in Japan: results of multicentre clinical trials.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Diuretics; Drug Therapy, Combination; Ethanol | 1982 |
A controlled comparison of the antihypertensive effects of labetalol and alpha-methyldopa.
Topics: Adult; Blood Pressure; Clinical Trials as Topic; Ethanolamines; Female; Heart Rate; Humans; Hyperten | 1982 |
Clinical evaluation of labetalol alone and combined with chlorthalidone in essential hypertension: a double-blind multicentre controlled study.
Topics: Adult; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, | 1982 |
[Clinical, ergometric and polygraphic evaluation of the effects of metoprolol and labetalol administration in essential arterial hypertension. Comparative study].
Topics: Adult; Electrocardiography; Ethanolamines; Female; Humans; Hypertension; Labetalol; Male; Metoprolol | 1982 |
Comparison of labetalol and clonidine in hypertension.
Topics: Adult; Clonidine; Ethanolamines; Female; Heart Rate; Humans; Hypertension; Labetalol; Male; Middle A | 1982 |
Renal haemodynamics after chronic treatment with labetalol and propranolol.
Topics: Adult; Aged; Blood Pressure; Ethanolamines; Female; Heart Rate; Humans; Hypertension; Labetalol; Mal | 1982 |
Prolactin stimulation by intravenous labetalol is mediated inside the central nervous system.
Topics: Administration, Oral; Adult; Carbidopa; Central Nervous System; Ethanolamines; Female; Humans; Hyper | 1982 |
A five-year study of labetalol in hypertension.
Topics: Adult; Aged; Ethanolamines; Female; Humans; Hypertension; Labetalol; Male; Middle Aged | 1981 |
[Comparative study of labetolol and propranolol in patients with untreated hypertension].
Topics: Adult; Aged; Double-Blind Method; Ethanolamines; Female; Humans; Hypertension; Labetalol; Male; Midd | 1981 |
An analysis of the blood pressure response to labetalol in hypertensive patients.
Topics: Adult; Blood Pressure; Dose-Response Relationship, Drug; Ethanolamines; Female; Humans; Hypertension | 1981 |
Comparison of the alpha and beta blocking drug, labetalol, and methyl dopa in the treatment of moderate and severe pregnancy-induced hypertension.
Topics: Adult; Blood Pressure; Creatinine; Ethanolamines; Female; Fetus; Humans; Hydralazine; Hypertension; | 1980 |
Blood pressure, plasma volume, extracellular volume and glomerular filtration rate during treatment with labetalol in essential hypertension.
Topics: Adult; Aged; Blood Pressure; Ethanolamines; Extracellular Space; Female; Glomerular Filtration Rate; | 1980 |
The relationship of plasma norepinephrine levels and aortic distensibility in elderly with isolated systolic hypertension.
Topics: Aged; Aged, 80 and over; Aorta; Blood Pressure; Echocardiography; Female; Heart Rate; Humans; Hypert | 1995 |
A dose-ranging study of labetalol in moderate to moderately severe hypertension.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Dose-Response Relationship, Drug; Drug Hypersensi | 1995 |
Labetalol vs. methyldopa in the treatment of pregnancy-induced hypertension.
Topics: Adult; Blood Pressure; Cesarean Section; Dose-Response Relationship, Drug; Drug Administration Sched | 1995 |
Treatment with a beta-blocker with beta 2-agonism improves glucose and lipid metabolism in essential hypertension.
Topics: Adult; Aged; Blood Glucose; Double-Blind Method; Female; Humans; Hypertension; Insulin; Labetalol; L | 1994 |
Effect of atenolol and labetalol on serum lipids.
Topics: Atenolol; Female; Humans; Hyperlipidemias; Hypertension; Labetalol; Lipids; Male | 1993 |
Effects of dilevalol (R,R-labetalol) compared with nifedipine on heart rate, blood pressure and muscle blood flow at rest and on exercise in hypertensive patients.
Topics: Adolescent; Adult; Aged; Blood Pressure; Double-Blind Method; Exercise; Heart Rate; Humans; Hyperten | 1993 |
Oral labetalol versus oral nifedipine in hypertensive urgencies in the ED.
Topics: Administration, Oral; Blood Pressure; Clinical Protocols; Diastole; Drug Administration Schedule; Em | 1993 |
Effect of antihypertensive agents on the arterial partial pressure of oxygen and venous admixture after cardiac surgery.
Topics: Aged; Antihypertensive Agents; Cardiac Surgical Procedures; Female; Humans; Hypertension; Intensive | 1997 |
Metoclopramide enhances labetalol-induced antihypertensive effect during handgrip in hypertensive patients.
Topics: Antihypertensive Agents; Blood Pressure; Drug Synergism; Drug Therapy, Combination; Female; Hand Str | 1998 |
A randomized, double-blind trial of oral nifedipine and intravenous labetalol in hypertensive emergencies of pregnancy.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Blood Pressure; Calcium Channel Blockers; | 1999 |
A randomized, double-blind, hemodynamic evaluation of nifedipine and labetalol in preeclamptic hypertensive emergencies.
Topics: Adrenergic beta-Antagonists; Adult; Blood Pressure; Calcium Channel Blockers; Double-Blind Method; E | 1999 |
A comparative study between a calcium channel blocker (Nicardipine) and a combined alpha-beta-blocker (Labetalol) for the control of emergence hypertension during craniotomy for tumor surgery.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Analysis of Variance; Anesth | 2000 |
A comparative study between a calcium channel blocker (Nicardipine) and a combined alpha-beta-blocker (Labetalol) for the control of emergence hypertension during craniotomy for tumor surgery.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Analysis of Variance; Anesth | 2000 |
A comparative study between a calcium channel blocker (Nicardipine) and a combined alpha-beta-blocker (Labetalol) for the control of emergence hypertension during craniotomy for tumor surgery.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Analysis of Variance; Anesth | 2000 |
A comparative study between a calcium channel blocker (Nicardipine) and a combined alpha-beta-blocker (Labetalol) for the control of emergence hypertension during craniotomy for tumor surgery.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Analysis of Variance; Anesth | 2000 |
Comparative hemodynamic effects of urapidil and labetalol after electroconvulsive therapy.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Dose-Response Relationship, | 2001 |
Intravenous labetalol in hypertensive patients treated with beta-adrenoreceptor-blocking drugs.
Topics: Adrenergic beta-Antagonists; Adult; Blood Pressure; Dose-Response Relationship, Drug; Drug Resistanc | 1976 |
Antihypertensive effect of labetalol, a new alpha- and beta-adrenergic blocking agent.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Blood Pressure; Clinical Trials as | 1976 |
Hemodynamic effects of labetalol, an alpha and beta adrenergic blocking agent, in hypertensive subjects.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Amyl Nitrite; Blood Pressure; Card | 1977 |
Randomised study of six beta-blockers and a thiazide diuretic in essential hypertension.
Topics: Acebutolol; Adrenergic beta-Antagonists; Adult; Atenolol; Bendroflumethiazide; Clinical Trials as To | 1978 |
Labetalol in hypertensive patients with angina pectoris: beneficial effect of combined alpha- and beta-adrenoreceptor blockade.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Clinical Tr | 1978 |
Labetalol in the treatment of severe essential hypertension: relationship between arterial blood pressure, plasma catecholamines, plasma renin activity, plasma aldosterone and body weight.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Aldosterone; Blood Pressure; | 1979 |
A double-blind crossover comparison of pindolol, metoprolol, atenolol and labetalol in mild to moderate hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Clinical Trials as Topic; Double-Blind Method; E | 1979 |
Letter: Intravenous labetalol in severe hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Ethanolamines; Humans; Hypertensi | 1975 |
Rapid onset of action of oral labetalol in severe hypertension.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Clinical Trials as Topic; Ethanolamines; Female; | 1977 |
Alpha and beta adrenergic blockade with orally administered labetalol in hypertension. Studies on blood volume, plasma renin and aldosterone and catecholamine excretion.
Topics: Adult; Aged; Aldosterone; Blood Pressure; Blood Volume; Body Weight; Chlorthalidone; Clinical Trials | 1978 |
Labetalol compared with prindolol plus hydraliazine in the treatment of hypertension: a double-blind cross-over study.
Topics: Adult; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Ethanolamines; Fema | 1978 |
[Changes in rest and exercise hemodynamics during long term therapy with a combination alpha and beta blocker in essential hypertension].
Topics: Blood Pressure; Cardiac Output; Clinical Trials as Topic; Drug Evaluation; Ethanolamines; Humans; Hy | 1977 |
Intravenous labetalol in hypertensive patients given by fast and slow injection.
Topics: Adult; Blood Pressure; Clinical Trials as Topic; Ethanolamines; Female; Humans; Hypertension; Inject | 1978 |
Effect of labetalol on plasma noradrenaline and adrenaline in hypertensive man.
Topics: Adult; Blood Glucose; Clinical Trials as Topic; Epinephrine; Ethanolamines; Female; Hemodynamics; Hu | 1978 |
Labetalol, a cross-over double blind controlled trial.
Topics: Clinical Trials as Topic; Double-Blind Method; Ethanolamines; Female; Humans; Hypertension; Labetalo | 1978 |
A controlled trial of labetalol (Trandate), propranolol and placebo in the management of mild to moderate hypertension.
Topics: Adult; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Ethanolamines; Female; Heart R | 1979 |
Vascular symptoms in patients with primary Raynaud's phenomenon are not exacerbated by propranolol or labetalol.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Ethanolamines; Female; H | 1979 |
A comparison of the effects of labetalol, bendrofluazide and their combination in hypertension.
Topics: Adult; Bendroflumethiazide; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Drug Comb | 1979 |
Labetalol and bendrofluazide: comparison of their antihypertensive effects.
Topics: Adult; Bendroflumethiazide; Clinical Trials as Topic; Double-Blind Method; Ethanolamines; Female; Hu | 1979 |
Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 7. New horizons in beta-adrenoceptor blockade therapy: labetalol.
Topics: Arrhythmias, Cardiac; Chemical Phenomena; Chemistry; Clinical Trials as Topic; Coronary Disease; Eth | 1979 |
Labetalol in the treatment of hypertension in general practice.
Topics: Clinical Trials as Topic; Diuretics; Ethanolamines; Female; Humans; Hypertension; Labetalol; Male; M | 1979 |
A multicentre open trial of labetalol in New Zealand.
Topics: Adolescent; Adult; Aged; Blood Pressure; Child; Clinical Trials as Topic; Ethanolamines; Female; Hum | 1979 |
A comparative study of methyldopa and labetalol in the treatment of hypertension.
Topics: Blood Cell Count; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Ethanolamines; Fema | 1979 |
Effect of increasing doses of labetalol on blood pressure, plasma renin activity and aldosterone in hypertensive patients.
Topics: Adult; Aldosterone; Blood Pressure; Clinical Trials as Topic; Dose-Response Relationship, Drug; Etha | 1979 |
Labetalol and pindolol in the treatment of hypertension: a comparative study.
Topics: Adult; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Ethanolamines; Female; Humans; | 1979 |
Antihypertensive effect and plasma levels of labetalol. A comparison with propranolol and dihydrallazine.
Topics: Adult; Dihydralazine; Drug Therapy, Combination; Ethanolamines; Female; Heart Rate; Humans; Hydralaz | 1979 |
Mean steady-state plasma concentrations of labetalol in patients undergoing antihypertensive therapy.
Topics: Adult; Dose-Response Relationship, Drug; Ethanolamines; Female; Humans; Hypertension; Kinetics; Labe | 1979 |
Pharmacokinetics and pharmacodynamic studies of labetalol in hypertensive subjects.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Ethanolamines; Female; Half-Life; Humans; Hyperte | 1979 |
A comparison and an investigation of a potential synergistic effect of labetalol and bethanidine in patients with mild hypertension.
Topics: Adult; Aged; Bethanidine; Blood Pressure; Drug Synergism; Ethanolamines; Female; Guanidines; Heart R | 1979 |
Comparison of effects on cerebral blood flow of rapid reduction in systemic arterial pressure by diazoxide and labetalol in hypertensive patients: preliminary findings.
Topics: Blood Pressure; Cardiac Output; Cerebrovascular Circulation; Diazoxide; Electrocardiography; Ethanol | 1979 |
Use of labetalol and methyldopa in pregnancy-induced hypertension.
Topics: Administration, Oral; Blood Pressure; Ethanolamines; Female; Humans; Hypertension; Injections, Intra | 1979 |
Catecholamines and haemodynamics in fixed essential hypertension.
Topics: Adult; Aged; Blood Pressure; Cardiac Output; Epinephrine; Female; Heart Rate; Humans; Hypertension; | 1979 |
Combined alpha- and beta-adrenoceptor blockade with labetalol in hypertension.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Depression, Chemical; Ethanolamines; Female; | 1976 |
Haemodynamic effects of long-term oral labetalol.
Topics: Administration, Oral; Adult; Blood Pressure; Cardiac Output; Clinical Trials as Topic; Drug Administ | 1976 |
Double-blind trial of labetalol.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Evalua | 1976 |
Experience with labetalol in hypertension.
Topics: Adult; Aged; Blood Pressure; Body Weight; Clinical Trials as Topic; Diuretics; Drug Evaluation; Drug | 1976 |
Controlled comparison of labetalol and propranolol in the management of severe hypertension.
Topics: Adult; Antibodies, Antinuclear; Aspartate Aminotransferases; Blood Pressure; Clinical Trials as Topi | 1976 |
Comparative anti-hypertensive effects of labetalol and the combination of oxprenolol and phentolamine.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Dose-Response Relati | 1976 |
Effect of blood pressure angiotensin II and aldosterone concentrations during treatment of severe hypertension with intravenous labetalol: comparison with propranolol.
Topics: Aldosterone; Angiotensin II; Blood Pressure; Clinical Trials as Topic; Ethanolamines; Heart Rate; Hu | 1976 |
The anti-hypertensive efficacy of combined alpha- and beta-adrenoreceptor blockade with phentolamine-oxprenolol or with labetalol (AH 5158).
Topics: Adult; Aged; Clinical Trials as Topic; Drug Therapy, Combination; Ethanolamines; Female; Humans; Hyp | 1976 |
Some haemodynamic effects of compound AH 5158 compared with propranolol, propranolol plus hydrallazine, and diazoxide: the use of AH 5158 in the treatment of hypertension.
Topics: Blood Pressure; Cardiac Output; Clinical Trials as Topic; Diazoxide; Drug Therapy, Combination; Etha | 1975 |
Effects of intravenous labetalol on blood pressure, angiotensin II and aldosterone in hypertension: comparison with propranolol.
Topics: Aldosterone; Angiotensin II; Depression, Chemical; Ethanolamines; Heart Rate; Humans; Hypertension; | 1976 |
Combined alpha- and beta-adrenoreceptor blockade in hypertension: a controlled trial of labetalol (AH 5158) compared with propranolol and placebo.
Topics: Adult; Aged; Ethanolamines; Female; Humans; Hypertension; Labetalol; Male; Middle Aged; Physical Exe | 1976 |
A comparison of esmolol and labetalol for the treatment of perioperative hypertension in geriatric ambulatory surgical patients.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Ambulatory Surgical Procedures; Analysis of Va | 1992 |
A randomised placebo controlled trial of labetalol in the treatment of mild to moderate pregnancy induced hypertension.
Topics: Administration, Oral; Adult; Female; Gestational Age; Humans; Hypertension; Labetalol; Length of Sta | 1992 |
[Absence of labetalol interference on urine metanephrine determination in hypertensive patients].
Topics: Adrenal Gland Neoplasms; Adult; Aged; Chromatography, Liquid; Female; Humans; Hypertension; Labetalo | 1992 |
Metabolic effects of carteolol and dilevalol in essential hypertension.
Topics: Carteolol; Humans; Hypertension; Labetalol | 1992 |
Does labetalol influence the development of proteinuria in pregnancy hypertension? A randomised controlled study.
Topics: Adult; Female; Humans; Hypertension; Labetalol; Pregnancy; Pregnancy Complications; Pregnancy Compli | 1992 |
The short term effects of oral labetalol in patients with chronic renal disease and hypertension.
Topics: Administration, Oral; Adult; Blood Pressure; Chronic Disease; Double-Blind Method; Female; Glomerula | 1992 |
Influence of beta-blockade on circulating plasma levels of 3-methoxy-4-hydroxy phenylethylene glycol (MHPG) during exercise in moderate hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Blood Pressure; Double-Blind Method; Exercise; Exercise Test; Hu | 1991 |
Double-blind study of dilevalol and captopril, both in combination with hydrochlorothiazide, in patients with moderate to severe hypertension.
Topics: Adult; Aged; Blood Pressure; Body Weight; Captopril; Double-Blind Method; Drug Therapy, Combination; | 1990 |
Oral labetalol versus oral clonidine in the emergency treatment of severe hypertension.
Topics: Administration, Oral; Blood Pressure; Clonidine; Diastole; Emergencies; Female; Heart Rate; Humans; | 1992 |
Lack of effect of labetalol on platelet aggregation in hypertensive patients.
Topics: Adult; Blood Pressure; Dosage Forms; Female; Humans; Hypertension; Labetalol; Male; Middle Aged; Pla | 1991 |
The effectiveness of labetalol compared to hydrochlorothiazide in hypertensive black patients.
Topics: Black People; Blood Pressure; Double-Blind Method; Drug Administration Schedule; Drug Evaluation; Fe | 1991 |
Regression of structural vascular changes after chronic treatment in hypertensives.
Topics: Acebutolol; Adult; Aged; Blood Pressure; Captopril; Female; Hemodynamics; Humans; Hypertension; Labe | 1991 |
Evaluation of labetalol in elderly patients with essential hypertension.
Topics: Aged; Aged, 80 and over; Blood Pressure; Diastole; Double-Blind Method; Evaluation Studies as Topic; | 1991 |
Continuous opioid infusions for neurosurgical procedures: a double-blind comparison of alfentanil and fentanyl.
Topics: Adult; Aged; Alfentanil; Anesthesia Recovery Period; Anesthesia, Intravenous; Blood Pressure; Consci | 1991 |
Renin profile, race, and antihypertensive efficacy with atenolol and labetalol.
Topics: Atenolol; Black People; Blood Pressure; Double-Blind Method; Humans; Hypertension; Labetalol; Middle | 1991 |
Hemodynamic and hemorheologic effects of i.v. Dilevalol in hypertensive patients.
Topics: Blood Viscosity; Evaluation Studies as Topic; Female; Hemodynamics; Humans; Hypertension; Infusions, | 1991 |
Clinical and biological evaluation of dilevalol vasodilating properties in mild to moderate hypertension.
Topics: Administration, Oral; Adult; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; | 1991 |
The effects of age on the pharmacokinetics, antihypertensive efficacy and general tolerability of dilevalol.
Topics: Adult; Age Factors; Aged; Blood Pressure; Double-Blind Method; Drug Tolerance; Female; Heart Rate; H | 1991 |
Safety and efficacy of once-daily carvedilol vs twice-daily labetalol in mild to moderate hypertension.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Carbazoles; Carvedilol; Double-Blind Method; Drug Admin | 1990 |
Oral labetalol in hypertensive urgencies.
Topics: Administration, Oral; Adult; Blood Pressure; Clinical Protocols; Emergencies; Emergency Service, Hos | 1991 |
Comparison of labetalol versus enalapril as monotherapy in elderly patients with hypertension: results of 24-hour ambulatory blood pressure monitoring.
Topics: Aged; Blood Pressure; Blood Pressure Determination; Electrocardiography, Ambulatory; Enalapril; Fema | 1991 |
Dose-response evaluation of oral labetalol in patients presenting to the emergency department with accelerated hypertension.
Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Blood Pressure; Body Weight; Dose-Response | 1991 |
The effects of labetalol and prazosin on exercise haemodynamics in hypertensive patients.
Topics: Adult; Aged; Female; Headache; Hemodynamics; Humans; Hypertension; Labetalol; Male; Middle Aged; Phy | 1991 |
The effectiveness of labetalol in treating postoperative hypertension.
Topics: Adult; Aged; Female; Humans; Hypertension; Incidence; Labetalol; Male; Middle Aged; Postoperative Co | 1991 |
Interaction of indomethacin and sulindac with labetalol.
Topics: Adult; Aged; Analysis of Variance; Blood Pressure; Body Weight; Chlorides; Drug Interactions; Humans | 1991 |
Maternal and fetal haemodynamics in hypertensive pregnancies during maternal treatment with intravenous hydralazine or labetalol.
Topics: Adult; Blood Flow Velocity; Blood Pressure; Female; Heart Rate; Heart Rate, Fetal; Hemodynamics; Hum | 1991 |
Labetalol for the control of elevated blood pressure following coronary artery bypass grafting.
Topics: Analysis of Variance; Blood Pressure; Cardiac Output; Coronary Artery Bypass; Diastole; Female; Hear | 1990 |
A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy.
Topics: Adult; Female; Humans; Hypertension; Infant Mortality; Infant, Newborn; Labetalol; Methyldopa; Pregn | 1990 |
Dilevalol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension.
Topics: Animals; Dogs; Female; Guinea Pigs; Humans; Hypertension; Labetalol; Pregnancy; Randomized Controlle | 1990 |
Treatment of isolated systolic hypertension with labetalol in the elderly.
Topics: Age Factors; Aged; Double-Blind Method; Humans; Hypertension; Labetalol; Male; Middle Aged; Multicen | 1990 |
Comparison of the renal effects of dilevalol and carteolol in patients with mild to moderate essential hypertension.
Topics: Adult; Aldosterone; Blood Proteins; Carteolol; Female; Glomerular Filtration Rate; Hemodynamics; Hum | 1990 |
[Hypertension in the elderly. Comparison of the efficacy and tolerability of labetalol and nifedipine. A multicenter, randomized, single-blind study].
Topics: Aged; Aged, 80 and over; Humans; Hypertension; Labetalol; Multicenter Studies as Topic; Nifedipine; | 1990 |
Antihypertensive activity and duration of action of dilevalol in hypertensive patients at rest and during exercise. A comparison with captopril.
Topics: Adult; Blood Pressure; Captopril; Double-Blind Method; Drug Administration Schedule; Drug Evaluation | 1990 |
Comparative effects of dilevalol and atenolol on lung function and airway response to methacholine in hypertensive subjects.
Topics: Adult; Aged; Atenolol; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Hypertension; | 1990 |
Atenolol in essential hypertension during pregnancy.
Topics: Atenolol; Female; Fetal Growth Retardation; Humans; Hypertension; Labetalol; Pregnancy; Pregnancy Co | 1990 |
Combined alpha/beta-blockade versus beta 1-selective blockade in essential hypertension in black and white patients.
Topics: Atenolol; Black People; Blood Pressure; Double-Blind Method; Heart Rate; Humans; Hypertension; Labet | 1990 |
Labetalol in the control of cardiovascular responses to electroconvulsive therapy in high-risk depressed medical patients.
Topics: Aged; Arrhythmias, Cardiac; Blood Pressure; Cardiovascular Diseases; Depressive Disorder; Double-Bli | 1990 |
Labetalol and nifedipine in the management of essential hypertension.
Topics: Blood Pressure; Double-Blind Method; Female; Humans; Hypertension; Labetalol; Male; Middle Aged; Nif | 1990 |
A comparison of dilevalol and placebo in the management of isolated systolic hypertension using ambulatory monitoring.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Blood Pressure; Blood Pressure Determination; Double-Blind | 1990 |
[Evaluation of labetalol in general medicine in aged patients with hypertension. Compliance, efficacy and safety in long-term treatment].
Topics: Aged; Ambulatory Care; Female; Follow-Up Studies; Humans; Hypertension; Labetalol; Male; Middle Aged | 1990 |
Clinical pharmacology of dilevalol (i.v.). Influence of hepatic and renal functions on the disposition of dilevalol and atenolol in hypertensive subjects.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Atenolol; Female; Humans; Hypertension; Kidney | 1990 |
Comparison of labetalol and hydrochlorothiazide in elderly patients with hypertension using 24-hour ambulatory blood pressure monitoring.
Topics: Aged; Blood Pressure; Blood Pressure Determination; Female; Heart Rate; Humans; Hydrochlorothiazide; | 1990 |
The influence of age on the pharmacokinetics and antihypertensive responses to dilevalol.
Topics: Adult; Aged; Aging; Female; Hemodynamics; Humans; Hypertension; Labetalol; Male; Middle Aged | 1990 |
Comparison of central and peripheral haemodynamic effects of dilevalol and atenolol in essential hypertension.
Topics: Analysis of Variance; Atenolol; Blood Flow Velocity; Blood Pressure; Cardiac Output; Echocardiograph | 1990 |
A comparison of the hemodynamic effects of labetalol and sodium nitroprusside in patients undergoing carotid endarterectomy.
Topics: Carotid Artery Diseases; Endarterectomy; Female; Ferricyanides; Hemodynamics; Humans; Hypertension; | 1990 |
Left ventricular filling in hypertensive blacks and whites following adrenergic blockade.
Topics: Adult; Analysis of Variance; Atenolol; Black People; Cardiac Volume; Diastole; Double-Blind Method; | 1990 |
[Essential arterial hypertension and quality of life. Comparative crossed double-blind study of labetalol and captopril].
Topics: Adult; Aged; Captopril; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Female; Huma | 1989 |
[Effects of labetalol and nitroglycerin during induction of anesthesia and endotracheal intubation in hypertensive patients].
Topics: Adult; Aged; Anesthesia; Blood Pressure; Female; Humans; Hypertension; Intubation, Intratracheal; La | 1989 |
Comparison of dilevalol and enalapril administered once daily for mild hypertension.
Topics: Adult; Aged; Double-Blind Method; Enalapril; Female; Heart Rate; Humans; Hypertension; Labetalol; Ma | 1989 |
Comparison of intravenous dilevalol with placebo in moderate hypertension.
Topics: Aldosterone; Atrial Natriuretic Factor; Catecholamines; Cyclic GMP; Double-Blind Method; Humans; Hyp | 1989 |
Effects of dilevalol, metoprolol and atenolol on left ventricular mass and function in nonelderly and elderly hypertensive patients.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Double-Blind Method; Echocardiography; Female; Heart; H | 1989 |
Influence of beta 2 agonism and beta 1 and beta 2 antagonism on adverse effects and plasma lipoproteins: results of a multicenter comparison of dilevalol and metoprolol.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Aged; Cholesterol; Coronary Disease; Double-B | 1989 |
Comparative effects of labetalol and bromazepam on ambulatory blood pressure of Nigerians with labile and stress hypertension.
Topics: Adult; Ambulatory Care; Anti-Anxiety Agents; Blood Pressure; Bromazepam; Female; Humans; Hypertensio | 1989 |
Regression of left ventricular hypertrophy in treated hypertensive patients with dilevalol and metoprolol--a double blind randomized study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Cardiomegaly; Double-Blind Method; Echocardiography; Elect | 1989 |
Attenuation of the hemodynamic responses to endotracheal intubation with preinduction intravenous labetalol.
Topics: Adult; Female; Humans; Hypertension; Infusions, Intravenous; Intubation, Intratracheal; Labetalol; M | 1989 |
Comparative hemodynamic effects of labetalol and hydralazine in the treatment of postoperative hypertension.
Topics: Aged; Female; Hemodynamics; Humans; Hydralazine; Hypertension; Labetalol; Male; Middle Aged; Postope | 1989 |
Effects of prazosin and labetalol on blood pressure control and blood lipid levels in patients with mild-to-moderate essential hypertension.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Female; Humans; Hypertension; Labetalol; Lipi | 1989 |
The fetal outcome in a randomized double-blind controlled trial of labetalol versus placebo in pregnancy-induced hypertension.
Topics: Adult; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Hypertension; Infant, Newborn; | 1989 |
Dilevalol compared with propranolol and placebo for systemic hypertension.
Topics: Aged; Double-Blind Method; Drug Administration Schedule; Female; Heart Rate; Humans; Hypertension; L | 1989 |
Labetalol compared with propranolol in patients with both angina pectoris and systemic hypertension: a double-blind study.
Topics: Adult; Aged; Angina Pectoris; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Exercis | 1989 |
Intravenous labetalol versus sodium nitroprusside for treatment of hypertension postcoronary bypass surgery.
Topics: Adult; Aged; Coronary Artery Bypass; Ferricyanides; Humans; Hypertension; Infusions, Intravenous; La | 1989 |
A multicenter double-blind study of the efficacy and safety of once and twice daily dilevalol compared to propranolol.
Topics: Adolescent; Adult; Aged; Blood Pressure; Double-Blind Method; Drug Administration Schedule; Female; | 1989 |
Dilevalol in severe hypertension. A multicenter trial of bolus intravenous dosing.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Heart Rate; Humans; Hypertension; Infusions, Intr | 1989 |
Effect of labetalol or lidocaine on the hemodynamic response to intubation: a controlled randomized double-blind study.
Topics: Adult; Aged; Analysis of Variance; Blood Pressure; Double-Blind Method; Female; Heart Rate; Humans; | 1989 |
Vasodilation and reduction in forearm vascular resistance after acute administration of dilevalol.
Topics: Administration, Oral; Adult; Female; Forearm; Humans; Hypertension; Labetalol; Male; Middle Aged; Re | 1989 |
Antihypertensive effect of dilevalol is directly related to dose and plasma concentrations.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Female; Heart Rate; Humans; Hypertension; Labetalol; | 1989 |
Arterial dilation and reduced wave reflection. Benefit of dilevalol in hypertension.
Topics: Adult; Aged; Aorta; Arteries; Atenolol; Blood Pressure; Brachial Artery; Carotid Arteries; Extremiti | 1989 |
The renal function and blood pressure effects of dilevalol in the normotensive and hypertensive elderly.
Topics: Aged; Blood Pressure; Double-Blind Method; Female; Glomerular Filtration Rate; Heart Rate; Humans; H | 1989 |
[Combined alpha and beta blockade with labetalol. Multicenter general practice study in hypertensive patients with concomitant coronary heart disease].
Topics: Clinical Trials as Topic; Coronary Disease; Humans; Hypertension; Labetalol; Receptors, Adrenergic, | 1987 |
Labetalol and hydrochlorothiazide in hypertension. Labetalol/Hydrochlorothiazide Multicenter Study Group.
Topics: Administration, Oral; Adult; Aged; Aging; Analysis of Variance; Blood Pressure; Clinical Trials as T | 1985 |
Beta blockade and intermittent claudication.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Clinical Trials as Topic; Coronary Disease; Female; Gait; | 1985 |
Respiratory effects of four adrenergic blocking agents combined with a diuretic in treating hypertension with concurrent chronic obstructive lung disease.
Topics: Adrenergic beta-Antagonists; Airway Resistance; Atenolol; Chlorthalidone; Drug Therapy, Combination; | 1986 |
Labetalol in the treatment of angina pectoris.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angina Pectoris; Clinical Trials as Topic | 1987 |
Haemodynamic effects of atenolol, labetalol, pindolol and captopril: a comparison in hypertensive patients with special reference to changes in limb blood flow, heart rate and left ventricular function.
Topics: Adrenergic beta-Antagonists; Atenolol; Blood Pressure; Captopril; Female; Forearm; Heart; Heart Rate | 1987 |
Placebo-controlled comparison of captopril, atenolol, labetalol, and pindolol in hypertension complicated by intermittent claudication.
Topics: Atenolol; Blood Pressure; Captopril; Clinical Trials as Topic; Double-Blind Method; Exercise Test; F | 1987 |
Myocardial ischemia in untreated hypertensive patients: effect of a single small oral dose of a beta-adrenergic blocking agent.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Anesthesia; Atenolol; Clinical Trials as To | 1988 |
Effects of dilevalol, an R, R-isomer of labetalol, on blood pressure and renal function in patients with mild-to-moderate essential hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Blood Pressure; Female; Glomerular Filtration Rate; Humans; Hype | 1988 |
Sympathetic (alpha-beta) or calcium channel blockade for hypertensive myocardial infarction? A haemodynamic comparison of labetalol and nifedipine.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Calcium Channel Blockers; He | 1988 |
Multicenter comparison of dilevalol to placebo in patients with mild hypertension.
Topics: Adolescent; Adult; Aged; Blood Pressure; Clinical Trials as Topic; Dose-Response Relationship, Drug; | 1988 |
Comparison of antihypertensive efficacy and perinatal safety of labetalol and methyldopa in the treatment of hypertension in pregnancy: a randomized controlled trial.
Topics: Adult; Clinical Trials as Topic; Female; Fetal Death; Fetus; Hemodynamics; Humans; Hypertension; Inf | 1988 |
[Non-invasive ambulatory blood pressure measurement over 24 hours: effects of labetalol on the rise of blood pressure in the early morning].
Topics: Adult; Blood Pressure; Blood Pressure Determination; Circadian Rhythm; Female; Humans; Hypertension; | 1988 |
[Maternal effects and perinatal safety of labetalol in the treatment of hypertension in pregnancy. Comparison with methyldopa in a randomized cooperative trial].
Topics: Adult; Clinical Trials as Topic; Female; Humans; Hypertension; Labetalol; Methyldopa; Pregnancy; Pre | 1987 |
Cost effectiveness of labetalol and propranolol in the treatment of hypertension among blacks.
Topics: Aged; Black People; Clinical Trials as Topic; Cost-Benefit Analysis; Female; Humans; Hypertension; L | 1987 |
[Randomized, comparative study on the treatment of moderate arterial hypertension during pregnancy: methyldopa, acebutolol, labetalol].
Topics: Acebutolol; Adult; Female; Heart Rate, Fetal; Humans; Hypertension; Hypoglycemia; Infant, Newborn; L | 1988 |
Labetalol blunts morning pressor surge in systolic hypertension.
Topics: Blood Pressure; Circadian Rhythm; Clinical Trials as Topic; Female; Heart Rate; Humans; Hypertension | 1988 |
Comparison of labetalol and prazosin in hypertensive patients using automated ambulatory monitoring.
Topics: Activities of Daily Living; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Female; H | 1988 |
Hypertension: a view from Detroit.
Topics: Adult; Aged; Black People; Clinical Trials as Topic; Humans; Hypertension; Labetalol; Middle Aged; P | 1987 |
A comparative trial of labetalol and hydralazine in the acute management of severe hypertension complicating pregnancy.
Topics: Adult; Blood Pressure; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Humans; H | 1987 |
The safety and efficacy of once-daily dilevalol in patients with mild hypertension: a placebo-controlled study.
Topics: Clinical Trials as Topic; Double-Blind Method; Female; Heart Rate; Humans; Hypertension; Labetalol; | 1987 |
Labetalol compared with propranolol in the treatment of black hypertensive patients.
Topics: Adolescent; Adult; Aged; Black People; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, | 1987 |
A comparative study on the effect of atenolol and labetalol on exercise capacity and lipid serum levels in essential hypertension.
Topics: Adult; Atenolol; Clinical Trials as Topic; Combined Modality Therapy; Exercise Test; Female; Humans; | 1987 |
Left ventricular function in mild hypertension after adrenergic blockade.
Topics: Atenolol; Double-Blind Method; Echocardiography; Female; Humans; Hypertension; Labetalol; Male; Midd | 1988 |
Renal function effects of dilevalol, a nonselective beta-adrenergic blocking drug with beta-2 agonist activity.
Topics: Administration, Oral; Adult; Aged; Atenolol; Double-Blind Method; Female; Glomerular Filtration Rate | 1988 |
Hemodynamic effects of labetalol in young and older adult hypertensives.
Topics: Adult; Aging; Blood Pressure; Cardiac Output; Dosage Forms; Heart Rate; Humans; Hypertension; Labeta | 1988 |
The use of labetalol for attenuation of the hypertensive response to endotracheal intubation in preeclampsia.
Topics: Adolescent; Adult; Anesthesia, Obstetrical; Blood Pressure; Cesarean Section; Female; Humans; Hypert | 1988 |
The role of calcium channel blockers in the treatment of hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Clinical Trials as Topic; Diltiaz | 1986 |
Intravenous labetalol and intravenous diazoxide in severe hypertension complicating pregnancy.
Topics: Adolescent; Adult; Birth Weight; Clinical Trials as Topic; Delivery, Obstetric; Diazoxide; Female; H | 1986 |
[Effect on lipids, lipoproteins and apoproteins of labetalol prescribed in doses of 400 mg/day in hypertensive patients. Double-blind versus placebo study].
Topics: Adult; Apoproteins; Clinical Trials as Topic; Double-Blind Method; Humans; Hypertension; Labetalol; | 1986 |
Evaluation of verapamil in the treatment of hypertension.
Topics: Adult; Benzothiadiazines; Clinical Trials as Topic; Diuretics; Drug Therapy, Combination; Female; He | 1986 |
Comparison of labetalol and dihydralazine in hypertensive emergencies of pregnancy.
Topics: Blood Pressure; Clinical Trials as Topic; Dihydralazine; Female; Heart Rate; Heart Rate, Fetal; Huma | 1987 |
Results obtained from labetalol therapy in essential hypertension.
Topics: Adult; Blood Pressure; Female; Heart Rate; Humans; Hypertension; Labetalol; Lipids; Male; Middle Age | 1987 |
Low starting dose labetalol--a new approach for the elderly hypertensive.
Topics: Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Female; Humans; Hypertension; Labetalol; | 1986 |
The effects of single-dose atenolol, labetalol, and propranolol on cardiac and vascular function.
Topics: Aged; Atenolol; Cardiac Output; Cardiovascular System; Heart Rate; Humans; Hypertension; Labetalol; | 1986 |
[Arterial hypertension in the elderly. Double-blind study versus placebo of the efficacy and tolerability of an alpha-beta blocker: labetalol].
Topics: Aged; Aged, 80 and over; Double-Blind Method; Female; Humans; Hypertension; Labetalol; Male; Random | 1987 |
The effects of treatments with labetalol and hydrochlorothiazide on ventilatory function of asthmatic hypertensive patients with demonstrated bronchosensitivity to propranolol.
Topics: Adolescent; Adult; Aged; Asthma; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Hydr | 1985 |
A double-blind crossover clinical trial of labetalol and propranolol in patients of essential hypertension.
Topics: Clinical Trials as Topic; Double-Blind Method; Ethanolamines; Female; Humans; Hypertension; Labetalo | 1985 |
Propranolol versus labetalol: interesting differences in efficacy.
Topics: Adult; Aged; Black People; Clinical Trials as Topic; Double-Blind Method; Ethanolamines; Humans; Hyp | 1985 |
Labetalol infusion in hypertensive emergencies.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Emergencies; Ethanolamines; Female; Heart Rat | 1985 |
A comparison of labetalol and prazosin combined with atenolol in non-responders to atenolol plus hydrochlorothiazide in uncomplicated hypertension.
Topics: Adult; Atenolol; Chlorothiazide; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans | 1985 |
Concomitant therapy with labetalol and hydrochlorothiazide in moderate to moderately severe essential hypertension.
Topics: Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Humans; Hydrochlorothiazid | 1985 |
Comparison of the effects of labetalol and hydrochlorothiazide on the ventilatory function of hypertensive patients with asthma and propranolol sensitivity.
Topics: Adolescent; Adult; Aged; Asthma; Clinical Trials as Topic; Drug Evaluation; Female; Forced Expirator | 1985 |
Antihypertensive and metabolic effects of nifedipine and labetalol alone and in combination in primary hypertension.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Drug Ther | 1985 |
Intravenous labetalol in the emergency treatment of hypertension.
Topics: Antihypertensive Agents; Cardiac Output; Clinical Trials as Topic; Emergencies; Humans; Hypertension | 1985 |
Double-blind trial comparing labetalol with atenolol in the treatment of systemic hypertension with angina pectoris.
Topics: Adult; Angina Pectoris; Atenolol; Clinical Trials as Topic; Double-Blind Method; Ethanolamines; Fema | 1985 |
Effects of atenolol, labetalol and propranolol on the peripheral circulation in hypertensive patients without obstructive vascular disease.
Topics: Adolescent; Adult; Atenolol; Blood Circulation; Ethanolamines; Female; Fingers; Humans; Hypertension | 1985 |
529 other studies available for labetalol and Hypertension
| Article | Year |
|---|---|
Severe hypertension in pregnancy.
Topics: Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Labetalol; Pre-Eclampsia; Pre | 2021 |
Renin secreting tumour: a rare cause of secondary hypertension.
Topics: Adult; Amlodipine; Antihypertensive Agents; Female; Humans; Hypertension; Kidney Neoplasms; Labetalo | 2021 |
Gestational weight gain among gravidae with hypertension receiving labetalol versus nifedipine.
Topics: Antihypertensive Agents; Blood Pressure; Female; Gestational Weight Gain; Humans; Hypertension; Labe | 2022 |
In Vitro Toxicological Profile of Labetalol-Folic Acid/Folate Co-Administration in H9c2(2-1) and HepaRG Cells.
Topics: Dietary Supplements; Female; Folic Acid; Humans; Hypertension; Labetalol; Neural Tube Defects; Pregn | 2022 |
Race/ethnicity differences in response to acute antihypertensive treatment of peripartum severe hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Ethnicity; Female; Humans; Hydralazine; Hypertension; Labet | 2022 |
Postpartum Readmission for Hypertension After Discharge on Labetalol or Nifedipine.
Topics: Antihypertensive Agents; Cohort Studies; Female; Humans; Hypertension; Hypertension, Pregnancy-Induc | 2022 |
Treatment of Post-Coarctectomy Hypertension With Labetalol-A 9-Year Single-Center Experience.
Topics: Antihypertensive Agents; Blood Pressure; Child; Humans; Hypertension; Labetalol; Nitroprusside; Post | 2022 |
Postpartum medical management of hypertension and risk of readmission for hypertensive complications.
Topics: Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Labetalol; Nifedipine; Patien | 2023 |
Postpartum medical management of hypertension and risk of readmission for hypertensive complications.
Topics: Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Labetalol; Nifedipine; Patien | 2023 |
Postpartum medical management of hypertension and risk of readmission for hypertensive complications.
Topics: Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Labetalol; Nifedipine; Patien | 2023 |
Postpartum medical management of hypertension and risk of readmission for hypertensive complications.
Topics: Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Labetalol; Nifedipine; Patien | 2023 |
Use of continuous infusion of nicardipine to control persistent postpartum hypertension: A retrospective study.
Topics: Antihypertensive Agents; Blood Pressure; Female; Humans; Hydralazine; Hypertension; Labetalol; Nicar | 2022 |
Identifying Targets to Improve the Management of Severe Hypertension in Pregnancy and Postpartum.
Topics: Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Hypertension, Pregnancy-Induc | 2023 |
A Giant Pheochromocytoma Presenting in Pheochromocytoma Crisis: A Case Report.
Topics: Adrenal Gland Neoplasms; Antihypertensive Agents; Female; Humans; Hypertension; Labetalol; Middle Ag | 2023 |
Critical commentary on labetalol and nifedipine use in postpartum hypertension management.
Topics: Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Hypertension, Pregnancy-Induc | 2023 |
Reply to 'Critical commentary on labetalol and nifedipine use in postpartum hypertension management'.
Topics: Antihypertensive Agents; Female; Humans; Hypertension; Labetalol; Nifedipine; Postpartum Period | 2023 |
Comparison of efficacy of intravenous labetalol and intravenous hydralazine for management of pre-eclampsia in pregnant women.
Topics: Antihypertensive Agents; Blood Pressure; Female; Humans; Hydralazine; Hypertension; Hypotension; Lab | 2023 |
Comparison of outcomes following intravenous magnesium compared with intravenous labetalol and oral nifedipine in 355 pregnant Han Chinese women with preeclampsia.
Topics: Antihypertensive Agents; Blood Pressure; East Asian People; Female; Humans; Hypertension; Infant, Ne | 2023 |
Improving the use of intravenous antihypertensive medications in the hospital setting: a quality improvement initiative for patient safety.
Topics: Administration, Intravenous; Antihypertensive Agents; Enalapril; Female; Health Personnel; Hospitals | 2019 |
Delay to Tissue Plasminogen Activator in Hypertensive Stroke Patients: An Analysis of Delay Duration Across Agents.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Drug Administration Schedule; Female; Fibrinolytic Ag | 2020 |
Identification of factors associated with delayed treatment of obstetric hypertensive emergencies.
Topics: Administration, Intravenous; Administration, Oral; Adult; After-Hours Care; Antihypertensive Agents; | 2020 |
Labetalol Infusion Attenuates Paradoxical Hypertension and Decreases Plasma Renin Activity After Repair of Coarctation of the Aorta in Children.
Topics: Aortic Coarctation; Blood Pressure; Child; Child, Preschool; Humans; Hypertension; Labetalol; Plasma | 2020 |
Clinical Experiences of Intravenous Hydralazine and Labetalol for Acute Treatment of Severe Hypertension in Pregnant Thai Women.
Topics: Administration, Intravenous; Adult; Antihypertensive Agents; Apgar Score; Asian People; Blood Pressu | 2020 |
Coarctation of the aorta: a rare cause of severe hypertension in pregnancy.
Topics: Adolescent; Antihypertensive Agents; Aortic Coarctation; Computed Tomography Angiography; Electrocar | 2020 |
Retrospective evaluation of labetalol as antihypertensive agent in dogs.
Topics: Adrenalectomy; Animals; Antihypertensive Agents; Craniotomy; Dogs; Heart Rate; Hypertension; Intraop | 2020 |
Labetalol Infusion Controls Paradoxical Hypertension and Decreases Plasma Renin Activity Following Repair of Coarctation of the Aorta in Children.
Topics: Aortic Coarctation; Blood Pressure; Child; Humans; Hypertension; Labetalol; Plasma; Renin | 2020 |
In response.
Topics: Aortic Coarctation; Child; Humans; Hypertension; Labetalol; Plasma; Renin | 2020 |
Recycle: Do It for the Kids.
Topics: Aortic Coarctation; Child; Humans; Hypertension; Labetalol; Plasma; Renin | 2020 |
Efficacy and Safety of Intravenous Labetalol in Acute Hypertensive Crisis in Children.
Topics: Administration, Intravenous; Antihypertensive Agents; Blood Pressure; Child; Humans; Hypertension; L | 2022 |
Blood Pressure Control in Acute Stroke: Labetalol or Nicardipine?
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pre | 2021 |
Committee Opinion No. 692 Summary: Emergent Therapy for Acute-Onset, Severe Hypertension During Pregnancy and the Postpartum Period.
Topics: Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Drug Administration Routes; E | 2017 |
Committee Opinion No. 692: Emergent Therapy for Acute-Onset, Severe Hypertension During Pregnancy and the Postpartum Period.
Topics: Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Drug Administration Routes; E | 2017 |
A case of paradoxical presentation of a postural postdural puncture headache after combined spinal-epidural anesthesia.
Topics: Acetaminophen; Adult; Analgesics, Opioid; Anesthesia, Epidural; Anesthesia, Obstetrical; Anesthesia, | 2017 |
β-Blocker Exposure in Pregnancy and Risk of Fetal Cardiac Anomalies.
Topics: Adrenergic beta-Antagonists; Age Factors; Arrhythmias, Cardiac; Atenolol; Body Mass Index; Californi | 2017 |
Labetalol Use Is Associated With Increased In-Hospital Infection Compared With Nicardipine Use in Intracerebral Hemorrhage.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Cerebral Hemorrhage; Cross Infect | 2017 |
Response & Side Effects of Injectable Labetalol in Pregnancy Induced Severe Hypertension.
Topics: Antihypertensive Agents; Bangladesh; Blood Pressure; Female; Humans; Hypertension; Hypertension, Pre | 2017 |
Continuous-Infusion Labetalol vs Nicardipine for Hypertension Management in Stroke Patients.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Calci | 2018 |
Retrospective review of the use of as-needed hydralazine and labetalol for the treatment of acute hypertension in hospitalized medicine patients.
Topics: Acute Disease; Administration, Intravenous; Administration, Oral; Adrenergic Antagonists; Adult; Age | 2018 |
Management of Hypertension on the Labor and Delivery Unit: Delivering Care in the Era of Protocols and Algorithms.
Topics: Algorithms; Antihypertensive Agents; Delivery Rooms; Delivery, Obstetric; Female; Guideline Adherenc | 2018 |
Without Warning: Scleroderma Renal Crisis.
Topics: Acute Kidney Injury; Amlodipine; Antihypertensive Agents; Humans; Hypertension; Labetalol; Lisinopri | 2019 |
Nicardipine Associated Risk of Short-Term Mortality in Critically Ill Patients with Ischemic Stroke.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Brain Ischemia; Critical Illness; Databases, Factual; | 2019 |
Safety of high-dose intravenous labetalol in hypertensive crisis.
Topics: Administration, Intravenous; Adult; Aged; Antihypertensive Agents; Blood Pressure; Bradycardia; Dose | 2019 |
Reducing Unnecessary Treatment of Asymptomatic Elevated Blood Pressure with Intravenous Medications on the General Internal Medicine Wards: A Quality Improvement Initiative.
Topics: Administration, Intravenous; Antihypertensive Agents; Blood Pressure; Female; Hospitalization; Hospi | 2019 |
Assess Before Rx: Reducing the Overtreatment of Asymptomatic Blood Pressure Elevation in the Inpatient Setting.
Topics: Administration, Intravenous; Antihypertensive Agents; Blood Pressure; Electronic Health Records; Fem | 2019 |
Hypertensive Urgency: An Undesirable Complication of a "Male Performance" Herbal Product.
Topics: Antihypertensive Agents; Blood Pressure; Clonidine; Dietary Supplements; Electrocardiography; Emerge | 2019 |
Juxtaglomerular Cell Tumor: A Rare, Curable Cause of Hypertension in a Young Patient.
Topics: Adult; Antihypertensive Agents; Diagnosis, Differential; Drug Resistance; Female; Humans; Hypertensi | 2019 |
Oral regimen management of acute hypertension in pregnancy.
Topics: Antihypertensive Agents; Female; Humans; Hypertension; Labetalol; Methyldopa; Nifedipine; Pregnancy; | 2019 |
Outpatient calcium-channel blockers and the risk of postpartum haemorrhage: a cohort study.
Topics: Adolescent; Adult; Antihypertensive Agents; Calcium Channel Blockers; Cohort Studies; Female; Humans | 2013 |
Trends in using beta-blockers and methyldopa for hypertensive disorders during pregnancy in a Canadian population.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Female; Humans; Hypertension; Hypertens | 2013 |
Cerebral hyperperfusion syndrome after endovascular reconstruction of carotid artery in high-flow carotid-jugular fistula.
Topics: Adult; Angiography, Digital Subtraction; Antihypertensive Agents; Arteriovenous Fistula; Carotid Art | 2014 |
Hypertension during intravenous immune globulin infusion for Kawasaki's disease: an underreported phenomenon?
Topics: Antihypertensive Agents; Child, Preschool; Female; Humans; Hypertension; Immunoglobulins, Intravenou | 2015 |
Hypertensive urgency: an important aetiology of rebound hypertension.
Topics: Adrenergic alpha-2 Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Clonidine; Emergen | 2014 |
Labetalol for hypertension during pregnancy and nipple pain.
Topics: Adult; Antihypertensive Agents; Female; Humans; Hypertension; Labetalol; Nipples; Pain; Pregnancy; P | 2014 |
The benefits/risks of treatment of non-severe hypertension in pregnancy and choice of drug remain unanswered.
Topics: Antihypertensive Agents; Female; Humans; Hypertension; Labetalol; Methyldopa; Pregnancy; Risk Assess | 2016 |
Use of enoximone in management of anaphylaxis complicated by labetalol use.
Topics: Adult; Anaphylaxis; Antihypertensive Agents; Diagnosis, Differential; Enoximone; Female; Humans; Hyp | 2015 |
Time to Blood Pressure Control Before Thrombolytic Therapy in Patients With Acute Ischemic Stroke: Comparison of Labetalol, Nicardipine, and Hydralazine.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Brain Ischemia; Female; Fib | 2015 |
Fulminant antenatal pulmonary oedema in a woman with hypertension and superimposed preeclampsia.
Topics: Adult; Antihypertensive Agents; Cesarean Section; Female; Follow-Up Studies; Humans; Hypertension; L | 2015 |
Posterior reversible encephalopathy syndrome complicating diabetic ketoacidosis; an important treatable complication.
Topics: Adolescent; Blindness, Cortical; Brain Edema; Diabetic Ketoacidosis; Electrolytes; Female; Fluid The | 2017 |
Intravenous labetolol in treating hypertensive crisis following dexmedetomidine infusion for procedural sedation.
Topics: Adrenergic alpha-2 Receptor Agonists; Adult; Antihypertensive Agents; Conscious Sedation; Dexmedetom | 2016 |
A case of posterior reversible encephalopathy syndrome.
Topics: Aged; Antihypertensive Agents; Female; Humans; Hypertension; Kidney Failure, Chronic; Labetalol; Pos | 2016 |
Late Pregnancy β Blocker Exposure and Risks of Neonatal Hypoglycemia and Bradycardia.
Topics: Adrenergic beta-Antagonists; Atenolol; Bradycardia; Cohort Studies; Female; Humans; Hypertension; Hy | 2016 |
Acute Toxicity from Topical Cocaine for Epistaxis: Treatment with Labetalol.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Analgesics; Cocaine; Emergency Service, Hospit | 2017 |
Longitudinal hemodynamics in acute phase of treatment with labetalol in hypertensive pregnant women to predict need for vasodilatory therapy.
Topics: Drug Therapy, Combination; Female; Hemodynamics; Humans; Hypertension; Infant, Low Birth Weight; Inf | 2017 |
Glucagon-induced hypertensive emergency: a case report.
Topics: Antihypertensive Agents; Emergencies; Female; Gastrointestinal Agents; Glucagon; Humans; Hydralazine | 2016 |
Controversies Regarding Diagnosis and Treatment of Severe Hypertension in Pregnancy.
Topics: Antihypertensive Agents; Blood Pressure; Female; Humans; Hydralazine; Hypertension; Labetalol; Pre-E | 2017 |
Postpartum preeclampsia: emergency department presentation and management.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Anticonvulsants; Antihypertensive Agents; Benzodiazepines; E | 2011 |
Blood pressure in acute stroke: lower it or let the CHHIPS fall where they will.
Topics: Acute Disease; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Humans; Hypertensi | 2009 |
Catecholamine-secreting neuroblastoma in a 4-month-old infant: perioperative management.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Catecholamines; Female; Humans; Hypertens | 2009 |
[Anesthesia for the surgical removal of bilateral pheochromocytomas during the second trimester of pregnancy].
Topics: Adrenal Gland Neoplasms; Adrenergic alpha-Antagonists; Adult; Anesthesia, Epidural; Anesthesia, Gene | 2009 |
Placental and fetal hemodynamics after labetalol or pindolol in a sheep model of increased placental vascular resistance and maternal hypertension.
Topics: Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Disease Models, Anima | 2009 |
Meticulous blood pressure control is mandatory for symptomatic primitive trigeminal artery.
Topics: Antihypertensive Agents; Basilar Artery; Female; Humans; Hypertension; Labetalol; Middle Aged; Ophth | 2009 |
Treatment of hypertension in the inpatient setting: use of intravenous labetalol and hydralazine.
Topics: Adult; Aged; Antihypertensive Agents; Female; Hospitalization; Humans; Hydralazine; Hypertension; In | 2010 |
Intravenous labetalol is available in Australia.
Topics: Antihypertensive Agents; Humans; Hypertension; Injections, Intravenous; Labetalol | 2010 |
Safety and efficacy of intravenous labetalol for hypertensive crisis in infants and small children.
Topics: Analysis of Variance; Antihypertensive Agents; Chi-Square Distribution; Female; Humans; Hypertension | 2011 |
[Pregnancy and advanced chronic kidney disease].
Topics: Ductus Arteriosus, Patent; Epilepsy; Female; Fetal Growth Retardation; Humans; Hyaline Membrane Dise | 2010 |
Neurocognitive development of children following in-utero exposure to labetalol for maternal hypertension: a cohort study using a prospectively collected database.
Topics: Adult; Analysis of Variance; Child; Child Development; Child, Preschool; Databases, Factual; Female; | 2010 |
Postoperative blindness associated with posterior reversible encephalopathy syndrome: a case report.
Topics: Adrenergic beta-Antagonists; Adult; Blindness; Brain Diseases; Brain Ischemia; Diagnosis, Differenti | 2010 |
Similar renoprotection after renin-angiotensin-dependent and -independent antihypertensive therapy in 5/6-nephrectomized Ren-2 transgenic rats: are there blood pressure-independent effects?
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2010 |
[HTA-pre-eclampsia-postpartum haemolytic-uraemic syndrome: good results can be achieved].
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Anti-Inflammatory Agents; Antihypertensive Agents; C | 2010 |
Dutch guideline for the management of hypertensive crisis -- 2010 revision.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calc | 2011 |
Severe circadian hypertension in a young man.
Topics: Amlodipine; Angioplasty, Balloon; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Ci | 2011 |
Cardiovascular collapse after labetalol for hypertensive crisis in an undiagnosed pheochromocytoma during cesarean section.
Topics: Adrenal Gland Neoplasms; Adrenergic beta-Antagonists; Adult; Cesarean Section; Female; Humans; Hyper | 2011 |
False-positive amphetamine toxicology screen results in three pregnant women using labetalol.
Topics: Amphetamine; Amphetamine-Related Disorders; Antihypertensive Agents; False Positive Reactions; Femal | 2011 |
Retrospective evaluation of nicardipine versus labetalol for blood pressure control in aneurysmal subarachnoid hemorrhage.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Critical Care; Female; Humans; Hypertension; L | 2012 |
Multiple cerebral infarctions related to famotidine-induced eosinophilia.
Topics: Acarbose; Adrenergic alpha-1 Receptor Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulc | 2012 |
Effectiveness and safety of nicardipine and labetalol infusion for blood pressure management in patients with intracerebral and subarachnoid hemorrhage.
Topics: Adult; Aged; Antihypertensive Agents; Cerebral Hemorrhage; Cohort Studies; Drug Therapy, Combination | 2013 |
Is labetalol really a culprit in neonatal hypoglycaemia?
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Female; Humans; Hypertension; Hypoglycemia; In | 2013 |
Raynaud's phenomenon of the nipple associated with labetalol use.
Topics: Adult; Antihypertensive Agents; Female; Humans; Hypertension; Labetalol; Nipples; Pregnancy; Raynaud | 2013 |
48-year-old man with cough and leg swelling.
Topics: Acute Disease; Antihypertensive Agents; Cerebrovascular Circulation; Cough; Dyspnea; Echocardiograph | 2012 |
Labetalol decreases cerebral perfusion pressure without negatively affecting cerebral blood flow in hypertensive gravidas.
Topics: Adult; Analysis of Variance; Antihypertensive Agents; Blood Flow Velocity; Cerebrovascular Circulati | 2002 |
Scleroderma renal crisis sine scleroderma during pregnancy.
Topics: Adult; Antihypertensive Agents; Arteries; Captopril; Drug Therapy, Combination; Female; Humans; Hype | 2003 |
Left ventricular diastolic function in pregnancy-induced hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Diastole; Echocardiography, Doppler; Female; Humans; Hypertensio | 2003 |
Autonomic dysreflexia manifested by severe hypertension.
Topics: Adult; Antihypertensive Agents; Autonomic Dysreflexia; Blood Pressure; Drainage; Humans; Hypertensio | 2004 |
Administering antihypertensive drugs after acute ischemic stroke: timing is everything.
Topics: Acute Disease; Antihypertensive Agents; Brain; Brain Ischemia; Cerebrovascular Circulation; Homeosta | 2005 |
Renal cell carcinoma presenting as hypertension in pregnancy.
Topics: Adult; Antihypertensive Agents; Body Mass Index; Carcinoma, Renal Cell; Diagnosis, Differential; Fem | 2004 |
[Pregnancy and hypertension].
Topics: Adult; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Cesarean Section; Diagnosis, | 2005 |
Hypertensive crisis with optic disc edema and cerebral white matter lesions.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Female; Humans; Hypertension; Labetalol; Magne | 2005 |
Inadvertent intrathecal injection of labetalol in a patient undergoing post-partum tubal ligation.
Topics: Adult; Analgesia, Obstetrical; Anesthesia, Spinal; Anesthetics, Local; Antihypertensive Agents; Bupi | 2005 |
Paroxysmal sympathetic storm.
Topics: Adrenergic beta-Antagonists; Adult; Analgesics, Opioid; Brain Injuries; Fever; Heart Arrest; Humans; | 2005 |
Hypertensive emergencies.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Clonidine; Diuretics; | 2006 |
An unusual presentation of a pheochromocytoma.
Topics: Adrenal Gland Neoplasms; Humans; Hypertension; Labetalol; Male; Middle Aged; Pheochromocytoma | 2006 |
An odd case of hypertension.
Topics: Adrenal Cortex Hormones; Adult; Antihypertensive Agents; Cyclophosphamide; Female; Humans; Hypertens | 2006 |
Hepatocellular necrosis associated with labetalol.
Topics: Antihypertensive Agents; Chemical and Drug Induced Liver Injury; Chemical and Drug Induced Liver Inj | 2007 |
A comparison of nicardipine and labetalol for acute hypertension management following stroke.
Topics: Acute Disease; Aged; Antihypertensive Agents; APACHE; Blood Pressure; Brain Ischemia; Cerebral Hemor | 2008 |
Severe labetalol overdose in an 8-month-old infant.
Topics: Antihypertensive Agents; Aortic Coarctation; Female; Humans; Hypertension; Infant; Labetalol; Medica | 2008 |
Adrenergic crisis after penile epinephrine injection for priapism.
Topics: Adrenergic beta-Antagonists; Adult; Epinephrine; Humans; Hypertension; Labetalol; Male; Nitroglyceri | 2009 |
Undulating blood pressure.
Topics: Adrenal Gland Neoplasms; Adrenal Glands; Adrenalectomy; Antihypertensive Agents; Blood Pressure; Fem | 2008 |
Detection of some antihypertensive drugs and their metabolites in urine by thin-layer chromatography: II. A further five beta blockers and dihydralazine.
Topics: Adrenergic beta-Antagonists; Alprenolol; Atenolol; Chromatography, Thin Layer; Dihydralazine; Humans | 1980 |
Anti-mitochondrial antibodies associated with labetalol.
Topics: Adult; Autoantibodies; Ethanolamines; Female; Humans; Hypertension; Labetalol; Male; Middle Aged; Mi | 1980 |
beta-Blockers, autoimmunity, and rashes.
Topics: Autoantibodies; Ethanolamines; Female; Humans; Hypertension; Labetalol; Lichen Planus; Middle Aged; | 1980 |
[Hypertensive emergencies: clinical evaluation of the use of a new drug: labetalol hydrochloride].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Drug Evalu | 1980 |
[Exogenous adrenergic stimulation by intravenous infusions of isoproterenol and blood levels of cyclic AMP before and after beta-blocking in humans].
Topics: Adrenergic beta-Antagonists; Adult; Cyclic AMP; Cyclic GMP; Ethanolamines; Female; Humans; Hypertens | 1980 |
Labetalol therapy in patients with systemic hypertension and angina pectoris: effects of combined alpha and beta adrenoceptor blockade.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Angina Pectoris; Echocardiography; | 1981 |
Failure of anti-hypertensive drugs to control blood pressure rise with isometric exercise in hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Blood Pressure; Diuretics; Drug Therapy | 1981 |
[Drug therapy for arterial hypertension].
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Diuretics; Humans; Hypertension; Labetalol; Va | 1982 |
[Therapeutic effect of trandat, an alpha- and beta-adrenergic receptor blockader, and its effect on central, regional and intracardiac hemodynamics].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Drug Evaluation; Echocardiography; | 1982 |
Labetalol in the preoperative management of phaeochromocytoma.
Topics: Adrenal Gland Neoplasms; Adrenergic alpha-Antagonists; Blood Pressure; Dopamine; Epinephrine; Ethano | 1982 |
Hemodynamic effects of antihypertensive agents.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Antihypertensive Agent | 1983 |
Antihypertensive actions of an isomer of labetalol and other vasodilator-beta-adrenoceptor blockers.
Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Dogs; Ethanolamines; Female; Heart Rate; Hexam | 1983 |
Alpha-adrenoceptor blockade by labetalol during long-term dosing.
Topics: Adrenergic alpha-Antagonists; Adult; Blood Pressure; Dose-Response Relationship, Drug; Ethanolamines | 1983 |
Beta-blockers for pregnancy hypertension.
Topics: Adrenergic beta-Antagonists; Atenolol; Female; Humans; Hypertension; Labetalol; Pregnancy; Pregnancy | 1983 |
Alpha-blockers and converting enzyme inhibitors.
Topics: Adrenergic alpha-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Heart Failure; Hu | 1983 |
[Clinico-experimental study of the new antihypertensive preparation abletol (labetalol)].
Topics: Adrenergic beta-Antagonists; Animals; Calcium; Ethanolamines; Female; Heart; Hemodynamics; Humans; H | 1983 |
Labetalol: an alpha- and beta-adrenoceptor blocking drug.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Ethanolamines; Humans; Hypertension; Labe | 1983 |
Pharmacologic and physiologic considerations of adrenoceptor blockade.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Pressure; Cardiac Output; Hemodynamics; | 1983 |
Which beta-blocker in pregnancy-induced hypertension?
Topics: Atenolol; Birth Weight; Ethanolamines; Female; Humans; Hypertension; Infant, Newborn; Labetalol; Pre | 1983 |
Raynaud's phenomenon caused by beta-receptor blocking drugs. Improvement after treatment with a combined alpha- and beta-blocker.
Topics: Adrenergic beta-Antagonists; Adult; Antibodies, Antinuclear; Ethanolamines; Female; Hemodynamics; Hu | 1984 |
Labetalol for hypertension.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Drug Interactions; Ethanolamines; Humans; | 1984 |
Effects of the R, R-isomer of labetalol, SCH 19927, in isolated tissues and in spontaneously hypertensive rats during a repeated treatment.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Aorta, Thoracic; Blood Pressure; | 1984 |
Combined labetalol plus flunarizine treatment for arterial hypertension.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Calcium Chan | 1984 |
[Treatment of arterial hypertension in pregnancy with an alpha-beta blocker. 58 Cases treated with labetalol].
Topics: Adrenergic beta-Antagonists; Adult; Ethanolamines; Female; Fetal Diseases; Humans; Hypertension; Hyp | 1984 |
Use of vecuronium and labetalol in patients with phaeochromocytoma.
Topics: Adrenal Gland Neoplasms; Adult; Anesthesia; Humans; Hypertension; Jaw Fractures; Labetalol; Male; Pa | 1984 |
Combined alpha- and beta-adrenergic blockade in the treatment of hypertension: myth or reality? Workshop held in Corsendonck (Belgium) on February 28, 1981.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Congresses as Topic; Ethanolamin | 1981 |
Labetalol and 24-hour monitoring of arterial blood pressure in hypertensive patients.
Topics: Blood Pressure; Ethanolamines; Heart Rate; Humans; Hypertension; Labetalol; Time Factors | 1981 |
Effects of labetalol on left ventricular mass and function in hypertension--an assessment by serial echocardiography.
Topics: Adult; Cardiomegaly; Echocardiography; Ethanolamines; Female; Heart; Humans; Hypertension; Labetalol | 1984 |
Labetalol: potent antihypertensive agent that blocks both alpha- and beta-adrenergic receptors.
Topics: Adult; Blood Pressure; Ethanolamines; Female; Humans; Hypertension; Labetalol; Male; Middle Aged; Re | 1980 |
[Forum on hypertension. Part 5. New anti-hypertensive agents in the therapy of hypertension].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Diuretics; Enzyme Inhi | 1981 |
Use of labetalol in hypertensive patients during discontinuation of clonidine therapy.
Topics: Adult; Blood Pressure; Catecholamines; Clonidine; Cyclic AMP; Ethanolamines; Female; Humans; Hyperte | 1981 |
Sympathetic nervous activity and the pressor effect of noradrenaline under chronic alpha-beta-adrenoceptor blockade with labetalol in hypertension.
Topics: Adult; Blood Pressure; Chronic Disease; Dose-Response Relationship, Drug; Drug Interactions; Ethanol | 1983 |
[Treatment of hypertension with the alpha- and beta-adrenergic blockader trandat].
Topics: Adult; Ethanolamines; Hemodynamics; Humans; Hypertension; Labetalol; Middle Aged; Receptors, Adrener | 1983 |
Pharmacology of labetalol in experimental animals.
Topics: Animals; Blood Pressure; Catecholamines; Dogs; Ethanolamines; Guinea Pigs; Heart Conduction System; | 1983 |
Renin and aldosterone concentrations in pregnant essential hypertensives - a prospective study.
Topics: Adult; Aldosterone; Female; Humans; Hypertension; Labetalol; Methyldopa; Potassium; Pregnancy; Pregn | 1983 |
[Clinical pharmacology of the newer antihypertensive agents].
Topics: Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Captopril; Guanfacine; Guanidines | 1983 |
[Evaluation of the efficacy of various hypotensive drugs in broad-breasted white turkeys as an experimental model of arterial hypertension with high catecholamine levels].
Topics: Animals; Antihypertensive Agents; Captopril; Catecholamines; Disease Models, Animal; Furosemide; Hyp | 1983 |
[Comparative effects of an alpha 1 and beta 1-2 blocker (labetalol) and a beta-1 blocker (atenolol) in the hypertensive patient].
Topics: Adult; Atenolol; Blood Pressure; Ethanolamines; Female; Heart Rate; Hemodynamics; Humans; Hypertensi | 1983 |
[New aspects in the therapy of pregnancy-induced hypertension].
Topics: Anesthesia, Epidural; Epoprostenol; Female; Fenoterol; Humans; Hypertension; Labetalol; Metoprolol; | 1983 |
Relationships between plasma catecholamines, renin, age and blood pressure in essential hypertension.
Topics: Adult; Age Factors; Aged; Blood Pressure; Epinephrine; Female; Humans; Hypertension; Labetalol; Male | 1983 |
Acute effect of labetalol on blood pressure in relation to the sympathetic nervous system and plasma renin activity.
Topics: Blood Pressure; Catecholamines; Ethanolamines; Female; Humans; Hypertension; Labetalol; Male; Middle | 1984 |
[Labetalol and guanfacine in the treatment of arterial hypertension in patients with chronic renal failure].
Topics: Adolescent; Adult; Antihypertensive Agents; Drug Therapy, Combination; Ethanolamines; Female; Guanfa | 1984 |
Alternative mechanisms for the hypotensive effects of adrenergic blockade.
Topics: Epoprostenol; Ethanolamines; Female; Humans; Hypertension; Labetalol; Pregnancy | 1983 |
Hyperadrenergic syndrome in severe tetanus: extreme rise in catecholamines responsive to labetalol.
Topics: Adrenergic Fibers; Aged; Catecholamines; Ethanolamines; Humans; Hypertension; Labetalol; Male; Nervo | 1984 |
[Clinical use of new antihypertensives].
Topics: Alkaloids; Antihypertensive Agents; Benzylisoquinolines; Captopril; Diazoxide; Diterpenes; Humans; H | 1984 |
[Malignant pheochromocytoma: blood pressure controlled by labetalol].
Topics: Adrenal Gland Neoplasms; Adult; Ethanolamines; Humans; Hypertension; Labetalol; Male; Pheochromocyto | 1984 |
[Labetalol--ergometric and polycardiographic studies].
Topics: Adult; Ethanolamines; Follow-Up Studies; Heart Function Tests; Hemodynamics; Humans; Hypertension; L | 1984 |
Labetalol and phaeochromocytoma.
Topics: Adrenal Gland Neoplasms; Ethanolamines; Female; Humans; Hypertension; Labetalol; Pheochromocytoma | 1984 |
A clinical trial in general practice. Part 1: Report and comments.
Topics: Adult; Clinical Trials as Topic; Ethanolamines; Humans; Hypertension; Labetalol; Middle Aged; Placeb | 1984 |
Labetolol in patients with hypertension and varying degrees of renal impairment.
Topics: Adult; Aged; Ethanolamines; Female; Glomerular Filtration Rate; Humans; Hypertension; Kidney Disease | 1984 |
[Hypertensive response to labetalol in pheochromocytoma].
Topics: Adrenal Cortex Neoplasms; Anesthesia, Intravenous; Ethanolamines; Female; Humans; Hypertension; Labe | 1984 |
Clinical pharmacology of hypertension: amelioration of left ventricular performance by treatment with labetalol.
Topics: Blood Pressure; Ethanolamines; Female; Heart Rate; Hemodynamics; Humans; Hypertension; Labetalol; Ma | 1984 |
[Treatment of arterial hypertension in the pregnant woman with labetalol. A propos of 24 cases].
Topics: Adult; Apgar Score; Birth Weight; Ethanolamines; Female; Fetus; Humans; Hypertension; Infant, Newbor | 1984 |
The effects of beta blockers on exercise capacity and on training response in elderly subjects.
Topics: Aged; Atenolol; Coronary Disease; Ethanolamines; Exercise Test; Female; Humans; Hypertension; Labeta | 1984 |
Labetalol for the treatment of hypertension in pregnancy. Pharmacokinetics and effects on the uteroplacental blood flow.
Topics: Ethanolamines; Female; Humans; Hypertension; Kinetics; Labetalol; Placenta; Pregnancy; Pregnancy Com | 1984 |
Uteroplacental blood flow in pregnancy induced hypertension.
Topics: Blood Flow Velocity; Blood Pressure; Dihydralazine; Female; Fetal Heart; Heart Rate; Humans; Hyperte | 1984 |
[Effects of labetalol on the response of arterial blood pressure to exercise in hypertensive patients].
Topics: Adult; Blood Pressure; Ethanolamines; Exercise Test; Female; Humans; Hypertension; Labetalol; Middle | 1983 |
Side effects of labetalol in newborn infants.
Topics: Ethanolamines; Female; Humans; Hypertension; Infant, Newborn; Infant, Newborn, Diseases; Labetalol; | 1983 |
The response of plasma catecholamines to intravenous labetalol: a comparison with sodium nitroprusside.
Topics: Adult; Blood Pressure; Epinephrine; Ethanolamines; Ferricyanides; Heart Rate; Humans; Hypertension; | 1983 |
Haemodynamic effects of intravenous labetalol in hypertensive patients with obstructive coronary heart disease complicated by acute myocardial infarction of recent origin.
Topics: Adult; Coronary Disease; Ethanolamines; Exercise Test; Female; Hemodynamics; Humans; Hypertension; I | 1983 |
Interaction of clonidine and labetalol in hypertension.
Topics: Adult; Benzothiadiazines; Blood Pressure; Clonidine; Diuretics; Drug Interactions; Ethanolamines; Fe | 1983 |
Short- and long-term (six-year) hemodynamic effects of labetalol in essential hypertension.
Topics: Adult; Aged; Blood Pressure; Cardiac Output; Ethanolamines; Female; Hemodynamics; Humans; Hypertensi | 1983 |
Systemic, pulmonary, and coronary hemodynamic effects of labetalol in hypertensive subjects.
Topics: Adult; Aged; Blood Pressure; Cardiac Output; Ethanolamines; Heart Rate; Hemodynamics; Humans; Hypert | 1983 |
[Use of the alpha- and beta-adrenergic blocker labetalol in hypertensive crises].
Topics: Adult; Aged; Emergencies; Ethanolamines; Female; Humans; Hypertension; Labetalol; Male; Middle Aged | 1983 |
The use of systolic time intervals in the evaluation of antihypertensive treatment with metoprolol, labetalol and prazosin.
Topics: Adult; Aged; Ethanolamines; Female; Humans; Hypertension; Labetalol; Male; Metoprolol; Middle Aged; | 1983 |
Hypertension in pregnancy: evaluation of two beta blockers atenolol and labetalol.
Topics: Adolescent; Adult; Atenolol; Ethanolamines; Female; Fetus; Humans; Hypertension; Infant, Newborn; La | 1983 |
[Effect of 2 beta-blockers on arterial hypertension during pregnancy. Results of a prospective study on 56 pregnant hypertensive women treated with atenolol and labetalol].
Topics: Adolescent; Adult; Atenolol; Delivery, Obstetric; Ethanolamines; Female; Fetal Heart; Fetal Monitori | 1983 |
Use of labetalol during anesthesia for pheochromocytoma removal.
Topics: Adrenal Gland Neoplasms; Aged; Anesthesia; Epinephrine; Ethanolamines; Female; Humans; Hypertension; | 1983 |
Intravenous labetalol in the management of severe hypertension and hypertensive emergencies.
Topics: Adolescent; Adult; Aged; Blood Pressure; Diazoxide; Ethanolamines; Female; Humans; Hypertension; Inj | 1984 |
Evaluation of I.V. labetalol for treatment of posttraumatic hyperdynamic state.
Topics: Adult; Aged; Cardiovascular System; Ethanolamines; Female; Heart Rate; Hemodynamics; Humans; Hyperte | 1984 |
[Effect of labetalol on antipyrine metabolism in the liver].
Topics: Adult; Aged; Antipyrine; Biotransformation; Ethanolamines; Humans; Hypertension; Kinetics; Labetalol | 1984 |
Tetanus: sympathetic overactivity.
Topics: Aged; Hemodynamics; Humans; Hypertension; Labetalol; Male; Sympathetic Nervous System; Tetanus | 1984 |
[Recent antihypertensive agents].
Topics: Antihypertensive Agents; Guanfacine; Guanidines; Humans; Hypertension; Labetalol; Minoxidil; Phenyla | 1982 |
[Adrenergic factors in the hemodynamic adaptation to effort].
Topics: Adaptation, Physiological; Aldosterone; Catecholamines; Hemodynamics; Humans; Hypertension; Labetalo | 1981 |
[Electrophysiologic properties of intravenous labetalol in normotensive and hypertensive patients].
Topics: Electrophysiology; Ethanolamines; Female; Heart; Humans; Hypertension; Injections, Intravenous; Labe | 1981 |
Labetalol-induced toxic myopathy.
Topics: Adult; Creatine Kinase; Ethanolamines; Fructose-Bisphosphate Aldolase; Humans; Hypertension; L-Lacta | 1981 |
Adrenal phaeochromocytoma in familial neurofibromatosis with initial control of hypertension by labetalol.
Topics: Adrenal Gland Neoplasms; Female; Humans; Hypertension; Labetalol; Middle Aged; Neurofibromatosis 1; | 1982 |
Hemodynamic effects of intravenous labetalol in essential hypertension.
Topics: Adult; Drug Evaluation; Ethanolamines; Female; Hemodynamics; Humans; Hypertension; Isometric Contrac | 1983 |
Blood pressure variability at normal and high blood pressure.
Topics: Adolescent; Adult; Aged; Blood Pressure; Blood Pressure Determination; Clonidine; Heart Rate; Humans | 1983 |
Side-effects with long-term labetalol: an open study of 251 patients in a single centre.
Topics: Adult; Aged; Asthma; Ethanolamines; Female; Humans; Hypertension; Hypotension, Orthostatic; Labetalo | 1983 |
Treatment of hypertension with labetalol in neurosurgical practice. Influence of labetalol on cerebral perfusion pressure in dogs without and with intracranial mass lesions.
Topics: Animals; Blood Pressure; Cardiac Output; Cerebrovascular Circulation; Dogs; Ethanolamines; Hypertens | 1983 |
Treatment of hypertension in acute stage of myocardial infarction. Haemodynamic effects of labetalol.
Topics: Adolescent; Adult; Aged; Drug Tolerance; Ethanolamines; Female; Hemodynamics; Humans; Hypertension; | 1983 |
Labetalol disposition and concentration-effect relationships during pregnancy.
Topics: Adolescent; Adult; Blood Pressure; Ethanolamines; Female; Humans; Hypertension; Injections, Intraven | 1983 |
[Changes in water-sodium balance in patients with hypertension subjected to different types of hypotensive therapy].
Topics: Adult; Aged; Aldosterone; Angiotensin I; Chlorthalidone; Extracellular Space; Female; Hemodynamics; | 1983 |
[Hypotensive effect and changes of arterial pressure variability induced by treatment with labetalol in patients with slight and moderate arterial hypertension].
Topics: Blood Pressure; Ethanolamines; Heart Rate; Hemodynamics; Humans; Hypertension; Labetalol | 1983 |
Magnitude and mechanisms of the antihypertensive action of labetalol, including ambulatory assessment.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Ethanolamines; Humans; Hypertension; Isometric Contr | 1983 |
Labetelol as a hypotensive agent compared to other sympatholytic or vasodilator agents.
Topics: Animals; Dose-Response Relationship, Drug; Ethanolamines; Humans; Hypertension; Labetalol; Rats | 1980 |
Treatment of moderate to severe hypertension with labetalol.
Topics: Adolescent; Adult; Blood Pressure; Ethanolamines; Female; Follow-Up Studies; Heart Rate; Humans; Hyp | 1981 |
[Labetalol in ambulatory therapy of hypertension].
Topics: Adult; Aged; Ambulatory Care; Diabetes Mellitus, Type 1; Drug Evaluation; Dyspnea; Ethanolamines; Fe | 1981 |
[Therapy of hypertensive crises with a mono-substance with alpha- and beta-blocking properties (labetalol)].
Topics: Adult; Aged; Ethanolamines; Female; Heart Rate; Humans; Hypertension; Hypertension, Renal; Labetalol | 1981 |
[The use of labetalol in the so-called "post-shock phase" in intensive care patients].
Topics: Adult; Creatinine; Critical Care; Epinephrine; Ethanolamines; Female; Heart Rate; Humans; Hypertensi | 1981 |
[Experiences with Trandate in geriatrics].
Topics: Aged; Aging; Drug Evaluation; Ethanolamines; Female; Humans; Hypertension; Labetalol; Male | 1981 |
[Ergometric control in hypertension treatment with labetalol].
Topics: Bundle-Branch Block; Dose-Response Relationship, Drug; Drug Evaluation; Ejaculation; Ethanolamines; | 1981 |
Labetalol in resistant hypertension.
Topics: Adult; Antihypertensive Agents; Drug Resistance; Drug Therapy, Combination; Ethanolamines; Female; H | 1982 |
Labetalol, a combined alpha- and beta-blocker, in hypertension of pregnancy.
Topics: Adult; Ethanolamines; Female; Hemodynamics; Humans; Hypertension; Labetalol; Placenta; Pregnancy; Pr | 1982 |
Review of long-term treatment with labetalol.
Topics: Adolescent; Adult; Aged; Antibodies, Antinuclear; Blood Pressure; Child; Ethanolamines; Female; Huma | 1982 |
[Essential arterial hypertension. Effects of labetalol on blood pressure and renin-angiotensin system (author's transl)].
Topics: Adult; Angiotensin II; Blood Pressure; Ethanolamines; Female; Heart Rate; Humans; Hypertension; Labe | 1980 |
Plasma catecholamines, renin and aldosterone during combined alpha- and beta- adrenoceptor blockade in patients with severe arterial hypertension.
Topics: Adult; Aged; Aldosterone; Body Weight; Epinephrine; Ethanolamines; Female; Humans; Hypertension; Lab | 1980 |
[Clinical evaluation of labetalol in essential hypertension. Effects of long-term treatment in conditions of rest and stress].
Topics: Adult; Aged; Drug Evaluation; Ethanolamines; Female; Humans; Hypertension; Labetalol; Male; Middle A | 1980 |
[Effects of labetalol, a new alpha- and beta-adrenoreceptor blocking drug, on arterial pressure, renal function and renin activity (author's transl)].
Topics: Adolescent; Adult; Aged; Blood Pressure; Ethanolamines; Female; Humans; Hypertension; Kidney; Kidney | 1980 |
Intravenous labetalol in severe hypertension. Effects on blood pressure, plasma renin activity and catecholamines.
Topics: Adult; Blood Pressure; Catecholamines; Ethanolamines; Female; Humans; Hypertension; Infusions, Paren | 1981 |
Role of the renin-angiotensin and of the adrenergic system in the blood pressure regulation at exercise in normotensive subjects and in hypertensive patients.
Topics: Adaptation, Physiological; Atenolol; Blood Pressure; Brachial Artery; Hemodynamics; Humans; Hyperten | 1981 |
Treatment of severe essential hypertension with labetalol: effect on active and inactive renin.
Topics: Adult; Blood Pressure; Cardiovascular Diseases; Ethanolamines; Female; Heart Rate; Humans; Hypertens | 1981 |
[New hypotensive drugs].
Topics: Antihypertensive Agents; Captopril; Drug Evaluation; Guanfacine; Guanidines; Humans; Hypertension; L | 1981 |
Response of the systemic pulmonary circulation to labetalol at rest and during exercise.
Topics: Adult; Aldosterone; Ethanolamines; Female; Hemodynamics; Humans; Hypertension; Labetalol; Male; Phen | 1982 |
Rapid reduction of blood pressure with acute oral labetalol.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Ethanolamines; Female; Heart Rate; Humans; Hypert | 1982 |
Proceedings of the Third Symposium on Labetalol.
Topics: Ethanolamines; Humans; Hypertension; Labetalol | 1982 |
Alternatives to beta-blockade in therapy of hypertension with angina pectoris: role of nifedipine or of labetalol.
Topics: Angina Pectoris; Blood Pressure; Drug Therapy, Combination; Ethanolamines; Exercise Test; Hemodynami | 1982 |
The use of labetalol in anaesthesia.
Topics: Anesthesia; Blood Pressure; Ethanolamines; Halothane; Heart Rate; Humans; Hypertension; Hypotension, | 1982 |
The evaluation of labetalol in the treatment of hypertension complicating pregnancy.
Topics: Ethanolamines; Female; Fetus; Humans; Hypertension; Kidney; Labetalol; Liver; Milk, Human; Placenta; | 1982 |
Labetalol: the nineteen-eighties.
Topics: Adrenal Gland Neoplasms; Anesthesia; Coronary Disease; Ethanolamines; Female; Humans; Hypertension; | 1982 |
A review of the haemodynamic effects of labetalol in man.
Topics: Blood Pressure; Ethanolamines; Heart Failure; Heart Rate; Hemodynamics; Humans; Hypertension; Labeta | 1982 |
Labetalol steady-state pharmacokinetics in hypertensive patients.
Topics: Adult; Aged; Blood Pressure; Ethanolamines; Female; Humans; Hypertension; Kinetics; Labetalol; Male; | 1982 |
Blood pressure response to labetalol in twice and three times daily administration during a 24-hour period.
Topics: Adult; Blood Pressure; Drug Administration Schedule; Ethanolamines; Female; Heart Rate; Humans; Hype | 1982 |
Labetalol in general practice: a review.
Topics: Blood Pressure; Drug Interactions; Drug Therapy, Combination; Ethanolamines; Family Practice; Heart | 1982 |
The acute and chronic hypotensive effect of labetalol and the relationship with pretreatment plasma noradrenaline levels.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Cardiac Output; Epinephrine; Ethanolamines; Femal | 1982 |
Intravenous labetalol in severe hypertension.
Topics: Administration, Oral; Amiloride; Ethanolamines; Hydrochlorothiazide; Hypertension; Infusions, Parent | 1982 |
Intravenous labetalol in the treatment of severe hypertension.
Topics: Adrenal Gland Neoplasms; Catecholamines; Clonidine; Ethanolamines; Humans; Hypertension; Infusions, | 1982 |
The effect of different antihypertensive therapies on plasma lipids.
Topics: Aged; Bendroflumethiazide; Cholesterol; Ethanolamines; Female; Humans; Hypertension; Labetalol; Lipo | 1982 |
Aortic rigidity and plasma catecholamines in essential hypertensive patients.
Topics: Adult; Aged; Aorta, Thoracic; Blood Pressure; Compliance; Epinephrine; Hemodynamics; Humans; Hyperte | 1982 |
Adrenergic activity in systolic hypertension.
Topics: Aged; Epinephrine; Female; Hemodynamics; Humans; Hypertension; Labetalol; Male; Middle Aged; Norepin | 1982 |
Treatment of severe hypertension with intravenous labetalol.
Topics: Adult; Aging; Dose-Response Relationship, Drug; Ethanolamines; Heart Rate; Humans; Hypertension; Inj | 1982 |
I.v. labetalol in the treatment of hypertension following coronary-artery surgery.
Topics: Aged; Blood Pressure; Ethanolamines; Heart Rate; Humans; Hypertension; Injections, Intravenous; Labe | 1982 |
A study of labetalol, a new alpha- and beta-adrenoceptor blocking agent, in humans.
Topics: Adult; Blood Pressure; Ethanolamines; Heart Rate; Humans; Hypertension; Labetalol; Middle Aged; Post | 1982 |
[Use of labetalol in the treatment of hypertensive crises].
Topics: Ethanolamines; Female; Humans; Hypertension; Infusions, Parenteral; Injections, Intravenous; Labetal | 1982 |
Effect of labetalol on intracranial pressure in dogs with and without intracranial hypertension.
Topics: Animals; Blood Pressure; Cardiac Output; Cerebrovascular Circulation; Dogs; Ethanolamines; Female; H | 1982 |
[Double-blind study against placebo of the efficacy and tolerance of labetalol 400 mg/day in moderate arterial essential hypertension in the adult].
Topics: Adolescent; Adult; Blood Pressure; Double-Blind Method; Ethanolamines; Female; Humans; Hypertension; | 1982 |
[Treatment of arterial hypertension with labetalol. A polycentric study].
Topics: Adult; Aged; Blood Pressure; Ethanolamines; Female; Heart Rate; Humans; Hypertension; Labetalol; Mal | 1982 |
[Effectiveness of antihypertensive treatment with labetalol as compared with the combination of hydralazine and propranolol].
Topics: Adult; Drug Evaluation; Drug Therapy, Combination; Ethanolamines; Female; Humans; Hydralazine; Hyper | 1981 |
Effects of labetalol and methyldopa on renal function.
Topics: Adult; Aged; Double-Blind Method; Ethanolamines; Humans; Hypertension; Inulin; Kidney; Kidney Concen | 1981 |
[Hemodynamic effects of labetalol in patients with acute myocardial infarct and systemic arterial hypertension].
Topics: Adult; Aged; Ethanolamines; Female; Hemodynamics; Humans; Hypertension; Labetalol; Male; Middle Aged | 1981 |
Use of the the combination labetalol plus chlorthalidone in essential arterial hypertension therapy.
Topics: Adult; Aged; Blood Pressure; Chlorthalidone; Drug Therapy, Combination; Ethanolamines; Female; Human | 1981 |
Labetalol infusion for the treatment of hypertension in acute myocardial infarction.
Topics: Adult; Aged; Ethanolamines; Hemodynamics; Humans; Hypertension; Infusions, Parenteral; Labetalol; Ma | 1980 |
Labetalol and renal function.
Topics: Ethanolamines; Humans; Hypertension; Kidney; Kidney Function Tests; Labetalol | 1981 |
Hypertension in general practice: a comparative study of labetalol and metoprolol (+/- prazosin) in general practice.
Topics: Adult; Benzothiadiazines; Diuretics; Ethanolamines; Humans; Hypertension; Labetalol; Metoprolol; Mid | 1981 |
[Antihypertensive effects of labetalol in three types of hypertensive models of rats (author's transl)].
Topics: Animals; Blood Pressure; Disease Models, Animal; Ethanolamines; Female; Heart Rate; Hypertension; La | 1981 |
[Labetalol for the management of hypertensive crises during surgery of cerebral aneurysm; a haemodynamic study (author's transl)].
Topics: Adolescent; Adult; Blood Pressure; Ethanolamines; Heart Rate; Hemodynamics; Humans; Hypertension; Hy | 1981 |
Circulatory and metabolic effects of a combined alpha- and beta-adrenoceptor blocker (labetalol) in hypertension of pregnancy.
Topics: Blood Pressure; Ethanolamines; Female; Heart Rate; Humans; Hypertension; Labetalol; Lipid Metabolism | 1981 |
Blood pressure, body fluid volumes and glomerular filtration rate during treatment with labetalol in essential hypertension.
Topics: Adult; Aged; Blood Pressure; Ethanolamines; Extracellular Space; Female; Glomerular Filtration Rate; | 1981 |
Effects of treatment on circadian rhythms of blood pressure.
Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Circadian Rhythm; Heart Rate; Humans; Hypertensio | 1981 |
[Labetalol in the treatment of resistant hypertension].
Topics: Ethanolamines; Female; Humans; Hypertension; Hypertension, Renal; Labetalol; Male | 1981 |
Effects of combined alpha- and beta-receptor blockade on peripheral circulation in essential hypertension.
Topics: Adult; Blood Pressure; Ethanolamines; Fingers; Humans; Hypertension; Labetalol; Male; Middle Aged; R | 1981 |
[Labetalol in resistant hypertension].
Topics: Ethanolamines; Humans; Hypertension; Labetalol | 1981 |
[Effect of labetalol on the excretion of catecholamines and their metabolites in primary hypertension].
Topics: Adult; Catecholamines; Dose-Response Relationship, Drug; Epinephrine; Ethanolamines; Female; Humans; | 1981 |
[Clinical and polygraphic evaluation of the effects of metoprolol and labetalol in essential arterial hypertension. Comparative study].
Topics: Adult; Ethanolamines; Female; Humans; Hypertension; Labetalol; Male; Metoprolol; Middle Aged; Propan | 1981 |
Clinical pharmacology of the new beta-adrenergic blocking drugs. Part II. Effects of oral labetalol in patients with both angina pectoris and hypertension: a preliminary experience.
Topics: Administration, Oral; Angina Pectoris; Blood Pressure; Ethanolamines; Exercise Test; Heart Rate; Hum | 1980 |
Experience with labetalol in essential hypertension.
Topics: Adult; Blood Pressure; Ethanolamines; Female; Heart Rate; Humans; Hypertension; Labetalol; Male; Mid | 1980 |
Acute and long-term effects of labetalol on systemic and pulmonary haemodynamics in hypertensive patients.
Topics: Administration, Oral; Adult; Ethanolamines; Female; Hemodynamics; Humans; Hypertension; Injections, | 1980 |
Effects of chronic alpha and beta adrenoceptor blockade with labetalol on plasma catecholamines and renal function in hypertension.
Topics: Adult; Aged; Catecholamines; Ethanolamines; Female; Glomerular Filtration Rate; Humans; Hypertension | 1980 |
Minoxidil and labetalol: very effective antihypertensive combination.
Topics: Adult; Drug Therapy, Combination; Ethanolamines; Female; Furosemide; Humans; Hypertension; Labetalol | 1980 |
Use of labetalol in moderate to severe hypertension.
Topics: Benzothiadiazines; Diuretics; Drug Therapy, Combination; Ethanolamines; Female; Humans; Hypertension | 1980 |
Long-term experiences with labetalol.
Topics: Adult; Aged; Ethanolamines; Evaluation Studies as Topic; Female; Humans; Hypertension; Labetalol; Ma | 1980 |
[Acute and chronic respiratory effects of an alpha-beta antagonist with antihypertensive action].
Topics: Aged; Bronchial Spasm; Bronchitis; Ethanolamines; Humans; Hypertension; Labetalol; Lung Diseases, Ob | 1980 |
Labetalol ('trandate') in hypertension: a multicentre study in general practice.
Topics: Adult; Aged; Ethanolamines; Eye Diseases; Female; Humans; Hypertension; Labetalol; Male; Middle Aged | 1980 |
An open comparison of labetalol with previous antihypertensive therapy.
Topics: Adult; Aged; Blood Pressure; Female; Heart Rate; Humans; Hypertension; Labetalol; Male; Middle Aged | 1980 |
Comparison of the effects of propranolol and labetalol on renal haemodynamics at rest and during exercise in essential hypertension.
Topics: Adult; Ethanolamines; Female; Glomerular Filtration Rate; Hemodynamics; Humans; Hypertension; Kidney | 1980 |
Sequential haemodynamic effects of labetalol at rest and during exercise in essential hypertension.
Topics: Blood Pressure; Cardiac Output; Ethanolamines; Female; Heart Rate; Hemodynamics; Humans; Hypertensio | 1980 |
Effect of propranolol and labetalol on renal haemodynamics at rest and during exercise in essential hypertension.
Topics: Blood Pressure; Ethanolamines; Female; Glomerular Filtration Rate; Heart Rate; Humans; Hypertension; | 1980 |
Immediate effects of labetalol on central, splanchnic-hepatic, and forearm haemodynamics during pleasant emotional stress in hypertensive patients.
Topics: Ethanolamines; Female; Forearm; Hemodynamics; Humans; Hypertension; Labetalol; Male; Regional Blood | 1980 |
Effect of labetalol on plasma catecholamines at rest and during increased sympathetic activity.
Topics: Adult; Blood Glucose; Blood Pressure; Epinephrine; Ethanolamines; Female; Heart Rate; Humans; Hypert | 1980 |
Long-term treatment of hypertension with labetalol.
Topics: Adolescent; Adult; Aged; Blood Pressure; Ethanolamines; Female; Humans; Hypertension; Labetalol; Mal | 1980 |
Effects of long-term high-dose labetalol on blood pressure in patients with severe hypertension resistant to previous therapy.
Topics: Blood Pressure; Diuretics; Drug Administration Schedule; Ethanolamines; Female; Humans; Hypertension | 1980 |
The effect of exercise on intra-arterial blood pressure and pulse rate before and during long-term high-dose treatment with labetalol in patients with severe, therapy-resistant hypertension.
Topics: Blood Pressure; Drug Administration Schedule; Ethanolamines; Female; Heart Rate; Humans; Hypertensio | 1980 |
Comparison of labetalol and propranolol in treatment of hypertension.
Topics: Blood Pressure; Ethanolamines; Female; Heart Rate; Humans; Hypertension; Labetalol; Male; Propranolo | 1980 |
Labetalol in inadequately controlled hypertensive patients. A twice-daily oral regimen.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Drug Administration Schedule; Ethanolamines; Fema | 1980 |
[Use of labetalol hydrochloride by continuous infusion in managing the hypertensive state; a clinical case].
Topics: Aorta, Thoracic; Aortic Aneurysm; Aortic Dissection; Electrocardiography; Emergencies; Ethanolamines | 1980 |
Sympathetic hyperreflexia in tetraplegics. The value of systolic time intervals in assessing drug effects.
Topics: Adult; Guanethidine; Humans; Hypertension; Labetalol; Male; Middle Aged; Myocardial Contraction; Phe | 1980 |
Influence of the sympathetic nervous system on aortic compliance.
Topics: Adult; Aged; Aorta; Compliance; Epinephrine; Humans; Hypertension; Labetalol; Middle Aged; Muscle, S | 1980 |
[Long-term therapy with labetalol in medium and high grade arterial hypertension].
Topics: Adult; Ethanolamines; Female; Humans; Hypertension; Labetalol; Male; Middle Aged; Time Factors | 1980 |
[The effect of combined alpha and beta blockade with labetalol on the haemodynamics of stress reaction in hypertensives (author's transl)].
Topics: Adult; Blood Pressure; Cardiac Output; Ethanolamines; Female; Forearm; Heart Rate; Humans; Hypertens | 1980 |
[Treatment of hypertension by labetalol (author's transl)].
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Drug Evaluation; Ethanolamines; Female; Heart | 1980 |
[Acute hemodynamic effect of labetalol in severe hypertension].
Topics: Adult; Dose-Response Relationship, Drug; Ethanolamines; Female; Hemodynamics; Humans; Hypertension; | 1980 |
[Effect of treatment with labetalol on renal function in arterial hypertension secondary to parenchymal nephropathy and in essential arterial hypertension].
Topics: Adult; Chronic Disease; Ethanolamines; Glomerulonephritis; Humans; Hypertension; Hypertension, Renal | 1980 |
Cardiovascular morbidity and ECT.
Topics: Arrhythmias, Cardiac; Cardiovascular Diseases; Comorbidity; Depressive Disorder; Drug Therapy, Combi | 1995 |
Characterization of the adrenoceptor antagonistic and antihypertensive activity of oral amosulalol, a combined alpha- and beta-adrenoceptor antagonist, in hypertensive rats.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Antihypert | 1994 |
Intravenous antihypertensive agents for patients unable to take oral medications.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Calcium Channel Blockers; Enalaprilat; Furosem | 1995 |
Acute hemodynamic and neurohumoral profile of dilevalol in hypertensive patients with ischemic heart disease.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II; Cardiac Catheterization; Dopamine; Epinephrine; F | 1993 |
Interference of MIBG uptake by medication: a case report.
Topics: 3-Iodobenzylguanidine; Adrenal Gland Neoplasms; Contrast Media; Diagnosis, Differential; Drug Intera | 1995 |
Dosage guidelines for pediatric hypertension.
Topics: Child; Diazoxide; Humans; Hypertension; Labetalol | 1995 |
Beta-adrenergic blocking treatment and 24-hour baroreflex sensitivity in essential hypertensive patients.
Topics: Acebutolol; Adrenergic beta-Antagonists; Adult; Baroreflex; Blood Pressure; Circadian Rhythm; Female | 1994 |
Diaspirin crosslinked hemoglobin (DCLHb): control of pressor effect with anti-hypertensive agents.
Topics: Animals; Antihypertensive Agents; Aspirin; Blood Pressure; Blood Substitutes; Hemoglobins; Hypertens | 1994 |
Heart rate and heart rate variability during sleep in small-for-gestational age newborns.
Topics: Basal Metabolism; Birth Weight; Female; Fetal Growth Retardation; Gestational Age; Heart Rate; Human | 1994 |
Acute exercise- and drug-induced potassium shifts during pregnancy.
Topics: Adult; Exercise; Exercise Test; Female; Humans; Hypertension; Labetalol; Potassium; Pregnancy; Refer | 1994 |
Time-dependent efficacy of antihypertensive agents in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Captopril; Circadian Rhythm; Clonidine; Felodipine | 1993 |
Effect of labetalol infusion on uterine and fetal hemodynamics and fetal cardiac function.
Topics: Blood Pressure; Female; Fetal Heart; Hemodynamics; Humans; Hypertension; Infusions, Intravenous; Lab | 1993 |
Dopamine-induced antihypertensive effects and plasma insulin rise are blocked by metoclopramide in labetalol-treated patients.
Topics: Blood Glucose; Blood Pressure; Dopamine; Dopamine Antagonists; Female; Humans; Hypertension; Infusio | 1994 |
Effect of intravenous dopamine on blood pressure and plasma insulin in hypertensive patients.
Topics: Blood Glucose; Blood Pressure; Dopamine; Female; Heart Rate; Humans; Hypertension; Infusions, Intrav | 1993 |
Cardiovascular complications of ECT.
Topics: Cardiovascular Diseases; Depressive Disorder; Electroconvulsive Therapy; Humans; Hypertension; Labet | 1994 |
Labetalol as prophylaxis of cardiovascular instability after cerebral angioma surgery.
Topics: Brain Neoplasms; Epinephrine; Hemangioma; Humans; Hypertension; Labetalol; Norepinephrine; Postopera | 1993 |
Hypertension and thirst outlasting renal vasoconstriction as effects of a brief evaluation of systemic angiotensin II in sheep.
Topics: Angiotensin II; Animals; Blood Pressure; Female; Hypertension; Infusions, Intra-Arterial; Infusions, | 1994 |
Labetalol in hypertension during the third trimester of pregnancy: its antihypertensive effect and pharmacokinetic-dynamic analysis.
Topics: Adult; Apgar Score; Birth Weight; Blood Pressure; Drug Administration Schedule; Female; Gestational | 1993 |
De novo hypertension after liver transplantation.
Topics: Adult; Azathioprine; Cyclosporine; Humans; Hypertension; Immunosuppression Therapy; Labetalol; Liver | 1993 |
Long-term hemodynamic effects at rest and during exercise of newer antihypertensive agents and salt restriction in essential hypertension: review of epanolol, doxazosin, amlodipine, felodipine, diltiazem, lisinopril, dilevalol, carvedilol, and ketanserin.
Topics: Adult; Amlodipine; Antihypertensive Agents; Benzeneacetamides; Carbazoles; Carvedilol; Diet, Sodium- | 1993 |
Effects of labetalol on uterine blood flow and cardiovascular hemodynamics in the hypertensive gravid baboon.
Topics: Animals; Female; Hemodynamics; Hypertension; Iliac Artery; Labetalol; Papio; Pregnancy; Pregnancy Co | 1993 |
Transverse limb deficiency, facial clefting and hypoxic renal damage: an association with treatment of maternal hypertension?
Topics: Abnormalities, Drug-Induced; Adult; Child, Preschool; Facial Bones; Female; Fetal Death; Fetus; Huma | 1995 |
Acute secondary erythermalgia and hypertension in children. Erythermalgia Multidisciplinary Study Group.
Topics: Acute Disease; Adolescent; Alprostadil; Child; Child, Preschool; Erythromelalgia; Female; Humans; Hy | 1995 |
Hypertensive crisis in children.
Topics: Antihypertensive Agents; Emergencies; Enalapril; Humans; Hypertension; Isradipine; Labetalol; Nicard | 1996 |
Phenoxybenzamine placental transfer during the third trimester.
Topics: Adrenal Gland Neoplasms; Adult; Antihypertensive Agents; Female; Fetal Blood; Humans; Hypertension; | 1996 |
Pregnancy-induced hypertension, antihypertensive drugs and the development of fetal behavioural states.
Topics: Antihypertensive Agents; Cohort Studies; Embryo, Mammalian; Embryonic and Fetal Development; Female; | 1998 |
Acute hypertension promotes hemorrhagic transformation in a rabbit embolic stroke model: effect of labetalol.
Topics: Acute Disease; Angiotensin II; Animals; Antihypertensive Agents; Cerebral Hemorrhage; Cerebral Infar | 1998 |
Comparative doses and cost: esmolol versus labetalol during electroconvulsive therapy.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Blood Pressure; Cost Savings; Drug Cost | 1998 |
An unusual toxic reaction to axillary block by mepivacaine with adrenaline.
Topics: Absorption; Aged; Akathisia, Drug-Induced; Anesthetics, Local; Anti-Arrhythmia Agents; Antihypertens | 1998 |
Intrapartum labetalol for the treatment of maternal and fetal thyrotoxicosis.
Topics: Adolescent; Female; Fetal Diseases; Heart Rate, Fetal; Humans; Hypertension; Infant, Newborn; Infant | 1998 |
Outcome of twin pregnancy in a renal transplant recipient treated with tacrolimus.
Topics: Azathioprine; Cesarean Section; Cyclosporine; Fatal Outcome; Female; Graft Rejection; Humans; Hypert | 1999 |
[Use of labetalol in the anesthetic management of pheochromocytoma].
Topics: Adrenal Gland Neoplasms; Adult; Antihypertensive Agents; Carcinoma, Medullary; Humans; Hypertension; | 1999 |
Transplacental distribution of labetalol stereoisomers at delivery.
Topics: Adult; Antihypertensive Agents; Female; Humans; Hypertension; Labetalol; Labor, Obstetric; Maternal- | 1999 |
Autonomic instability and hypertension resulting in subarachnoid haemorrhage in the Guillain-Barré syndrome.
Topics: Antihypertensive Agents; Autonomic Nervous System Diseases; Diagnosis, Differential; Female; Guillai | 1999 |
Stroke precipitated by moderate blood pressure reduction.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Emergency Treatment; Felodipine; Female; Humans; Hyp | 2000 |
Serum leptin concentration in cord blood: relationship to birth weight and gender in pregnancies complicated by pre-eclampsia.
Topics: Adult; Antihypertensive Agents; Birth Weight; Female; Fetal Blood; Gestational Age; Humans; Hyperten | 2000 |
Factor analysis, including antihypertensive medication, of the outcome of pregnancy in pregnancy-associated hypertension.
Topics: Antihypertensive Agents; Apgar Score; Cesarean Section; Comorbidity; Disease Susceptibility; Female; | 2001 |
Rapid preparation of a patient with pheochromocytoma with labetolol and magnesium sulfate.
Topics: Adult; Antihypertensive Agents; Hemodynamics; Humans; Hypertension; Intraoperative Period; Labetalol | 2001 |
Guidelines on high blood pressure in pregnancy give new classifications of disease.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Contra | 2000 |
Acute and chronic hypertensive headache and hypertensive encephalopathy.
Topics: Acute Disease; Antidepressive Agents; Antihypertensive Agents; Anxiety; Arterioles; Cerebral Arterie | 2002 |
Haemodynamic effects of combined alpha- and beta-adrenoreceptor blockade after intravenous labetalol in hypertensive patients at rest and during exercise.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Blood Pressure; Cardiac Output; Et | 1976 |
Combined alpha- and beta-adrenoreceptors blockade with oral labetalol in hypertensive patients with reference to haemodynamic effects at rest and during exercise.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Blood Pressu | 1976 |
Labetalol, a new alpha- and beta-adrenoreceptor blocking agent, in hypertension.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Drug Evaluation; Ethanolamines; Fe | 1976 |
Labetalol, an alpha- and beta-adrenergic blocking drug in the treatment of hypertension.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Blood Pressure; Ethanolamines; Humans; Hy | 1977 |
Labetalol (AH5158), a competitive alpha- and beta-receptor blocking drug, in the management of hypertension.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aldosterone; Angiotensin II; Cloni | 1976 |
Labetalol in the treatment of hypertensive renal patients.
Topics: Adrenergic beta-Antagonists; Adult; Drug Therapy, Combination; Ethanolamines; Female; Humans; Hydral | 1978 |
Beta-blockers in treatment of hypertension.
Topics: Adrenergic beta-Antagonists; Ethanolamines; Humans; Hypertension; Labetalol | 1978 |
Treatment of severe and resistant hypertension.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Clonidine; Diazoxide; Diet, Sodium-Restricted; | 1978 |
Labetolol--combined alpha and beta blockade for hypertension.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Pressure; | 1978 |
Response of the systemic and pulmonary circulation to alpha- and beta-receptor blockade (labetalol) at rest and during exercise in hypertensive patients.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Blood Circulation; Blood Pressure; | 1979 |
Alpha- and beta-receptor blocking drugs in the treatment of hypertension.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Humans; Hypertension; Labetalol; Prazosin | 1979 |
The relationships between the cardiovascular effects, alpha- and beta-adrenoceptor blocking actions and plasma concentration of labetalol in doca hypertensive rats.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Blood Pressure; Depression, Chem | 1979 |
Interdose control of beta-blockade and arterial blood pressure during chronic oral labetalol treatment.
Topics: Adrenergic beta-Antagonists; Adult; Blood Pressure; Drug Administration Schedule; Ethanolamines; Hea | 1979 |
Labetalol in long-term treatment of hypertension.
Topics: Adrenergic Agents; Adrenergic beta-Antagonists; Adult; Aged; Dose-Response Relationship, Drug; Drug | 1976 |
Labetalol in hypertension.
Topics: Drug Evaluation; Ethanolamines; Humans; Hypertension; Labetalol; Receptors, Adrenergic; Receptors, A | 1977 |
Labetalol in hypertension.
Topics: Adolescent; Adrenergic alpha-Antagonists; Antihypertensive Agents; Drug Evaluation; Ethanolamines; F | 1977 |
Labetalol in hypertension.
Topics: Blood Pressure; Ethanolamines; Hypertension; Labetalol | 1977 |
Scalp tingling and difficulty in micturition in patients on labetalol.
Topics: Ethanolamines; Female; Humans; Hyperesthesia; Hypertension; Labetalol; Male; Middle Aged; Scalp; Uri | 1977 |
Labetalol in hypertension.
Topics: Dose-Response Relationship, Drug; Ethanolamines; Female; Humans; Hypertension; Hypotension, Orthosta | 1978 |
Hypertensive response to labetalol in phaeochromocytoma.
Topics: Adrenal Gland Neoplasms; Blood Pressure; Ethanolamines; Female; Humans; Hypertension; Labetalol; Mid | 1978 |
Hypertensive response to labetalol in phaeochromocytoma.
Topics: Adrenal Gland Neoplasms; Ethanolamines; Humans; Hypertension; Labetalol; Pheochromocytoma; Receptors | 1978 |
Intravenous labetalol in hypertensive emergency.
Topics: Adult; Aorta, Thoracic; Aortography; Blood Pressure; Emergencies; Ethanolamines; Humans; Hypertensio | 1979 |
Haemodynamic adaptation at rest and during exercise to long-term antihypertensive treatment with combined alpha- and beta-adrenoreceptor blockade by labetalol.
Topics: Administration, Oral; Ethanolamines; Hemodynamics; Humans; Hypertension; Injections, Intravenous; La | 1979 |
A long-term study of labetalol in general practice.
Topics: Adult; Aged; Blood Pressure; Ethanolamines; Family Practice; Humans; Hypertension; Labetalol; Long-T | 1979 |
[Systolic time intervals in essential hypertension. II. Variations produced by treatment with labetalol].
Topics: Adult; Aged; Ethanolamines; Female; Humans; Hypertension; Labetalol; Male; Middle Aged; Myocardial C | 1979 |
Cutaneous reaction to labetalol.
Topics: Aged; Drug Eruptions; Ethanolamines; Female; Humans; Hypertension; Labetalol | 1978 |
Effects of labetalol on lipid and carbohydrates metabolism.
Topics: Adult; Blood Pressure; Carbohydrate Metabolism; Cholesterol; Ethanolamines; Female; Glucose; Glucose | 1979 |
Effects of labetalol on systemic and pulmonary haemodynamics at rest and during exercise in hypertensive patients.
Topics: Adult; Aldosterone; Ethanolamines; Female; Hemodynamics; Humans; Hypertension; Labetalol; Male; Midd | 1978 |
Hemodynamic long-term effects of labetalol in essential hypertension.
Topics: Administration, Oral; Drug Evaluation; Ethanolamines; Hemodynamics; Humans; Hypertension; Labetalol; | 1979 |
Hemodynamic effects of acute and long-term treatment with labetalol.
Topics: Administration, Oral; Adult; Drug Evaluation; Ethanolamines; Female; Hemodynamics; Humans; Hypertens | 1979 |
Labetalol: bioavailability, drug plasma levels, plasma renin and catecholamines in acute and chronic treatment of resistant hypertension.
Topics: Administration, Oral; Adult; Aged; Biological Availability; Chlorothiazide; Cyclopenthiazide; Dose-R | 1978 |
A pilot trial of labetalol (AH 5158A): a combined alpha and beta blocker in treatment of hypertension.
Topics: Antibodies, Antinuclear; Ethanolamines; Female; Humans; Hypertension; Labetalol; Male; Middle Aged; | 1977 |
Treatment of hypertension with labetalol.
Topics: Adult; Aged; Antibodies, Antinuclear; Ethanolamines; Female; Humans; Hypertension; Labetalol; Male; | 1977 |
Poor hypotensive response and tachyphylaxis following intravenous labetalol.
Topics: Adult; Ethanolamines; Hemodynamics; Humans; Hypertension; Infusions, Parenteral; Injections, Intrave | 1978 |
Treatment of severe hypertension by repeated bolus injections of labetalol.
Topics: Adolescent; Adult; Aged; Angiotensin II; Blood Pressure; Creatinine; Ethanolamines; Female; Humans; | 1979 |
[Effects of labetalol on glucose metabolism in hypertensive subjects].
Topics: Blood Glucose; Drug Evaluation; Ethanolamines; Glucose; Humans; Hypertension; Insulin; Insulin Secre | 1979 |
A new alpha and beta receptor antagonist in general practice.
Topics: Ethanolamines; Family Practice; Humans; Hypertension; Labetalol | 1979 |
Failure of labetalol to prevent hypertension due to clonidine withdrawal.
Topics: Adult; Clonidine; Drug Combinations; Ethanolamines; Female; Humans; Hypertension; Labetalol; Substan | 1979 |
Paroxysmal neurogenic hypertension and its prevention in patients with cervical spinal cord lesions.
Topics: Adult; Blood Pressure; Ethanolamines; Heart Rate; Humans; Hypertension; Labetalol; Middle Aged; Nore | 1979 |
Blood pressure reduction by incremental infusion of labetalol in patients with severe hypertension.
Topics: Adolescent; Adult; Aged; Aldosterone; Angiotensin II; Blood Pressure; Ethanolamines; Female; Heart R | 1979 |
Labetalol and bendrofluazide.
Topics: Bendroflumethiazide; Diuretics; Drug Therapy, Combination; Ethanolamines; Humans; Hypertension; Labe | 1979 |
Left ventricular failure with labetalol.
Topics: Adult; Ethanolamines; Heart Diseases; Heart Failure; Humans; Hypertension; Labetalol; Male | 1979 |
Effect of oral labetalol on plasma catecholamines, renin and aldosterone in patients with severe arterial hypertension.
Topics: Adult; Aged; Aldosterone; Blood Pressure; Body Weight; Catecholamines; Epinephrine; Ethanolamines; F | 1979 |
Comparison of labetalol, clonidine and diazoxide intravenously administered in severe hypertension.
Topics: Adult; Clonidine; Diazoxide; Ethanolamines; Female; Humans; Hypertension; Injections, Intravenous; L | 1979 |
Effect of an alpha- and beta-adrenoceptor-blocking agent (labetalol) on haemodynamics in hypertension.
Topics: Adult; Blood Pressure; Ethanolamines; Heart Rate; Hemodynamics; Humans; Hypertension; Hypertension, | 1979 |
Effect of labetalol on continuous ambulatory blood pressure.
Topics: Adult; Blood Pressure; Dose-Response Relationship, Drug; Electrocardiography; Ethanolamines; Female; | 1979 |
Monotherapy with labetalol for hypertensive patients with normal and impaired renal function.
Topics: Blood Pressure; Creatinine; Dose-Response Relationship, Drug; Ethanolamines; Humans; Hypertension; K | 1979 |
Labetalol in the treatment of patients with hypertension and renal function impairment.
Topics: Adolescent; Adult; Aged; Blood Pressure; Child; Emergencies; Ethanolamines; Female; Glomerular Filtr | 1979 |
Labetalol in the treatment of a patient with phaechromocytoma: a case report.
Topics: Adrenal Gland Neoplasms; Blood Pressure; Child; Ethanolamines; Female; Humans; Hypertension; Injecti | 1979 |
Labetalol in severe and resistant hypertension.
Topics: Adult; Aged; Blood Pressure; Drug Resistance; Ethanolamines; Humans; Hypertension; Labetalol; Middle | 1979 |
Long-term treatment of hypertension with labetalol.
Topics: Adult; Aged; Blood Cell Count; Blood Pressure; Body Weight; Drug Tolerance; Ethanolamines; Female; H | 1979 |
Acute management of severe hypertension with oral labetalol.
Topics: Adult; Aged; Blood Pressure; Ethanolamines; Female; Humans; Hypertension; Labetalol; Male; Middle Ag | 1979 |
Use of labetalol in the treatment of severe hypertension during pregnancy.
Topics: Adolescent; Adult; Amniotic Fluid; Birth Weight; Ethanolamines; Female; Fetal Blood; Humans; Hyperte | 1979 |
Open evaluation of labetalol in the treatment of angina pectoris occurring in hypertensive patients.
Topics: Angina Pectoris; Blood Pressure; Electrocardiography; Ethanolamines; Eye Manifestations; Female; Hea | 1979 |
Labetalol infusion in acute myocardial infarction with systemic hypertension.
Topics: Adult; Electrocardiography; Ethanolamines; Female; Heart Rate; Hemodynamics; Humans; Hypertension; I | 1979 |
Proceedings of the Second Symposium on Labetalol, London, March 1979.
Topics: Ethanolamines; Hemodynamics; Humans; Hypertension; Labetalol | 1979 |
Labetalol, an alpha- and beta-adrenoceptor-blocking agent: its use in therapeutics. A summary of the symposium.
Topics: Administration, Oral; Anesthesia; Angina Pectoris; Catecholamines; Ethanolamines; Female; Hemodynami | 1979 |
Effect of labetalol in hypertension during exercise and postural changes.
Topics: Blood Pressure; Ethanolamines; Female; Heart Rate; Humans; Hypertension; Isometric Contraction; Labe | 1979 |
Increased catecholamine excretion after labetalol therapy: a spurious effect of drug metabolites.
Topics: Catecholamines; Epinephrine; Ethanolamines; Humans; Hypertension; Labetalol; Metanephrine; Norepinep | 1979 |
[Effect of labetalol and chlorthalidone on exercise tolerance in hypertensive subjects].
Topics: Adult; Chlorthalidone; Ethanolamines; Exercise Test; Hemodynamics; Humans; Hypertension; Labetalol; | 1979 |
Treatment of hypertensive emergencies with oral labetalol.
Topics: Administration, Oral; Adult; Aged; Emergencies; Ethanolamines; Female; Humans; Hypertension; Labetal | 1978 |
The effect of labetalol in the treatment of severe drug-resistant hypertension.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Drug Resistance; Drug Therapy, Combination; Ethanolam | 1978 |
Labetalol in hypertensive emergencies.
Topics: Adult; Antihypertensive Agents; Drug Therapy, Combination; Emergencies; Ethanolamines; Female; Human | 1978 |
Treatment of hypertensive emergencies with oral labetalol.
Topics: Brain Diseases; Emergencies; Ethanolamines; Humans; Hypertension; Labetalol; Male; Middle Aged | 1978 |
Labetalol in hypertensive emergencies.
Topics: Adolescent; Adult; Aged; Emergencies; Ethanolamines; Humans; Hypertension; Injections, Intravenous; | 1978 |
Treatment of hypertensive emergencies with oral labetalol.
Topics: Emergencies; Humans; Hypertension; Labetalol | 1978 |
Labetalol in hypertensive emergencies.
Topics: Adolescent; Emergencies; Ethanolamines; Humans; Hypertension; Labetalol; Male; Tetanus | 1978 |
Labetalol for hypertension.
Topics: Ethanolamines; Humans; Hypertension; Hypotension, Orthostatic; Labetalol | 1978 |
Labetalol in the difficult hypertensive patient in general practice.
Topics: Adult; Aged; Blood Pressure; Ethanolamines; Family Practice; Female; Humans; Hypertension; Labetalol | 1978 |
Emergency treatment of severe hypertension with intravenous labetalol.
Topics: Adult; Aged; Angiotensin II; Emergencies; Ethanolamines; Female; Humans; Hypertension; Infusions, Pa | 1978 |
[Hemodynamic study of a new injectable anti-hypertensive: labetalol].
Topics: Adult; Ethanolamines; Hemodynamics; Humans; Hypertension; Injections, Intravenous; Labetalol; Male; | 1978 |
The treatment of hypertension in pregnancy.
Topics: Adolescent; Adult; Anticonvulsants; Antihypertensive Agents; Bethanidine; Eclampsia; Female; Humans; | 1978 |
[Action of labetalol on heart rate, arterial pressure and systolic time intervals at rest and during exercise in hypertensive subjects].
Topics: Adult; Blood Pressure; Ethanolamines; Heart Rate; Humans; Hypertension; Labetalol; Male; Middle Aged | 1978 |
Rate of onset of hypotensive effect of oral labetalol.
Topics: Administration, Oral; Ethanolamines; Female; Humans; Hypertension; Labetalol; Male; Middle Aged; Pla | 1979 |
Haemodynamic effects and plasma concentrations of labetalol during long-term treatment of essential hypertension.
Topics: Adult; Blood Pressure; Cardiac Output; Ethanolamines; Heart Rate; Hemodynamics; Humans; Hypertension | 1979 |
Acute hemodynamic effects of an alpha- and beta-receptor blocking agent (AH 5158) on the systemic and pulmonary circulation at rest and during exercise in hypertensive patients.
Topics: Acid-Base Equilibrium; Adult; Blood Circulation; Blood Pressure; Cardiac Output; Ethanolamines; Fema | 1977 |
Rate of onset of hypotensive response with oral labetalol [proceedings].
Topics: Administration, Oral; Blood Pressure; Ethanolamines; Humans; Hypertension; Labetalol; Time Factors | 1977 |
Pressor response after intravenous labetalol.
Topics: Adult; Drug Therapy, Combination; Ethanolamines; Humans; Hypertension; Injections, Intravenous; Labe | 1977 |
Labetalol in resistant hypertension.
Topics: Adult; Aged; Animals; Blood Pressure; Drug Evaluation; Ethanolamines; Female; Humans; Hypertension; | 1976 |
A study of labetalol in patients of European, West Indian and West African origin.
Topics: Adult; Africa, Western; Aged; Black People; Blood Pressure; Drug Evaluation; Drug Resistance; Ethano | 1976 |
Acute haemodynamic effects of labetalol and its subsequent use of an oral hypotensive agent.
Topics: Administration, Oral; Antihypertensive Agents; Blood Pressure; Cardiac Output; Creatinine; Drug Admi | 1976 |
Acute effect of intravenous labetalol in the treatment of systemic arterial hypertension.
Topics: Acute Disease; Adult; Aged; Blood Pressure; Drug Administration Schedule; Drug Evaluation; Ethanolam | 1976 |
Treatment of phaeochromocytoma and of clonidine withdrawal hypertension with labetalol.
Topics: Administration, Oral; Adult; Clonidine; Drug Evaluation; Ethanolamines; Female; Humans; Hypertension | 1976 |
Anti-hypertensive action, time of onset and effects on carbohydrate metabolism of labetalol.
Topics: Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Carbohydrate Metabolism; Dose-Respo | 1976 |
Letter: Emergency treatment of hypertensive crisis following clonidine withdrawal.
Topics: Clonidine; Humans; Hypertension; Labetalol; Pheochromocytoma; Substance Withdrawal Syndrome | 1976 |
Effects of maternal labetalol on the newborn infant.
Topics: Asphyxia Neonatorum; Female; Fetal Growth Retardation; Humans; Hypertension; Hypoglycemia; Incidence | 1992 |
Effect of oral dilevalol on forearm circulation in essential hypertension.
Topics: Administration, Oral; Antihypertensive Agents; Blood Pressure; Female; Forearm; Heart Rate; Humans; | 1992 |
Regression of left ventricular hypertrophy in "previously untreated" hypertensive blacks after 6 months of blood pressure reduction with alpha- and beta-adrenergic blockade and thiazide therapy.
Topics: Adult; Aged; Black People; Blood Pressure; Cardiomegaly; Drug Therapy, Combination; Echocardiography | 1992 |
Management of hypertensive emergencies.
Topics: Adolescent; Child; Child, Preschool; Diazoxide; Emergencies; Female; Humans; Hydralazine; Hypertensi | 1992 |
"Cardiovascular effects of cocaine".
Topics: Cocaine; Humans; Hypertension; Labetalol; Tachycardia | 1992 |
[Action of labetalol on norepinephrine myocardial content in left ventricular hypertrophy in hypertensive patients].
Topics: 3-Iodobenzylguanidine; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Iodine Radioisot | 1992 |
Transesophageal echocardiographic assessment of left ventricular function in response to labetalol for control of postoperative hypertension.
Topics: Adult; Aged; Anesthesia, Intravenous; Aorta, Abdominal; Blood Pressure; Cardiac Output; Echocardiogr | 1992 |
Labetalol study methodology.
Topics: Dose-Response Relationship, Drug; Humans; Hypertension; Labetalol; Research Design | 1992 |
A case of labetalol-induced hepatitis.
Topics: Adult; Chemical and Drug Induced Liver Injury; Female; Humans; Hypertension; Labetalol; Liver | 1992 |
[Labetalol in the prophylaxis of postoperative arterial hypertension in surgery of the posterior cranial fossa].
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Cranial Fossa, Posterior; Female; Humans; Hypertension; La | 1992 |
Maternal and fetal effects of labetalol in pregnant ewes.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Female; | 1991 |
Acute effects of combined alpha/beta-adrenoceptor blockade v combined beta-receptor and slow channel calcium blockade in ischemic heart disease complicated by hypertension. Hemodynamic and adrenergic responses.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Calcium Channel Blockers; Cardiac Output; | 1991 |
Prevention of cerebral stroke by arotinolol in salt-loaded SHRSP.
Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Brain; Cerebrovascular Disorders; Disease Susc | 1991 |
Intravenously administered labetalol for treatment of hypertension in children.
Topics: Adolescent; Child; Child, Preschool; Creatinine; Diazoxide; Heart Rate; Humans; Hydralazine; Hyperte | 1992 |
Single dose of labetalol in hypertensive pregnancy: effects on maternal hemodynamics and uterine and fetal flow velocity waveforms.
Topics: Adult; Blood Flow Velocity; Blood Pressure; Female; Fetus; Heart Rate; Heart Rate, Fetal; Hemodynami | 1991 |
Maternal and fetal haemodynamics in hypertensive pregnancies during maternal treatment with intravenous hydralazine or labetalol.
Topics: Female; Heart Rate, Fetal; Hemodynamics; Humans; Hydralazine; Hypertension; Labetalol; Pregnancy; Pr | 1991 |
Labetalol and ECT.
Topics: Age Factors; Aged; Coronary Disease; Depressive Disorder; Electroconvulsive Therapy; Humans; Hyperte | 1991 |
Labetalol and esmolol in the control of hypertension after intracranial surgery.
Topics: Adrenergic beta-Antagonists; Anesthesia, General; Brain; Heart Rate; Humans; Hypertension; Labetalol | 1990 |
Hybrid or multifactorial drugs in antihypertensive treatment.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Drug Combination | 1990 |
High costs associated with prolonged labetalol infusions.
Topics: Costs and Cost Analysis; Emergencies; Humans; Hypertension; Infusions, Parenteral; Labetalol | 1991 |
Long-term continuous infusion of labetalol.
Topics: Adult; Humans; Hypertension; Infusions, Intravenous; Labetalol; Male | 1991 |
Coronary vasospasm secondary to labetalol in a patient with aortic dissection.
Topics: Aged; Aorta, Thoracic; Aortic Aneurysm; Aortic Dissection; Coronary Vasospasm; Electrocardiography; | 1991 |
Ineffectiveness of oral labetalol for hypertensive urgency.
Topics: Emergencies; Female; Humans; Hypertension; Labetalol; Male; Middle Aged; Pilot Projects; Prospective | 1990 |
Labetalol and MRI as initial medical and diagnostic modalities in a marfanoid patient with expanding ascending aortic aneurysm.
Topics: Acute Disease; Aorta; Aortic Aneurysm; Aortic Dissection; Humans; Hypertension; Labetalol; Magnetic | 1990 |
Labetalol pharmacokinetics in pregnancy-induced hypertension.
Topics: Adolescent; Adult; Amniotic Fluid; Female; Fetal Blood; Humans; Hypertension; Labetalol; Metabolic C | 1990 |
Prolonged labetalol infusion for management of severe hypertension and tachycardia in a critically ill trauma patient.
Topics: Adult; Blood Pressure; Critical Care; Heart Rate; Humans; Hypertension; Infusions, Intravenous; Labe | 1990 |
Pharmacokinetics and pharmacodynamics of labetalol in elderly and young hypertensive patients following single and multiple doses.
Topics: Administration, Oral; Adult; Age Factors; Aged; Blood Pressure; Drug Administration Schedule; Female | 1990 |
The pharmacokinetics of dilevalol in renal impairment.
Topics: Administration, Oral; Adult; Aged; Female; Glomerular Filtration Rate; Half-Life; Humans; Hypertensi | 1990 |
Hyperkalemia associated with intravenous labetalol therapy for acute hypertension in renal transplant recipients.
Topics: Adult; Humans; Hyperkalemia; Hypertension; Infusions, Intravenous; Kidney Failure, Chronic; Kidney T | 1990 |
Mechanism of smooth muscle contraction: relevance to safety of beta-adrenergic blockade in hypertensive patients with reversible chronic obstructive airways disease.
Topics: Adrenergic beta-Antagonists; Atenolol; Bronchi; Calcium Channel Blockers; Calmodulin; Celiprolol; Cy | 1986 |
Antihypertensive treatment with dilevalol, a new beta-blocking vasodilator. A satellite symposium to the 1987 European Society of Hypertension meeting.
Topics: Animals; Humans; Hypertension; Labetalol; Vasodilator Agents | 1988 |
Hemodynamic effects of labetalol in patients with combined hypertension and left ventricular failure.
Topics: Angiography; Cardiac Output; Exercise Test; Female; Heart Failure; Hemodynamics; Humans; Hypertensio | 1988 |
Intravenous dilevalol in the treatment of severe hypertension.
Topics: Adult; Aged; Blood Pressure; Electrocardiography; Female; Humans; Hypertension; Labetalol; Male; Mid | 1989 |
Hemodynamic and humoral effects of intravenous dilevalol in patients with moderate hypertension.
Topics: Adult; Atrial Natriuretic Factor; Cardiac Output; Epinephrine; Female; Heart Rate; Hemodynamics; Hum | 1989 |
Effects of dilevalol on rest and supine exercise hemodynamics in mild to moderate systemic hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Blood Pressure; Carbon Dioxide; Cardiac Catheterization; Heart R | 1989 |
Effects of dilevalol on forearm circulation in essential hypertension.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adult; Female; Forearm; Hemodynamics; Humans; | 1989 |
[Clinical application of adrenoceptor blockers in the treatment of hypertension].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Humans; Hypertens | 1989 |
Clinical pharmacology of dilevalol (III). A pharmacokinetic study of dilevalol in elderly subjects with essential hypertension.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Blood Pressure; Female; Humans; Hypertension; | 1989 |
Intravenous labetalol for the treatment of hypertension after carotid endarterectomy.
Topics: Adrenergic beta-Antagonists; Aged; Blood Pressure; Calcium Channel Blockers; Clonidine; Endarterecto | 1989 |
Dosages for labetalol.
Topics: Emergencies; Humans; Hypertension; Infusions, Intravenous; Labetalol | 1989 |
[Vascular arterial effect of labetalol evaluated by measuring arterial distensibility during the exercise test].
Topics: Adult; Exercise Test; Female; Humans; Hypertension; Labetalol; Male; Middle Aged; Rest; Time Factors | 1989 |
Effects of age on the elimination of labetalol.
Topics: Adult; Aged; Aging; Female; Humans; Hypertension; Labetalol; Male; Middle Aged | 1989 |
[Treatment of postoperative hypertensive crisis with labetalol: effects on left ventricular function].
Topics: Heart; Heart Ventricles; Humans; Hypertension; Labetalol; Middle Aged; Postoperative Complications | 1989 |
Half-life of maternal labetalol in a premature infant.
Topics: Adult; Female; Half-Life; Humans; Hypertension; Infant, Newborn; Infant, Premature; Labetalol; Male; | 1989 |
Labetalol: time, experience, and adrenergic blockade.
Topics: Coronary Disease; Humans; Hypertension; Intubation, Intratracheal; Labetalol; Postoperative Complica | 1989 |
Prevention of aortic hypertrophy in spontaneously hypertensive turkeys.
Topics: Administration, Oral; Animals; Aorta; Drug Evaluation, Preclinical; Hypertension; Hypertrophy; Labet | 1989 |
A symposium: Antihypertension therapy in the 90s--the role of balanced hemodynamics.
Topics: Humans; Hypertension; Labetalol | 1989 |
Mechanism of antihypertensive action of dilevalol compared with that of "cardioselective" beta-blocking agents.
Topics: Adult; Aged; Atenolol; Female; Heart; Heart Rate; Humans; Hypertension; Labetalol; Male; Metoprolol; | 1989 |
Hemodynamic effects of dilevalol in patients with systemic hypertension and left ventricular dysfunction.
Topics: Aged; Exercise Test; Heart Failure; Heart Rate; Hemodynamics; Humans; Hypertension; Labetalol; Male; | 1989 |
Pharmacokinetics of dilevalol in normotensive and hypertensive volunteers.
Topics: Administration, Oral; Adult; Biological Availability; Drug Administration Schedule; Fasting; Food; H | 1989 |
Effects of dilevalol on renal function.
Topics: Adult; Aged; Female; Glomerular Filtration Rate; Humans; Hypertension; Kidney; Kidney Function Tests | 1989 |
Labetalol reduces iodine-131 MIBG uptake by pheochromocytoma and normal tissues.
Topics: 3-Iodobenzylguanidine; Adolescent; Adrenal Gland Neoplasms; Adult; Aged; Aged, 80 and over; Drug Int | 1989 |
The safety of cumulative doses of labetalol in perioperative hypertension.
Topics: Adult; Cerebrovascular Disorders; Female; Heart Rate; Hemodynamics; Humans; Hypertension; Infusions, | 1989 |
Prolonged continuous infusion labetalol: a new alternative for parenteral antihypertensive therapy.
Topics: Adult; Critical Care; Female; Humans; Hypertension; Infusions, Intravenous; Intensive Care Units; La | 1989 |
Fatal labetalol-induced hepatic injury.
Topics: Chemical and Drug Induced Liver Injury; Female; Humans; Hypertension; Labetalol; Liver Diseases; Mid | 1989 |
Hypertensive and catecholamine response to tracheal intubation in patients with pregnancy-induced hypertension.
Topics: Adult; Blood Pressure; Cesarean Section; Female; Heart Rate; Humans; Hypertension; Intubation, Intra | 1989 |
New approaches for the treatment of hypertensive urgencies and emergencies.
Topics: Antihypertensive Agents; Captopril; Emergencies; Enalapril; Humans; Hypertension; Labetalol; Nifedip | 1988 |
Clinical experience with labetalol and enalapril in combination in patients with severe essential and renovascular hypertension.
Topics: Adolescent; Adult; Aged; Drug Administration Schedule; Drug Therapy, Combination; Enalapril; Female; | 1988 |
[Circadian rise of blood pressure and combined alpha-beta adrenoceptor blockade].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Circadian Rhythm; Cold Temperature; Drug | 1985 |
Beta-adrenergic blocking agents. Effect of chronic dosage on a fit, middle-aged man: a case study and review.
Topics: Adrenergic beta-Antagonists; Atenolol; Energy Metabolism; Ethanolamines; Exercise Test; Hemodynamics | 1985 |
[Hypertension in pregnancy: proposed monitoring and therapy].
Topics: Adrenergic beta-Antagonists; Captopril; Diuretics; Female; Follow-Up Studies; Humans; Hydralazine; H | 1985 |
Current concepts in treatment of hypertensive urgencies.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angiotensin-Co | 1986 |
[Effect of beta-adrenergic blockaders and their combination with an alpha-adrenergic blockader on physical exertion tolerance in patients with hypertension].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Blood Pressure; Drug Therapy, Combination | 1986 |
Antihypertensive therapy with diuretics and beta-blockers at fixed dosage: comparison between the combinations labetalol plus chlorthalidone and atenolol plus chlorthalidone.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Blood Pressure; Chlorthalidone; Diuretics; Drug Therap | 1985 |
Labetalol as monotherapy in hypertensive black patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Black or African American; Diuretics; Drug Therapy, Combin | 1985 |
Hypertensive therapy in blacks. Significance of pathophysiologic observations.
Topics: Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Black or African American; Diuretics; | 1986 |
The effect of six beta-adrenolytics and labetalol on hepatic biotransformation studied by antipyrine test, in man.
Topics: Adrenergic beta-Antagonists; Adult; Antipyrine; Biotransformation; Coronary Disease; Half-Life; Huma | 1986 |
Labetalol in the treatment of hypertension in elderly and younger patients.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Blood Pressure; | 1987 |
The role of new antihypertensive drugs.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calc | 1988 |
Analysis of the mechanism underlying the vasodilator action of carvedilol in pithed spontaneously hypertensive rats.
Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Carbazoles; Carvedilol; Decerebrate State; Dos | 1988 |
Labetalol does not decrease placental perfusion in the hypertensive term-pregnant rat.
Topics: Animals; Female; Genitalia, Female; Hemodynamics; Hypertension; Labetalol; Muscles; Placenta; Pregna | 1989 |
Managing cocaine crisis.
Topics: Arrhythmias, Cardiac; Cocaine; Diazepam; Humans; Hypertension; Labetalol; Seizures; Substance-Relate | 1989 |
[Labetalol in the treatment of pregnancy arterial hypertension. 70 cases].
Topics: Adult; Female; Humans; Hypertension; Labetalol; Pregnancy; Pregnancy Complications, Cardiovascular | 1986 |
[Therapeutic monitoring of hypertensive syndrome in pregnancy].
Topics: Adult; Female; Humans; Hypertension; Labetalol; Monitoring, Physiologic; Pregnancy; Pregnancy Compli | 1988 |
[Structural and functional status of the myocardium in patients with hypertension after long-term use of albetol].
Topics: Adult; Cardiomegaly; Hemodynamics; Humans; Hypertension; Labetalol; Male; Middle Aged; Myocardial Co | 1988 |
An overview of labetalol and adrenergic effects.
Topics: Humans; Hypertension; Labetalol; Receptors, Adrenergic, alpha; Receptors, Adrenergic, beta; Vascular | 1985 |
A comparison of the effects of combined or separate alpha- and beta-blockade in the treatment of hypertension in the acute stage of myocardial infarction.
Topics: Adult; Aged; Blood Pressure; Carbon Dioxide; Female; Heart Rate; Humans; Hypertension; Infusions, Pa | 1986 |
Current concepts in treatment of hypertensive emergencies.
Topics: Diazoxide; Drug Therapy, Combination; Emergencies; Humans; Hydralazine; Hypertension; Labetalol; Met | 1986 |
Use of labetalol in trauma.
Topics: Adolescent; Adult; Craniocerebral Trauma; Female; Hemodynamics; Humans; Hypertension; Labetalol; Mal | 1988 |
[Arterial hypertension secondary to Guillain-Barré syndrome. Treatment with a labetalol and chlorpromazine combination. Apropos of a case].
Topics: Aged; Chlorpromazine; Drug Therapy, Combination; Female; Humans; Hypertension; Labetalol; Nitropruss | 1988 |
Labetalol is metabolized oxidatively in humans.
Topics: Adult; Biotransformation; Butylamines; Chromatography, Thin Layer; Female; Humans; Hypertension; Lab | 1988 |
[Labetalol treatment of patients with arterial hypertension].
Topics: Adult; Aged; Dose-Response Relationship, Drug; Drug Evaluation; Female; Hemodynamics; Humans; Hypert | 1988 |
Intravenous labetalol for the control of hypertension following repair of coarctation of the aorta.
Topics: Adolescent; Aortic Coarctation; Humans; Hypertension; Infusions, Intravenous; Labetalol; Male; Posto | 1988 |
Intravenous dilevalol. Effects of the R-R optical isomer of labetalol in patients with severe hypertension.
Topics: Administration, Oral; Adult; Blood Pressure; Epinephrine; Female; Heart Rate; Humans; Hypertension; | 1988 |
Control of cocaine-induced hypertension with labetalol.
Topics: Adult; Cocaine; Emergencies; Humans; Hypertension; Labetalol; Male | 1988 |
The use of labetalol in the management of cocaine crisis.
Topics: Adult; Cocaine; Hematuria; Humans; Hypertension; Labetalol; Male; Resuscitation; Tachycardia, Suprav | 1988 |
Labetalol in the treatment of elderly patients with mild essential hypertension.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochloro | 1988 |
Delayed hypertension with electroconvulsive therapy.
Topics: Affective Disorders, Psychotic; Aged; Electroconvulsive Therapy; Female; Humans; Hypertension; Labet | 1988 |
Continuous i.v. infusion of labetalol for postoperative hypertension.
Topics: Humans; Hypertension; Infusions, Intravenous; Labetalol; Postoperative Complications | 1988 |
Labetalol to control blood pressure after cerebrovascular surgery.
Topics: Adolescent; Adult; Aged; Arteriovenous Malformations; Brain; Female; Humans; Hypertension; Infusions | 1988 |
Clinical evaluation of intravenous labetalol for the treatment of hypertensive urgency.
Topics: Adult; Aged; Blood Pressure; Heart Rate; Humans; Hypertension; Injections, Intravenous; Labetalol; M | 1988 |
Possible revelation of latent myasthenia gravis by labetalol chlorhydrate.
Topics: Female; Humans; Hypertension; Labetalol; Middle Aged; Myasthenia Gravis | 1987 |
Acute effect of labetalol on hypertensive brachial artery.
Topics: Blood Flow Velocity; Blood Pressure; Brachial Artery; Compliance; Female; Humans; Hypertension; Labe | 1987 |
Labetalol in the treatment of patients with hypertension following coronary artery bypass surgery.
Topics: Aged; Coronary Artery Bypass; Drug Evaluation; Female; Hemodynamics; Humans; Hypertension; Labetalol | 1987 |
Effects of labetalol on lipid metabolism.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Female; Hemodynamics; Humans; Hypertension; Labetalol | 1987 |
Management of urgent hypertension: a comparison of oral treatment regimens in the emergency department.
Topics: Administration, Oral; Antihypertensive Agents; Captopril; Clonidine; Drug Administration Schedule; E | 1986 |
[Potentiation of the hypotensive effect of labetalol in hypertensive patients treated to maintain sodium balance in the body].
Topics: Adult; Aged; Blood Pressure; Cardiac Output; Chlorthalidone; Combined Modality Therapy; Diet, Sodium | 1987 |
Management of unique hypertensive situations: a focus on difficult, problematic, elderly black patients.
Topics: Aged; Black People; Female; Humans; Hypertension; Kinetics; Labetalol; Male | 1987 |
Treatment of severe hypertension with peroral labetalol.
Topics: Administration, Oral; Female; Humans; Hypertension; Labetalol; Male; Middle Aged; Regression Analysi | 1987 |
Fetal haemodynamics before and after treatment of maternal hypertension in pregnancy.
Topics: Blood Flow Velocity; Female; Fetus; Hemodynamics; Humans; Hypertension; Labetalol; Maternal-Fetal Ex | 1987 |
Intravenous labetalol in the management of resistant hypertensive emergency.
Topics: Adult; Drug Resistance; Female; Half-Life; Humans; Hypertension; Injections, Intravenous; Labetalol | 1987 |
Platelet function in pregnancy induced hypertension following treatment with labetalol and low dose aspirin.
Topics: Adenosine Diphosphate; Adult; Aspirin; Blood Platelets; Collagen; Dose-Response Relationship, Drug; | 1987 |
Intravenous labetalol for treatment of postoperative hypertension.
Topics: Adult; Aged; Humans; Hypertension; Injections, Intravenous; Labetalol; Middle Aged; Postoperative Co | 1987 |
[Clinical study of severe hypertension treated by intravenous labetalol].
Topics: Adult; Aged; Female; Humans; Hypertension; Injections, Intravenous; Labetalol; Male; Middle Aged | 1986 |
Comparison in young and elderly patients of pharmacodynamics and disposition of labetalol in systemic hypertension.
Topics: Adult; Aged; Blood Pressure; Female; Humans; Hypertension; Labetalol; Male; Middle Aged | 1987 |
Continuous i.v. infusion of labetalol for postoperative hypertension. Haemodynamic effects and plasma kinetics.
Topics: Adult; Aged; Hemodynamics; Humans; Hypertension; Infusions, Intravenous; Labetalol; Middle Aged; Pos | 1987 |
Falsely elevated urinary excretion of catecholamines and metanephrines in patients receiving labetalol therapy.
Topics: Adult; Aged; Catecholamines; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Epine | 1987 |
Rising multiple-dose pharmacokinetics of labetalol in hypertensive patients.
Topics: Adult; Aged; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Administra | 1986 |
[Pheochromocytoma and myocardial infarction (apropos of a case in a 34-year-old man)].
Topics: Adrenal Gland Neoplasms; Adult; Humans; Hypertension; Labetalol; Male; Myocardial Infarction; Pheoch | 1986 |
Labetalol by continuous intravenous infusion in severe hypertension.
Topics: Adult; Aged; Blood Pressure; Female; Humans; Hypertension; Infusions, Parenteral; Labetalol; Male; M | 1986 |
Adrenoceptor blocking drugs and cold feet in intermittent claudication.
Topics: Aged; Foot; Humans; Hypertension; Intermittent Claudication; Labetalol; Male; Middle Aged; Propranol | 1986 |
Use of atracurium and labetalol in a patient with phaeochromocytoma.
Topics: Adrenal Gland Neoplasms; Adult; Atracurium; Female; Humans; Hypertension; Intraoperative Complicatio | 1986 |
Postmarketing comparison of labetalol and propranolol in hypertensive patients.
Topics: Adult; Blood Pressure; Female; Heart Rate; Humans; Hypertension; Labetalol; Male; Middle Aged; Produ | 1986 |
Rebound hypertension following abrupt cessation of clonidine and metoprolol. Treatment with labetalol.
Topics: Aged; Clonidine; Humans; Hypertension; Labetalol; Male; Metoprolol; Substance Withdrawal Syndrome | 1987 |
The use of labetalol for the treatment of hypertension in patients with reversible airway obstruction.
Topics: Airway Resistance; Asthma; Bronchitis; Forced Expiratory Flow Rates; Forced Expiratory Volume; Human | 1985 |
Changes in blood pressure and thermographic values resulting from use of a beta-blocker plus diuretic and of an alpha-beta-blocker plus diuretic.
Topics: Adult; Atenolol; Body Temperature; Chlorthalidone; Drug Therapy, Combination; Heart Rate; Humans; Hy | 1985 |
Drugs for hypertensive emergencies.
Topics: Administration, Oral; Captopril; Clonidine; Diazoxide; Emergencies; Humans; Hydralazine; Hypertensio | 1985 |
Pseudoephedrine-induced hypertensive emergency: treatment with labetalol.
Topics: Adult; Cyproheptadine; Ephedrine; Humans; Hypertension; Infusions, Parenteral; Labetalol; Male; Subs | 1986 |
Oral labetalol in the urgent treatment of severe hypertension.
Topics: Administration, Oral; Adult; Aged; Female; Heart Rate; Humans; Hypertension; Labetalol; Male; Middle | 1986 |
Successful treatment of a monoamine oxidase inhibitor-tyramine hypertensive emergency with intravenous labetalol.
Topics: Adult; Drug Synergism; Ethanolamines; Female; Foodborne Diseases; Humans; Hypertension; Injections, | 1985 |
Erroneous diagnosis of phaeochromocytoma in hypertensive patient on labetalol.
Topics: Adrenal Gland Neoplasms; Diagnostic Errors; Ethanolamines; Humans; Hypertension; Labetalol; Male; Mi | 1985 |
Hypertensive emergencies.
Topics: Antihypertensive Agents; Blood Pressure; Clonidine; Diazoxide; Emergencies; Humans; Hydralazine; Hyp | 1985 |
Effect of labetalol on exercise tolerance and double product in mild to moderate essential hypertension.
Topics: Adult; Aged; Blood Pressure; Ethanolamines; Exercise Test; Heart Rate; Hemodynamics; Humans; Hyperte | 1985 |
Labetalol for hypertension.
Topics: Aged; Arrhythmias, Cardiac; Ethanolamines; Female; Humans; Hypertension; Hypotension; Labetalol; Mal | 1985 |
Transfer of labetalol into amniotic fluid and breast milk in lactating women.
Topics: Amniotic Fluid; Female; Humans; Hypertension; Labetalol; Lactation; Milk, Human; Pregnancy; Pregnanc | 1985 |
Effects of long-term therapy with labetalol on lipoprotein metabolism in patients with mild hypertension.
Topics: Adult; Fat Emulsions, Intravenous; Female; Heparin; Humans; Hypertension; Labetalol; Lipase; Lipopro | 1985 |
Pharmacodynamics of intravenous labetalol and follow-up therapy with oral labetalol.
Topics: Administration, Oral; Adult; Blood Pressure; Dose-Response Relationship, Drug; Female; Follow-Up Stu | 1985 |